### TRUST BOARD - PUBLIC SESSION AGENDA

**Venue:** Anne Gibson Board Room, City Hospital **Date:** 1<sup>st</sup> June 2017, 09:30h – 13:00h

Members: Mr R Samuda (RSM) Chairman Ms O Dutton Vice Chair (OD) Mr M Hoare (MH) Non-Executive Director Mr H Kang (HK) Non-Executive Director Cllr W Zaffar (WZ) Non-Executive Director **Prof K Thomas** (KT) Non-Executive Director Mr T Lewis (TL) **Chief Executive** Dr R Stedman (RST) **Medical Director** Ms E Newell (EN) **Chief Nurse** (RB) **Chief Operating Officer** Ms R Barlow Mr T Waite (TW) **Director of Finance Director of Governance** Miss K Dhami (KD) Mrs R Goodby (RG) Director of OD

In attendance:

Mrs C Rickards (CR) Trust Convenor

Mrs A Geary (AG) Group Director, W&CH

**Meeting support:** (RF)

Ms R Fuller

Time	Item	Title	Reference Number	Lead
0930h	1.	Welcome, apologies and declarations of interest  To declare any interests members may have in connection with the agenda and any further interests acquired since the previous meeting.  Apologies: Marie Perry, Rachel Barlow, Ruth Wilkin	Verbal	Chair
0930h	2.	Patient Story	Presentation	EN
0940h	3.	Questions from members of the public	Verbal	Chair
0945h	4.	Chair's opening comments	Verbal	Chair
		UPDATES FROM THE BOARD COMMITTEE	S	
0950h	5.	To:  (a) receive the update of the <b>Charitable Funds</b> meeting held on the 18 <sup>th</sup> May 2017  (b) receive the minutes of the <b>Charitable Funds Committee</b> meeting held on 13 <sup>th</sup> April 2017	SWBTB (06/17) 02 SWBTB (06/17) 03	WZ
	6.	To:  (a) receive the update of the Public Health, Community  Development and Equality Committee meeting held on 18 <sup>th</sup> May 2017  (b) receive the minutes of the Public Health, Community  Development and Equality Committee meeting held on 9 <sup>th</sup> February 2017	SWBTB (06/17) 04 SWBTB (06/17) 05	RSm

Time	Item	Title	Reference Number	Lead
	7.	To:  (a) receive the update of the Audit and Risk Management  Committee meeting held on 24 <sup>th</sup> May 2017  (b) receive the minutes of the Audit and Risk  Management Committee meeting held on 26 <sup>th</sup> April  2017	SWBTB (06/17) 06 To be tabled SWBTB (06/17) 07	MP
	8.	To:  (a) receive the update of the <b>Quality and Safety Committee</b> meeting held on 26 <sup>th</sup> May 2017  (b) receive the minutes of the <b>Quality and Safety Committee</b> meeting held on 28 <sup>th</sup> April 2017	SWBTB (06/17) 08 To be tabled SWBTB (06/17) 09	OD
	9.	To:  (a) receive the update of the <b>Finance and Investment Committee</b> meeting held on 31st May 2017	SWBTB (06/17) 10 To be tabled	RSm
		MATTERS FOR APPROVAL OR DISCUSSION	N	
1005h	10.	Chief Executive's Report	SWBTB (06/17) 11	TL
1015h	11.	Trust Risk Register	SWBTB (06/17) 12	KD
1025h	12.	Board Governance review: update on actions	Verbal	KD
1035h	13.	Integrated Performance Report	SWBTB (06/17) 13	TW
1045h	14.	Finance Report: Period 01	SWBTB (06/17) 14	TW
1055h	15.	Production Plan months 1 and 2	SWBTB (06/17) 15	TW
1105h	16.	2016/17 Never Events: action plan review	SWBTB (06/17) 16	KD
1115h	17.	A&E performance delivery in June	SWBTB (06/17) 17	AG
1125h	18.	2016/17 Annual Complaints and PALS report	SWBTB (06/17) 18	KD
1135h	19.	Research and Development Plan	SWBTB (06/17) 19	RST
1140h	20.	Diversity pledges	SWBTB (06/17) 20	RG
1205h	21.	Reduction in use of agency staff	SWBTB (06/17) 21	RG
1220h	22.	Never Event notification	Verbal	RST
1230h	23.	Midland Metropolitan Hospital: delay update	Verbal	TL
1240h	24.	Financial Statements for the Year Ended 31 <sup>st</sup> March 2017- to adopt	SWBTB (06/17) 22	TW
1250h	25.	Application of the Trust Seal	SWBTB (06/17) 23	AK
		UPDATE ON ACTIONS ARISING FROM PREVIOUS N	1EETINGS	
1255h	26.	Minutes of the previous meeting and action log  (a) To approve the minutes of the meeting held on 4 <sup>th</sup> May 2017 as a true and accurate records of discussions  (b) Update on actions from previous meetings (action log)	SWBTB (06/17) 24 To be tabled SWBTB (06/17) 25 To be tabled	Chair
1300h	27.	Any other business	Verbal	All
	28.	Details of next meeting		

Title Title		Reference Number	Lead	
		The next public Trust Board meeting will be held on 6 <sup>th</sup> July 2017 venue tbc	starting at 09:30am i	n



	CHARITABLE FUNDS COMMITTEE UPDATE	
Date of meeting	18 <sup>th</sup> May 2017	
Attendees	Cllr Waseem Zaffar (Chair), Mrs Ruth Wilkin, Mr Johnny Shah, Mrs E Newell, Mr Tony Waite, Mr Richard Samuda and Miss Yulander Charles.	
Apologies	Apologies were received from Mr Toby Lewis and Mr Chris Higgins	
Key points of discussion relevant to the Board	The key areas of focus were:	
	<ul> <li>Barclay Investment report</li> <li>Annual report and Accounts</li> </ul>	
Positive highlights of note	Barclay Investment report – Mr T Waite along with several members of the committee met with Barclays to discuss the Charity's investment strategy. Several investment portfolio options were put forward i) Alcohol, tobacco & arms; however the committee agreed that this was not in line with the Trusts Public Health Plan, an appropriate investment fund will be sourced. ii) Risk profile and return; whereas our mandate stands at 5 year time horizon Barclays has a 10 year time horizon. As a result it was noted that we could crystallise some of our cash as the market is in a good position at present. Amount discussed was around £2million.  Annual report and Accounts  The auditors expressed confidence in the accounts presented. There were not concerns with the information presented.	
Matters of concern or key risks to escalate to the Board	• None	
Matters presented for information or noting	• None	
Decisions made	<u>Barclay Investment:</u> the committee decided that the charity would not accept the invest portfolio put forward which incorporated Alcohol, tobacco and arms and this is in contradiction to the Trusts' Public Heath Plan. It was agreed to look at other alternatives.	
Actions agreed	No specific additional actions beyond those being progressed by management.  Next meeting: 14 <sup>th</sup> September 2017.	

Cllr Waseem Zaffar Chair of Charitable Funds Committee For the meeting of the Trust Board scheduled for 1<sup>st</sup> June 2017

SWBTB (06/17) 03

### **CHARITABLE FUNDS COMMITTEE - MINUTES**

**Date:** 13<sup>th</sup> April 2017, 11:30am Venue: D29 meeting room, City Hospital

#### Members present:

Cllr W Zaffar – Chair (WZ) Mr T Waite, Finance Director (TW) Mr T Lewis, Chief Executive (TL) Ms E Newell, Chief Nurse (EN)

#### In attendance:

Mrs R Wilkin, Director of Communications (RW) Mr J Shah, Head of the Trust Charity (JS) Ms Y Charles, Executive Assistant (YC)

Minutes	Paper Reference
Welcome, apologies and declarations of interest	Verbal
Apologies were received from Mr Richard Samuda	
2. Minutes of the previous meeting held on 9 <sup>th</sup> February 2017	SWBCF (04/17) 001
The minutes of the meeting held on 9 <sup>th</sup> February were agreed as a true re	cord.
3. Matters arising from the previous meeting	SWBCF (04/17) 002
(a) 50/50 fundraising rules: Mrs Wilkin provided clarity on the	
50:50 fundraising rules. There are three groups of charities	
involved in the Trust.	
Resident charities – almost exclusively provide support to	
SWBH departments. If they continue to operate and do not	
require 50:50 split of proceeds with Your Trust Charity and	
will be encouraged to collaborate in fundraising events with Your Trust Charity.	
Support/partner Charities – these are involved in partnership	
work with the Trust which include joint service delivery or	
partnership through funding. If they wish to fundraise on	
trust premises they will need to partner with Your Trust	
Charity and split funds 50:50.	
External charities – local, regional or national charities. Local	
and regional charities wishing to fundraise on Trust premises	
or promote fundraising activity they will be advised either	
partner with Your Trust Charity and split funds 50:50.	
National initiatives will not be promoted unless here is a split	
of proceeds with Your Trust Charity.	
(b) <u>Bike ride</u> : Mrs Wilkin summarized the background of this annua	ıl
event which was initially started 15 years ago as a health and	
wellbeing initiative for staff. Since then the group has actively	
fundraised for several charities. It has been recommended that	
there is scope for continued support of this initiative albeit with	1
a 50:50 split between Your Trust Charity and a local charity of	
their choice.	

## Sandwell and West Birmingham Hospitals

**NHS Trust** 

Historically staff was able to take an extra days' annual leave to their overall entitlement. However the committee is asked to agree that annual leave required to take part in the bike ride is on approval from the specific line manager i.e. either take time off in lieu or work flexibly to recover their hours. Also any other leave request for other Trust fundraising activities should be approved through the usual process. The Committee agreed with both proposals.

(c) Hospital radio business plan: Mrs Wilkin reported that the current site for the Hospital radio is no longer fit for purpose. The Hospital radio has recently been awarded a small grant of £5000 to support the purchase of equipment to enable the station to broadcast on-line. Currently it is only accessible by inpatients; an online service would increase accessibility across the wider trust. The committee was asked to note the planned activities and timescales for achieving this.

Other alternative sites are being considered for future physical location. The Chair suggested contacting New Style Radio – a local community radio station based between City and MMH sites. This would not only help in raising the profile of the Trust radio but also provide some capital saving as there are three studios on site all fully equipped –plus there is a shared expertise in offering professional support to the volunteers running the service.

- (d) Pathology fund closure: Mr Waite updated the committee that the BioChemistry fund tracked at £9300 has been transferred to the Charity finances.
- (e) **Income generating funds:** This will be discussed further under the agenda item:

#### **Action:**

 New Style Radio to be contacted to arrange an introductory meeting (WZ)

#### 4. Head of Trust Charity's programme report

Mr Shah provided an overview of the six program areas currently being undertaken. Particular attention was given to the strategy on the development of Legacies. The Charity has an exception report on legacy income, although the majority is classified as restricted this is the highest amount received to date.

This is mainly due to the reactive approach taken by the team; planting the seed in a sensitive manner via legacy packs.

The committee discussed at length how best to maximize on this measure. The route taken has been to create strong links with specialist SWBCF (04/17) 003

# Sandwell and West Birmingham Hospitals NHS

NHS Trust

# Sandwell and West Birmingham Hospitals NHS

NHS Trust

rolled out to support the fund managers. Mr Shah stressed that no	
retrospective grant requests were authorised.	
The committee was asked to approve the policy.	
Mr Lewis highlighted section 7.5.6 and noted the need for the policy to clarify around the Trust Study Leave policy so that the two documents reflect each other.	
Further clarity was requested by the Chair around sections 7.5.10 – Research funded by external parties – understanding was needed as to the arrangements around the funding of research. Mr Waite suggested that prior to the final approval by the committee this policy is reviewed by KPMG and RSM. This was agreed.	
It was also noted that the policy also needed to make it clear that all international travel costs should be authorized by Mr T Lewis.	
The committee asked that the relevant changes be made to the policy and that it is to be re- presented at the next meeting	
<ul> <li>Action:</li> <li>To contact Jocelyn Bell to clarify what the policy is around Research funding (RW and JS)</li> <li>Policy to be reviewed by KPMG and RSM (RW and JS)</li> <li>the policy also needs to make clear that all international travel costs should be authorized by Mr T Lewis (RW)</li> </ul>	
7. Conversion to single trust deed	SWBCF (04/17) 006
7. Conversion to single trust deed  Following the consolidation of funds and the establishment of new	SWBCF (04/17) 006
Following the consolidation of funds and the establishment of new	SWBCF (04/17) 006
	SWBCF (04/17) 006
Following the consolidation of funds and the establishment of new appeals and themes, the charity has undertaken due diligence on two options regarding single charity status conversion Mr Shah presented this	SWBCF (04/17) 006
Following the consolidation of funds and the establishment of new appeals and themes, the charity has undertaken due diligence on two options regarding single charity status conversion Mr Shah presented this paper.  The main areas of discussion were around the dissolution of the eight linked charities by merging them into the main umbrella charity and the	SWBCF (04/17) 006
Following the consolidation of funds and the establishment of new appeals and themes, the charity has undertaken due diligence on two options regarding single charity status conversion Mr Shah presented this paper.  The main areas of discussion were around the dissolution of the eight linked charities by merging them into the main umbrella charity and the possibility of initiating a subsidiary for the charity in 2017/18 that can account for trading income i.e. merchandise sales and corporate partnership income.	SWBCF (04/17) 006
Following the consolidation of funds and the establishment of new appeals and themes, the charity has undertaken due diligence on two options regarding single charity status conversion Mr Shah presented this paper.  The main areas of discussion were around the dissolution of the eight linked charities by merging them into the main umbrella charity and the possibility of initiating a subsidiary for the charity in 2017/18 that can account for trading income i.e. merchandise sales and corporate	SWBCF (04/17) 006  SWBCF (04/17) 007
Following the consolidation of funds and the establishment of new appeals and themes, the charity has undertaken due diligence on two options regarding single charity status conversion Mr Shah presented this paper.  The main areas of discussion were around the dissolution of the eight linked charities by merging them into the main umbrella charity and the possibility of initiating a subsidiary for the charity in 2017/18 that can account for trading income i.e. merchandise sales and corporate partnership income.  The Committee gave its approval to these recommendations.	
Following the consolidation of funds and the establishment of new appeals and themes, the charity has undertaken due diligence on two options regarding single charity status conversion Mr Shah presented this paper.  The main areas of discussion were around the dissolution of the eight linked charities by merging them into the main umbrella charity and the possibility of initiating a subsidiary for the charity in 2017/18 that can account for trading income i.e. merchandise sales and corporate partnership income.  The Committee gave its approval to these recommendations.  8. Midland met Hospital fundraising appeal	
Following the consolidation of funds and the establishment of new appeals and themes, the charity has undertaken due diligence on two options regarding single charity status conversion Mr Shah presented this paper.  The main areas of discussion were around the dissolution of the eight linked charities by merging them into the main umbrella charity and the possibility of initiating a subsidiary for the charity in 2017/18 that can account for trading income i.e. merchandise sales and corporate partnership income.  The Committee gave its approval to these recommendations.  8. Midland met Hospital fundraising appeal  Mr Shah presented this paper to the committee for approval. An update	
Following the consolidation of funds and the establishment of new appeals and themes, the charity has undertaken due diligence on two options regarding single charity status conversion Mr Shah presented this paper.  The main areas of discussion were around the dissolution of the eight linked charities by merging them into the main umbrella charity and the possibility of initiating a subsidiary for the charity in 2017/18 that can account for trading income i.e. merchandise sales and corporate partnership income.  The Committee gave its approval to these recommendations.  8. Midland met Hospital fundraising appeal  Mr Shah presented this paper to the committee for approval. An update was given pertaining to the consultancy work on the £2m fundraising campaign which has since been concluded. In addition an in-depth research has been undertaken on "prospect" charitable trusts and	
Following the consolidation of funds and the establishment of new appeals and themes, the charity has undertaken due diligence on two options regarding single charity status conversion Mr Shah presented this paper.  The main areas of discussion were around the dissolution of the eight linked charities by merging them into the main umbrella charity and the possibility of initiating a subsidiary for the charity in 2017/18 that can account for trading income i.e. merchandise sales and corporate partnership income.  The Committee gave its approval to these recommendations.  8. Midland met Hospital fundraising appeal  Mr Shah presented this paper to the committee for approval. An update was given pertaining to the consultancy work on the £2m fundraising campaign which has since been concluded. In addition an in-depth	
Following the consolidation of funds and the establishment of new appeals and themes, the charity has undertaken due diligence on two options regarding single charity status conversion Mr Shah presented this paper.  The main areas of discussion were around the dissolution of the eight linked charities by merging them into the main umbrella charity and the possibility of initiating a subsidiary for the charity in 2017/18 that can account for trading income i.e. merchandise sales and corporate partnership income.  The Committee gave its approval to these recommendations.  8. Midland met Hospital fundraising appeal  Mr Shah presented this paper to the committee for approval. An update was given pertaining to the consultancy work on the £2m fundraising campaign which has since been concluded. In addition an in-depth research has been undertaken on "prospect" charitable trusts and foundations as well as individuals with a net worth of £2m.  As a result the committee was asked for its approval of the estimated	
Following the consolidation of funds and the establishment of new appeals and themes, the charity has undertaken due diligence on two options regarding single charity status conversion Mr Shah presented this paper.  The main areas of discussion were around the dissolution of the eight linked charities by merging them into the main umbrella charity and the possibility of initiating a subsidiary for the charity in 2017/18 that can account for trading income i.e. merchandise sales and corporate partnership income.  The Committee gave its approval to these recommendations.  8. Midland met Hospital fundraising appeal  Mr Shah presented this paper to the committee for approval. An update was given pertaining to the consultancy work on the £2m fundraising campaign which has since been concluded. In addition an in-depth research has been undertaken on "prospect" charitable trusts and foundations as well as individuals with a net worth of £2m.  As a result the committee was asked for its approval of the estimated resource of 247k which is needed to deliver the campaign. This sum	
Following the consolidation of funds and the establishment of new appeals and themes, the charity has undertaken due diligence on two options regarding single charity status conversion Mr Shah presented this paper.  The main areas of discussion were around the dissolution of the eight linked charities by merging them into the main umbrella charity and the possibility of initiating a subsidiary for the charity in 2017/18 that can account for trading income i.e. merchandise sales and corporate partnership income.  The Committee gave its approval to these recommendations.  8. Midland met Hospital fundraising appeal  Mr Shah presented this paper to the committee for approval. An update was given pertaining to the consultancy work on the £2m fundraising campaign which has since been concluded. In addition an in-depth research has been undertaken on "prospect" charitable trusts and foundations as well as individuals with a net worth of £2m.  As a result the committee was asked for its approval of the estimated resource of 247k which is needed to deliver the campaign. This sum would cover the costs related to the recruitment of a fix-term FTE	
Following the consolidation of funds and the establishment of new appeals and themes, the charity has undertaken due diligence on two options regarding single charity status conversion Mr Shah presented this paper.  The main areas of discussion were around the dissolution of the eight linked charities by merging them into the main umbrella charity and the possibility of initiating a subsidiary for the charity in 2017/18 that can account for trading income i.e. merchandise sales and corporate partnership income.  The Committee gave its approval to these recommendations.  8. Midland met Hospital fundraising appeal  Mr Shah presented this paper to the committee for approval. An update was given pertaining to the consultancy work on the £2m fundraising campaign which has since been concluded. In addition an in-depth research has been undertaken on "prospect" charitable trusts and foundations as well as individuals with a net worth of £2m.  As a result the committee was asked for its approval of the estimated resource of 247k which is needed to deliver the campaign. This sum	

## Sandwell and West Birmingham Hospitals NHS

NHS Trust

to 4 days per week in 2018/19. As well as provisions for the Campaign Counsel/Director.  Mr Shah also asked the committee to consider the allocation of the estimated resource of 247k to either i) secure MMH funds present and future; the revaluation reserves and/or a combination of the two.  Both the Chair and Mr Lewis noted the need to be clear as to what the working targets will be i.e. the need to gauge the milestones. It was suggested that a target of 2.25m be set to cover tax costs. The committee discussed and agreed that the governance of these proposals needed to be confirmed with a clear and defined set of milestones e.g. 2019/20/21 targets needed to be clearer (also set too low needs to be higher) including expenditure breakdown was needed.  The Chair suggested that these issues be addressed and then to bring this proposal back to the committee at the next meeting for consideration. However the committee approved that the recruitment of the Campaign Manager should go ahead as soon as possible.  Action  To re-address the financial breakdown for the 2019/20/21 periods	
estimated resource of 247k to either i) secure MMH funds present and future; the revaluation reserves and/or a combination of the two.  Both the Chair and Mr Lewis noted the need to be clear as to what the working targets will be i.e. the need to gauge the milestones. It was suggested that a target of 2.25m be set to cover tax costs. The committee discussed and agreed that the governance of these proposals needed to be confirmed with a clear and defined set of milestones e.g. 2019/20/21 targets needed to be clearer (also set too low needs to be higher) including expenditure breakdown was needed.  The Chair suggested that these issues be addressed and then to bring this proposal back to the committee at the next meeting for consideration. However the committee approved that the recruitment of the Campaign Manager should go ahead as soon as possible.  Action  To re-address the financial breakdown for the 2019/20/21 periods	
working targets will be i.e. the need to gauge the milestones. It was suggested that a target of 2.25m be set to cover tax costs. The committee discussed and agreed that the governance of these proposals needed to be confirmed with a clear and defined set of milestones e.g. 2019/20/21 targets needed to be clearer (also set too low needs to be higher) including expenditure breakdown was needed.  The Chair suggested that these issues be addressed and then to bring this proposal back to the committee at the next meeting for consideration. However the committee approved that the recruitment of the Campaign Manager should go ahead as soon as possible.  Action  To re-address the financial breakdown for the 2019/20/21 periods	
proposal back to the committee at the next meeting for consideration.  However the committee approved that the recruitment of the Campaign Manager should go ahead as soon as possible.  Action  - To re-address the financial breakdown for the 2019/20/21 periods	
- To re-address the financial breakdown for the 2019/20/21 periods	
(JS/RW/TW) - Bring back to the next meeting ( JS/RW)	
9. Statement of financial activities SWBCF (04/17)	008
Mr Waite presented the financial update to the committee. The Portfolio	
is performing well and there are no real causes for concern.	
The net movement in funds currently stands at £200k. Mr Waite asked the committee to note that income for certain funds have been deemed as Trading in nature and so have been removed front the Charitable Funds transactions for the reported period. This income will transfer to the Trust's exchequer funds and will be reported in the Trusts accounts as revenue trading income. This activity had been scrutinized by KPMG as part an interim audit and it is understood that they would support this measure.	
The committee noted the report along with the impact of removing the Trading income	
10. Matters to raise to Trust Board Verbal	
Midland Met Hospital fundraising appeal – to update the Board on the consultancy work on the £2m fundraising campaign which has since been concluded. Also on the MMH income generating scheme.	
11. Meeting effectiveness Verbal	
Mr Lewis commented on the lack of Non-Exec representation. Mrs Wilkin highlighted she will be running a workshop around Board members relationship re MMH appeal.	
Mr Lewis also noted that we ought to invite members of staff particularly those who have benefited from the grants scheme to the committee this	



would add value to the committee.	
Mr Lewis also gave his apologies for the next meeting in May 2017.	
Action	
- To discuss staff-side representation at future committees (TL/RW)	
- To discuss further at the next committee meeting as part of the	
agenda – Committee structure (WZ/YC)	

# Sandwell and West Birmingham Hospitals NHS Trust

Date of meeting	18 <sup>th</sup> May 2017
Attendees	Mr. Richard Samuda, Cllr Waseem Zaffar, Mrs. Raffaela Goodby, Mrs. Elaine Newell, Dr. Roger Stedman, Mrs. Ruth Wilkin & Mrs. Chris Rickards
Apologies	Mr. Toby Lewis
Key points of discussion relevant to the Board	<ul> <li>Volunteering</li> <li>Community Development</li> <li>Alcohol Services</li> <li>Public Health Plan 2017-2020 (follow up discussion from Trust Board)</li> <li>Diversity Pledges (on Public Board Agenda)</li> </ul>
Positive highlights of note	<b>Volunteering</b> – plans are being put in place that he committee felt will have impact on patient experience and the Trusts profile in the Community i.e. transport scheme for "in need" patients, refer a friend, offers to students who want to volunteer. Substantive 'Volunteer Manager' in process to be recruited
	Community Development – work ongoing with partner organisations to ensure the patient population is represented in workstreams. Agreed to work with local government community engagement partners where possible. The Topping Out Ceremony would be a good opportunity to invite different community groups this event.
	Alcohol Services – recruitment of an alcohol nurse and working on reducing admissions and improvement of referrals to third party which has already started to have an impact – the funding of the post was secured from Your Trust Charity for 2 years. Focusing with partner organisations on referrals and also looking at how intervention with first time visitors (especially the young) to hospital can be targeted to stop them becoming frequent visitors.
	Public Health Plan – looking at objectives and how best services will be supported with the Trust and the Council
	<b>Diversity Pledges</b> – focus on staff and patient pledges and will update the Trust Board on patient pledges at its July meeting.
Matters to escalate to the Board	<ul><li>Alcohol Services</li><li>Diversity Pledges</li></ul>
Matters presented for information or noting	none
Decisions made	
Actions agreed	<ul> <li>Community Development – Cllr Zaffar and Mrs Wilkin to discuss how to reach communities via social media (twitter, Facebook etc.)</li> <li>Public Health Plan – Staff wellbeing, issues on stress. Mr. Samuda to contact colleagues at Deutsche Bank who have a good approach in helping staffs wellbeing.</li> <li>Diversity Pledges – guide and therapy dogs. Mr. Samuda to contact a colleague at Guide Dogs UK for a chat</li> </ul>

Mr. Richard Samuda

CHAIR OF THE PUBLIC HEALTH, COMMUNITY DEVELOPMENT AND EQUALITY COMMITTEE MEETING

For the meeting of the Trust Board scheduled for 1<sup>st</sup> June 2017



### **Public Health, Community Development and Equality Committee**

**Venue:** D29 Meeting Room, Corporate Suite, City Hospital **Date:** 2pm, 9<sup>th</sup> February 2017

#### Members present:

Mr R Samuda (Chair) (RS)
Cllr W Zaffar, Non-Executive Director (WZ)
Mr T Lewis, Chief Executive (TL)
Ms E Newell, Chief Nurse (EN
Dr R Stedman, Medical Director (RSt)

#### In attendance:

Mrs R Goodby, Director of Workforce & OD (RG) Ms R Wilkin, Director of Communications (RW) Mrs C Rickards, Trust Convenor (CR) Ms G Towns, Head of Corporate Governance (GT)

Minutes	Paper Reference
1 Welcome, apologies and declaration of interests	Verbal
The Chair welcomed all to the meeting.	
The members present did not have any interest to declare.	
2 Minutes of the meeting 1 <sup>st</sup> December 2016	SWBPH (02/17) 001
The Committee approved the minutes of the meeting held on $1^{\text{st}}$ Decembe amendments:	r 2016 subject to the following
<ul> <li>Page 2, Halal food: Cllr Zaffar advised the minute should read "City Serve" ra</li> <li>Page 3, Equality and Inclusion Plan: The minute should read "Stephen Ga Council"</li> </ul>	•
3 Minutes of the meeting 20 <sup>th</sup> January 2017	SWBPH (02/17) 002
The minutes of the meeting held on 20 <sup>th</sup> January 2017 were agreed as a true record.	
4 Matters arising	SWBPH (02/17) 003
The Committee received the action log and discussed the following items:	
Early release of bodies: Mr Lewis was keen for this matter to remain on the	e Committee's agenda to ensure it

- Early release of bodies: Mr Lewis was keen for this matter to remain on the Committee's agenda to ensure it remained a priority for the Trust. He suggested the Committee were presented with a proposal outlining what 'good' performance looked like. Mr Lewis suggested metrics to measure good would be helpful to the Committee. The Committee discussed the need to develop a strong working relationship with the Coroner's Office. Mr Lewis asked for this matter to be tracked on the action log and stated it was important a solution was identified prior to the opening of the Midland Met Hospital.
- Outpatient's ethnicity coding: This matter was being progressed and would be closed by the end of the

month.

- Equality Plan: This matter was on the agenda for the Public Trust Board meeting on 2<sup>nd</sup> March 2017 meeting. This matter was marked as closed on the action log.
- <u>Making Every Contact Count</u>: Mr Lewis confirmed he would include this item in the Initial Public Health Plan v2 item. This matter was marked as closed on the action log.

#### **Action:**

- Early release of bodies to remain on the agenda. A proposal outlining what 'good' performance looks like to be returned to the Committee for discussion

#### **5 Community Development Activities**

Verbal

Mrs Wilkin advised that the Trust continued to support a number of local organisations at Sandwell and City Hospital. The Trust had continued its outreach work by engaging with local community groups. Mrs Wilkin confirmed that volunteering remained a priority for the Trust. Mrs Wilkin advised the Committee that the Trust had undertaken work with local schools, mostly primary schools, in the local area. Pupils had been invited to Sandwell General Hospital to help assist carers with refreshments in the day room. Cllr Zaffar suggested the Association of Handsworth Schools may be able to assist with identifying schools in the West Birmingham catchment.

Mrs Wilkin advised that the *Kissing It Better* programme had been launched the previous week with college beauty students visiting wards to offer treatments to patients.

Mrs Wilkin informed the Committee that the Trust had recently attended an event hosted by Birmingham City Council targeting the Eastern European community. Mrs Wilkin confirmed this had been a good opportunity to learn from different groups and identify better ways to engage with the community. Cllr Zaffar stated there was an opportunity to educate the community so they were aware of their rights to access healthcare. Mr Lewis suggested there was an opportunity to engage with the community regarding HIV and caesarean section rates to particular issues which were more prevalent within the community.

Mrs Wilkin advised that community engagement activities continued. Five local groups were actively engaged with the Trust and involved in a number of schemes. Mrs Wilkin advised it was the Trust's intention to identify ambassadors who could act as a link between the community groups and the Midland Met Hospital, once open.

Mrs Wilkin confirmed that the Trust continued to engage with valuable third sector partners. She confirmed the matter had been reported to the December 2016 Trust Board meeting and a workshop had been held on the matter. A number of actions to take forward had been identified to ensure staff recognised the value of working with the third sector. Mrs Wilkin advised a number of senior leaders would be visiting community groups as part of the First Friday scheme.

Mr Lewis wished to ensure that the Trust's community engagement work engaged with all members of the community. Mrs Wilkin confirmed she was considering how best to present this and the Committee discussed how this could be visualised. Mrs Wilkin agreed to provide an initial outline for discussion at the next meeting.

#### **Action:**

- An outline of community engagement work to be provided for discussion at the next meeting (RW)

6 Diversity Pledges SWBPH (02/17) 004

Mrs Goodby advised the nine diversity pledges would be refreshed with the new Public Health Plan. Mrs Goodby stated that February was LGBT history month and the daily staff email had featured LGBT history stories to highlight the month. Mrs Goodby advised that social media interest had been good and highlighted the work of Stuart Young, the LGBT Staff Network Chair who had played an active role in promoting the LGBT history month. Mrs Goodby

advised the Trust planned to have a stall at Birmingham Pride which could jointly promote the Trust's LGBT network and recruitment for the Trust. Mrs Goodby advised that there was further work to be done to educate staff about the LGBT community and referred to a recent incident where her car had been vandalised on the staff car park with LGBT associated wording. Mrs Rickards was supportive of the proposals to develop the LGBT group and confirmed the need to educate staff members of the LGBT community.

Mrs Goodby informed the committee that March would focus on disability. Kam Dhami, Director of Governance, would be the Executive Sponsor for the Disability Staff Network. Mrs Goodby advised that the last Disability Staff Network meeting had not been well attended and therefore a strengthened communications plan would be implemented to raise the network's profile.

The Committee discussed each of the diversity pledges in turn:

- Pledge 1, analysis of training requests and training funds: Mr Lewis was of the view that whilst the pledge had been achieved, the general staff view was that the training had not been undertaken. He suggested a communications strategy was implemented to address this. Mrs Goodby advised that the analysis presently included Doctors and she planned to remove this group from the next data return to view the characteristics of the Agenda for Change group of staff. Mrs Goodby advised that the Trust would also be looking at the data for complaints which were resolved as informal grievances and was working with Mrs Rickards on this matter. The data would particularly consider BME staff members. The Committee discussed that the majority of staff did not declare their sexuality in any data return; it was hoped that the work with the LGBT staff network would encourage staff members to provide this information. This pledge had been met.
- Pledge 2, Trust Board training: this pledge had been achieved. This pledge had been met.
- Pledge 3, EDS2 self-assessment: Mrs Goodby advised that rather than ask each directorate to complete a
  return, a corporate EDS2 return would be completed. Mrs Goodby advised that much of the EDS2
  requirements were replaced with the Race Equality Standard. Mr Lewis disagreed and asked that the EDS2 be
  considered by the Executive Group and presented to the next Committee meeting.
- Pledge 4, protected characteristic data: Mr Lewis advised that the Trust was not an outlier regarding the
  representation of different staffing groups. Mrs Goodby advised that there were two sets of data available,
  ESR and the information gained through the 2016 declaration of interests return. Mr Lewis suggested this
  pledge remained open and that the Executive Group looked at this matter. This pledge remained open.
- Pledge 5, raising awareness of protected characteristics: Mrs Goodby confirmed events were held every month celebrating protected characteristics. A plan for events over the next twelve months had also been established. This pledge had been met. The Committee discussed the importance of mutual respect throughout the Trust. Mrs Rickards stated that UNISON had noted there were higher instances relating to issues of mutual respect than at other neighbouring Trusts. Mr Lewis agreed this matter remained a concern and stated this could be captured in the consequences work which would be implemented shortly. Mrs Rickards suggested that speedier resolution of issues could assist as it presently took some months to achieve a resolution. Mr Lewis suggested this linked to pledge 7.
- Pledge 6, structured programme: This pledge had been partly met.
- Pledge 7, review of workforce policies and procedures to see if they match our ambitions and commitments: Mrs Goodby confirmed the Trust's policies and procedures had been reviewed. Whilst the policies were in place, the culture and issues of mutual respect needed to be tackled. Mr Lewis asked if the practicalities of BME staff forming membership of every interview panel had been worked through. Mrs Goodby advised that in some areas of the Trust this would be of greater benefit as there had been a perception identified through grievances that many staff members did not believe BME staff members were being progressed. Mr Lewis suggested the Trust's focus moved to tackling the issues raised and was keen to resolve this issue. This pledge

had been met.

- Pledge 8, establish groups in each protected characteristic: Mrs Goodby confirmed this pledge had been met.
- Pledge 9, work with senior leaders with protected characteristics for them to provide visible support: Mrs
  Goodby advised that this work was still in action and would be completed by May. This pledge remained
  open.

#### **Action:**

- Pledge 3, EDS2 to be considered by the Executive Group and presented to the next Committee meeting (RG)
- Pledge 4, protected characteristics data to be considered by the Executive Group and presented to the next Committee meeting (RG)

## 7 Initial Public Health Plan v2 2017-2020 SWBPH (02/17)

Mr Lewis tabled a paper for this item and advised of his intention to present the Public Health Plan to the April/May 2017 Trust Board meeting.

Mr Lewis confirmed the current Public Health Plan was nearing its conclusion. The Trust had successfully achieved its goals for maternity, asthma and green food waste. Mr Lewis stated that staff mental health had also been successfully impacted upon although data was not fully available to support this.

Mr Lewis advised that the Trust had not achieved its aspirations for Making Every Contact Count and the alcohol plan. The Trust had also failed to deliver its plans regarding infant mortality and advised there was discord between the CCG, Sandwell Council and the Trust on what should be achieved around this issue. He noted Sandwell Council were focused on childhood matters but not on mortality. Mr Lewis identified a need to avoid duplication between the Quality Plans and the Public Health Plan. He advised there had been considerable delay from Sandwell Council and this had impacted upon the achievement of the Trust's public health plan goals. He suggested it may be useful for the Trust to wait for Sandwell Council to identify their key areas of action before developing the Public Health Plan 2017-2020 and was of the view that childhood obesity may be one such issue the Council focused upon. The Committee discussed that the Trust did not provide school nursing and discussed where the boundaries of support lay. Mr Lewis suggested that the Committee may in future wish to identify any new areas to focus upon and schools may feature in this.

Mr Lewis suggested the CCG may focus their plans on communicable diseases. He noted vaccination rates in the local communities could be higher; the Committee discussed the transient nature of some of the local population. The Committee discussed that vaccination could feature in any future plan. The Committee discussed the blend of staff and patient focus within any future Public Health Plan and were of the view a 50/50 split should be maintained.

The Committee discussed the areas Mr Lewis had suggested could feature in the Public Health Plan 2017-2020. For patients the Committee noted the following key issues could feature in the plan:

- <u>Isolation in older age</u>: The Committee noted that presently this did not feature explicitly in the Public Health Plan. The Committee noted isolation was not only a matter for the elderly. Cllr Zaffar suggested the Trust may be able to engage with London Cares, a third sector agency.
- Making Every Contact Count: Mr Lewis was of the view this had not been fully embedded into the Trust's
  culture. Mr Lewis suggested EPR would enable the Trust to track the success of Making Every Contact Count
  by identifying meaningful patient outcomes.
- Primary School age obesity: This had been discussed by the Committee.
- Reducing premature infant mortality: Mrs Newell suggested this was revised to reduce perinatal mortality instead.
- Addressing vaccination rates among local population: The Committee discussed the Trust's successful winter

flu vaccination scheme but suggested there may be other vaccinations which the Trust could offer. The Committee returned to the suggestion of developing a relationship with schools.

The Committee noted the following key issues for staff members which could feature in the plan:

- <u>Improving staff mental wellbeing:</u> Mr Lewis suggested that the plan should identify its interpretation of stress, bullying etc.
- Addressing specific issues in our staff health profile: Mr Lewis reflected on learning outcomes from the first
  Public Health Plan and suggested that identification of a single issue within the plan may result in more
  meaningful engagement from staff. Dr Stedman suggested muscular skeletal issues may be a suitable area to
  focus on as it was likely to affect a sizable proportion of staff members and was amenable to intervention.

Mr Lewis thanked the Committee for their comments. He was of the view the Public Health Plan 2017-2020 should have prominence within the Trust, particularly as EPR and the Midland Met Hospital would feature in the coming months and years. Mr Lewis was hopeful to secure a resource from Sandwell Council to support the Public Health Plan 2017-2020. He advised that further consideration would be given to how equality and community development featured in the plan.

- Public Health Plan 2017-2020 to be presented to the April/May 2017 Trust Board meeting (TL)

#### 8 Matters to raise to the Trust Board

Verbal

The Committee wished to highlight the following matters to the Trust Board:

- Diversity pledges: the Committee noted that five of the pledges had been met and one partly met;
- <u>Public Health Plan v2 2017-2020</u>: The Committee provided feedback on suggested areas for the Public Health Plan v2 2017-2020. This will be presented to the Trust Board by May 2017.

9 Any other business	Verbal
There were no items of any other business.	
Next meeting	
The next meeting will be held on 18 <sup>th</sup> May 2017 at 2pm in the meeting room, D29, Corporate Suite	, City Hospital.

Signed	
Print	
Date	

# Sandwell and West Birmingham Hospitals NHS Trust

#### **Audit and Risk Committee**

<u>Venue</u> Anne Gibson Board Room ,City Hospital <u>Date</u> 26<sup>th</sup> April 2017; 1400h – 1600h

**Present** 

Members PresentIn AttendanceMs M PerryChairMiss K DhamiCllr W ZaffarNon-Executive DirectorMr T Waite

Mrs E Newell
Mr R Chidlow
Mr M Gennard
Mr A Hussain
Ms E Simms
Mrs E Quinn

Minutes	Paper Reference
1 Welcome, apologies and declarations of interest	Verbal

Ms Perry welcomed all present to the meeting. Apologies had been received from Ms Olwen Dutton, Mr Harjinder Kang, Mr Andrew Bostock and Mr Tim Reardon.

The members present did not have any interests to declare.

#### 2 Minutes of the previous meeting held on 26<sup>th</sup> January 2017

SWBAR (04/17) 002

The minutes of the previous meeting held on 26<sup>th</sup> January 2017 were agreed as a true record, subject to an amendment to item 4.1 (a). This should reflect that the Committee noted that a forward plan to address aged debt was in place. Mr Waite to provide updated on an on-going basis.

#### 3 Matters and actions arising from previous meetings

SWBAR (04/17) 003

- **4.1** Governance Pack: The Committee noted that due to the amount of business on the agenda for this month, it had been agreed that the Governance pack would be deferred to the May 2017 meeting. It was reported that the Legal Services update, to incorporate negligence claims, will be included in the Governance pack at the July meeting. An update in relation to the overseas visitors/debt collection partner will be included as part of the Governance pack at the May meeting.
- **4.6** Data Quality: Mr Waite reported that he had not yet been able to progress this item. He confirmed that he would progress this via the Executive Group and bring an update to the next meeting in May.

- External Audit: Mr Chidlow confirmed that in relation to Payroll overpayments, KPMG provided a note to Mr Waite and Mr Reardon on 31 January to highlight that according to benchmarking data, SWBH had a payroll overpayment rate at approximately 0.08% of payroll expenditure, against a best in class of 0.03-0.04%. Reporting examples from other Trusts were provided. SWBH data highlights the risk of late notification to HR as a key risk, as only a minority of leavers were recorded as having notified HR before the leaving date. In terms of Tender Waivers, on 31 January, KPMG provided Mr Waite and Mr Reardon a best practice proforma of how other Audit Committees present single tender waivers at a granular level; specifically capturing the £5m gap that the Audit Committee doesn't currently see. The Committee confirmed that this action could now be closed.
- **6.1** Internal Audit overdue actions: It was reported that since the papers for meeting had been produced, a large number of overdue actions had now been closed. Ms Perry felt it would have been helpful if the actions had been closed prior to the papers being issued.
- **6.2** It was noted that the counter fraud actions had been included on the internal audit tracker for management. This action has now been closed.

5 Safe Staffing SWBAR (04/17) 005

Mrs Newell gave an overview of the April summary level data. She highlighted that the majority of wards achieved over 95% fill rates for both trained (RN) and untrained (HCA) staff. Paediatrics, D27 and Priory 4 wards all triggered red due to fill rates lower that the established norms. This was noted to be entirely appropriate and in response to reduced clinical activity/dependency.

The Committee noted the plans in place to support Thornbury switch off from 1<sup>st</sup> June and subsequent reduction in agency use. The plans are to be developed into full PMO/GPO plans and were noted to include:

- Efficient Rostering, measured and monitored against agreed KPI's including time owing to Trust;
- Recruit substantively to nursing vacancies;
- Substantively staff Lyndon 5;
- Halve sickness in Ophthalmology Theatres;
- Tighter escalation for approvals via prompt cards;
- Bed reduction programme delivered by 31<sup>st</sup> May;
- Staffing review commencing 1<sup>st</sup> May;
- Review heat maps for agency spend / sickness with a view to focussed support;
- Focussed care reduction across the Trust;
- Ban on all agency HCA's effective 1<sup>st</sup> April 2017;
- Substantive recruitment to HCA 100 WTE vacancies through recruitment drive (84 are in recruitment process);
- Growth of HCA numbers on Trust Bank Focussed care reduction across the Trust;
- Ban on all agency HCA's effective 1<sup>st</sup> April 2017;
- Substantive recruitment to HCA 100 WTE vacancies through recruitment drive (84 are in recruitment process);
- Growth of HCA numbers on Trust Bank.

Ms Perry raised the question in terms of meeting the internal audit requirements in this respect. Mr Hussain reported no concerns in terms of wards not being staffed, but rather of the process of data collection. Mrs Newell informed the Committee that since the audit had been undertaken, the 'Barnacle' tool/system had been implemented which removed the need for manual reporting processes. The system would be rolled out to all areas and e-rostering by July and would be capable of providing management information.

#### 6 Clinical Audit Progress Report

SWBAR (04/17) 006

Miss Dhami presented the report and updated the Committee on the progress of the 20 clinical audits that were included in the Clinical Audit plan for 2016/17. Of the 20 audits, 14 had been completed. The details of the findings were included

within the report, however, the main findings were noted to be in relation to the audits that had been carried out to:

- Determine whether there is full compliance with all the WHO Safer Surgery requirements;
- Confirm whether patients who present at the Trust with a retinal detachment are being managed according to best practice;
- Determine whether patients at the end of life are dying in a place of their choosing;
- Confirm whether DNACPR decisions are being made according to Trust standards.

Miss Dhami reassured the Committee that the actions resulting from the audits would be followed up.

Cllr. Zaffar highlighted the audit in relation to the preferred place of death and felt that the results were positive. He asked if the Trust was able to share data in relation to the patients' faith or ethnicity in this respect. Mrs Newell felt that it was was possible to obtain/share the ethnicity data, but was unsure if the data in relation to faith was recorded at this stage. She agreed to further explore this and share any relevant data with Cllr. Zaffar.

#### 7 Going Concern Review

SWBAR (04/17) 007

Mr Waite reported that in line with financial forecasts, the Trust was expected to report a deficit position for FY 2016/17 which, following the underlying deficit generated in FY 2015/16, is expected to result in a shortage of internally generated cash in FY 2017/18. The underlying deficit for FY 2016/17 was noted to be expected to be in the region of £24m which is carried forward into FY 2017/18. The reported and underlying deficits, taken in conjunction with a requirement for external cash support in the new financial year, had warranted review of the assumption that SWBH Trust is a going concern.

The review considered the following components:

- o An assessment of the financial plans
- Assessment of assumptions underpinning those plans and sensitivities
- Other environmental events or conditions
- GAM interpretations for the purpose of NHS organisations

The conclusion following management assessment is that SWBH Trust is a going concern and it is appropriate to prepare the 2017/18 annual accounts on that basis. It was noted that the Board was satisfied that there was a plausible route back to a balanced plan. Mr Chidlow confirmed his satisfaction that the report met the requirements of external audit.

#### 8 Review of unaudited draft annual accounts

SWBAR (04/17) 008

Mr Waite presented the report in relation to the Trust's draft financial statements for the year ended 31 March 2017. He highlighted that the statements demonstrate the Trust's performance against key financial duties, as follows:

- Duty to achieve income and expenditure breakeven not achieved. £11.9m deficit recorded versus a plan target
  of £6.6m surplus;
- Duty to maintain capital expenditure within CRL achieved. £19m capital expenditure against a £19.1m CRL;
- Duty to maintain cash usage within EFL achieved. £46.9m relevant net cash outflow against a £56.4m EFL.

In preparing the statements, management had made a number of judgements. These had been discussed in depth at the January committee, summarised as follows:

- The trust values on an alternative MEA basis and so does not account for individual assets. Surplus assets held by the trust therefore have no separate value. Consequently as individual assets are disposed of they will be valued with reference to contemporary guidance.
- The application of IFRS 9 is expected to result in the release of a credit note provision held at March 2016. It is also expected to impact on the level of bad debt provision, specifically that held for invoices in respect of DTOCs to Birmingham City Council.

• The trust's managed equipment service scheme falls within the scope of IFRIC 12. The contract will be treated "on balance sheet" and the accounting treatment will be consistent with that of the Birmingham treatment centre PFI scheme.

It was noted that the financial statements had been prepared on a going concern basis.

#### 9 Reference costs 2016/17

SWBAR (04/17) 009

Mr Waite presented the report that updated the Committee in respect of the following:

- Published reference cost information for 2015/16
- Published education and training cost information for 2015/16
- Update on audit findings in relation to the 2014/15 submission
- Proposed approach for 2016/17 reference cost submission

In order to improve the quality of reference cost returns nationally the guidance now requires board approval of the return. The board or a relevant sub-committee is required to take steps to satisfy themselves that:

- the cost return has been prepared in accordance with the Approved costing guidance, which includes the combined costs collection guidance
- the information, data and system underpinning the return are reliable and accurate
- there are proper internal controls over the collection and reporting of the information included in the combined costs collection, and these controls are subject to review to confirm that they are working effectively in practice
- costing and E&T teams are appropriately resourced to complete the return, including the selfassessment quality checklist and validations, accurately within the timescales set out in the reference costs guidance
- the content of the return is not inconsistent with internal and external sources of information.

The board or sub-committee should also ensure that the finance director and education lead have or will, on behalf of the board, approve the final combined costs collection return before submission.

In addition, a statement of directors' responsibilities will be completed and signed by both the finance director and education lead. In the 2016/17 process this must be kept on site available for audit review. This is in contrast to the 2015/16 process when it was returned to the DH with the reference cost return.

The Committee noted and approved that the 2016/17 reference cost submission would be aligned for consideration and sign-off at the September Trust Board meeting. Mr Waite proposed to circulate the timetable (to be agreed with NHSI) electronically to the Committee for virtual sign-off.

#### 10 External Audit Progress Report

SWBAR (0/17) 010

Mr Chidlow highlighted the work undertaken by External Audit since the last meeting, together with a summary of the upcoming work ahead of the next Committee meeting on 24<sup>th</sup> May.

The Committee received the report.

#### 11 Interim Report, including actions arising from previous year reviews

SWBAR (0/17) 011

Mr Chidlow presented the interim report and highlighted the progress made in terms of completing the first two stages (planning and control evaluation) of the four key aspects of the accounts audit. The work to date in relation to the

significant audit opinion risks was summarised, as follows:

- Valuation of property, plant and equipment (to include land and buildings, managed equipment service and capitalisation of staff costs);
- Recognition of NHS and non-NHS income
- Key areas of judgement, including accruals, provisions (including bad debt provision) and deferred income.

Mr Chidlow further summarised the risks for use of resources that had been highlighted in the 2016/17 External Audit Plan:

- Delivery of the 2016/17 financial plan in the context of the Trust's Long Term Financial Model;
- The Trust's work with its local health economy partners in its Sustainability and Transformation Plan;
- Working with regulators;
- Governance arrangements for significant projects.

The Committee received and noted the report.

#### 12 Approval of Internal Audit Plan

SWBAR (0/17) 012

Mr Gennard presented the plan for approval and made the assumption that it had been read in advance of the meeting. He confirmed that it had been approved by the Executive. He highlighted that that the plan sets out the review, lead sponsor and proposed timing. Any changes to the scheduling will be brought to the Committee throughout the year.

Ms Perry confirmed that the Committee was content with the areas of audit and it was therefore approved for the forthcoming twelve months.

NB: Subsequent communication established this process had not been completed and Executive 'sign-off' was pending. The plan will be presented to the Committee at its May meeting.

#### 13 Review of Internal Audit Progress

SWBAR (01/17) 013

Mr Hussain presented the reports and highlighted that ten reports had been finalised since the last meeting of the Committee in January. The Committee noted that there were a further three reports that had been issued in draft and were awaiting management responses. Mr Hussain assured the Committee that since the report had been issued, a number of outstanding actions had been closed off. Ms Perry was of the opinion that good progress had been made and noted that there was just one action outstanding.

#### 14 Receipt of annual Internal Audit report and associated opinions

SWBAR (01/17) 014

Mr Gennard presented the report that provides the Committee with an overview of the work completed by Internal Audit in 2016/17 and advises the Head of Internal Audit opinion, based on the work undertaken. He highlighted the importance of the report as this will be used by the Chief Executive when preparing the Trust's Annual Governance Statement.

Mr Gennard reported that the overall audit opinion was positive, although he stressed the importance of improving response times in future in relation to closing off outstanding actions.

The Committee received and noted the report.

#### 15 Agreement of Counter Fraud work plan

SWBAR (01/17) 015

Ms Simms presented the report and made the assumption that it had been read in advance of the meeting. She

highlighted that the report includes a fraud risk assessment in order to quantify the inherent and residual fraud risks to the Trust and dictate the focus of the work plan. The Committee noted that the report had been discussed and agreed with the Finance Director.

Ms Simms reported that the Local Counter Fraud Service had good visibility with Trust staff and planned to target specific areas of staff in order to promote visibility.

Mr Waite commended the plan to the Committee. The Committee challenged and confirmed the plan.

#### 16 Receipt of Counter Fraud annual report

SWBAR (01/17) 016

Ms Simms presented the annual report, which was noted to be in draft. She reported there were no significant issues that would raise concern. She highlighted that the 2016/17 work plan outlined the core Local Counter Fraud Service (LCFS) activities undertaken during the financial year, in line with the NHS Protect Standards.

The Committee noted the positive feedback from the (LCFS) in terms of reactive reporting, together with overall 'green' rating for the self-review tool.

#### 17 Update on Counter Fraud progress from 1st April to date

Verbal

Ms Sims confirmed a consistent number of referrals had been received by the LCFS. The Committee noted it was positive that staff were reporting their concerns. Since 1<sup>st</sup> April, three investigations were noted to be underway in relation to parking permits, driver's licence and an overpayment for staff verifying their own shifts.

#### 8 Matters to raise to the Trust Board

Verbal

The Committee agreed the following matters should be raised to Trust Board:

- (a) No major concerns from External Audit in relation to the annual draft annual accounts. Work to be concluded in May:
- (b) Positive annual internal audit opinion received;
- (c) Positive feedback from the Local Counter Fraud Specialist (LCFS) in terms of reactive reporting, together with overall 'green' rating for the self-review tool.

#### 10 Any other business

Verbal

None.

#### Details of the next meeting

The next meeting will be held on 24<sup>th</sup> May 2017 at 1400 – 1600h in Meeting Room 1, Old Management Block, City Hospital.

Signed	
Drint	
riiil	
Date	

**Executive Assistant** 



### **QUALITY AND SAFETY COMMITTEE MINUTES**

**Venue** Anne Gibson Committee Room, City Hospital **Date** 28<sup>th</sup> April 2017, 1030h – 1200h

Members attending:

Ms. O. Dutton

Chair and Non-Executive Director Mrs. S. Cattermole

Mr. M. Hoare Non-Executive Director
Ms. R. Barlow Chief Operating Officer
Miss K. Dhami Director of Governance

Ms. E. Newell Chief Nurse
Dr. R. Stedman Medical Director
Ms. C. Parker SWBH CCG

Non-Executive Director

Minutes	Paper Reference
1. Welcome, apologies for absence and declarations of interest	Verbal
Apologies were received from Mr. Samuda and Mr. Waite. The members present did not have a	ny interests to declare.
2. Minutes of the previous meeting	SWBQS (04/17) 002
The minutes of the meeting held on 24 <sup>th</sup> February 2017 were agreed as a true record.	
3. Matters and actions arising from previous meetings	SWBQS (04/17) 003
a) Minute 7: IPR Neutropenic Sepsis improvements: update given later in the meeting.	

- b) Minute 9: Clinical Audit, Retinal Detachment: information circulated to committee members.
- c) Minute 7: IPR Puerperal sepsis data clarification: item not discussed
- d) Minute 7: IPR Reasons for clinical cancellations: item not discussed
- e) Minute 7: IPR Confirmation of SOPs for new indicators: item not discussed

#### 4. Patient story for the May Trust Board

Verbal

Ms Newell advised that the patient story for the May Trust Board meeting would be delivered by Dr. Chizo Agwu and would focus on the experiences of a patient that has been through the transition from Paediatrics to Adult services. Work needs to be done on how to reflect on spreading good practice to the wider organisation. The Transition Paper came to Q&S two months prior showing compliance with better practice. Diabetes are proving successful in this area as they have a high volume of patients (100+). The patient story illustrates what good should look like. Ms. Dutton queried if departments liaise with other areas such as social services and this was confirmed to be correct.

#### 5. Safety Plan Update SWBQS (04/17) 004

Ms. Newell advised that 21 wards have engaged in the roll out of the safety plan. Maternity and neonatal wards have adopted a modified checklist which has been successfully implemented into neonates and is currently being piloted in

Maternity. A period of analysis and review is currently in progress in order to study outcomes, lessons learned and to plan the next roll out phase. Work has already begun to address some of these issues. Reports are being generated at 6am daily indicating compliance around input of data and adherence to standards. This allows very prompt action to address non-compliance. Medicine is being worked on under the Consistency of Care programme. Work continues on 'output data' which will be reported once several months in to the roll out phase.

The Safety Plan Statistics Numbers graph and Safety Plan Statistics Compliance/Non Compliance graph were briefly discussed. Ms. Newell confirmed that most wards are now reporting daily. However, at Sandwell SAU there is an issue, as the process and tool are not set up well for rapid response areas. The tool is being amended to work with 24 hour stats. Improvement plan in place for end of April (input data). Issues with accessing the portal are also being looked at. Dr. Stedman raised the query regarding VTE compliance and was informed that a new tool and process is being looked at to include this.

Ms. Dutton pointed out that some of the figures seemed incorrect. Ms. Newell explained that some of the areas needed more training on inputting the data. Once reviewed, the plan is to start the relaunch again so that data can be recorded and collected more accurately.

There is a lot of work being done on the Buddy Network Plan Roles which will be supported through Action Learning Sets that is being implemented. Buddies will be performance managed through PDR, improvement training, development of the role and given accreditation via work on a quality improvement plan. Buddies will also be trained on how to escalate problems. Skills will be developed through to 6/7's who will work in other areas and share knowledge where appropriate. Miss Dhami confirmed that Consistency of Care buddies have a different kind of role. Skilled buddies to deploy different skills for the wards in need of intensive support and suggested that we place people in their own specialties. However, it was agreed that the role of the buddies may change when things change in the organisation ie consistency of care moves to digital roll out. That is when we will have to build on role and they will be asked to work for other areas providing support.

Committee members agreed that the Safety Plan would stay on the agenda and output data and impact would be discussed at a future meeting. The Committee received the report.

#### 6. 2016/17 Quality Accounts

SWBQS (04/17) 005

Dr. Stedman outlined the Quality Accounts information that was circulated. The team are finalising the data and gaps will be filled by next week ready for information to be released to stakeholders. The committee members were asked to look at overall content of the document so that it could then go to key stakeholders for their opinions to be incorporated into the final version.

Ms. Dutton suggested that the Quality Plan be more reader friendly. Dr. Stedman advised that is have been aggregated from many services and it needs someone to read/check it and sign it off for the organisation. Miss Dhami suggested that we should add in our priorities such as work on the Digital programme, safety and quality plan. Ms. Barlow asked if some of the photographs could be changed to include patients from all areas of the organisation. Ms. Newell asked if the Quality Accounts would be available in other languages, Miss Dhami will check with Ms. Wilkin.

The Committee received the report.

ACTION: Quality Account to include work on Digital Programme, Safety and Quality Plan. Photographs to be changed. Miss Dhami to speak to Ms. Wilkin about Quality Account being printed in other languages.

#### 7. Ionising Radiation (Medical Exposure) Regulations Annual Report

SWBQS (04/17) 006

Dr. Stedman gave an update on the verbal feedback on the Imaging Service following the CQC Inspection last month which was positive. Evidence was available in the action plan and numbers of reportable incidents that improvements have been made. Ms. Dutton asked if we were confident that all incidents are reported and Dr.

Stedman confirmed that we report at 100% and compared to other reporting rates we either maintain or are better than other organisations. Ms. Parker confirmed that there are a low number of reportable near misses. Assurance is in the culture of team working and feedback from the inspection report. Ms. Barlow advised that activity needs to be looked at and discussed at Group Reviews.

#### 8. Integrated Performance Report

SWBQS (04/17) 007

In the absence of Mr Waite, Dr. Stedman highlighted the quality indicators that have consistently failed to meet the set performance targets. Discussions took place regarding the underperformance in these areas. Queries were raised as to whether we are measuring the data wrong or could anything be done to improve the figures. Miss Dhami confirmed that a conversation is taking place next week to look at thresholds. It was suggested that if areas are always reporting 99% compliance, should reasons on the other 1% non-compliance be broken down.

Hip fractures – Ms. Barlow confirmed that work has been done and improvements have been made to the pathway following scrutiny of the data. Katie Gray is currently working with theatre teams to work on improvements and work is being done on process mapping the patient journey from day of admission. End to end development session being worked on.

Mortality review rates – Dr. Stedman and Ms. Dutton have recently attended a "Death Matters" seminar and changes need to be made. More learning needs to take place when reviews are done by using a standardised checklist. It was also suggested that we need to create a medical examination function so that deaths can be reviewed and detailed with the aid of a filter mechanism. Dr. Stedman suggested that we work on what Leicester have done with cremation fees – fund daily session for medical examinations.

**A&E performance paper** – Ms. Barlow called out the A&E performance paper that is being presented at the Board meeting. The trajectory to reach that includes a marked step up in performance in July 2017 to 90% as measured against the 4 hour standard which is equivalent to 50 fewer breaches a day. There are two improvement weeks planned, May 29<sup>th</sup> and June 19<sup>th</sup>. A Project Board chaired by the COO will ensure design, sign off of standards and an engagement plan to oversee the project. Work will include increasing capacity in ED through different use of space in May 2017.

The Committee received the report.

#### 8.1 Neutropenic Sepsis – process improvements

Verbal

Ms. Barlow updated the committee members on the process improvements for Neutropenic Sepsis. Unfortunately the triple bleep system doesn't seem to be working and the breech analysis is not being followed. It has now been agreed that a three point escalation needs to be followed. Ms. Barlow has asked for a weekly progress report to be sent to her from now on as we need compliance.

#### 9. 2016/17 clinical audit plan Q4 progress report

SWBQS (04/17) 008

Dr. Stedman gave an update on the progress of the 20 clinical audits that were included in the Clinical Audit Plan for 2016/17. The report also contained reports on the following audits that were carried out:

- Determine whether there is full compliance with all the WHO Safer Surgery requirements. The audit highlighted that although the steps of the WHO checklist are followed and that no surgical procedure commenced without the WHO Checklist being completed, the full team was not always in attendance for all of the steps included on the checklist. The audit also showed that further work is required to embed the additional processes of initial image check, positive image ID and image final check, an action that was in response to a Never Event.
- Confirm whether patients who present at the Trust with a retinal detachment are being managed. The data shows that the target window for urgent surgery (within 24hrs) is being met and that the primary success rate of 80.9% is comparable to published rates which range from 75-90%. Whilst the

clinical aspects of the service appear to be performing well, there are areas for improvement, particularly with regard to the quality and consistency of record keeping and in the improving the capture of follow up data on patients repatriated to neighbouring Trusts post-surgery. Once changes have been implemented, a re-audit will take place in 12 months time.

- Determine whether patients at the end of life are dying in a place of their choosing. The audit found that 74% of patients registered on the SWBH palliative care register died in their preferred place during the 6 month monitoring period. This figure improved each month with 84% of people dying in their preferred place during the final month of the audit.
- Confirm whether DNACPR decisions are being made according to Trust standards. The audit found that although in the sample of 126 cases reviewed the DNACPR decision was considered to be appropriate, Trust standards were not met in all cases. The main areas were not documenting in all cases the involvement of family or carers in decisions where a patient's capacity is lacking. Concerns were raised about the inadequate documentation and it was agreed that Miss Dhami would send audit data to Ms. Dutton for information. Members agreed that this should be a topic on the May agenda and the full audit should be circulated with the papers.

ACTION: DNACPR - Members agreed that the response to the audit findings should be a topic on the May agenda and the full audit should be circulated with the papers.

#### 10. Monthly Serious Incident report

SWBQS (03/17) 009

Miss Dhami updated the committee members on a recent SI that took place in Cardiology when a patient died unexpectedly during an elective percutaneous coronary intervention. The incident was reported 27 February 2017. The Lead Investigator and Clinical Director for the specialty discussed the timeline of events and important aspects for the investigation were identified on the 28 February 2017. The operating surgeon, scrub nurse, theatre runner and ward nurse who removed the dressing were individually interviewed between the 1 and 3 March 2017 by the Lead Investigator and Patient Safety Manager. The "Safe Surgery Policy" and proposed addition were reviewed. Unfortunately the investigation demonstrates an inconsistent practice in the CAT Lab.

Queries were raised from Miss Dutton about the robustness of the policy and SOP and whether it could have been identified as a risk. She was advised that changes have been made to elements of practice to improve on this. A copy of the full investigation report will be sent to her for information.

Also in response, the Royal College of Physicians or other similar body will test the robustness of our in-Laboratory checks and controls in interventional cardiology.

The Committee received the report.

#### 11. PALS and Complaints Report

SWBQS (03/17) 010

Miss Dhami updated the committee members on the Complaints and PALS report that outlined the enquiries received between January and March 2017(Quarter 4).

The report provides high level data on PALS and Complaints, the reasons those complaints were made and work underway to improve complaints management.

In this quarter, it is reported that the complaints activity has decreased, from 235 to 253, and also shows that 87% (81% year to date) of complaints have been managed within their target date. Themes and outcomes remain consistent with previous quarters and show a continued focus on lessons learned, and quality responses that are caring, transparent, timely and responsive to the needs of complainants. There have been no breaches this month and information on categories has been broken down further. Following a query from Ms. Parker, Miss Dhami confirmed that patients receive telephone calls and emails to try and sort before they are escalated

to a formal complaint.	
12. Meeting effectiveness	Verbal
The Committee was of the view the meeting had been effective and useful.	
13. Matters to raise to the Trust Board	Verbal
The Committee wished to bring the following matters to Trust Board's attention:	
<ul> <li>2016/17 Clinical Audit Plan: The findings of two recent local clinical audits raised concerns.</li> <li>In the sample of cases reviewed the DNACPR decision was considered to be appropriately appr</li></ul>	ment of the family or ot all members of the the requirements for
• Consistent reds on IPR data A response for dealing with the quality indicators that have consistently failed to meet the set is required speedily.	performance targets
<ul> <li>NG Tube PSA action plan         The Board is recommended to note the Trust's compliance with the PSA relating to NG Tube in Plan delivery will be monitored by the Q&amp;S Committee.     </li> <li>In response to the recent Serious Incident in Cardiology the Royal College of Physicians or of test the robustness of our in-Laboratory checks and controls in interventional cardiology.</li> </ul>	·
14. Any other business	Verbal
Nasogastric Tube Misplacement PSA – Dr. Stedman updated the group on the work that has take PSA alert: Nasogastric tube misplacement: continuing risk of death and severe harm was particulated and the actions are to be completed by 21 April 2017.  The action plan that was circulated showed progress to date and outlined the future at plans that are currently being implemented. Compliance with the requirements of the alert at the public May Trust Board.	oublished on 22 July ents receiving NHS-
Next meeting: 26 <sup>th</sup> May 2017 at 10.30h in the Anne Gibson Committee Room at City Hospital.	
Signed	
Print	
Date	



### Trust Board Public 1<sup>st</sup> June 2017

#### **Report of the Chief Executive**

The last month has seen the Trust maintain our recent improvement in respect of planned care volumes. This is a very encouraging step to reduce waiting list scale and also to move towards the income targets agreed by the Board. These move the Trust towards the funding model assumed in the Midland Metropolitan Business Case.

At the same time the organisation has satisfactorily managed the cyber-attack seen across Western Europe. There remains work to be done to improve security and this is described further in our private board papers. The IT team are to be congratulated on both the work done in 2016 which addressed our historic use of XP and the patching and other work done during the period of the attack. Other IT resilience issues continue to apply and these can be explored within the Board, notably in preparation for case-note scanning commencing from June 20<sup>th</sup> 2017.

#### 1. Patient care

The first week of June sees the Trust implement the latest phase of our improvement plan to reduce waits in emergency care. The Board has approved previously the recovery plan which has also been reviewed by the A&E delivery board for SWB. Key to that, in phase one, was changing professional standards within each ED. From Tuesday May 30<sup>th</sup> extended day support is in place in each ED to embed new ways of working. These approaches are, among other benefits, aiming to bring forward the decision to admit (DTA) to earlier in the patients' pathway. Team working and great clinical engagement will be critical to success. Meanwhile preparations are in hand for phase two which focuses on both changes in ambulatory care and altering the relationship between base wards and the AMU.

The Board will examine both our historic improvement actions around Never Events and the latest report from the Never Event reported earlier this week. Ajai Tyagi, as the accountable group director, will attend the Board to discuss in particular actions to ensure that 'stop before you block' protocols are adhered to within our theatres. The implementation of the action plan from this Never Event will be specifically overseen via the Theatres Management Board chaired by the Chief Operating Officer.

Improving patient care within the Trust is clearly the sum of a great number of actions and initiatives. The Board may wish to discuss progress with our safety plan, and at its next meeting to consider the out brief from the first months of our consistency of care project within medicine. This month we have seen changes in our bed base at Sandwell with the expansion of the older people's assessment unit, and co-location of the two AMUs. During June we see beds close at both City and

Sandwell to try and live within our funded bed base. At the same time the annex to my report shows progress on staffing recruitment to tackle our vacancies and use of temporary staffing.

In line with prior reports to the Board, June 1<sup>st</sup> marks our switch off date for Thornbury as a particular high cost agency. This date is chosen because it is also the moment when our rosters uploaded onto e-roster are due to comply with our quality standards. An oral summary of progress to that end will be provided to the Board. Approval for any further use of Thornbury will be on the Chief Executive only basis. We understand that Walsall Healthcare are implementing a similar change at the same time. Part of the purpose of the change is to alter enrolment behaviour among staff wishing to work for agencies to improve fill rates among our bank and lower rate agency suppliers. The changes made have the strong support of NHS Improvement.

In the upcoming few weeks we are making a series of further changes to strengthen the safety of our most acutely unwell patients. These changes flow from analysis of how we manage the care of deteriorating patients. Information reviewed by both the CLE safety committee and the Critical Care Board seems to suggest that the Trust has both comparatively good escalation practice within our base wards and good outcomes after arrest. However, we know from prior incidents that, for example, our care of patients requiring non-invasive ventilation could be improved. At the end of July a new unit will be opened on Priory 5 at Sandwell cohorting the care of ceiling patients for NIV. This was a key recommendation from prior safety incidents. Similarly over Q2, and reflecting audit data on our performance of abdomen surgery, we will open a surgical HDU within Priory 2. Both investments are reflected in our planned budget for the year. They reflect a continuation of our so-called 'big cuts, big investments' strategy designed to ensure funds are committed where they are most needed.

During June across our hospital wards we again plan to implement the changes to our focused care arrangements which we have already operated in our community wards. We expect these changes to form part of our expenditure reduction plans, but more pertinently to improve the quality of our patient's experience of care.

#### 2. Our workforce

We ended 2016-17 with some work to do to complete appraisals for all employees, even as we launch the Board and Trust's new appraisal and PDR system. Engagement with both processes has been good. The recent Leadership Conference was used to showcase the People Plan as a whole, and to highlight work on objective setting which underpins our new potential/performance PDR model – Aspiring to Excellence.

The Board at today's meeting considers the next phase of diversity pledges proposed for both staff and patients. This discussion takes place in the context of the Trust being shortlisted for an award for inclusion, and our first ever official 'entry' within LGBT Pride in Birmingham. Equally recruitment has now begun to support our commitment to have consistently ethnically diverse interview panels. The intent is that the staff related diversity commitments are tracked within the People Plan workstream, and therefore considered by the Board's Workforce and OD committee.

Sickness rates remain stubbornly above plan. A review of Q1 actions will take place within the executive with a view to further initiatives which might make a contribution. Of course this focus

starts from our duty of care to our employees. In so far as sickness reduction underpins our plans for finance this will be tracked via our work on agency reduction which is described in a specific board paper at the meeting.

We will consider orally the latest position in respect of redeployment for those affected by last year's statutory consultation and the imminent closure of health records. At the same time, the Trust will move to implement with more rigour our agreed policies on access to retiring and returning, and on pay protection after redeployment. The Board's attention is draw within the rostering paper to actions taken to address hours owed.

For the first time, the Board is being advised of material and important progress in the recruitment landscape for senior leaders and managers. In practice this means that within our Clinical Groups we have all roles either filled or at final advert stage. This is in addition to the two Deputy COOs who have now started in post. Only the group director of nursing for medicine role is behind pace, with Allison Binns having completed her secondment from her substantive governance role. She will return to post to lead work on incident management and patient experience around complaints. Chetan Varma has been recruited to the role of Group Director for Medicine, and the restructure of medicine to move some ambulatory focused disciplines into the community group has been completed. Sexual health will make that move from WCH in due course, with the changes in directorate structure in that area associated with the notice we served to cease the provision of centre level gynae-oncology from Q3. Taken together with the merger last year of surgery A and B, the Trust is moving to a leaner, more clinically led structure – but crucially with key posts substantively filled. I am asking the Workforce and OD committee to take oversight of the sufficiency and delivery of the agreed interventions to create a peer group at tier 2 level. We have agreed previously that management capacity, and capability, is the underlying delivery risk to the organisation, and I am encouraged by progress in the last three months, on which we must build.

From August the new junior doctor's contract begins to apply to the greater majority of our rotas. A report will go from our Guardian, Zoe Huish, to the upcoming and relevant Board committee. I am assured that we have in place the required arrangements for reporting and funding, and that the rotas proposed are compliant. At the same time work continues on the models for trainee rotas which we would expect to apply in Midland Met. Some elements of those changes, including rotation into acute medicine, are being piloted in coming months.

#### 3. Our partners

On May 23/24<sup>th</sup> we confirmed in public, and with our employees, the delay to the opening date of Midland Met. A revised start date of spring 2019 will apply. The engineering specific issue was clearly articulated, as was our commitment to ensuring that the taxpayer does not suffer adversely from this delay. We will explore with NHS Improvement the impact of this delay on our 2018-19 savings profile, which was obviously weighted to take account of the single site opportunity.

We are considering whether we are yet ready to pass through the latest Cerner Gateway en-route to EPR. As discussed with the Board last month a successful future state event has taken place. This has surfaced remaining process issues with the product vs. our current and future workflow. There is encouraging joint work to resolve these issues and to spread knowledge within the Trust of the

work needed to address this. The MPA remains the principle location by which the Board tracks our delivery plans for this major work-stream.

The Connected Palliative Care partnership has celebrated its first anniversary. And contract compliance is strong, with all sub-contractors also meeting aims. Volumes have risen and we will work with commissioners to examine the long term trajectory for service that this implies.

We have completed contract signature on our innovative Cooperative Working agreement with Sandwell MBC. This covers a range of children's and sexual health services, as well as some infection related teams. The joint board for this work is now established and we might expect the scope of service to grow in the months ahead. Like the CPC arrangement this is a multi-year endeavour designed to produce stability and reform. The uncertain nature of public health funding does, on the other hand, require that the scale of investment being made is annually reviewed.

#### 4. Our commissioners and regulators

We believe we remain on track to receive a CQC draft report during the early part of Q2. No notifications of any escalated action since the visit almost three months ago have been issued, which suggests that the initial oral feedback of positive improvement remains the emerging consensus.

Chairs and Chief Executives continue to work to resolve the funding issues which lie at the heart of our 2017-2019 contract dispute. Brokered work to review the finances of the health economy, including the bed base for Midland Met, starts in June and is expected to report in the latter part of July. Among other issues, this latter timeline is consistent with the delay to Midland Met, addressed above, under which some greater latitude will exist to look again at the use of the 9<sup>th</sup> floor space.

#### 5. Sustainability and Transformation Planning

The Black Country STP has had its first quarterly evaluation by NHSI and NHSE. Dale Bywater is the single named individual taking accountability for that oversight. The process has confirmed the leadership arrangements and has put forward proposed governance. These are discussed further in the private board's papers. More importantly, work continues to develop our shared pathology model, and the four Chief Executives have agreed an accelerated timetable for that project to reach OBC stage. After the completion of purdah, the role of STPs will undoubtedly continue to evolve. As previously outlined to the Board, there is some evidence in guidance of these structures taking on a more traditional 'SHA' type role in the management of basic national standards. Within our STP it is clear we need to manage intelligently which things are best done in aggregate at scale and which things merit the local place based approach operating differently four times within the wider system. In that context we continue to discuss with Local Authorities and the CCG the locus for SWB-wide discussions, with the abolition last year of the RCRH Board.

#### 6. Clinical Leadership Executive – May

In line with our governance review, I am specifically annotating the work of this committee in my report. The last meeting focused on digital readiness once again, as well as CIP delivery. A new sub committee to ensure good visibility of estate developments and changes has started work. I am reviewing with colleagues the work of the historic three committees which cover safety, quality and experience with the intent to streamline a single structure across the relevant areas of work and

directors. For a time limited period this is overseen via a QUOD meeting which I chair designed on a monthly basis to make sure that risk and safety issues are synthesised for priority actions at executive level. I will work further with the corporate office to create a standard reporting format for the CLE infrastructure to make its deliberations and decisions more readily accessible to board level colleagues. Our aim remains that most decisions are taken at group and directorate level, and aggregated via CLE – with the Board taking strategic oversight for the work done, through delivery of our 2020 vision and relevant pillar plans.

Toby Lewis – Chief Executive

May 25<sup>th</sup> 2017



TRUST BOARD								
DOCUMENT TITLE:	Safe staffing							
SPONSOR (EXECUTIVE DIRECTOR):	Elaine Newell –Chief Nurse							
AUTHOR:	Elaine Newell							
DATE OF MEETING:	1 <sup>st</sup> June 2017							

#### **EXECUTIVE SUMMARY:**

#### **April Summary**

The summary level data does not demonstrate any major variance month on month across this period. The average CHPPD for registered nurses across the trust is 4.8 hours which is consistent with the rolling 3 month average

The average fill rates across the trust for registered nurses, which includes permanent, bank and Agency staff for both day and night shifts has remained stable at 97.1% and 95.1% respectively. This slight underfill is offset by daytime fill rates for support staff at 102.4% and 103.7%. This is again consistent with previous month's figures.

#### **REPORT RECOMMENDATION:**

The Board are requested to receive this update and agree to publish the data on our public website.

#### **ACTION REQUIRED** (Indicate with x' the purpose that applies):

The receiving body is asked to receive, consider and:

Accept	Approve the reco	ommendation	Discuss						
х									
KEY AREAS OF IMPACT (Indicate with 'x' all those that apply):									
e: · · ·	F		. 0 . 4 . 1:						

	KEY AREAS OF IIVIPACT (Indicate	with .	x all those that apply):		
	Financial	Х	Environmental	Communications & Media	
	Business and market share		Legal & Policy	Patient Experience	Х
	Clinical		Equality and	Workforce	,
1	Lillical	X	Diversity		Х

#### Comments:

#### ALIGNMENT TO TRUST OBJECTIVES, RISK REGISTERS, BAF, STANDARDS AND PERFORMANCE METRICS:

#### PREVIOUS CONSIDERATION:

May Trust Board

				D	ay			Ni	ght		Ī				Care Hou	rs Per Patie	nt Day (CH	HPPD)
	s	afe Staffing Return Summary	_	stered s/nurses	Care	Staff	_	stered s/nurses	Care	Staff	D	lay	Ni	ght	Cumulative count over the		0	
Month	Site Code	s Site Name	Total monthly planned staff hours	Total monthly actual staff hours	Total monthly planned staff hours	Total monthly actual staff hours	Total monthly planned staff hours	Total monthly actual staff hours	Total monthly planned staff hours	Total monthly actual staff hours	Average fill rate - registered nurses/mid wives (%)	Average fill	Average fill rate - registered nurses/mid wives (%)	Average fill	month of patients at 23:59 each day	d midwives / nurses	Care Staff	Overal
Jul-14	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	2138		526		414	500		18		100.2%	120.8%	0.0%				
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	Ü	0		0	0	0	0	0.070	0.0%	0.0%	0.0%				
	RXK02	CITY HOSPITAL	25676				-			8503		109.5%	123.3%	123.1%				
	RXK10	ROWLEY REGIS HOSPITAL	2826		4417			1985		2085		103.2%	159.7%	116.6%				
	RXK01	SANDWELL GENERAL HOSPITAL	30666							13232		115.1%	119.1%	150.1%				
	Total		61305												4			
Aug-14	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)			497					28		95.6%	118.7%	0.0%	4			
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	_	0	0			0		0.0.0	0.0%	0.0%	0.0%	4			
	RXK02	CITY HOSPITAL	24155				-	16362		8233		106.4%	117.2%	120.0%	-			
	RXK10 RXK01	ROWLEY REGIS HOSPITAL SANDWELL GENERAL HOSPITAL	2964 28245	3200 29172	3816 16759		1176 14679	1794 16520		1860 11384		103.2% 114.5%	152.6% 112.5%	119.8% 143.5%	-			
	Total	SANDWELL GENERAL HOSPITAL	57202		34879			35236	16343			109.8%	116.3%	131.6%	ł			
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	2137	2080	454					119		104.5%	112.8%	0.0%	1			
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0		434	4/3		0	0			0.0%	0.0%	0.0%	†			
Sep-14	RXK02	CITY HOSPITAL	24208	Ū	Ŭ	Ū		20283		10406		120.8%	144.9%	153.2%	•			
5cp 1.	RXK10	ROWLEY REGIS HOSPITAL	1274		1216			1185		756		113.6%	294.4%	128.9%				
	RXK01	SANDWELL GENERAL HOSPITAL	27883	32528	16822	23743				15185		141.1%	137.3%	205.4%				
	Total		55501	63684	32800	42877	29521	42124							i			
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	2199		546.75							100.3%	119.4%	0.0%	Ĭ			
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0		0	0	0		0	0		0.0%	0.0%	0.0%				
Oct-14	RXK02	CITY HOSPITAL	25273	27384.5	14779.5	15814.42	14038.5	16711.07	6797	8913.5	108.4%	107.0%	119.0%	131.1%				
	RXK10	ROWLEY REGIS HOSPITAL	3308	3480.067	3886.5	4283.25	1230	1876.5	1590	2006	105.2%	110.2%	152.6%	126.2%				
	RXK01	SANDWELL GENERAL HOSPITAL	31768.25	33296.75	19265.22	21818.3	16182.5	19034.25	8175	11998.83	104.8%	113.3%	117.6%	146.8%				
	Total		62548		38478			38141	16562						į.			
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	2082.5	2122.167	569.75	590.9167	490.25			55.75		103.7%	101.9%	0.0%				
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	0	0	- v	Ū		0	0	0.0%	0.0%	0.0%	0.0%				
Nov-14	RXK02	CITY HOSPITAL	26188.75									99.3%	108.4%	117.3%	į.			
	RXK10	ROWLEY REGIS HOSPITAL	3040.5		3894			1463		1800		95.6%	112.0%	119.1%	A			
	RXK01	SANDWELL GENERAL HOSPITAL	29371						7733			109.2%	111.6%	143.8%	ł			
	Total	DIDMINIOLIAM MIDLAND EVE OFNITDE (DMEO)	60683		37751	39171	32300	35535					110.0%		<u> </u>			
	RXK03 RXKTC	BIRMINGHAM MIDLAND EYE CENTRE (BMEC) BIRMINGHAM TREATMENT CENTRE			554		-	465.5 0	0	139.25		85.1%	89.9%	0.0%				
Dec-14	RXK02	CITY HOSPITAL	00007.75	26839.52	15860.5		Ū			7930	0.070	0.0% 100.1%	0.0% 106.9%	0.0%	ı			
Dec-14	RXK10	ROWLEY REGIS HOSPITAL	3280					1255.5		1622.5		97.8%	99.4%	112.6% 108.1%	4			
	RXK01	SANDWELL GENERAL HOSPITAL		30848.75								108.8%	104.5%	127.1%				
	Total	GANDWELL GENETIAL HOOF TIAL	62288	62535	37871	39288	34130	35906		20082			105.2%	120.1%	i			
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)			505.5					157.5		97.4%	95.2%	121.6%	İ			
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0			0			0	0	0.0%	0.0%	0.0%	0.0%				
Jan-15	RXK02	CITY HOSPITAL	30328.5	30574.63	15962.5	15937.82	18989.5	20653.42	7731	8767.25		99.8%	108.8%	113.4%				
	RXK10	ROWLEY REGIS HOSPITAL	2919		3472.5		1333	1558.5		1542.25		98.2%	116.9%	107.9%				
	RXK01	SANDWELL GENERAL HOSPITAL	29286.5	30702.12				18341	8455			112.9%	110.7%	137.9%				
			64657	66688	37550	39725	37467	41108	17745	22127	103.1%	105.8%	109.7%	124.7%	í			
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	1867.25	2053.5	464.5	462	490.25	518	129.5	101.75	110.0%	99.5%	105.7%	78.6%				
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	_	-			0	0	0	0.0%	0.0%	0.0%	0.0%	l e			
Feb-15	RXK02	CITY HOSPITAL		27677.75								100.5%	104.5%	107.2%	1			
	RXK10	ROWLEY REGIS HOSPITAL	2542				1194.5			1407		106.2%	99.8%	96.5%				
	RXK01	SANDWELL GENERAL HOSPITAL	25298.5		14521.5			16798				111.8%	114.1%	135.3%	l .			
	D)///00		57098		32531	34509		36702							4			
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	2353.25		501.5		-			139.5		89.1%	98.6%	94.3%	4			
Mar 15	RXKTC	BIRMINGHAM TREATMENT CENTRE	00000 70	0 20744 15		15515.00		0	7507.5	7750	0.0%	0.0%	0.0%	0.0%	4			
Mar-15	RXK02	CITY HOSPITAL		30744.15		15515.32						92.8%	113.2%	103.3%	4			
	RXK10	ROWLEY REGIS HOSPITAL	2702.5	3084.9	3546./5	3896.583	1211.5	1717.75	1670.5	2067	114.1%	109.9%	141.8%	123.7%	J			

Overall

	RXK01	SANDWELL GENERAL HOSPITAL	28133.5			17373.25				10975.02	107.9%	108.7%	126.0%	141.4%
			63013	66547	36765	37232	36450	43566	17087	20934	105.6%	101.3%	119.5%	122.5%
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	1502	1941	305.5		444	536.5	92.5		129.2%	129.7%	120.8%	110.0%
Anr 1E	RXKTC	BIRMINGHAM TREATMENT CENTRE CITY HOSPITAL	30171.5	01770 00	0 16684	0 15468.25	10010 5	00001.75	7005 5	8325	0.0%	0.0%	0.0%	0.0%
Apr-15	RXK02 RXK10	ROWLEY REGIS HOSPITAL	2614	31776.33 2568.5	3772		18810.5 1116.5	20221.75 1351.5	7285.5 1763	1778	105.3% 98.3%	92.7% 91.4%	107.5% 121.0%	100.9%
	RXK01	SANDWELL GENERAL HOSPITAL	27100	29153.3			16443.5		7508	10431.5	107.6%	110.2%	112.2%	138.9%
	1000	ON THE VELL GENERAL TIOUR THE	61388	65439	36612	36773	36815	40555	16649	20636	106.6%	100.4%	110.2%	123.9%
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	2034.5	1941	434	402.25	573.5	527.25	138.75	138.75	95.4%	92.7%	91.9%	100.0%
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	0	0		0	0	0	0	0.0%	0.0%	0.0%	0.0%
May-15	RXK02	CITY HOSPITAL	32094.5	32675.33			19465	21176.25	7493	8437	101.8%	96.6%	108.8%	112.6%
	RXK10 RXK01	ROWLEY REGIS HOSPITAL	2645.5	2576.067 27802.15		3169.083 17242.17	1083.5	1475.067	1842.5 8199.5	2033 10655	97.4%	90.3%	136.1%	110.3% 129.9%
	HANUI	SANDWELL GENERAL HOSPITAL	26561 <b>63336</b>	64995	36356		16839 <b>37961</b>	17383.17 40562	17674	21264	104.7% 102.6%	110.6% 102.0%	103.2% 106.9%	120.3%
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	2276.25	2172.167	419		555	527.25	166.5	184.75	95.4%	101.7%	95.0%	111.0%
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0.22	0	0	0	000	027.20	0.00	0	0.0%	0.0%	0.0%	0.0%
Jun-15	RXK02	CITY HOSPITAL	28309.5	29468.17	15410.18		18281	19637.77	6748.5	·	104.1%	95.8%	107.4%	111.2%
Juli 15	RXK10	ROWLEY REGIS HOSPITAL	2442	2374.75	3676.5	3263	1302.5	1494	1587	1916.5	97.2%	88.8%	114.7%	120.8%
	RXK01	SANDWELL GENERAL HOSPITAL	26826	28578.08		17366.28	15139.5		8432.5	10183	106.5%	111.9%	113.8%	120.8%
	ITANUT	SANDWELE GENERAL HOSI HAE	59854	62593	35022	35811	35278	38882	16935	19789	104.6%	102.3%	110.2%	116.9%
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	930	1951.583	465	512.75	589	555	0	166.5	209.8%	110.3%	94.2%	0.0%
	RXKTC	BIRMINGHAM TREATMENT CENTRE	000	0	0		000	0	0	0	0.0%	0.0%	0.0%	0.0%
Jul-15	RXK02	CITY HOSPITAL	32069.5	27187.57	13190.5		27450.5	19260.02	8199.5		84.8%	99.6%	70.2%	92.9%
	RXK10	ROWLEY REGIS HOSPITAL	3208	2495	3565		2139	1486.75	2495.5	1923	77.8%	83.3%	69.5%	77.1%
	RXK01	SANDWELL GENERAL HOSPITAL	30178.5	26279.73	15686		23885.5	17973.25	11764.5		87.1%	97.1%	75.2%	96.4%
	TIXINOT	DANDWELL GENETIAL HOOF TIAL	66386	57914	32907	31854	54064	39275	22460		87.2%	96.8%	72.6%	93.7%
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	930	806	465	370.75	573	518.25	0	171	86.7%	79.7%	90.4%	0.0%
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	0	0	0	0	0	0	0	0.0%	0.0%	0.0%	0.0%
Aug-15	RXK02	CITY HOSPITAL	31861.5	24502		11459.75	27419.5	18006.17	7843	7162.517	76.9%	87.1%	65.7%	91.3%
-	RXK10	ROWLEY REGIS HOSPITAL	3208.5	2431.5	3565		2139	1589.75	2495.5	2150.5	75.8%	87.2%	74.3%	86.2%
	RXK01	SANDWELL GENERAL HOSPITAL	29192	24223	14735.5	15146	22765.5	17481.07	11251	11176.75	83.0%	102.8%	76.8%	99.3%
			65192	51963	31924	30085	52897	37595	21590	20661	79.7%	94.2%	71.1%	95.7%
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	900	935	450	378.5	555	472	166.5	194.75	103.9%	84.1%	85.0%	117.0%
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	0	0	0	0	0	0	0	0.0%	0.0%	0.0%	0.0%
Sep-15	RXK02	CITY HOSPITAL	28394	26595.9	11679	13003.83	24495	20277.5	7651	7903	93.7%	111.3%	82.8%	103.3%
	RXK10	ROWLEY REGIS HOSPITAL	3105	2663	3450	3364.5	2070	1881.25	2415	2336	85.8%	97.5%	90.9%	96.7%
	RXK01	SANDWELL GENERAL HOSPITAL	27587	25604	14651	16277.83	21016	18495	11561.5	11814.52	92.8%	111.1%	88.0%	102.2%
			59986	55798	30230	33025	48136	41126	21794	22248	93.0%	109.2%	85.4%	102.1%
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	930	969.3333	465	344.75	573.5	536.75	157.25	178.25	104.2%	74.1%	93.6%	113.4%
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	0	0	0	0	0	0	0	0.0%	0.0%	0.0%	0.0%
Oct-15	RXK02	CITY HOSPITAL	30986	34295.28	13485.5	16855.07	26737.5	28120.5	8215	10881.25	110.7%	125.0%	105.2%	132.5%
	RXK10	ROWLEY REGIS HOSPITAL	3208.5	3267.667	3565	3678	2139	2590.25	2495.5	2913.5	101.8%	103.2%	121.1%	116.8%
	RXK01	SANDWELL GENERAL HOSPITAL	27183.5	30355.55	15523.5	21546.75	21761	24224.5	10848	16673.5	111.7%	138.8%	111.3%	153.7%
			62308	68888	33039	42425	51211	55472	21716	30647	110.6%	128.4%	108.3%	141.1%
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	435	435	217	191	536	536	157	138	104.2%	74.1%	93.6%	113.4%
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	0	0	0	0	0	0	0	0.0%	0.0%	0.0%	0.0%
Nov-15	RXK02	CITY HOSPITAL	24755	23194	9789	9919	22694	21079	7217	7434	110.7%	125.0%	105.2%	132.5%
	RXK10	ROWLEY REGIS HOSPITAL	2738	2309	1738	1837	1826	1871	1493	1446	101.8%	103.2%	121.1%	116.8%
	RXK01	SANDWELL GENERAL HOSPITAL	24276	23016	12497	12096	20417	19181	10173	9660	111.7%	138.8%	111.3%	153.7%
	DVIII		52204	48954	24241	24043	45473	42667	19040	18678	93.8%	99.2%	93.8%	98.1%
	RXK03 RXKTC	BIRMINGHAM MIDLAND EYE CENTRE (BMEC) BIRMINGHAM TREATMENT CENTRE	465 0	450 0	232	195 0	573 0	545 0	185 0	148 0	96.8%	84.1% 0.0%	95.1% 0.0%	80.0% 0.0%
Dec-15	RXK02	CITY HOSPITAL	28783	27400	12089	11327	27170	24752	9454	8471	95.2%	93.7%	91.1%	89.6%
200 13	RXK10	ROWLEY REGIS HOSPITAL	3044	2561	1975	2027	2030	2007	1689	1586	84.1%	102.6%	98.9%	93.9%
	RXK01	SANDWELL GENERAL HOSPITAL	26109	24203	13225	12669	21872	20396	10342	10095	92.7%	95.8%	93.3%	97.6%
			58401	54614	27521	26218	51645	47700	21670	20300	93.5%	95.3%	92.4%	93.7%
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	465	465	232	198	573	564	148	148	100.0%	85.3%	98.4%	100.0%

	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	0	0	0	0	0	0	0	0.0%	0.0%	0.0%	0.0%	1			
Jan-16	RXK02	CITY HOSPITAL	26001	24220	10586	9949	24291	23361	8611	7795	93.2%	94.0%	96.2%	90.5%	•			
	RXK10	ROWLEY REGIS HOSPITAL	2867	2417	1798	1775	1912	1888	1235	1223	84.3%	98.7%	98.7%	99.0%	•			
	RXK01	SANDWELL GENERAL HOSPITAL	25861	24488	12914	12728	21731	20994	10454	10439	94.7%	98.6%	96.6%	99.9%	1			
			55194	51590	25530	24650	48507	46807	20448	19605	93.5%	96.6%	96.5%	95.9%	1			
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	420	420	210	195	518	518	148	148	100.0%	92.9%	100.0%	100.0%	•			
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	0	0	0	0	0	0	0	0.0%	0.0%	0.0%	0.0%	•			
Feb-16	RXK02	CITY HOSPITAL	27047	25992	11249	10768	25705	24916	8501	8412	96.1%	95.7%	96.9%	99.0%	•			
	RXK10	ROWLEY REGIS HOSPITAL	3906	3279	3664	3960	2604	2557	2779	3098	83.9%	108.1%	98.2%	111.5%	1			
	RXK01	SANDWELL GENERAL HOSPITAL	25483 56856	23052 52743	12166 27289	12244	21532 50359	19958 47949	9856 <b>2128</b> 4	9788 21446	90.5% 92.8%	100.6% 99.6%	92.7% 95.2%	99.3% 100.8%	1			
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	555	465	27269	27167 221	462	573	157	194	83.8%	79.8%	124.0%	123.6%	•			
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	0	0	0	0	0	0	0	0.0%	0.0%	0.0%	0.0%	•			
Mar-16	RXK02	CITY HOSPITAL	24357	27553	10043	11106	22770	26280	7890	8653	113.1%	110.6%	115.4%	109.7%	1			
	RXK10	ROWLEY REGIS HOSPITAL	3936	3194	4367	4836	2625	2530	3224	3693	81.1%	110.7%	96.4%	114.5%	•			
	RXK01	SANDWELL GENERAL HOSPITAL	28158	25581	13813	13543	23643	21025	10958	10617	90.8%	98.0%	88.9%	96.9%	1			
			57006	56793	28500	29706	49500	50408	22229	23157	99.6%	104.2%	101.8%	104.2%	1			
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	450	457	225	206	555	555	148	175	101.6%	91.6%	100.0%	118.2%	1			
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	0	0	0	0	0	0	0	0.0%	0.0%	0.0%	0.0%	•			
Apr-16	RXK02	CITY HOSPITAL	28863	27928	11830	10759	27267	25879	9244	8557	96.8%	90.9%	94.9%	92.6%	1			
	RXK10	ROWLEY REGIS HOSPITAL	4185	3631	4702	5260	2790	2754	3417	3881	86.8%	111.9%	98.7%	113.6%	1			
	RXK01	SANDWELL GENERAL HOSPITAL	27066	24907	13360	13080	21663	20686	10532	10611	92.0%	97.9%	95.5%	100.8%	1			
	D)///cee		60564	56923	30117	29305	52275	49874	23341	23224	94.0%	97.3%	95.4%	99.5%				
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	435	435	217	195	536	536	166	185	100.0%	89.9%	100.0%	111.4%	192	5.1	2.0	7.0
May-16	RXKTC RXK02	BIRMINGHAM TREATMENT CENTRE CITY HOSPITAL	0 29134	0 29287	0 11975	0 11748	0 27549	0 27239	9115	0 8696	0.0% 100.5%	0.0%	0.0%	0.0%	0 8856	C 4	0.0	8.7
iviay-10	RXK10	ROWLEY REGIS HOSPITAL	4323	3879	4858	5417	2883	2871	3605	4005	89.7%	98.1% 111.5%	98.9% 99.6%	95.4% 111.1%	2624	6.4 2.6	2.3 3.6	6.2
	RXK01	SANDWELL GENERAL HOSPITAL	28077	26369	14260	13294	22336	21643	10737	10506	93.9%	93.2%	96.9%	97.8%	9535	5.0	2.5	7.5
	TIXITOT	DANDWELL GENETIAL HOOF HAL	61969	59970	31310	30654	53304	52289	23623	23392	96.8%	97.9%	98.1%	99.0%		5.3	2.5	7.8
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	450	453	225	198	555	555	166	138	100.7%	88.0%	100.0%	83.1%	135	7.5	2.5	10.0
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	0	0	0	0	0	0	0	0.0%	0.0%	0.0%	0.0%	0			
Jun-16	RXK02	CITY HOSPITAL	28741	27744	12036	11512	27323	25997	9142	8558	96.5%	95.6%	95.1%	93.6%	8704	6.2	2.3	8.5
	RXK10	ROWLEY REGIS HOSPITAL	4144	3873	4656	4953	2790	2801	3495	3805	93.5%	106.4%	100.4%	108.9%	2222	3.0	3.9	6.9
	RXK01	SANDWELL GENERAL HOSPITAL	26756	25382	13609	13418	21064	20441	10916	10982	94.9%	98.6%	97.0%	100.6%	9235	5.0	2.6	7.6
			60091	57452	30526	30081	51732	49794	23719	23483	95.6%	98.5%	96.3%	99.0%	20296			
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	465	465	232	232	573	573	148	148	100.0%	100.0%	100.0%	100.0%	228	4.6	1.7	6.2
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	0	0	0	0	0	0	0	0.0%	0.0%	0.0%	0.0%	0			
Jul-16	RXK02	CITY HOSPITAL	29688	29249	12664	12068	28090	27187	9242	8886	98.5%	95.3%	96.8%	96.1%	9155	6.2	2.3	8.5
	RXK10	ROWLEY REGIS HOSPITAL	4242	3762	5170	5197	3500	3465	3455	3540	88.7%	100.5%	99.0%	102.5%	2178	3.3	4.0	7.3
	RXK01	SANDWELL GENERAL HOSPITAL	27279	25652 59128	14225 32291	14196 <b>31693</b>	21640 <b>53803</b>	20847 <b>52072</b>	11353 24198	11587 24161	94.0% 95.9%	99.8%	96.3%	102.1% 99.8%	9872 21433	4.7	2.6	7.3
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	61674 465	465	232	221	573	52072	175	175	100.0%	98.1% 95.3%	96.8% 100.0%	100.0%	21433	4.6	11	6.3
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	0	232	0	0	0	0	0	0.0%	0.0%	0.0%	0.0%	0	4.0	1.7	0.3
Aug-16	RXK02	CITY HOSPITAL	29313	27693	12062	12037	27582	25849	8198	8735	94.5%	99.8%	93.7%	106.6%	9155	5.8	2.3	8.1
Aug 10	RXK10	ROWLEY REGIS HOSPITAL	3967	3395	4972	4965	3439	3310	3067	3079	85.6%	99.9%	96.2%	100.4%	2178	3.1	3.7	6.8
	RXK01	SANDWELL GENERAL HOSPITAL	25853	25600	20636	14598	21640	20464	11640	12846	99.0%	70.7%	94.6%	110.4%	9872	4.7	2.8	7.4
			59598	57153	37902	31821	53234	50196	23080	24835	95.9%	84.0%	94.3%	107.6%	21433	18		29
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	450	476	225	195	555	555	157	222	105.8%	86.7%	100.0%	141.4%	174	5.9	2.4	8.3
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	0	0	0	0	0	0	0	0.0%	0.0%	0.0%	0.0%	0			
Sep-16	RXK02	CITY HOSPITAL	29457	28063	12304	12574	27112	25549	8197	8677	95.3%	102.2%	94.2%	105.9%	9026	5.9	2.4	8.3
	RXK10	ROWLEY REGIS HOSPITAL	3028	2638	3851	3963	2773	2726	2426	2426	87.1%	102.9%	98.3%	100.0%	1852	2.9	3.4	6.3
	RXK01	SANDWELL GENERAL HOSPITAL	26309	25107	13815	14727	20919	19649	11129	12282	95.4%	106.6%	93.9%	110.4%	9236	4.8	2.9	7.8
			59244	56284	30195	31459	51359	48479	21909	23607	95.0%	104.2%	94.4%	107.8%	20288	20		31
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	465	446	232	217	573	573	157	120	95.9%	93.5%	100.0%	76.4%	144	7.1	2.3	9.4
0	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	0	0	0	0	0	0	0	0.0%	0.0%	0.0%	0.0%	0	0.0		0.0
Oct-16	RXK02	CITY HOSPITAL	32594	31145	15120	15025	28558	26663	9885	10501	95.6%	99.4%	93.4%	106.2%	9327	6.2	2.7	8.9
	RXK10 RXK01	ROWLEY REGIS HOSPITAL SANDWELL GENERAL HOSPITAL	2219 28494	2103 27372	2656 14486	2717 16860	2744 22514	1844 21304	2560 12135	2536 13988	94.8% 96.1%	102.3% 116.4%	67.2% 94.6%	99.1% 115.3%	2262 10266	1.7 4.7	2.3 3.0	4.1 7.7
	INVINI	DANDWELL GENERAL MUSTIFAL	63772	61066	32494	34819	54389	50384	24737	27145	96.1%	107.2%	94.6%	109.7%	21999	4.7		30
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	450	442	225	210	555	545	166	148	98.2%	93.3%	98.2%	89.2%	557	1.8	0.6	2.4
	RXKTC	BIRMINGHAM TREATMENT CENTRE	450	0	0	0 Z 10	000	0	0	0	0.0%	0.0%	0.0%	0.0%	0	1.0	0.0	۵.4
Nov-16	RXK02	CITY HOSPITAL	31002	30282	13483	13765	27240	25886	8953	9971	97.7%	102.1%	95.0%	111.4%	8630	6.5	2.8	9.3
			5.00L	55252	. 5 100	.0700	_, _¬	_55555	3000	3071	J /0	. 52.176	33.370		0000	5.5	0	0.0

	RXK10	ROWLEY REGIS HOSPITAL	3382	3220	4072	4197	3874	3257	2981	2957	95.2%	103.1%	84.1%	99.2%	808	8.0	8.9	16.9
	RXK01	SANDWELL GENERAL HOSPITAL	27689	27013	14098	15959	21701	21057	11727	13140	97.6%	113.2%	97.0%	112.0%	7341	6.5	4.0	10.5
			62523	60957	31878	34131	53370	50745	23827	26216	97.5%	107.1%	95.1%	110.0%	17336	23	16	39
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	465	465	232	202	573	573	157	138	100.0%	87.1%	100.0%	87.9%	188	5.5	1.8	7.3
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	0	0	0	0	0	0	0	0.0%	0.0%	0.0%	0.0%	0			
Dec-16	RXK02	CITY HOSPITAL	31106	30016	13528	12482	27055	26094	8854	8909	96.5%	92.3%	96.4%	100.6%	8615	6.5	2.5	9.0
	RXK10	ROWLEY REGIS HOSPITAL	3242	3102	3941	4041	3456	2845	2830	2890	95.7%	102.5%	82.3%	102.1%	2679	2.2	2.6	4.8
	RXK01	SANDWELL GENERAL HOSPITAL	28559	27573	14815	15907	22509	21876	12260	13625	96.5%	107.4%	97.2%	111.1%	10387	4.8	2.8	7.6
			63372	61156	32516	32632	53593	51388	24101	25562	96.5%	100.4%	95.9%	106.1%	21869	19	10	29
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	322	356	217	210	536	536	37	37	110.6%	96.8%	100.0%	100.0%	180	5.0	1.4	6.3
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	0	0	0	0	0	0	0	0.0%	0.0%	0.0%	0.0%	0			
Jan-17	RXK02	CITY HOSPITAL	31579	31020	13938	13564	27429	26766	8904	9225	98.2%	97.3%	97.6%	103.6%	9215	6.3	2.5	8.7
	RXK10	ROWLEY REGIS HOSPITAL	2924	3101	3578	4062	3168	2880	2614	2998	106.1%	113.5%	90.9%	114.7%	2607	2.3	2.7	5.0
	RXK01	SANDWELL GENERAL HOSPITAL	28919	27969	14877	17262	22491	22021	12307	14590	96.7%	116.0%	97.9%	118.6%	10304	4.9	3.1	7.9
			63744	62446	32610	35098	53624	52203	23862	26850	98.0%	107.6%	97.4%	112.5%	22306	18	10	28
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	270	315	210	191	518	481	0	46	116.7%	91.0%	92.9%	#DIV/0!	175	4.5	1.4	5.9
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	0	0	0	0	0	0	0	0.0%	0.0%	0.0%	0.0%	0			
Feb-17	RXK02	CITY HOSPITAL	27838	27199	13363	13030	24460	23721	8831	9138	97.7%	97.5%	97.0%	103.5%	8319	6.1	2.7	8.8
	RXK10	ROWLEY REGIS HOSPITAL	2852	2816	3409	3694	3110	2722	2512	2655	98.7%	108.4%	87.5%	105.7%	2242	2.5	2.8	5.3
	RXK01	SANDWELL GENERAL HOSPITAL	26276	25767	13759	15260	19922	19628	12317	13527	98.1%	110.9%	98.5%	109.8%	9359	4.9	3.1	7.9
			57236	56097	30741	32175	48010	46552	23660	25366	98.0%	104.7%	97.0%	107.2%	20095	18	10	28
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	1361	1521	945	615	1642	1430	356	525	111.8%	65.1%	87.1%	147.5%	207	14.3	5.5	19.8
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	0	0	0	0	0	0	0	0.0%	0.0%	0.0%	0.0%	0			
Mar-17	RXK02	CITY HOSPITAL	27241	26683	13748	13163	24777	23662	10047	9645	98.0%	95.7%	95.5%	96.0%	9536	5.3	2.4	7.7
	RXK10	ROWLEY REGIS HOSPITAL	3239	3038	3947	4107	3588	3072	3340	3328	93.8%	104.1%	85.6%	99.6%	2420	2.5	3.1	5.6
	RXK01	SANDWELL GENERAL HOSPITAL	23762	23020	13865	15342	18052	17437	12492	13552	96.9%	110.7%	96.6%	108.5%	9625	4.2	3.0	7.2
			55603	54262	32505	33227	48059	45601	26235	27050	97.6%	102.2%	94.9%	103.1%	21788	26	14	40
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	1335	1416	915	648	1590	1541	345	363	106.1%	70.8%	96.9%	105.2%	210	14.1	4.8	18.9
	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	0	0	0	0	0	0	0	0.0%	0.0%	0.0%	0.0%	0			
Apr-17	RXK02	CITY HOSPITAL	28695	27561	13723	13252	26964	24779	9890	9750	96.0%	96.6%	91.9%	98.6%	9329	5.6	2.5	8.1
	RXK10	ROWLEY REGIS HOSPITAL	3144	2958	3855	4022	2820	2460	3885	3897	94.1%	104.3%	87.2%	100.3%	2274	2.4	3.5	5.9
	RXK01	SANDWELL GENERAL HOSPITAL	23021	21873	13713	14464	17400	16747	12336	12769	95.0%	105.5%	96.2%	103.5%	9569	4.0	2.8	6.9
			56195	53808	32206	32386	48774	45527	26456	26779	95.8%	100.6%	93.3%	101.2%	21382	26		40
	RXK03	BIRMINGHAM MIDLAND EYE CENTRE (BMEC)	651	731	457	339	899	816	131	203	112.2%	74.1%	90.8%	154.7%	187	8.3	2.9	11.1
3-month	RXKTC	BIRMINGHAM TREATMENT CENTRE	0	0	0	0	0	0	0	0	0.0%	0.0%	0.0%	0.0%	0	#DIV/0!	#DIV/0!	#DIV/0!
Avges	RXK02	CITY HOSPITAL	28886	28301	13683	13252	25555	24716	9261	9336	98.0%	96.9%	96.7%	100.8%	9023	5.9	2.5	8.4
Avyes	RXK10	ROWLEY REGIS HOSPITAL	3005	2985	3645	3954	3289	2891	2822	2994	99.3%	108.5%	87.9%	106.1%	2423	2.4	2.9	5.3
	RXK01	SANDWELL GENERAL HOSPITAL	26319	25585	14167	15955	20155	19695	12372	13890	97.2%	112.6%	97.7%	112.3%	9763	4.6	3.1	7.7
	Total	Latest 3 month average===>	56345	54722	31817	32596	48281	45893	25450	26398	97.1%	102.4%	95.1%	103.7%	21088	4.8	2.8	7.6

#### Recruitment Activity Report

Rep	Report Date: 19/05/2017  Criteria					_	-								
	Criteria	Measu	re/Month	Ad	ctual	Confirmed	I start dates				Fore	ecast			
				Apr-17	May-17	Jun-17	Jul-17	Aug-17	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18
		FTE Establish		969.47	972.39	1010.34	1033.64	1033.64	1033.64	1033.64	1033.64	1033.64	1033.64	1033.64	1033.64
	SIP	FTE FTE In Po		830.10 5.83	820.97 1.97	815.65 4.93	818.58 5.53	813.76 8.22	811.63 51.00	852.28 7.62	849.55 7.62	846.82 7.62	844.09 54.00	887.74 22.62	900.01
Band 5 Nurses	SIF	FTE Leavers	C13	15.43	7.29	2.00	10.35	10.35	10.35	10.35	10.35	10.35	10.35	10.35	7.62 10.35
Dana 5 Nai 303			in month	139.37	151.42	194.69	215.06	219.88	222.01	181.36	184.09	186.82	189.55	145.90	133.63
	Offers External Applicants	FTE Condition	al offers (in month)	5.60	8.04										
	Offers External Applicants		nfirmed (in month)	3.00	6.93										
		FTE Establish		572.09	576.36	576.36	576.36	576.36	576.36	576.36	576.36	576.36	576.36	576.36	576.36
		FTE FTE In Po		527.99	530.10	530.63	534.43	531.18	531.65	532.13	532.60	533.08	533.56	534.03	534.51
D 1011	SIP	FTE New Start	ers	2.93	2.45 1.92	3.80	0.00	3.73 3.25	3.73	3.73	3.73	3.73	3.73	3.73 3.25	3.73
Band 6 Nurses		FTE Leavers FTE Vacancies	in month	1.00		0.00	3.25		3.25	3.25	3.25	3.25	3.25		3.25
			in month al offers (in month)	44.10 9.80	46.26 2.60	45.73	41.93	45.18	44.71	44.23	43.76	43.28	42.80	42.33	41.85
	Offers External/Internal Applicants		nfirmed (in month)	2.00	1.72			<b></b>		<b></b>			<b></b>		
		FTE Establish		8.25	8.25	8.25	8.25	8.25	8.25	8.25	8.25	8.25	8.25	8.25	8.25
		FTE FTE In Po		28.08	28.08	28.88	25.16	22.68	22.10	21.51	22.92	23.54	21.12	21.54	21.94
	SIP	FTE New Start	ers	0.00	0.80	1.00	0.00	2.10	2.10	2.10	2.10	2.10	2.10	2.10	2.10
<b>Band 5 Midwives</b>		FTE Leavers		0.00	0.00	4.72	2.48	2.68	2.68	0.69	1.48	4.52	1.68	1.69	1.69
			in month	-19.83	-19.83	-20.63	-16.91	-14.43	-13.85	-13.26	-14.67	-15.29	-12.87	-13.29	-13.69
	Offers External Applicants		al offers (in month)	0.00	0.00		ļ				<b>.</b>				
		FTE Offers Co	nfirmed (in month)	0.00	1.80	400.00	100.00	400.00	100.00	400.00	400.00	400.00	400.00	100.00	400.00
		FTE FTE In Po		183.80 130.67	184.30 129.59	183.80 128.78	183.80 124.06	183.80 122.80	183.80 122.59	183.80 122.38	183.80 122.17	183.80 121.96	183.80 121.76	183.80 121.55	183.80 121.34
	SIP	FTE New Start		0.00	0.00	0.00	0.00	1.05	1.05	1.05	1.05	1.05	1.05	1.05	1.05
Band 6 Midwives	OII	FTE Leavers		0.00	0.81	4.72	1.26	1.26	1.26	1.26	1.26	1.26	1.26	1.26	1.26
		harman and harman and an income	in month	53.13	54.71	55.02	59.74	61.00	61.21	61.42	61.63	61.84	62.04	62.25	62.46
	Offers External/Internal Applicants		al offers (in month)	1.00	1.00		1								
	Offers External/Internal Applicants	FTE Offers Co	nfirmed (in month)	0.00	0.80		·	1		1	1		•		
		FTE Establish		485.02	482.30	511.56	523.37	523.37	523.37	523.37	523.37	523.37	523.37	523.37	523.37
		FTE FTE In Po		411.72	417.04	423.44	423.44	419.26	419.69	420.12	420.56	420.99	421.42	421.86	422.29
	SIP	FTE New Start	ers	2.53	6.80	0.00	0.00	4.61	4.61	4.61	4.61	4.61	4.61	4.61	4.61
Band 2 HCAs		FTE Leavers		3.92	0.40	0.00	4.18	4.18	4.18	4.18	4.18	4.18	4.18	4.18	4.18
			in month al offers (in month)	73.30 7.61	65.26 6.56	88.12	99.93	104.11	103.68	103.25	102.81	102.38	101.95	101.51	101.08
	Offers External Applicants	harman and him and an income	nfirmed (in month)	5.25	1.61			<b>†</b>							
		FTE Establish	nent	95.44	93.14	93.14	93.14	93.14	93.14	93.14	93.14	93.14	93.14	93.14	93.14
		FTE FTE In Po	st	93.21	91.63	89.83	89.71	89.71	89.11	88.52	87.92	87.32	86.73	86.13	85.53
	SIP	FTE New Start	ers	0.00	0.00	0.80	0.60	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Band 3 HCAs		FTE Leavers		1.00	1.80	0.92	0.60	0.60	0.60	0.60	0.60	0.60	0.60	0.60	0.60
			in month	2.23	1.51	3.31	3.43	3.43	4.03	4.62	5.22	5.82	6.41	7.01	7.61
	Offers External/Internal Applicants	harman and him and an income	al offers (in month) nfirmed (in month)	0.00 0.00	3.16 4.20										

#### Notes:

Establishment: WTE contracted. Figures still to be adjusted in light of March vacancy reconciliation exercise.

May wre establishment: For nurses and HCA's includes a wre increase due to the opening of Lyndon 5 as a substantive ward from May 17 and OPAU amd New starters - May, June: Figures based on agreed dates with new hires

New starters forecast: Based on new starters in previous year and estimated starters as a result of recruitment campaigns held in and response rate of FYS to conditional offers.

Leavers - May, June: Figures based on terminations received into ESR and assuming that managers are submitting termination data in a timely fashion.

Leavers: With the exception of band 5 staff nurses and midwives, the leaver figure is based on the wte leaving the organisation. For band 5 staff nurses/midwives, this also includes the wte moving internally to take into account the impact of internal promotion.

Turnover forecast: Based on average for the staff group/band over the previous year.

Student Nurse Offers: Forecast assumes that 50% of offers made to date will be successful (based on 2016 student recruitment)

Band 5 Midwives: Decision taken to overestablish at band 5 and develop post holders to fill band 6 midwifery vacancies.

Band 6 Midwives: New starters includes an assessment of the number of band 5 midwives due to move to band 6 positions following successful completion of training (see note above).

Band 5 Nurses: Report includes data on band 5 nursing posts within the Trust with the exception of midwives. Reporting on external recruitment activity i.e. activity that improves vacancy bottom line given this is an entry level post.

Band 6 Nurses: Figures include all band 6 nurses i.e. charge nurses, sisters, community practitioners with the exclusion of midwives

#### Data source: ESR and Recruitment data base

The board has previously received updates on the number of offers made to band 5 and band 6 nurses each month, totalling 180 since February 2017. This includes 100 offers made to our final year nursing students, 33 offers at the RCn Birmingham Recuritment Fayre, and clinical group recuritment offers each month. The information reported included internal offers made (e.g. where an acute SWBH nurse is offered a community nurse role) therefore creating another vacancy in the Trust.

There is a 50-60% 'take up' of the offers made, this means the number of people who actually start with the Trust.

Band 5 Nurses

Definition includes all band 5 nurses employed in the Trust with the exception of midwives
Assuming appointing 3 wite per month based on general recruitment
Have identified the number leaving band 5 positions for internal promotion - had to inflate the leavers figure by 0.60 wite (normally just includes people exiting the organisation) to take into account the impact of internal promotion.

Forecast for Student Nurses

Assume 50% acceptance of offers and commencement Sent letters to 58 students due to qualify in September 2 students offered posts due to qualify in Jan '18 another 34 students were offered jobs via the recruitment fair. Total students = 29 c assuming 50% will commence in September i.e. 46 January '18 - Assume that we will be able to offer a further 66 final placement students a job with the Trust. Assume that 50% will accept = 33 wite

Band 6 Nurses

Band 6's - counting all band 6 nurses with the exception of midwives

Band 6 nurses - new starters of 2.85 based on average number of new starters (internal and external) to the band

Band 5 Midwives - New starters - median number of new starters based on last 12 months - 1.97 Band 5 Midwives

New starters - median based on recruitment activity over the last 12 months + number of band 5's due to commence in band 6 roles following successful completion of training. Band 6 Midwives

Band 3 HCA's New starters - median based on recruitment activity over the last 12 months.

Band 2 HCAS Excludes care support workers (Occ code - all H1's)

# Sandwell and West Birmingham Hospitals

Discuss

	TRUST BOARD
DOCUMENT TITLE:	Risk Registers
SPONSOR (EXECUTIVE DIRECTOR):	Kam Dhami, Director of Governance
AUTHOR:	Dalvinder Masaun, Head of Health and Safety
DATE OF MEETING:	1 June 2017

#### **EXECUTIVE SUMMARY:**

The Trust Risk Register compromises high (red) risks that have been through the validation processes at directorate / group and Executive Committee levels.

The Trust Risk Register was last reported to the Board at its May meeting and Executive Director updates are highlighted where these were provided. No additional risks have been escalated to the Board from the Risk Management or Clinical Leadership committees.

### REPORT RECOMMENDATION:

The Board is recommended to:

Accept

**RECEIVE** monthly updates from Executive Directors for high (red) risks on the Trust Risk Register.

#### **ACTION REQUIRED** (*Indicate with 'x' the purpose that applies*):

The receiving body is asked to receive, consider and:

		✓		✓	
<b>KEY AREAS OF IMPACT (Indicate</b>	with '	x' all those that apply):			
Financial	<b>√</b>	Environmental	✓	Communications & Media	
5 1 1 1 1		1 10 D II	/	D 11 1 E 1	

Approve the recommendation


Financial	✓	Environmental	✓	Communications & Media	
Business and market share		Legal & Policy	✓	Patient Experience	✓
Clinical	./	Equality and	✓	Workforce	./
Cililical	*	Diversity			•

Comments:

### ALIGNMENT TO TRUST OBJECTIVES, RISK REGISTERS, BAF, STANDARDS AND PERFORMANCE METRICS:

Aligned to BAF, quality and safety agenda and requirement for risk register process as part of external accreditation programmes.

#### PREVIOUS CONSIDERATION:



#### Report to the Trust Board on 1 June 2017

#### 1. EXECUTIVE SUMMARY

1.1 This report includes the Trust Risk Register and an update on the implementation of the electronic risk system.

#### 2. TRUST RISK REGISTER (TRR)

- 2.1 Clinical Group and Corporate Directorate risks were reviewed at Risk Management and Clinical Leadership Committees. There are no additional risks escalated to the Board from the Risk Management or Clinical Leadership committees. The Trust Risk Register is at **Appendix A**.
- 2.2 As a reminder, the options available for handling risks are:

Terminate	Cease doing the activity likely to generate the risk
Treat	Reduce the probability or severity of the risk by putting appropriate controls in place
Tolerate	Accept the risk or tolerate the residual risk once treatments have been applied
Transfer	Redefine the responsibility for managing the risk e.g. by contracting out a particular activity.

#### 3. ELECTRONIC RISK SYSTEM

- 3.1 Implementation of the electronic risk system is ongoing. Implementation of the electronic risk system is ongoing.
- 3.2 Risk register reports at various levels, including the Trust Risk Register, are available for all staff to access on the Connect Intranet System. Additional risk reports include archive summaries at ward/department level and a detailed risk report, which includes status of individual actions and a summary of risk review history. Risk review and action notification emails are now in place.
- 3.3 Further development of risk report library is planned.

### 4. RECOMMENDATION(S)

- 4.1 The Board is recommended to:
  - RECEIVE monthly updates from Executive Directors for high (red) risks on the Trust Risk

Dalvinder Masaun Head of Health and Safety


Appendix A: Trust Risk Register

# Sandwell and West Birmingham Hospitals **NHS**



**NHS Trust** 

Status od yasin Directorate Dept.	മ് Risk Statement	Initial risk rating (Likelihood x Severity)	Existing controls	Current risk score (LxS)	Actions	Lead Owner	Expected completion	Latest review	Review	Control potential
Live (With Actions)  Emergency And	The Trust has un-substantiated beds oped due to: _admissions above plan _extended Length of Stay (LOS) above bed plan assumptions _too many Delayed Trans of Care bed days (DTOC) plan accommodated 35 accor pending DTOC patients; those numbers have increased to 89-109 over November/December period.  We are unable to consiste staff the additional beds safely. The Trust will consiste staff the additional beds safely. The Trust will consiste staff the new year. The impact this would potentially resure overcrowding in ED and a deterioration in time to assessment, diagnosis and treatment, which would resin decreased patient and sexperience, longer ambulat waiting times and will undoubtedly adversely impacts.	fers our tual  d ntly ider ds ct of t in d sult taff nce	Activate business continuity for 10 additional patients in ED: For up to 10 patients additional to ED cubicle capacity - likelihood this occurs 12 hours of the day -Receive patients and starting assessment in the circulating corridor areas of ED -Staffing of the above areas to be put in place utilising block booking of bank / agencyEquipping area with privacy screens , dynamap and patient trollies to be available -A computer on wheels to be allocated to this team so they can process and document assessment and care. A CAD screen should be installed in the main desk to anticipate incoming ambulances outside of RAM2 RAM cubicles to be kept for rotation of WMAS presenting patients through this area for detailed examination etc; 2 majors cubicles would rotate patients from the waiting room dependent on triage scores	5x4=20	Seek social care business continuity response to eradicate all acute delayed transfer of care patients. Plans not available  Raise at A&E Delivery Group.  Command and control structure with documented continuity plan to manage this scenario. Complete written guidance for both scenarios (a) and (c)  Command and control structure to be put in place if plan activated to support ED and live assessment of risk  Work with WMAS on risk assessment to understand their response to these scenarios	Rachel Barlow	31/03/2017	07/02/2017	Monthly	Treat



NHS Trust

Status on yes yes Directorate Dept.	ed Risk Statement	Initial risk rating (Likelihood x Severity) slouthood x	Current risk score (LxS)  Vertical Actions	Lead Owner Expected completion Latest review Review Control potential
	on patient outcomes.	Queue ambulances on ambulance arrival point x 10: Ambulances would be held for up to 60 minutes on the ambulance arrival area and remain under the care of the WMAS staff until the patients could be handed over on the ED environment safely.  Activate business continuity for 20 additional patients in ED and or patients waiting for 60 minutes on the ambulance arrival area: For up to 20 patients additional to ED cubicle capacity - likelihood estimated to be up to 6 hours a day The approach to mitigate, the ED capacity would need to be expanded. This would be through 2 options:  1)A temporary tent on the ambulance arrival area 2)Expand ED in line with the major incident plan. This would displace adjacent out patients, which would need to be relocatedStaffing and equipment would need to be in place -Access to patient first IT system to be in place		


Date run: 23/05/2017



**NHS Trust** 

Status Status	Directorate	Dept.	Туре	Risk Statement	Initial risk rating (Likelihood x Severity)	Existing controls	Current risk score (LxS)	Actions	Lead Owner	Expected completion	Latest review	Review	Control potential
						Further to the above measures, if ambulance waits persisted and delays to patient assessment exceeded an hour, the Trust would seek to close to further arrivals of urgent care patients: Attendance avoidance would be sought by: Triage all non-majors activity to urgent care centres Divert WMAS to other							
Live (With Actions)	Paediatrics	Lyndon Ground	Incident	Lack of Tier 4 bed facilities for Children-Young people with mental health conditions means that they are admitted to the paediatric ward. There is no specialist medical or nursing MH team to care for their needs with limited access to in/OOH CAMHS support. Whilst safety for the children can be maintained, therapeutic care is compromised and there can be an impact on other children and parents.		Mental health agency nursing staff utilised to provide care 1:1  All admissions monitored for internal and external monitoring purposes.  Awareness training for Trust staff to support management of patients is in place  Children are managed in appropriate risk free environments	4x4=16	The LA and CCG are looking to develop a Tier 3+ service. An update has been requested through the CCG and a response is awaited. Tier 4 beds are being reviewed nationally.	Rachel Barlow	31/03/2017	03/04/2017	Quarterly	Tolerate


Date run: 23/05/2017





Status Status	Directorate	Dept.	Туре	Risk Statement	Initial risk rating (Likelihood x Severity)	Existing controls	Current risk score (LxS)	Actions	Lead Owner	Expected completion	Latest review	Review	Control potential
Live (With Actions)	Waiting List	Waiting List Management	Performance	Due to lack of EAB bed, nursing home capacity and waits for domically care there is a deteriorating level of Delayed Transfers of Care (DTOC) bed days which results in an increased demand on acute beds.	4x5=20	ADAPT joint health and social care team in place. Progress made on new pathway.  Joint health and social care ward established in October at Rowley.	4x4=16	EAB and nursing home capacity remain unmitigated risks. System Resilience partners review of demand and capacity still outstanding.  Nursing home and domiciliary care provision is potentially vulnerable across the market place. The system resilience partners considering risk and mitigation as part of A&E delivery group.	Rachel Barlow	31/03/2017	26/10/2016	Quarterly	Treat
Live (With Actions)	Sinance Einance		Costs Not Planned	As a result of significant reliance on non-recurrent measures and balance sheet flexibility to support the Trust's financial performance cash balances have been eroded and there is a risk that this may compromise future investment plans.	4x5=20	Management controls - Routine cash flow forecasting including rolling 15 month outlook - Routine five year capital programme review & forecast - Routine medium term financial plan update - Routine monitoring of supplier status avoiding any 'on	3x5=15	- Deliver operational performance consistent with delivery of financial plan to mitigate further cash erosion - Establish and conclude task & finish programme to resolve significant outstanding debtor and creditor issues - Excellence in working capital management including	Tony Waite	31/03/2018	22/11/2016	Quarterly	Treat

Date run: 23/05/2017





Status No.	Directorate	Dept.	Туре	Risk Statement	Initial risk rating (Likelihood x Severity)	Existing controls	Current risk score (LxS)	Actions	Lead Owner	Expected completion	Latest review	Review	Control potential
						stop' issues Independent controls / assurance - Internal audit review of core financial controls - External audit review of trust Use of Resources including financial sustainability - Regulator scrutiny of financial plans		appropriate creditor stretch, timely debtor recovery and pharmacy stock reduction - Establish and progress cash generation programme including accelerated programme of surplus asset realisation					
Live (With Actions)	gency And	Accident & Emergency (S)	Staffing	STAFFING - SENIOR MEDICAL STAFF There is a risk that further reduction or failure to recruit senior medical staff in ED leads to an inability to provide a viable rota at consultant level which may impact on delays in assessment, treatment and patient safety.	4x5=20	Recruitment campaign through local networks, national adverts, head-hunters and international recruitment expertise. Leadership development and mentorship. Programme to support staff development.  Robust forward look on rotas through leadership team reliance on locums (37% shifts filled with locums). Registrar vacancy rate 59%. Consultant vacancy rate 35%.	3x5=15	Recruitment ongoing with marketing of new hospital.  CESR middle grade training programme to be implemented as a "grow your own" workforce strategy.  Development of recruitment strategy	Rachel Barlow	31/03/2017	22/05/2017	Quarterly	Treat

Risks that feature on the Trust Risk Register (TRR) have been escalated and reviewed by management teams through to Clinical

Leadership Executive Committee and Trust Board. Trust Board takes the decision whether risks feature on the TRR including approval of requests for risks to be removed from the TRR for them to managed at the relevant Clinical Group / Corporate Directorate.



**NHS Trust** 


Status .oV	Directorate	Dept.	Туре	Risk Statement	Initial risk rating (Likelihood x Severity)	Existing controls	Current risk score (LxS)	Actions	Lead Owner	Expected completion	Latest review	Review	Control potential
Live (With Actions)	Human Resources	Human Resources	Cost Improvement Not Met	Insufficient policy levers to ensure effective delivery of Trust workforce plan establishment establishment reduction of 1400 WTEs, leading to excess pay costs	4x5=20	The Executive led delivery plan is progressing the reduction of WTEs alongside a change management programme. Learning from previous phases, changes in legislation and broad stakeholder engagement are factored into the delivery plan.	3x4=12	Phase 2 Transformation implementation in progress. Consultation sign-off October 2016. Phased implementation of individual plans over a two year period, started Q1 2016-17.	Raffaela Goodby	31/03/2018	20/09/2016	Quarterly	Treat
Live (With Actions)	Operations		Incident	Unfunded beds staffed by temporary staff in medicine place an additional ask on substantive staff elsewhere, in both medicine and surgery. This reduces time to care, raises experience, safety and financial risks.	5x4=20	Overseas recruitment drive (pending) Use of bank staff including block bookings Close working with partners in relation to DTOCs	3x4=12	Contingency bed plan to be agreed in October for winter 2016/17. Current unfunded beds have temporary staffing. Bed programme to ensure robust implementation of EDD planning on admission and implementation of red/green working on wards.	Rachel Barlow	31/03/2017	26/10/2016	Monthly	Treat

Date run: 23/05/2017



Status No.	Dept.	Туре	Risk Statement	Initial risk rating (Likelihood x Severity)	Existing controls	Current risk score (LxS)	Actions	Lead Owner	Expected completion	Latest review	Kevlew Control potential
					Close monitoring and response as required.  Partial control - Bed programme did initially ease the situation but different ways of working not fully implemented as planned.						
Live (With Actions)	BMEC Outpatients - Eye	Ouality Of Care	There is a risk that children, particularly under 3 years of age, who attend the ED at BMEC with an emergency eye condition, do not receive either timely or appropriate treatment, due to limited availability OOH of specialist paediatric ophthalmologists and/or the availability of a paediatric anaesthetist.	4x4=16	Contingency arrangement is for a general ophthalmologist to deal with OOH emergency cases.  Agreement with BCH to access paediatric specialists advice and where specialist care is required patients can be transferred to BCH.  There is a cohort of anaesthetists who are capable of anaesthetising children under 3 who can provide back-up services when required.  Where required patients can be transferred to alternative paediatric ophthalmology services beyond the local area.	3x4=12	Actions agreed following a meeting of senior clinicians and Executive Directors, some of which are in progress or completed: Engage with ophthalmology clinical lead at BCH and agree a plan for delivering an on call service. SWBH MD to engage with BCH MD re. joint working (completed). Liaise with commissioners over the funding model for the Paediatric OOH service. Paediatric ophthalmologists from around the region to participate in OOH service (for discussion and agreement at a paediatric ophthalmology summit meeting). Clarify with Surgery Group leads what the paediatric anaesthetic	Roger Stedman	30/11/2018	22/05/2017 Ouedediv	Quarterly Treat


Date run: 23/05/2017



**NHS Trust** 

Risk Ref No.	Directorate Dept.	Туре	Risk Statement	Initial risk rating (Likelihood x Severity)	Existing controls	Current risk score (LxS)	Actions	Lead Owner	Expected completion	Latest review	Review	Control potential
							resourcing capacity is.  A full OOH paediatric on-call service to be set up in negotiation with commissioners, BCH and other ophthalmology units across the region.  Midland Met will treat paediatric emergencies and will have access to paediatric anaesthetists within 24 hours.					
Live (With Actions)	Ophthalmology Outpatients - EYE (S)	Clinical Environment IC Related	Risk of Breach of Privacy and Dignity Standard, Information Governance Risk and Infection Control Risk at Sandwell Outpatient Department as a consequence of poor building design in SGH Ophthalmology OPD. Clean/dirty utility failings cannot be addressed without re-development of the area. Risk that either a patient's health, or privacy/dignity will be compromised as a consequence of poor building design. Clean / dirty utility failings cannot be addressed without re-development of the	5x4=20	Reviewing plans in line with STC retained estate  Staff trained in IG and mindful of conversations being overheard by nearby patients / staff / visitors	3x4=12	To continue to work with STC design team and Ophthalmology team to ensure design and build of OPD2 is fit for purpose to ensure patient privacy, dignity and associated infection control issues are prioritised in the new build. April 2017 - informed by Jayne Dunn that OPD2 was no longer going to be for ophthalmology and would remain in current area. Raised at RMC May 2017.	Rachel Barlow	31/03/2017	22/05/2017	Ouarterly	Treat


Date run: 23/05/2017



Risk Ref No.	Directorate	Dept.	Туре	Risk Statement	Initial risk rating (Likelihood x Severity)	Existing controls	Current risk score (LxS)	Actions	Lead Owner	Expected completion	Latest review	Review	Control potential
121				area.  There is a risk that due to the	4x4=16	Maximisation of tariff income	3x4=12	Options for management of					
Live (With Actions)	Maternity_ Health	Maternity 1	Costs Not Planned	unpredictable birth activity and the impact of cross charging from other providers against the AN / PN tariff, as a result is significantly affecting the financial position of the service impacting on the affordability and quality provision of the service.		through robust electronic data capture. Robust validation of cross charges from secondary providers.	JA4=1Z	maternity pathways payment between primary and secondary provider for AN/PN care in progress by the Finance Director - with cross provider SLA planned. Risk proposed for removal from TRR when 2016-17 SLA is signed.	Rachel Barlow	29/12/2017	17/05/2017	Monthly	Treat

Risks that feature on the Trust Risk Register (TRR) have been escalated and reviewed by management teams through to Clinical

Leadership Executive Committee and Trust Board. Trust Board takes the decision whether risks feature on the TRR including approval of requests for risks to be removed from the TRR for them to managed at the relevant Clinical Group / Corporate Directorate.




**NHS Trust** 

Page

10

Status Status	Directorate Dept.	Туре	Risk Statement	Initial risk rating (Likelihood x Severity)	Existing controls	Current risk score (LxS)	Actions	Lead Owner	Expected completion	Latest review	Review	Control potential
Live (With Actions)	Informatics Medical Director's Office	IT Software - Clinical System Failure / Issue	There is a risk of a breach of patient or staff confidentiality due to cyber attack which could result in loss of data and/or serious disruption to the operational running of the Trust. This recognises advice from NHS CareCERT and Government about an ongoing threat to UK infrastructure from cyber attack.	4x4=16	Prioritised and protected investment for security infrastructure via Infrastructure Stabilisation approved Business Case Information security assessment completed and actions underway.	3x4=12	MDM Tighten up use of MDM controls. Remove out of date accounts and update old OS versions. This has been neglected and therefore is a security risk. Complete rollout of Windows 7. Upgrade servers from version 2003. 287 servers have been moved to Windows Server 2008 and 2012. There are 104 using Windows Server 2003 that need to be migrated. These will be completed by Christmas. Review Network Firewall Rules Review network firewalls rules. Remove inessential services. Achieve Cyber Security Essentials The Trust must achieve cyber-security essentials as part of the minimum commitment to security. This will likely form part of our CQC inspections. Restricted Devices Security Controls Implement security controls (VLAN, IPSEC) to stop access to and from restricted devices. Over time this	Mark Reynolds	30/06/2017	20/01/2017	Quarterly	Treat

Date run: 23/05/2017






Status Status	Directorate	Dept.	Туре	Risk Statement	Initial risk rating (Likelihood x Severity)	Existing controls	Current risk score (LxS)	Actions	Lead Owner	Expected completion	Latest review	Review	Control potential
								should harden the Trust infrastructure against attack, recognising that securing the physical network is a challenge on the estate.					
Live (With Actions)	Operations	Operations Management	Staffing	Clinical Groups are unable to transact basic business processes because of key person gaps resulting in performance delays and failures.	4x4=16	Investment in high quality agency staff and internal cover of the senior team  Deputy COO for Planned Care appointed.	3x3=9	Recruitment to Medicine Director Operations continues to be of focus. Deputy COO for Urgent Care vacant and also subject to recruitment.	Rachel Barlow	31/12/2016	26/10/2016	Quarterly	Treat

Risks that feature on the Trust Risk Register (TRR) have been escalated and reviewed by management teams through to Clinical

Leadership Executive Committee and Trust Board. Trust Board takes the decision whether risks feature on the TRR including approval of requests for risks to be removed from the TRR for them to managed at the relevant Clinical Group / Corporate Directorate.






Status Status	Directorate	Dept.	Туре	Risk Statement	Initial risk rating (Likelihood x Severity)	Existing controls	Current risk score (LxS)	Actions	Lead Owner	Expected completion	Latest review	Review	Control potential
Live (With Actions)	Informatics	Informatics(C)	IT Hardware - Clinical System Failure / Issue	There is a risk that a not fit for purpose IT infrastructure will result in a failure to achieve strategic objectives and significantly diminishes the ability to realise benefits from related capital investments. e.g. successful move to paperlite MMH, successful implementation of Trust Wide EPR.	3x4=12	Approved Business Case in place for Infrastructure Stabilisation programme (approved by Trust Board June 2015)  Specialist technical resources engaged (both direct and via supplier model) to deliver key activities  Informatics has undergone organisational review and restructure to support delivery of key transformational activities  Informatics governance structures and delivery mechanisms have been initiated to support of transformational activities  Infrastructure work to refresh networks and desktops is underway.	3x3=9	Complete network and desktops refresh.  Stabilisation of all aspects of the local IT infrastructure will be completed end March 2017. The replacement of PCs, printers, monitors, etc., and upgrade of the network is conducted in parallel. 80% of the work was completed by December 2016	Mark Reynolds	31/03/2017	16/01/2017	Quarterly	Treat

Risks that feature on the Trust Risk Register (TRR) have been escalated and reviewed by management teams through to Clinical

Leadership Executive Committee and Trust Board. Trust Board takes the decision whether risks feature on the TRR including approval of requests for risks to be removed from the TRR for them to managed at the relevant Clinical Group / Corporate Directorate. 12



**NHS Trust** 

Status Status	Directorate	Dept.	Туре	Risk Statement	Initial risk rating (Likelihood x Severity)	Existing controls	Current risk score (LxS)	Actions	Lead Owner	Expected completion	Latest review	Review	Control potential
Live (With Actions)	Scheduled Care	Oncology Medical	Service Level Agreement - Operational	The Trust has excess waits for oncology clinics because of non-replacement of roles by UHB and pharmacy gaps.	3x5=15	Being tackled through use of locums and waiting times monitored through cancer wait team.	3x3=9	Recruitment being managed by UHB. Good progress reported for the GI position.	Roger Stedman	31/01/2017	28/10/2016	Quarterly	Treat
Live (With Actions)	Operations	Elective Access Inpatient	Performance	There is a risk that data quality errors arise due to an inadequate referral management system which could lead to delays for patients.	5x3=15	Historical backlog of open referrals closed in Q3 2015. SOP and training in place as part of actions at time.  Audit of current open referrals open pathways completed and shows some remaining inconsistencies in referral management practice.	3x3=9	Closed referral validation to be completed. The programme is near completion with a delivery plan for the end of October.  CSC to fix bug on PAS system. The initial technical development has not fully fixed the bug. the further development would require a full PAS upgrade and CSC / HIS have advised this is not likely to be	Rachel Barlow	31/12/2016	26/10/2016	Quarterly	Treat

Date run: 23/05/2017



Status Status	Directorate	Dept.	Туре	Risk Statement	Initial risk rating (Likelihood x Severity)	Existing controls	Current risk score (LxS)	Actions	Lead Owner	Expected completion	Latest review	Review	Control potential
								until later than 2017-18.  Data quality programme to be completed.					
Live (With Actions)	Waiting List	Waiting List Management	Performance	Lack of assurance of standard process impact on 18 week data quality which results in underperformance of access target.	4x3=12	SOP in place Substantive Deputy COO for Planned Care appointed and new Head of Elective Access in place. Improvement plan in place for elective access with training being progressed. 52 week breaches continue to be an issue for the Trust. The RCA identified historical incorrect pathway administration and clock stops. There has been no clinical harm caused to patients.  The 52 week review was completed with TDA input. The action plan is focused on prospective data quality check points in the RTT pathway,	3x3=9	Implement full action plan. Planned care PMO is being established to oversee programme delivery as scheduled.  Source e-learning module for RTT with a competency sign off for all staff in delivery chain. Decision to be made on the support training product in November.  Data quality process to be audited	Rachel Barlow	31/03/2017	26/10/2016	Quarterly	Treat


Date run: 23/05/2017



Status on status	Directorate	Dept.	Туре	Risk Statement	Initial risk rating (Likelihood x Severity)	Existing controls	Current risk score (LxS)	Actions	Lead Owner	Expected completion	Latest review	Review	Control potential
						competency and training.							
Live (With Actions)	Scheduled Care	Oncology Medical	Performance	Trust non-compliance with some peer review standards due to a variety of factors, including lack of oncologist attendance at MDTs, which gives rise to serious concern levels.	3x4=12	Oncology recruitment ongoing and longer term resolution is planned as part of the Cancer Services project.	3x3=9	Contingent on start date for GI appointments	Roger Stedman	31/03/2017	28/10/2016	Monthly	Treat

Risks that feature on the Trust Risk Register (TRR) have been escalated and reviewed by management teams through to Clinical

Leadership Executive Committee and Trust Board. Trust Board takes the decision whether risks feature on the TRR including approval of requests for risks to be removed from the TRR for them to managed at the relevant Clinical Group / Corporate Directorate.



**NHS Trust** 

Page

16

Status Status	Directorate	Dept.	Туре	Risk Statement	Initial risk rating (Likelihood x Severity)	Existing controls	Current risk score (LxS)	Actions	Lead Owner	Expected completion	Latest review	Review	Control potential
Live (With Actions)	Informatics	Informatics(C)	IT Software - Clinical System Failure / Issue	There is a risk of failure of a trust wide implementation of a new EPR due to insufficient skilled resources within the Trust given the fixed time and budgetary constraints. This now focuses on resources to deliver the implementation including business change, training and champions.	4x4=16	Recruitment of suitably skilled specialist resources for EPR Programme and Infrastructure Stabilisation Funding allocated to LTFM Delivery risk shared with supplier through contract Project prioritised by Board and management.	3x3=9	Embed Informatics implementation and change activities in Group PMOs and production planning Develop and publish implementation checklists and timescales for eDocs and EPR. Report progress at Digital PMO and Ctte  Agree and implement super user and business change approaches.	Mark Reynolds	30/06/2017	22/03/2017	Monthly	Treat
Sive (With Actions)	Interventional	Imaging Management (C)	Recruitment	Reduced ability to provide an Interventional Radiology service as a result of difficulties in recruiting Interventional Radiology consultants, results in delays for patients and loss of business.	4x3=12	Interventional radiology service is available Mon - Fri 9-5pm across both sites. The QE provides an out of hours service for urgent requests.	2x3=6	BCA plans to be delivered to commence in April 2016. PPAC & staff currently being consulted and volunteers for rotas sought. Working on Rota to cover our first commitment Saturday 30th April. The BCA service started in April as planned, with 1st SWBH weekend end April. So far, all weekends have been covered but there are	Rachel Barlow	31/12/2016	12/04/2017	Quarterly	Treat

Date run: 23/05/2017



Status od yasia Directorate Dept.	Туре	Risk Statement	Initial risk rating (Likelihood x Severity)	Existing controls	Current risk score (LxS)	Actions	Lead Owner Expected completion	Latest review Review Control potential
				Locum arrangements in place to support workforce plan. Two consultants recruited who will start in 2017.		some concerns around potential shortages of radiographers, with no radiographer currently available for a weekend in November and at the New Year - the qualified ones are committed in CT. The CD for IR is arranging radiologist locum cover for some of the weekends, and Walsall is providing some additional cover.  Pilot to cover Saturday and Sunday 9-5pm at SWBH, Wolverhampton and Dudley with BCA commenced April 16; SWBH has received it's first OOH patient. To be done on a rotational basis. Over reliance on one consultant, but 2 more are starting in the New Year.  Recruitment is progressing but availability of vascular IR sessions is proving an potential barrier, as our sessions at UHB have been taken. Some sessions have been arranged at Dudley, and talks are taking place with UHB.		

Risks that feature on the Trust Risk Register (TRR) have been escalated and reviewed by management teams through to Clinical

Leadership Executive Committee and Trust Board. Trust Board takes the decision whether risks feature on the TRR including approval of requests for risks to be removed from the TRR for them to managed at the relevant Clinical Group / Corporate Directorate.



Risk Ref No.	Directorate	Dept.	Туре	Risk Statement	Initial risk rating (Likelihood x Severity)	Existing controls	Current risk score (LxS)	Actions	Lead Owner	Expected completion	Latest review	Review	Control potential
								Medical Director of Dudley Group of Hospitals working to create vascular access at Russell's Hall. Some sessions have been arranged at Dudley, and talks are taking place with UHB.					
Live (With Actions)	Scheduled Care	Oncology Medical	Performance	Differential and extended chemotherapy wait times between sites due to staff vacancies results in inequality of service for patients.	2x4=8	Review / amend pathway  Staff vacancies recruited to. Latest audit (Nov 15) provides assurance that wait times have significantly improved; 9 days on each site.  Monthly monitoring of performance carried out to check that staff recruitment maintains sustainable change.  New 2 stop chemotherapy model introduced to equalise waits from beginning of May 2016. New model implemented and improvements being monitored by Cancer Board.	1x4=4	Further Executive review at performance management review in November to confirm if the solution has succeeded in full.	Rachel Barlow	31/12/2016	28/10/2016	Quarterly	Treat

Leadership Executive Committee and Trust Board. Trust Board takes the decision whether risks feature on the TRR including

## Sandwell and West Birmingham Hospitals



**NHS Trust** 

### TRUST BOARD

DOCUMENT TITLE:	Integrated Performance Report – P01 April 2017
SPONSOR (EXECUTIVE DIRECTOR):	Tony Waite, Finance Director
AUTHOR:	Yasmina Gainer, Head Performance Management & Costing
DATE OF MEETING:	1 June 2017

#### **EXECUTIVE SUMMARY:**

### IPR - Summary Scorecard for April 2017 (In-Month)

		Red	Green		
	Section	Rated	Rated	None	Total
	Infection Control	1	5	0	6
2	Harm Free Care	9	4	9	22
Summary Scorecard	Obstetrics	2	5	6	13
6	Mortality and Readmissions	1	1	11	13
JC	Stroke and Cardiology	2	9	0	11
Ö	Cancer	0	10	5	15
	FFT. MSA, Complaints	14	2	5	21
	Cancellations	6	2	0	8
Ja	Emergency Care & Patient I	7	7	4	18
JΙ	RTT	7	1	6	14
III	Data Completeness	2	8	9	19
S	Workforce	5	1	13	19
	Temporary Workforce	1	0	27	28
	SQPR	10	0	0	10
	Total	67	55	95	217

- Formal performance notices received from CC March
- Cancelled Operations:
- Community Gynae referral to 1st OP within 4 weeks also not performed all year.
- Safeguarding training Children level 3 below agreed trajectory as is adult advanced - RAP agreed but will show as not achieving
- Dementia and Falls Assessments (Community)
- RAP for A&E, RTT and Diagnostics to be discussed during April contract review meeting
- On-going action to secure effective resolution and to mitigate risk of financial penalty
- Red rated performance concentrating in certain areas – persistent 'reds' are being reviewed and prioritised for remediation by the Exec Group through PMC.

#### **Key targets – April Delivery**

- **ED 4 hour** performance for April was 84.95%, non-compliant with 95% national target;
- \* Acute Diagnostic waiting times within 6 weeks as at April 98.23% non-compliant with the national standard of 99%; mainly due to echograms breaches. 132 breaches were declared for the month of which echos at 65, which was due to cardiology capacity issues. Plan for remediation in place for May.
- **Neutropenic sepsis** improvement on prior months, but remains below 100% standard [11/44 (25%) patients did not receive treatment within the required 1hr timeframe]. 11 patients missed the standard.
- **Elective Operations Cancellations** at 1.3% against 0.8% target; cancellations remain high at 47 on day cancellations of which 24 were validated as avoidable; 28 Day Guarantee non-compliance x1 case for April in Dermatology being validated.
- **★ Hip fractures** best practice tariff performance in month worsened to 41% from last month at 91.3% caused by 13x NOFs in one day plus elevated trauma lists.
- **Mortality reviews** completed to time continue to improve; mortality indicators remain within confidence limits.
- ✓ 62 day cancer compliant at 91.6% at March vs. target of 85%; Q4 delivery at 85.7%. This means that
  the Trust has delivered every quarter in 16/17. April projection of delivery for this indicator as well as
  May, but the 2WW indicator is at risk (93% target) due to lost bank holiday capacity not being replaced
  as yet, but actively pursued.

- ✓ RTT April delivery at 92.76% against the national standard of 92%. Waiting list at 32,000, patient backlog of patients at 2,350 up by 250 from March. There were 2x 52 week incomplete breaches in month in Urology and Dermatology. May tracking projections to deliver standard.
- ✓ VTE delivers full year to national standard at 96.4% in April.
- ✓ MRSA no cases in April
- ✓ CDiff x1 case in April; a full year target of 30 was agreed in contract.
- ✓ **Readmissions** at 7.1% in April (7.4%) showing an improvement to last month with more work anticipated which will further improve this. The Trust now tracks better than peer group.

### Positive delivery

- **62 day cancer** projected to deliver for April and May having achieved every quarter in 2016/17, which is a significant achievement.
- RTT successful continuation of delivery to forecast
- Infection control indicators are in line with targets across the board.

#### Requiring attention - action for improvement :

### IPR Indicators where Performance during the Last Year was Consistently below Targets

- A PMC review is under-going to establish the priority in which to address
- Robust plans are expected to then flow through based on this

#### **Neutropenic Sepsis**

 Shows improvement but stubborn to further reduction to secure 100% local 'always event' compliance standard. MD to action improvement. 137 patients have missed the 1 hour treatment threshold in the last year 16/17. 11 patients missed it in April

#### **Cancelled operations**

- We continue to see an unchanged position
- End to end process review to ensure that admin processes are as best practice and appropriately recorded
- High levels of breaches against the 28 day guarantee is likely to cause attention with regulators
- High levels of 'on day' cancellations, coupled with late starts and low theatre utilisation
- High levels of late starts are experienced
- Remedial action plan agreed with CCG to be overseen through Theatres Management Board

#### **Complaints**

• Rate of complaints and timeliness of response in Q4 contrary to recent track record of excellent performance; Governance team to review for hotspots and to remedy. 79% of complaints have not met to agreed deadlines. Improved in April to 36% (from 79% in March) of responses have been reported beyond agreed target time, showing improvement to last month but still on the high side.

#### **Recovery Action Plans (RAPs)**

- Require oversight at PMC / OMC to ensure ongoing engagement across the services and EG
- The Trust now has a higher number of RAPs ongoing (outlined in the IPR 'at a glance' section)

#### **CQUIN 2016/17 Full Year Performance**

The trust has under-recovered against the £8.6m total CQUIN income available for 2016.17.

The final sum secured remains to be confirmed in closing out negotiations for that year.

The key areas of variance are mainly due to under-delivery on requirements:

- to improve on staff survey results year on year on 2x questions, failing one question and delivering one with a partial delivery on the 3<sup>rd</sup>.
- Sepsis fails to deliver on required level of samples for sepsis due to the manual/labour intensive approach on the wards.
- Mortality reviews missed 2 quarters due to low level of reviews.
- Specialised commissioning neonates scheme which was not taken up by the Trust but signed off in the contract and the long term conditions scheme has not been taken up fully in year (continuous into 17/18)

#### **REPORT RECOMMENDATION:**

The Board is asked to consider the content of this report.

Its attention is drawn to the matters above and commentary at the 'At a glance' summary page in the IPR report

### **ACTION REQUIRED** (*Indicate with 'x' the purpose that applies*):

The receiving body is asked to receive, consider and:

The receiving body is asked to receive, con	isidei aild.	
Accept	Approve the recommendation	Discuss
		Х

KEY AREAS OF IMPACT (Indica	te with	'x' all those that apply):			
Financial	х	Environmental	х	Communications & Media	X
Business and market share	х	Legal & Policy	х	Patient Experience	Х
Clinical	х	Equality and Diversity		Workforce	Х

Comments:

### ALIGNMENT TO TRUST OBJECTIVES, RISK REGISTERS, BAF, STANDARDS AND PERFORMANCE METRICS:

Accessible and Responsive Care, High Quality Care and Good Use of Resources.

#### **PREVIOUS CONSIDERATION:**

Operational Management Committee, Performance Management Committee, CLE



# **Integrated Quality & Performance Report**

SWBTB (06/17) 13

Month Reported: April 2017

Reported as at: 25/05/2017

**TRUST BOARD** 

# Contents

Item	Page	Item	Page
		Referral To Treatment	12
At A Glance	2	Data Completeness	13
Patient Safety - Infection Control	3	Workforce	14
Patient Safety - Harm Free Care	4	CQUIN	15 & 16
Patient Safety - Obstetrics	5	Service Quality Performance Report - Local Quality Requirements 2016-17 & 17-18	17
Clinical Effectiveness - Mortality & Readmissions	6		18
Clinical Effectiveness - Stroke Care & Cardiology	7		19
Clinical Effectiveness - Cancer Care	8	Legend	20
Patient Experience - Friends & Family Test, Mixed Sex Accommodation and Complaints	9		
Patient Experience - Cancelled Operations	10		
Emergency Care & Patient Flow	11	Group Performance	


### April 2017


Infection Control	Harm Free Care	Obstetrics	Mortality & Readmissions	Stroke Care & Cardiology
	93.7% reported for April against NHS Safety Thermometer against the target 95%; Consistent marginal under-performance		The Trust overall RAMI for most recent 12-mth cumulative period is 106 (latest available data is as at	Stroke data for April indicates that 87.3% of patients are spending >90% of their time on a stroke ward which is not compliant with the 90% operational threshold.
1x C. Diff case reported during the month of April ;	ополит падна инстренитале.	The overall Caesarean Section rate for April is 26.2% and fails to achieve the standard of 25%. Elective and non-elective rates are 8.9% and 17.3% respectively.	January) RAMI for weekday and weekend each at 104 and 112 respectively. Reassurance is required from MD on the levels reported.	stroke ward which is not compliant with the 90% operational threshold.  First failure following 10 months consistent achievement.
An annual trajectory of 30 has been agreed with the CCG for 17/18	x69 [x74] falls reported in April with x0 [x2] falls resulting in serious injury. 23 falls within community and 46 in acute setting.	9/12 months elevated levels.  Matter considered at Q&S & Board and to be kept in view.	SHMI measure which includes deaths 30-days after hospital discharge is at 104 for the month of December (latest available data).	
	23 falls within community and 46 in acute setting. Falls remain subject to ongoing CNO scrutiny.	monter considered at Que a board and to be kept III VIEW.		April admittance to an acute stroke unit within 4 hours is at 97.1% [90.5%] and for the second
		Alienta accepta matella, esta (acc 1000 historia)	Deaths in Low Risk Diagnosis Groups (RAMI) - month of January is 105. This indicator measures inmonth expected versus actual deaths so subject to larger month on month variations.     Orude in-month mortality rate for March is 1.0 [1.6] reduced to last month;	month meeting the ambitious 90% internal target (National is consistently met at 80%).
	x13 [x6] avoidable, hospital acquired pressure sores reported in April of which 6x grade 3; 7x grade 2;	Adjusted perinatal mortality rate (per 1000 births) for April is 4.1 (12.66 Mar).  The indicator represents an in-month position and which, together with the small numbers involved	<ul> <li>The rolling crude year to date mortality rate remains consistent at 1.3 and consistent with last year same period at this stage.</li> </ul>	
Nil cases of MRSA Bacteraemia were reported in April;	x6 [x6] separate cases reported within the DN caseload.  Year on year comparison indicates elevated level, which merits CNO scrutiny.	provides for sometimes large variations.  The year to date position is within the tolerance at 7.56 and just meeting the target of 8.	-There were x100 [x139] deaths in our hospitals in the month of March; lower than last year same period.	Pts receiving CT Scan within 1 hour of presentation is at 87.2% [83.7%] in April March being compliant with 50% standard consistently;
Annual target set at zero .		Nationally, this indictor is monitored using a 3 year cumulative trend, based on which the Trust is within normal confidence limits.		Pts receiving CT Scan within 24 hrs of presentation delivery in month at 95.8% [97.7%] meeting
	x4 [x5] serious incidents reported in April; routine collective review in place and reported to the Q&S Cittee.			the 95% standard in month
	No never events were reported in April;     WHO Safer Surgery performance consistently below 100% standard for a			
MRSA Screening - April month: - Non-elective patients screening 94.0%	prolonged period of time, this is subject to MD review and re-positioning of target with CCG.	Puerperal Sepsis indicators showing increased levels from last month; referred to Group Director and Medical Director for review & assurance. A report was presented to the Q&S Cttee in May17 explaining	Mortality review rate in February at 52% worsening to previous monthly trends, drawn to MDO attention for remedy	April performance for thrombolysis is 75% [100%] vs the 85% target;
- Elective patients screening 87.0% - both indicators are compliant with 80% target in-month		the increases.	ion cincay.	
both indicators are compliant with 80% target in-month	There were no medication error causing serious harm in April continuing a trend of		Readmissions (in-hospital) reported at 7.1% in March (7.4% Feb, 7.1% Jan, 7.5% Dec, 6.8% Nov, 7.5%	For April, Primary Angioplasty Door to balloon time (<90 minutes) was at 94.1% and Call to
Whilst elective screening is compliant with standard at a whole trust level,	no occurrences.	- Early Booking Assessment (<12 + 6 weeks) - SWBH specific definition target of 90% has consistently	Oct, Sep 6.3%, 6.5% in August) showing an improvement again in the performance to last month	balloon time (<150 minutes) at 93.3% hence both indicators delivering consistently against 80% targets
Medicine Group is at 68.3% (with Scheduled Care @ 35% only) - escalation to CNO to ensure effective remedial action within the group.	x15 (x23) DOLS have been raised in April of which 15 were 7-day urgents;	not been met and for April the delivery is 80.8%; however, performance is consistently delivering to nationally specified definitions in large part due to significant excess of registrations over births in the	7.1% rolling 12 mths. The equivalent peer group rate is at 7.7% increasing significantly in the last months.	RACP performance for April is at 100% [100%] exceeding the 98% target for over 14
	Vaccus Thromboombolism (ITE) Access - 1 - 1 - 1 - 2 - 2 - 4 - 1 - 1 - 2 - 3 - 4 - 1 - 1 - 2 - 3 - 4 - 1 - 1 - 2 - 3 - 4 - 1 - 1 - 3 - 3 - 4 - 1 - 1 - 3 - 3 - 4 - 1 - 1 - 3 - 3 - 4 - 1 - 1 - 3 - 3 - 4 - 1 - 1 - 3 - 3 - 4 - 1 - 1 - 3 - 3 - 3 - 3 - 3 - 3 - 3 - 3	Trust, so not a fully reflective indicator as such.  - Deliveries, reducing to last month and still continue to be below registrations.		consecutive mths
MSSA Bacteraemia (expressed per 100,000 bed days) for the month of April at	Venous Thromboembolism (VTE) Assessments in April at 96.4% compliant with 95% standard across all Groups except Medicine & EC.			TIA (High Risk) Treatment <24 Hours from receipt of referral delivery as at April is at 95.8% against the target of 70%.
21.1 against a tolerance rate of 9.42. 7/12 months elevated levels. Escalated to CNO for review & assurance	Missing 262 assessments in April . Stubborn number of assessments missed -	Breastfeeding initiation performance as at March quarter is at 73.7% just below the target of 74.0%.		TIA (Low Risk) Treatment <7 days from receipt of referral delivery at April is 100% against a target of 75%.
Escalated to CNO for review & assurance  Cancer Care	escalated to MD to resolve.  Patient Experience - MSA & Complaints	Patient Experience - Cancelled Operations	Emergency Care	Referral To Treatment
33,107 33,10	Taton Exponence men a complaina	- 47 [57] sitrep declared late (on day) cancelations were reported in April of which avoidable were at	- The Trust's performance against the 4-hour ED wait target in April was 84.95% [85.22%] against the 95%	
- March performance delivery across all cancer targets including 62 Days .	There were 21 MSA breaches in April.	47 [37] Strep declared late (on day) cancellations were reported in April or which avoidable were at the highest level for a number of months.  From the 47 patients who were cancelled, 24 were validated as avoidable in April month.	national target  - 2,814 breaches were incurred in April; (2,875 Mar, 3,046 Feb, 2,821 Jan, 3,324 Dec, 3,237 Nov, 2,676	- RTT incomplete pathway for April is at 92.76% [93.08%]; continuing to perform closely to trajectory
- 62 day performance in March at 91.6% - March Q4 delivery at 85.7% of the 62 days target		- Cancellations remained high for the Trust in April.	Oct, 2,051 Sept, 1,884 Aug) .  - ED quarterly performance trend for 16/17 : Q1 at 91.9%, Q2 at 89.2%, Q3 at 83.64% and Q4 at 84.0%;	<ul> <li>- April forecast was for the Trust to deliver 93.08% again as per previous month but this was not achieved mainly across surgical specialities</li> </ul>
- Full year the 62 Day indicator reflects 86.2% delivery to the 85% national target.		The proportion of elective operations cancelled at the last minute for non-clinical reasons was 1.3% for April (rising since Jun16 when at 0.7%) failing the tolerance of 0.8% consistently.	<u>Full Year 16/17</u> performance at 87.22%;	- The backlog for April is at 2,350 patients (April forecast was set at 2,237) - The backlog for April is now largely inpatient driven (55% of backlog); 23% is follow ups and - The backlog for April is now largely inpatient driven (55% of backlog); 23% is follow ups and
<ul> <li>This completes the 16/17 year with delivery of the 62 Day target for each quarter.</li> </ul>		10/12 months failure to achieve standard		the remaining element is OP indicating a significant IP pressure  - The total waiting list has remained fairly static for the last three months stabilising at 32,000-
				33,000 patients (Sept16 high at 37,380)  -This is a significant and credible achievement for the Trust which needs to now be sustainably
	Friends & Family reporting requires a review to understand the consistent under- delivery across several areas.			managed across all services
	delively acioss several aleas.	There was 1x 28 days guarantee breach in April in Dermatology;     No urgent cancellations took place during the month	- WMAS fineable 30 - 60 minutes delayed handovers at 110 in April (107) x0 [x5] cases were > 60 minutes delayed handovers in April	
March validated position is that x8 [x15] patients waited longer than the 62 days.			- Handovers >60mins (against all conveyances) 0.00% in April exceeding the target of 0.02%.	2x 52 week breach has been identified against incomplete pathways in the month
x 5 patients waited more than 104 days at the end of March -The longest waiting patient as at the end of March was at 162 days				
- 25% (11/44 patients) neutropenic sepsis April cases failed to receive treatment			Fractured Neck of Femur Best Practice Tariff delivery for April is 41.4% [91.3%] showing a significant worsening to previous months and against the national target of 85%.	
within prescribed period (less than 1hr). Delivery therefore at 75% [84%] still below the 100% target.	The number of complaints received for the month of April is 83 with 2.9 formal complaints per 1000 bed days.	Theatre utilisation is consistently below the target of 85% at a Trust average of 71.8% in April impacted by a large number of cancellations in the month: The theatre capacity and performance is subject to		- Diagnostics performance under-performing again in April and delivers 98.23% (132 breaches
- 50% of Tertiary referrals were met within 38 days by the Trust for the month of March - the consistent failure to meet this target requires attention and escalated	100% have been acknowledged within target timeframes (3 days).  36% of responses have been reported beyond agreed target time, showing	remedial action through Theatres Board and part of the productivity management focus as part of the		at month end); mainly due to locum issues in cardiology (66) which will have a knock-on effect still for May;  - From May
to GD0 for review & assurance.	improvement to last month but still on the high side.	'production plan'.	DTOCs accounted for 546 [583] bed days in April; of which 324 [375] beds were fineable to BCC.  Notable increase on prior year with prospect of further deterioration as social care budgets further	performance is projected to pick up to national standard of 99%.
			constrained.	
Data Completeness  - The Trust's internal assessment of the completion of valid NHS Number Field	Staff  PDR overall compliance as at the end of April is at 87.9% against the 95% target.	CQUINs, Local Quality Requirements 2016/17	STF Criteria & NHSI Single Oversight Framework	Summary Scorecard - April (In-Month)
within inpatient data sets remains below the 99.0% operational threshold (Mar 97.7%). Expected to recover to target when the annual update is run later in the	Medical Appraisal at 81.8% worsening this month to previous periods (performance indicates appraisals 'validated' not 'carried out').	Quarter 4 CQUIN and amount has been finalized.		Section   Rated   Rated   None   Total   Infection Control   1   5   0   6
month.		Quarter 4 CQUIN performance has been finalised, although not confirmed as yet through the year end settlement process. Expected issues with CCG Schemes have materialised and Sepsis, Staff Survey		Harm Free Care 9 4 9 22 Obstetrics 2 5 6 13
- ED required to improve patient registration performance as this has a direct effect on emergency admissions.	In-month sickness for April is at 4.40% against the 2.5% target; the number of short term sickness 414 cases (785) has sharply reduced to last months and long	and mortality reviews have failed to deliver the full values. Specialised CQUINs delivered 1 out of 3 schemes. All Public Health schemes are expected to deliver. The total financial impact of non-		Mortality and Readmissions
- Patients who have come through Malling Health will be validated via the Data Quality Department.	term 214 (213) cases remainly static to the recently observed reduced levels. The cumulative sickness rate is at 4.45%. RTW is at 79.4% in month	delivery is in the region of £0.6m-£1m.		Cancer 0 10 5 15  FFT. MSA, Complaints 14 2 5 21
<ul> <li>Ethnicity coding is performing for Inpatients at 91% against 90% target, but under delivering for Outpatients. This is attributed to the capture of data in the Kiosks</li> </ul>	[-		30% [c£3.1m] performance related STF to be assessed against achievement of ED 4hr improvement	Cancellations 6 2 0 8 Emergency Care & Patient 1 7 7 4 18
and revision to capture fields is being considered.		Local Quality Requirements 2017/18 are monitored by CCG and there is no confirmation at this stage how Key Access Targets (A&E, RTT, Diagnostics and Cancer) will be treated this year in relation to STF	trajetory.  That trajectory remains to be confirmed by NHSi.	RTT 7 1 6 14  Data Completeness 2 8 9 19
	The Trust annualised turnover rate is at 11.5% in April [11.3%]. Specifically, nursing turnover is in April to 11.7%. Both are still well above trust	criteria. Last year these were excluded directly from CCG fines.  Last year the Trust falled to deliver across a number of indicators and these have been subject	Balance of STF (c£7.4m) related to achievement of financial plan.	Workforce 5 1 13 19 Temporary Workforce 1 0 27 28
	aspirations in respect of turnover rate, and remain fairly static now for the last year.	to formal RAPs (recovery action plans) which continue into 17/18:  • Safeguarding training for which the performance notice action plan has been accepted, but failing to	P01 financial performance reported as being on plan but supported by c£0.6m of non-recurrent masures.	SQPR 10 0 0 10 Total 67 55 95 217
Open Referrals, without future activity, stand at 111,000 as at April showing an increasing trend again as administration/IT processes persistently do not close down		deliver trajectory (the trust may be liable to repay the full fine c£200k)  Community falls & dementia		Tracking CCG Performance Notices :
as appropriate. We will be investigating the impact of recently identified Partial Booking issues on open referrals. (Note: these open referral numbers 'exclude'	Mandatory Training at the end of April is at 87.6% overall against target of 95%;	On the Day Cancellations • Gynae 4 week community clinics     A&E including morning discharges.		Cancelled Operations: on-day cancelled operations     Community Gynae referral to 1st OP within 4 weeks – also not performed all year.
patients on the RTT pathway and waiting list). 50% of open referrals are generated in outpatients cohort and we are now pursuing a specific line of enquiry in respect of	Health & Safety related training is above the 95% target at 96.4% in April.	A new IPR page has been added to highlight and monitor areas of non-compliance (Local Quality Requirements page).		RAP for Dementia & Falls Assessment not delivering and exception report was submitted     Safeguarding training RAP – Children level 3 below agreed trajectory as is adult advanced
PB. Low patient risk rated (green risk) amount to c15,000 which are part of the 111,000, are subject to auto-closures since Jan2016.	extending delivery further out. A significant proportion of all training is below the 85% delivery at present.	<ul> <li>The Trust received confirmation that RAPs (recovery plans) provided in April for the above have been accepted. It is now down to the groups to monitor and deliver the required improvements.</li> </ul>		training - exception report required  RAP for A&E, RTT and Diagnostics to be specifically discussed during April
		accepted. It is now down to the groups to monitor and deriver the required improvements.		


## **Patient Safety - Infection Control**

Data	Data	PAF	Indicator	Measure	Traj	ectory
Source	Quality	PAF	indicator	Weasure	Year	Month
4		•d••	C. Difficile	<= No	30	2.5
4		• d •	MRSA Bacteraemia	<= No	0	0
4			MSSA Bacteraemia (rate per 100,000 bed days)	<= Rate2	9.42	9.42
4			E Coli Bacteraemia (rate per 100,000 bed days)	<= Rate2	94.9	94.9
3			MRSA Screening - Elective	=> %	80	80
3		·	MRSA Screening - Non Elective	=> %	80	80

Previous Months Trend (From Nov 2015)  N D J F M A M J J A S O N D J F M A	Data Period	Group       C   CO	Month	Year To Date Trend
	Apr 2017	0 1 0	1	1
	Apr 2017	0 0 0	0	•
	Apr 2017		21.1	21.1
	Apr 2017		0.0	0.0
	Apr 2017	68 89 94	87.0	87.0
	Apr 2017	93 95 100	94.0	94.0









PAGE 3

### **Patient Safety - Harm Free Care**

Data Source	Data Quality	PAF	Indicator	Measure	Trajectory Year Month	Previous Months Trend (since Nov 2015)   N   D   J   F   M   A   M   J   J   A   S   O   N   D   J   F   M   A	Data Period		Month	Year To Date	Trend
8	(4)	•d	Patient Safety Thermometer - Overall Harm Free Care	=> %	95 95		Apr 2017		93.7	93.7	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
8		•d	Patient Safety Thermometer - Catheters & UTIs	%		2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	Apr 2017		0.27	0.27	<b>^</b> ,
	NEW		Number of DOLS raised	No		25 22 15 14 23 15	Apr 2017	9 1 1 4	15	15	
	NEW		Number of DOLS which are 7 day urgent	No		25 22 14 14 23 15	Apr 2017	9 1 1 4	15	15	
	NEW		Number of delays with LA in assessing for standard DOLS application	No			Apr 2017	0 0 0 0	0	0	Λ
	NEW		Number DOLs rolled over from previous month	No		4 15 14 8 8 15	Apr 2017	11 1 0 - 3	15	15	<b>\</b>
	NEW		Number patients discharged prior to LA assessment targets	No		6 6 2 11 6 3	Apr 2017	1 0 0 2	3	3	
	NEW		Number of DOLs applications the LA disagreed with	No		1 0 1 1 0 1	Apr 2017	0 1 0 0	1	1	<b>//</b> V
	NEW		Number patients cognitively improved regained capacity did not require LA assessment	No		5 2 1 0 0 3	Apr 2017	1 0 0 2	3	3	
8			Falls	<= No	804 67	72 75 89 67 68 79 86 86 83 94 85 81 87 88 84 67 74 69	Apr 2017	36 10 0 0 0 23	69	69	<b>^</b>
9			Falls with a serious injury	<= No	0 0	3 1 2 2 2 1 0 4 1 3 3 1 2 3 3 1 2 1	Apr 2017	1 0 0 0 0	1	1	<b>√</b> //~
8	<b>(</b>		Grade 2,3 or 4 Pressure Ulcers (Hospital Aquired Avoidable)	<= No	0 0	6 5 9 6 9 8 9 5 10 8 5 9 8 13 8 9 6 13	Apr 2017	6 1 0 6	13	13	mn.
	NEW		Avoidable Grade 2,3 or 4 Pressure Ulcers (DN Caseload Acquired)	<= No	0 0	3 3 2 1 4 3 2 0 2 5 6 8 6 6	Apr 2017	6	6	6	~
3	0	•d•	Venous Thromboembolism (VTE) Assessments	=> %	95 95		Apr 2017	95.1 98.5 95.4	96.4	96.4	·~~
3			WHO Safer Surgery - Audit - 3 sections (% pts where all sections complete)	=> %	100 100		Mar 2017	100.0 100.0 99.7 0.0	100.0	99.9	\
3			WHO Safer Surgery - brief (% lists where complete)	=> %	100 100		Mar 2017	100 98 100 0	99.4	98.9	\
3			WHO Safer Surgery - Audit - brief and debrief (% lists where complete)	=> %	100 100		Mar 2017	99 98 100 0	98.7	98.3	
9	•	•d•	Never Events	<= No	0 0	0 0 0 1 0 0 0 1 1 0 0 0 1 1 0 0 0 1 0 0 0	Apr 2017	0 0 0 0 0 0	0	0	$\mathcal{M}_{\mathcal{A}} \wedge \mathcal{M}_{\mathcal{A}} \wedge $
9		•d	Medication Errors causing serious harm	<= No	0 0	1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Apr 2017	0 0 0 - 0 0	0	0	<u>\</u>
9		•d•	Serious Incidents	<= No	0 0	6 2 12 8 5 2 1 10 5 6 4 6 5 10 5 6 5 4	Apr 2017	3 0 1 0 0 0 0	4	4	\^~
9			Open Central Alert System (CAS) Alerts	<= No		4 9 7 6 5 1 13 3 11 12 12 14 10 8 6 5 4 8	Apr 2017		8	8	~\\ <u></u>
9	0	•d	Open Central Alert System (CAS) Alerts beyond deadline date	No	0 0	0 0 2 1 2 0 0 0 1 1 2 1 2 0 0	Apr 2017		0	0	.M/M.









# **Patient Safety - Obstetrics**


_						ectory																		_		
Data Source	Data Quality	PAF	Indicator	Measure	2016 Year	6-2017	_	N	D .	I F	М	Prev	/ious I	Months	Trend (	`			D ,		MIA	Data Period	Month		Year To Date	Trend
Source	Quality				rear	Month		N	D ,	)   F	IVI	А	IVI	J	J A	1 5	U	N	U ,	JF	WA	Periou			Date	
3			Caesarean Section Rate - Total	<= %	25.0	25.0									•							Apr 2017	26.2		26.2	<b>~~~</b>
3		•	Caesarean Section Rate - Elective	<= %				9	9 8	8	8	10	7	9	8 9	9 10	8	11	8 7	7 9	8 9	Apr 2017	8.9		8.9	~\\\~
3		•	Caesarean Section Rate - Non Elective	<= %			1	16	14 1	7 15	18	17	15	15	19 19	9 19	23	17	20 1	5 17	7 17 17	Apr 2017	17.3		17.3	~~~
2		•d	Maternal Deaths	<= No	0	0			•						• •				•			Apr 2017	0		0	
3			Post Partum Haemorrhage (>2000ml)	<= No	48	4									•				•			Apr 2017	1		1	$\bigvee \bigvee \bigwedge$
3			Admissions to Neonatal Intensive Care (Level 3)	<= %	10.0	10.0									• •				•			Apr 2017	1.83		1.83	~~~
12			Adjusted Perinatal Mortality Rate (per 1000 babies)	<= Rate1	8.0	8.0									• •						•	Apr 2017	4.07		4.07	M
12			Early Booking Assessment (<12 + 6 weeks) - SWBH Specific	=> %	90.0	90.0									• •							Apr 2017	80.8		80.8	<b>~</b>
12			Early Booking Assessment (<12 + 6 weeks) - National Definition	=> %	90.0	90.0			•						• •				•			Apr 2017	134.1		134.1	M
2			Breast Feeding Initiation (Quarterly)	=> %	74.0	74.0		->		> ->		>	>		->	>	>	>	•	->	->	Apr 2017	-		-	<b>\</b> \\\
2		•	Puerperal Sepsis and other puerperal infections (variation 1 - ICD10 O85 or O86) (%) -	<= %			1	.3	1.3 0.	7 1.6	1.8	1.8	3.7	1.9	1.4 1.	8 3.2	2.9	2.8	3.5 2.	.9 1.9	9 2.6 4.4	Apr 2017	4.39		4.39	<b>~~~</b>
2		•	Puerperal Sepsis and other puerperal infections (variation 2 - ICD10 O85 or O86 Not O864) (%)	<= %			1	.3	0.3 -	0.8	1.5	1.3	3.4	1.3	1.4 1.	5 3.0	1.8	1.9	1.7 2.	.5 1.6	6 2.3 3.0	Apr 2017	3.00		3.00	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
2		•	Puerperal Sepsis and other puerperal infections (variation 3 - ICD10 O85) (%)	<= %			1	.0	0.0	0.8	1.1	1.0	2.4	1.3	1.4 1.	5 3.0	1.4	1.3	1.0 2.	.0 1.6	6 2.1 2.3	Apr 2017	2.31		2.31	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\






### **Clinical Effectiveness - Mortality & Readmissions**

Data	Data	PAF	Indicator	Maggura	Trajectory				
Source	Quality	PAF	indicator	Measure	Year	Month			
_			Risk Adjusted Mortality Index (RAMI) - Overall		Below	Below			
5		• C •	(12-month cumulative)	RAMI	Upper CI	Upper CI			
			/						
			Risk Adjusted Mortality Index (RAMI) - Weekday		Below	Below			
5		• C •	Admission (12-month cumulative)	RAMI	Upper CI	Upper CI			
			(		оррог от	орро. о.			
			Risk Adjusted Mortality Index (RAMI) - Weekend		Below	Below			
5		• C •	Admission (12-month cumulative)	RAMI	Upper CI	Upper CI			
			Admission (12 month cumulative)		Opper Cr	Оррег Ст			
			Summary Hospital-level Mortality Index (SHMI)		D. I.	D. L.			
6		• C •	(12-month cumulative)	SHMI	Below	Below			
			(12-month cumulative)		Upper CI	Upper CI			
			L			1			
5		• C •	Hospital Standardised Mortality Rate (HSMR) - Overall	HSMR					
		-0-	(12-month cumulative)	11011111					
				1					
5		• C •	Deaths in Low Risk Diagnosis Groups (RAMI) - month	RAMI	Below	Below			
0			Deaths in Low Mak Diagnosis Groups (10 twil) Month	IXAWII	Upper CI	Upper CI			
3			Mortality Reviews within 42 working days	. 0/	90	90			
3			Mortality Reviews within 42 working days	=> %	90	90			
					•				
			Crude In-Hospital Mortality Rate (Deaths / Spells) (by						
3			month)	%					
			Crude In-Hospital Mortality Rate (Deaths / Spells) (12-						
3			month cumulative)	%					
					l				
	NEW		Deaths in the Trust	No					
			Emergency Readmissions (within 30 days) - Overall (exc.		1				
20	(0)		Deaths and Stillbirths) month	%	1				
			Deaths and Guilbritis) month		l				
			Te		1				
20			Emergency Readmissions (within 30 days) - Overall (exc.	%	l				
_0			Deaths and Stillbirths) 12-month cumulative	,,,					
5		• C •	Emergency Readmissions (within 30 days) - CQC CCS	%	l				
		<b>-</b> (	Diagnosis Groups (12-month cumulative)	/0	1				







Month

Date


1044


Trend












PAGE 6


# Clinical Effectiveness - Stroke Care & Cardiology


Data	Data	PAF	Indicator	Measure	Traj	ectory
Source	Quality	PAF	indicator	Weasure	Year	Month
3			Pts spending >90% stay on Acute Stroke Unit	=> %	90.0	90.0
3			Pts admitted to Acute Stroke Unit within 4 hrs	=> %	90.0	90.0
3		•	Pts receiving CT Scan within 1 hr of presentation	=> %	50.0	50.0
3			Pts receiving CT Scan within 24 hrs of presentation	=> %	95.0	95.0
3			Stroke Admission to Thrombolysis Time (% within 60 mins)	=> %	85.0	85.0
3			Stroke Admissions - Swallowing assessments (<24h)	=> %	98.0	98.0
3			TIA (High Risk) Treatment <24 Hours from receipt of referral	=> %	70.0	70.0
3			TIA (Low Risk) Treatment <7 days from receipt of referral	=> %	75.0	75.0
9			Primary Angioplasty (Door To Balloon Time 90 mins)	=> %	80.0	80.0
9			Primary Angioplasty (Call To Balloon Time 150 mins)	=> %	80.0	80.0
9			Rapid Access Chest Pain - seen within 14 days	=> %	98.0	98.0


Previous Months Trend (Since Nov 2015)  Data  Year To  Total																					
																		Data	Month	Year To	Trend
N	D	J	F	M	Α	M	J	J	Α	S	0	N	D	J	F	M	Α	Period		Date	
									•									Apr 2017	87.3	87.3	<b>\</b>
																		Apr 2017	97.1	97.1	~~
																		Apr 2017	84.2	84.2	~~~
																		Apr 2017	97.4	97.4	<b>1</b>
																		Apr 2017	75.0	75.0	
																		Apr 2017	100.0	100.0	
																		Apr 2017	100.0	100.0	<b>V V</b>
	•	•														•		Apr 2017	100.0	100.0	V
																		Apr 2017	94.1	94.1	<b>W/</b> \\
																		Apr 2017	93.3	93.3	
																		Apr 2017	100.0	100.0	


### 

























### Patient Experience - FFT, Mixed Sex Accommodation & Complaints

	Data PAF	Indicator	Measure	Trajectory Year Mont	nth	Previous Months Trend (since Nov 2015)   N   D   J   F   M   A   M   J   J   A   S   O   N   D   J   F   M   A	Data Period	Group  M   SS   W   P   I   C   CO	Month	Year To Date	Trend
8	<b>b•</b>	FFT Response Rate - Adult and Children Inpatients (including day cases and community)	=> %	50.0 50.0	.0	16 15 15 15 14 17 16 17 17 13 20 22 17 10 15 9.7 8 9.3	Apr 2017		9	9	~~~~
8	•a•	FFT Score - Adult and Children Inpatients (including day cases and community)	=> No	95.0 95.0	.0	93 96 96 95 95 96 90 83 86 83 86 88 94 97 97 95 96 95	Apr 2017		95		
8	<b>6</b>	FFT Response Rate: Type 1 and 2 Emergency Department	=> %	50.0 50.0	.0	5.9 5.7 6.3 6 5.3 5.1 8.3 10 7.8 7.5 7.1 5.6 4.8 5.9 5.4 4.3 4 5.5	Apr 2017	5.5	5.5	5.5	~~~
8	•a•	FFT Score - Adult and Children Emergency Department (type 1 and type 2)	=> No	95.0 95.0	.0	82 81 79 74 74 78 85 87 86 83 78 73 75 73 77 76 73 75	Apr 2017	75	75		$\sim$
8		FFT Response Rate: Type 3 WiU Emergency Department	=> %	50.0 50.0	.0	0 0.1 1.5 0.1 0 0.3 2.5 0.1 1.3 0.6 0.5 0.5 0.3 1.2 0.6 0 0 0 0.1	Apr 2017		0.1	0.1	1/2
8		FFT Score - Adult and Children Emergency Department (type 3 WiU)	=> No	95.0 95.0	.0	0 50 85 0 0 100 96 50 95 100 86 64 100 100 65 0 0 0	Apr 2017	-	0		<b>\\\\\</b>
8	<u> </u>	FFT Score - Outpatients	=> No	95.0 95.0	.0	87 86 90 88 87 87 88 88 86 89 88 88 89 90 88 88 89 90 90	Apr 2017		90		~~~
8 1	NEW	FFT Score - Maternity Antenatal	=> No	95.0 95.0	.0	100 100 96 100 95 100 91 100 94 86 79 86 90 86 97 11 95 88	Apr 2017		88		$\overline{}$
8 1	NEW	FFT Score - Maternity Postnatal Ward	=> No	95.0 95.0	.0	97 97 95 91 91 97 100 100 100 100 74 81 93 90 91 29 83 91	Apr 2017		91		~~~
8 1	NEW	FFT Score - Maternity Community	=> No	95.0 95.0	.0	95 98 96 99 99 99 99 100 98 96 91 100 100 50 0 0 80 100	Apr 2017		100		\ <u>/</u>
8		FFT Score - Maternity Birth	=> No	95.0 95.0	.0	86 82 90 94 93 92 90 0 0 100 87 71 88 90 88 23 92 82	Apr 2017		82		
8		FFT Response Rate - Maternity Birth	=> %	50.0 50.0	.0	28 14 23 15 10 12 9 0 0 1.4 15 5.9 17 13 8.2 5.4 21 8.9	Apr 2017		9	9	~~~
13	•a	Mixed Sex Accommodation Breaches	<= No	0.0 0.0	0	0 0 0 0 0 0 0 0 0 0 0 1 6 38 2 0 4 21	Apr 2017	21 0 0 0 0	21	21	
9	•	No. of Complaints Received (formal and link)	No			104 83 88 100 112 115 94 84 74 115 82 95 104 96 111 98 ## 83	Apr 2017	34 24 13 1 4 4 3	83	83	<b>/////////////////////////////////////</b>
9	<b>O</b>	No. of Active Complaints in the System (formal and link)	No			145 121 113 128 147 154 144 147 127 143 144 152 148 157 176 177 ## 205	Apr 2017	79 78 19 3 1 9 16	205		<b>/</b>
9	•a	No. of First Formal Complaints received / 1000 bed days	Rate1			3.4 2.7 2.7 3.3 3.3 3.4 2.9 2.3 4.5 3.4 2.6 2.8 3.1 2.6 3.2 3.9 3.9 2.9	Apr 2017	2.3 4.5 3	2.86	2.86	~~~
9		No. of First Formal Complaints received / 1000 episodes of care	Rate1			6.0 5.1 5.4 6.2 6.0 6.9 5.8 4.4 4.5 7.1 5.1 5.5 6.1 5.4 6.5 7.6 7.4 6.1	Apr 2017	5.7 7.2 5.8 0	6.11	6.11	~~~
9		No. of Days to acknowledge a formal or link complaint (% within 3 working days after receipt)	=> %	100 100	0	100 100 100 100 100 100 100 100 100 100	Apr 2017	100 100 100 100 100 100 100	100	100	
9		No. of responses which have exceeded their original agreed response date (% of total active complaints)	<= %	0 0		4.1 2.5 0.9 1.6 0 2.6 5.6 8.2 2.4 4.2 6.3 6.6 11 13 22 25 79 36	Apr 2017	35 38 26 0 0 33 44	36	36	^
9		No. of responses sent out	No			94 98 69 81 84 98 81 103 103 80 110 87 79 79 76 95 84 67	Apr 2017	19 21 12 1 2 1 11	67	67	~~~
14	•e•	Access to healthcare for people with Learning Disability (full compliance)	Yes / No	Yes Yes	s		Apr 2017	N N N N N N N	No		
						Compleints Number and Bate					










### **Patient Experience - Cancelled Operations**

Data	Data	PAF	Indicator	Measure	Traj	ectory
Source	Quality	PAF	Indicator	Weasure	Year	Month
2			No. of Sitrep Declared Late Cancellations - Total	<= No	320	27
2	NEW		No. of Sitrep Declared Late Cancellations - Avoidable	No		
2	NEW		No. of Sitrep Declared Late Cancellations - Unavoidable	No		
2	0	•	Elective Cancellations at last minute for non-clinical reasons (as a percentage of elective admissions)	<= %	0.8	0.8
2		•e•	Number of 28 day breaches	<= No	0	0
2		•e	No. of second or subsequent urgent operations cancelled	<= No	0	0
2			Urgent Cancellations	<= No	0.0	0.0
3			No. of Sitrep Declared Late Cancellations (Pts. >1 occasion)	<= No	0	0
			Multiple Hospital Cancellations experienced by same patient (all cancellations)	<= No	0	0
3			All Hospital Cancellations, with 7 or less days notice	<= No	0	0
3			Weekday Theatre Utilisation (as % of scheduled)	=> %	85.0	85.0

						Previou	ıs Mon	the Tr	and (e	ince N	ov 201	5)						Data	Group			Year To	
N	D	J	F	М	Α.	M	J	J	A	S	0	N	D	J	F	М	Α	Period		с со	Month	Date	Trend
33	40	24	41	34	22	31	31	49	55	42	41	69	43	45	67	57	47	Apr 2017	32 12		47	47	~~~
-	-	-	-	-	6	9	11	9	9	15	17	28	19	13	19	17	24	Apr 2017	17 5		24	24	_~~
-	-	-	-	-	16	22	19	40	43	27	22	41	18	29	48	37	23	Apr 2017	15 7		23	23	
•				•			•											Apr 2017	1.76 4.53		1.3	1.3	$\sim$
0	0	0	0	0	0	0	0	0	0	0	1	0	3	6	0	0	1	Apr 2017	0 0		1	1	
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Apr 2017	0 0		0	0	
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Apr 2017	0.0 0.0		0	0	
0	0	0	0	0	0	0	1	2	0	0	1	3	4	0	3	0	3	Apr 2017	3 0		3	3	<b>\</b> _W
57	39	63	56	57	79	63	43	56	51	60	49	50	63	61	62	67	51	Apr 2017	44 6		51	51	M
238	194	210	228	223	229	257	229	241	223	258	234	273	272	269	284	257	219	Apr 2017	161 27		219	219	~~~\
																		Apr 2017	76.5 83.1		71.8	71.9	VV









PAGE 10

### **Access To Emergency Care & Patient Flow**

Data Source	Data Quality	PAF	Indicator	Measure	Trajectory Year Month	Previous Months Trend (From   N   D   J   F   M   A   M   J   J   A   S   O   1			Unit S C B	Month	Year To Date	Trend
2	0	•e••	Emergency Care 4-hour waits	=> %	95.00 95.00		Apr 20	017	86.1 97.7	84.95	84.95	<b>~~~</b>
2	0		Emergency Care 4-hour breach (numbers)	No		1103 1715 1757 1956 2342 1608 1451 1625 2168 1884 2051 2676	3324 4 3324 4 3281 4 3281 4 3281 4 4 3281 4 4 3281 4 4 3281 4 4 3281 4 4 3281 4 4 3281 4 4 3281 4 4 3281 4 4 3281 4 4 3281 4 4 3281 4 4 3281 4 4 3281 4 4 32	017 15	33 1232 49	2814	2814	<b>~~~</b>
2		•e	Emergency Care Trolley Waits >12 hours	<= No	0.00 0.00		Apr 20	017	0 0	0	0	
3			Emergency Care Timeliness - Time to Initial Assessment (95th centile)	<= No	15.00 15.00		Apr 20	017 1:	5 15 63	15	15	~~~
3	0		Emergency Care Timeliness - Time to Treatment in Department (median)	<= No	60 60		Apr 20	017	8 53 107	65	65	MM
3	0		Emergency Care Patient Impact - Unplanned Reattendance Rate (%)	<= %	5.0 5.0		Apr 20	017	8.39 3.30	7.62	7.62	~~
3			Emergency Care Patient Impact - Left Department Without Being Seen Rate (%)	<= %	5.0 5.0		Apr 20	017 4.4	45 6.10 1.99	4.89	4.89	MM
11	0		WMAS - Finable Handovers (emergency conveyances) 30 - 60 mins (number)	<= No	0 0	67 1116 97 117 81 65 70 112 112 113 113	Apr 20	017	9 51	110	110	~~~
11	0		WMAS -Finable Handovers (emergency conveyances) >60 mins (number)	<= No	0 0	16 9 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	7 01 11 E	017	0	0	0	$\sim\sim$
11	0	•	WMAS - Handover Delays > 60 mins (% all emergency conveyances)	<= %	0.02 0.02		Apr 20	0.0	0.00	0.00	0.00	~~~
11	0		WMAS - Emergency Conveyances (total)	No		4202 4573 4679 3961 4513 4115 4604 4099 4363 4204 4138	4410 4410 470 470 470 470 470 470 470 470 470 47	20	49 2088	4137	4137	<b>////</b>
2	0		Delayed Transfers of Care (Acute) (%)	<= %	3.5 3.5		Apr 20	0.017	.8 2.9	1.6	2	<b>\\\\\</b>
2			Delayed Transfers of Care (Acute) (Av./Week) attributable to NHS	<= No	<10 per site <10 per site		Apr 20	017 4.6	67 11	16		<b>~~~</b>
2	0		Delayed Transfers of Care (Acute) - Total Bed Days (All Local Authorities)	<= No	0 0	497 498 318 426 397 454 494 588 617 530	85 212 88 8 8 4 Apr 20	017		546	546	~~~
2	0		Delayed Transfers of Care (Acute) - Finable Bed Days (Birmingham LA only)	<= No	0 0	254 267 287 288 288 288 288 288 288 288 288 28	7/7 64 47 80 80 80 87 87 87 87 87 87 87 87 87 87 87 87 87	017		324	324	~~~~
2			Patient Bed Moves (10pm - 6am) (No.) -ALL	No		518 540 632 543 548 451 578 578 578 578 578 578 578	Apr 20	017		584	584	~~~
2	0		Patient Bed Moves (10pm - 6am) (No.) - exc. Assessment Units	No		209 236 330 269 223 225 222 204 204 248 219	Apr 20	017		229	229	<b>////</b>
			Hip Fractures - Best Practice Tarriff - Operation < 36 hours of admission (%)	=> %	85.0 85.0		Apr 20	017		41	41.4	<b>√</b> ~~~
			ED 4-Hour Recovery Pla	n		Available Re	ds Month End		Hip Fractu	res - RPT -	Oneration	Within










### **Referral To Treatment**


Data	Data	PAF	Indicator	Measure	Traj	ectory
Source	Quality	PAF	indicator	weasure	Year	Month
2		•6••	RTT - Admitted Care (18-weeks)	=> %	90.0	90.0
2		• 6 • •	RTT - Non Admittted Care (18-weeks)	=> %	95.0	95.0
2		•6••	RTT - Incomplete Pathway (18-weeks)	=> %	92.0	92.0
	NEW		RTT - Backlog	No		
2		•e	Patients Waiting >52 weeks	<= No	0	0
2	NEW	•e	Patients Waiting >52 weeks (Incomplete)	<= No	0	0
2	0		Treatment Functions Underperforming (Admitted, Non-Admitted, Incomplete)	<= No	0	0
	NEW		Treatment Functions Underperforming (Incomplete)	<= No	0	0
2		•e•	Acute Diagnostic Waits in Excess of 6-weeks (End of Month Census)	<= %	1.0	1.0
	NEW		Acute Diagnostic Waits in Excess of 6-weeks (In Month Waiters)	No		


l					Pre	vious	Mont	hs Tr	end (s	since I	Nov 2	015)						Data	ſ	Group		Year To	Total
N	D	J	F	М	Α	M	J	J	Α	S	0	N	D	J	F	M	Α	Period	Ī	M SS W P I C CO	Month	Date	Trend
																		Apr 2017		85.5 72.4 78.7	77.60		7~~
																		Apr 2017		81.3 94.8 95.8	91.55		~~
																		Apr 2017		91.7 92.2 93.4	92.77		<b>—</b>
2512	2463	2468	2423	2557	2566	2561	2515	2870	2968	3289	3728	3417	3908	3204	2578	2214	2327	Apr 2017		610 1304 98	2327		
4	2	4	5	8	3	2	4	4	0	1	4	3	2	0	3	6	5	Apr 2017		1 4 0	5	5	<b>√</b> ~
2	0	3	3	2	0	2	2	0	0	1	2	2	2	1	3	2	3	Apr 2017		1 2 0	3	3	<b>/</b> ///
20	24	28	23	22	31	26	28	35	32	33	34	31	34	31	29	28	26	Apr 2017		9 14 1.0	26		~~~
6	5	4	4	2	3	3	3	4	4	5	6	6	8	5	4	5	5	Apr 2017		2 3 0	5		\_^\
																		Apr 2017		3.6 1.9 0.0 0.9	1.77		~~
2258	1593	1250	273	281	542	480	419	502	470	500	711	817	498	902	387	577	942	Apr 2017		354 149 - 439	942		\


























### **Data Completeness**


Data Source	Data P Quality	PAF Indicator	Measure Trajectory Year Month	Previous Months Trend (since Nov 2015)   N	Data Period	Group	Month	Year To Date	Trend
14		Data Completeness Community Services	=> % 50.0 50.0		Apr 2017	61.2	61.2		
2	C	Percentage SUS Records for AE with valid entries in mandatory fields - provided by HSCIC	=> % 99.0 99.0		Mar 2017		99.5		<b>~~</b>
2	C	Percentage SUS Records for IP care with valid entries in mandatory fields - provided by HSCIC	99.0 99.0		Mar 2017		99.2		~~
2	C	Percentage SUS Records for OP care with valid entries in mandatory fields - provided by HSCIC	=> % 99.0 99.0		Mar 2017		99.3		~_
2	C	Completion of Valid NHS Number Field in acute (inpatient) data set submissions to SUS	=> % 99.0 99.0	97.4 97.0 97.5 96.5 96.1 96.7 96.7 96.9 96.3 97.9 96.5 97.3 97.5 98.3 97.7 98.3 97.7 98.2	Apr 2017		98.2	98.2	<b>~</b> ~~
2	C	Completion of Valid NHS Number Field in acute (outpatient) data set submissions to SUS	=> % 99.0 99.0	99.5 99.5 99.5 99.5 99.6 99.5 99.5 99.5	Apr 2017		99.4	99.5	~~
2	C	Completion of Valid NHS Number Field in A&E data set submissions to SUS	=> % 95.0 95.0	97.1 96.8 97.3 97.0 97.1 96.7 96.8 97.2 97.0 96.7 97.0 97.2 97.6 97.0 97.7 97.3 97.3 97.3	Apr 2017		97.3	97.3	<b>~~~</b>
2	C	Ethnicity Coding - percentage of inpatients with recorded response	d => % 90.0 90.0		Apr 2017		90.5	90.5	~
	NEW	Ethnicity Coding - percentage of outpatients with recorded response	=> % 90.0 90.0		Apr 2017		89.4	89.4	
	NEW	Protected Characteristic - Religion - INPATIENTS with recorded response	%	71.2 70.8 68.9 70.3 68.6 69.6 69.9 69.5 69.8 69.2 68.9 69.6 69.2 69.1 68.7 69.2 68.8 70.3	Apr 2017		70.3	70.3	W~~~
	NEW	Protected Characteristic - Religion - OUTPATIENTS with recorded response	h %	59.9         59.3         59.3         58.4         58.1         58.1         58.2         57.8         58.0         57.8         57.9         58.1         57.5         56.9         57.0         57.2         56.9         56.7	Apr 2017		56.7	56.7	~~~
	NEW	Protected Characteristic - Religion - ED patients with recorded response	%	62.9 62.0 63.9 62.3 62.3 64.8 63.3 64.3 66.5 65.3 64.0 64.3 64.1 64.7 64.1 64.7 64.2 64.7	Apr 2017		64.7	64.7	~~~
	NEW	Protected Characteristic - Marital Status - INPATIENTS with recorded response	%	99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 100.0 100.0 100.0 100.0 100.0 100.0 99.9 100.0 99.9 99.9	Apr 2017		99.9	99.9	<b>/////</b>
	NEW	Protected Characteristic - Marital Status - OUTPATIENTS with recorded response	%	41.1 40.7 40.8 40.5 40.5 39.8 39.8 39.9 40.1 40.8 40.3 40.4 39.9 35.8 40.8 41.3 41.5 41.3	Apr 2017		41.3	41.3	~~~
	NEW	Protected Characteristic - Marital Status - ED patients with recorded response	%	42.0 41.5 41.7 42.5 41.2 40.9 41.3 41.9 40.9 39.5 40.6 40.9 41.5 40.8 40.5 41.3 41.1 39.8	Apr 2017		39.8	39.8	~~~
2	C	Maternity - Percentage of invalid fields completed in SUS submission	S <= % 15.0 15.0		Apr 2017		6.2	6.2	<b>////</b>
2		Open Referrals	No		Apr 2017	59 512 6,601 30,091 ######	239,934		1
	NEW	Open Referrals - Awaiting Management	No	######################################	Apr 2017	2,782 454 2,845 15,253 53,057	111242		

















### CQUINs - Q4 Reporting (page 1 of 2)

		Annual Plan	Full Year	Value at Risk		Trajectory		201	6-17			Monthly T	rend					Т	
	CQUIN	Values (000s)	Delivery	(000s)	Indicator	Notes	Q1	Q2	Q3	Q4	A M .	-	N D J F M	Comments	Data Period	FULL YEAR	Trend	Next Month 3	Months
1a	National	£792k	£400k	£392k	Staff Health & Wellbeing - Introduction of health & wellbeing initiatives	Annual Staff Survey results to improve by 5% for full payment		eline 2015/16: Q9a, 9	•	2016 Results to 3xQs to improve by 5% for full payment	Met	n/a	Paradis Ma	A number of initiatives in place to improve results for Survey Questions 9a, 9b and 9c. Unfortunately, only 9c ( During the last 12 months have you felt unwell as a result of work related stress?) has improved by 5%. 3e improved partially by 3% (Does your organisation take positive action on health and well-being?) and 59b (In the last 12 months have you expenienced musculoskeletal problems (MSK) as a result of work activities?) has in fact worsened by 3%.	Mar-17	•			
1b	National	£792k	£792k	£0k	Staff Health & Wellbeing - Healthy food for NHS staff, visitors and patients	CQUIN funds will be paid on delivering the four outcomes opposite.	Unify Return submission	Renegotiate contracts	Renegotiate contracts	All four outcomes delivered	Met	n/a	Med	a) The banning of price promotions on sugary drinks and foods high in fat, sugar and salt (HFSS). The majority of HFSS fall within the five product categories; pre-sugared breakfast cereals, soft drinks, confectionery, seaury snacks and fast food sulters. b) The banning of advertisement on NHS premises of sugary drinks and foods high in fat, sugar and salt (HFSS); or) The banning of sugary drinks and foods high in fat, sugar and salt (HFSS) from checkous; and of Ensuring that healthy options are available at any point including for those staff working night shifts. Awaiting confirmation from CO and Steve Clarke that this COUIN is fully completed for the Trust or what work is ongoing to complete	Mar-17	•			
1c	National	£792k	£792k	£0k	Staff Health & Wellbeing - Improving uptake of flu vaccination	Annual submission; flu vaccination at 75%+	No	returns	Report %age achieved	Report %age achieved		N/A	Met Met	Completes at 81% for front line staff on which the CQUIN is based (60% across all staff)	Mar-17	•			
28	National	£396k	£296k	£100k	Sepsis - A&E Screening & Review	Trajectory to be agreed based on Q1 baseline	Q1 numbers in sample (50+) Screened & Reviewed in 72 hrs	Q1 numbers in sample (50+) Screened & Reviewed in 72 hrs	Q1 numbers in sample (50+) Screened & Reviewed in 72 hrs	Q1 numbers in sample (50+) Screened & Reviewed in 72 hrs				Partially delivered, failing to deliver the required sample levels.	Mar-17	•			
2b	National	£396k	£296k	£100k	Sepsis - Inpatient Screening & Review	Trajectory to be agreed based on Q1 baseline	Q1 numbers in sample (50+) Screened & Reviewed in 72 hrs	Q1 numbers in sample (50+) Screened & Reviewed in 72 hrs	Q1 numbers in sample (50+) Screened & Reviewed in 72 hrs	Q1 numbers in sample (50+) Screened & Reviewed in 72 hrs		Met	Med	Partial delivery.	Mar-17	•			
4a	National	£633k	£633k	£0k	Antimicrobial Resistance and Antimicrobial Stewardship - Reduction of antibiotic consumption		2015/16 data for AB consumption	Reporting	Reporting	2016/17 data for AB consumption	Met	Met	Met Met	Achieved	Mar-17	•			
4b	National	£158k	£158k	£0k	Antimicrobial Resistance and Antimicrobial Stewardship - Review of antibiotic prescribing		Q1 Reviews up to 25% of sample	Q2 Reviews up to 50% of sample	Q3 Reviews up to 75% of sample	Q4 Reviews up to 90% of Sample	Met	Met	Met Met	Achieved	Mar-17	•			
5a	Local	£633k	£633k	£0k	Cancer - Audit of 2ww cancellations		N/A	Reporting	Reporting	Reporting	N/A	Met	Met Met	CCG are very pleased with the audit that has been conducted and would like to thank the Trust for their work on this.	Mar-17	•			
5b	Local	£633k	£633k	£0k	Cancer - Cancer Treatment Summary Record in Discharge Care Plans		N/A	Reporting	Reporting	Reporting	N/A	Met	Met Met	Achieved	Mar-17	•			
5c	Local	£475k	£475k	£0k	Cancer - Cancer VTE Advice		N/A	N/A			N/A	N/A	Met Met	Achieved	Mar-17	•			
6	Local	£317k	£317k	£0k	Safeguarding CSE - Production of a CSE awareness video that is used in staff training sessions		Script	Shooting	Share in training	Share in training		Met		Milestone passed successfully. CCG would acknowledges early completion of this CQUIN by the Trust.	Mar-17	•			
7	Local	£950k	£712k	£237k	Mortality - Achieve an improvement in the % of avoidable and unavoidable death reviews within 42 days		Improvement on 15/16 Q4 Avg 68%	Improvement on last quarter avg	t Improvement on last quarter avg	Improvement on last quarter avg	Met Q1	Falled Q2	Met C3 Due in May	Has met Q3 submission (submitted in Q4 as in arrears); unlikelity to achieve full value	Mar-17	•			
8a	Local	£475k	£475k	£0k	Discharges - Implementation of transfer of care plans		Q1 Audit of 50 Notes	Q1 Audit of 50 Notes	Q1 Audit of 50 Notes	Q1 Audit of 50 Notes		Met	Met Met	Milestone in Q4 passed successfully, but findings from audits require robust action plans which are being put in place by lead over the next year to continue on this work.	Mar-17	•			
8b	Local	£475k	£475k	£0k	Discharges - Reduction in Readmission Rate (Adults)		Q1 Position compared to 15/16 Baseline	Improvement on last quarter	t Improvement on last quarter	Improvement on last quarter		Met	Met Met	Achieved	Mar-17	•			

	Target	Achieved	
SWBCCG	£7,915	£7,087	£829
SCG & PH	£675	£317	£357
Total	£8,590	£7,404	£1,186

### CQUINs - Q4 Reporting (page 2 of 2)

		Annual Plan	Full Year	Value at			Trajectory					Previous Months Trend	Data		Year To		Next 2 Months
	CQUIN	Values (000s)	Delivery	Risk (000s)	Indicator	Note	Year Month	Q1	Q2	Q3	Q4	AMJJASONDJFM	Period	Comments	Date	Trend	Month 3 Months
9	Specialis Service	sed £211k	£0k	£211k	Preventing term admissions to NIC			Carried forward to Q3	Carried forward to Q3	Reporting to Commence	Reporting	C/F C/F Not progressed	Mar-17	Due to resource implications the full CQUIN is not deliverable by the Trust. A partial delivery has been proposed to the commissioner which was accepted originally, but the patient numbers fall below expectations. An additional condor was proposed for inclusions which has not been accepted	•		
10	Specialis Service		£75k	£0k	Haemoglobinopathy improving pathways			Evidence meetings, action log and minutes.	Progress reporting; protocols			Met Met Met Met	Mar-17	Achieved - carries forward into 17/18	•		
11	Specialis Service		£106k	£106k	Activation systems for patients with long term conditions							C/F C/F Parady Met Parady Met	Mar-17	Initially, the Trust has not yet identified appropriate long term conditions of the relevant sample size. The reduced sample size now acceptabed by SCG and plans need to be put in place by the HIV service lead. Implementation plan outstanding.	•		
12	Public Health		£55k	£0k	Breast Screening - improvement in uptake - Local information collection on reasons for non-participation in screening amongst the general population							Mer Mer Mer Mer	Mar-17	being assessed	•		
13	Public Health		£36k	£0k	Breast Screening - improvement in uptake - Promotion of screening programme							Mer Mer Mer Mer	Mar-17	being assessed	•		
14	Public Health	£19k	£19k	£0k	Bowel Screening - improvement in uptake - Local information collection on reasons for non-participation in screening amongst the general population							Mar blue blue blue	Mar-17	being assessed	•		
15	Public Health		£12k	£0k	Bowel Screening - improvement in uptake - Promotion of screening programme							Med Med Shee May	Mar-17	being assessed	•		
16	Seconda Care Der		£54k	£0k	Sugar Free Medicines Audit						Q4 Reporting	N/A	Mar-17	being assessed			

#### Full Year Delivery Overview ..

- The Trust was contracted to deliver a total of 16 CQUIN schemes during 2016 / 2017 across CCG, Specialised Commissioning and Public Health schemes
   The collective financial value of the schemes was c.88.6m; Local & National schemes at £7.9m and Specialised & PH at £0.7m.
   The Trust is likely to deliver around £7.5m which is £1.1m short of full value schemes. To be confirmed as yet as part of the year end settlement process.

#### CCG Schemes (c800k loss)...

- x Staff & Welbeing scheme has failed to deliver improvement against last year's staff survey on two out of three specific questions (£397k loss);
- Sepsis screening & review performance is below expected levels (£200K loss); manual audits have been cumbersome for many wards hence have not resulted in required samples and documentation reviews to satisfy the requirement of the CQUIN (£PR delivers easier processes for this).


  \* Mortality Reviews (£200K loss) due to reviews being below the improvement required for 2 quarters in the year.


#### Specialised Services Schemes (c£300k loss)...

- x NICU the trust did not progress the scheme (£200k)
  x Long term conditions HIV service commenced the initiative but did not manage to catch up with all expected activity and hence a financial loss will be incurred (£100k)

### Workforce

Data Source	Data Quality	PAF	Indicator	Measure	Trajectory Year Month	Previous Months Trend (since Nov 2015)   N	Data Period	Group     Group     Group	Month	Year To Date	Trend
3		•b•	PDRs - 12 month rolling	=> %	95.0 95.0		Apr 2017	82.2 81.7 89.8 95.7 82.0 96.8 91.8		87.9	5
7	C	•b	Medical Appraisal	=> %	95.0 95.0		Apr 2017	87.0 76.1 77.3 87.5 86.2 0.0 50.0	81.8	81.8	~~~
3		•b	Sickness Absence (Rolling 12 Months)	<= %	3.15 3.15		Apr 2017	4.7 4.7 4.5 4.1 4.2 4.0 4.4	4.45	4.45	
3	NEW		Sickness Absence (Monthly)	<= %	3.15 3.15		Apr 2017	5.3 4.5 4.5 2.8 3.5 3.9 4.3	4.40	4.40	\\\\\
3	NEW		Sickness Absence - Long Term (Monthly)	No		240 250 256 249 247 253 245 247 246 253 205 213 214	Apr 2017	53 30 27 6 6 24 2	214	214	
3	NEW		Sickness Absence - Short Term (Monthly)	No		812 779 780 752 745 727 837 922 911 956 808 785 414	Apr 2017	66 61 50 30 29 57 3	414	414	
3			Return to Work Interviews following Sickness Absence	=> %	100.0 100.0		Apr 2017	71.8 84.3 84.3 83.9 70.8 78.6 81.1	79.4	79.4	
3			Mandatory Training	=> %	95.0 95.0		Apr 2017	82.7 86.5 88.9 92.8 87.8 92.1 89.8		87.6	~~
3	0		Mandatory Training - Staff Becoming Out Of Date	%			Jan-00			-	
3		•	Mandatory Training - Health & Safety (% staff)	=> %	95.0 95.0		Apr 2017	94.0 0.0 95.7 98.2 95.2 97.7 98.7		96.4	W
7		•b•	Employee Turnover (rolling 12 months)	<= %	10.0 10.0		Apr 2017		11.5	11.5	
	NEW		Nursing Turnover	%		- 14.6 14.7 14.8 13.8 13.6 12.6 11.8 11.3 11.2 11.9 12.4 11.7 11.4 11.6 11.2 11.7 11.7	Apr 2017		11.7	11.7	
7	0		New Investigations in Month	No		6 2 5 12 9 6 4 3 8 4 4 3 0 3 4 3 9 -	Mar 2017	2 2 1 0 0 0 4	9		$\sim$
7			Vacancy Time to Fill	Weeks		23 23 24 26 23 26 25 23 24 24 21 25 21 21 21 22 21 20	Apr 2017		20		~~~
7		•	Professional Registration Lapses	<= No	0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Apr 2017	0 0 0 0 0 0	0	0	
7			Qualified Nursing Variance (FIMS) (FTE)	No		267 293 272 274 293 292 315 317 339 343 341 313 293 305 268 246 257 256	Apr 2017		256		~~~
15			Your Voice - Response Rate	No		-> 12.6 -> -> -> -> -> -> -> -> -> ->	Jan 2017	8 30 13 22 20 29 18	16		Λ
15			Your Voice - Overall Score	No		-> 3.57 -> -> -> -> -> -> -> -> -> ->	Jan 2017	3.68 3.79 3.66 3.82 3.58 3.83 3.64	3.7		<b>//</b>





					Temporary Workforce
Data Source	Data Quality	PAF	Indicator	Measure Trajectory Year Month	Previous Months Trend (since Nov 2015)   Data   Group   Month   Trend   Data   Group   Trend   Data   M   S   W   P   1   C   CO   Date   Trend   Data   C   C   C   C   C   C   C   C   C
	(4)		Medical Staffing - Number of instances when junior rotas not fully filled	<= % 0 0	
			Medical Staffing - Demand	No No	- · · · · 1443 1429 1522 1491 1419 1419 1598 1788 1699 1534 1703 1682 Apr 2017 1130 343 200 0 9 0 0 1682 16820
			Medical Staffing - Total Filled	%	
			Medical Staffing - Bank Filled	%	
			Medical Staffing - Agency Filled	%	
			Medical Staffing - Filled Shifts - Snr Consultant	No	114 110 107 137 177 243 237 187 152 217 270 120 Apr 2017 101 11 0 0 8 0 0 120 120 120.
			Medical Staffing - Filled Shifts - Jnr Doctor	No	- · · · · · · 1089 951 1021 1010 998 951 1108 1196 1144 1001 1026 896 Apr 2017 544 251 100 0 1 0 0 896 896.0
			Nursing - Demand	No	- · · · · 8158 8413 9220 9887 9312 9476 9802 9935 ### 9268 ### 8625 Apr 2017 4721 1692 928 0 76 1258 150 8825 8825
			Nursing - Total Filled	%	
			Nursing - Qualified - Bank Filled	%	
			Nursing - Qualified - Agency Filled	%	
			Nursing - HCA - Bank Filled	%	
			Nursing - HCA - Agency Filled	%	
			AHPs - Radiography - Demand (Shifts)	No	138 97 79 55 289 332 321 290 528 332 525 332 Apr 2017 0 0 0 0 332 0 0 332 332 332
			AHPs - Radiography - Filled (Shifts)	No	- · · · · · 138 97 73 55 249 324 299 256 496 302 502 329 Apr 2017 0 0 0 0 329 0 0 329 329 329
			AHPs - Physiotherapy - Demand (Shifts)	No	191 156 192 55 63 38 190 186 276 478 356 180 Apr 2017 0 0 0 0 180 0 180 180
			AHPs - Physiotherapy - Filled (Shifts)	No	- · · · · · 191 156 192 55 63 38 190 186 274 478 346 180 Apr 2017 0 0 0 0 180 0 180 180
			AHPs - Other - Demand (Shifts)	No	- · · · · · 301 336 289 66 98 139 96 567 413 530 1009 459 Apr 2017 180 27 20 35 9 168 20 459
			AHPs - Other - Filled (Shifts)	No	
			Admin - Demand (Shifts)	No	1994 1954 1902 2147 2765 2639 2479 2442 2381 4128 5135 4198 Apr 2017 1112 768 236 271 80 83 1648 4198 4198
			Admin - Filled (Shifts)	No	- · · · · 1988 1937 1855 2061 2450 2589 2452 2405 2349 4026 5079 4162 Apr 2017 1097 764 235 271 80 83 1632 4162
			Facilities - Demand (Shifts)	No	
			Facilities - Filled (Shifts)	No	1898 1933 1405 1337 1942 2135 1968 2107 1992 1928 2425 1737 Apr 2017 23 32 0 0 9 20 1653 1737
			Interpreters - Demand (Shifts)	No	
			Interpreters - Total Filled	%	
			Interpreters - Bank Filled	%	
			Interpreters - Agency Filled	%	
			Interpreters - Unfilled	%	
2000			Medical Staffing - Number of Shift	s	Nurse Staffing - Number of Shifts
1800 1600					10000
# 1400 1200 1000				111111	# 8000 6
800 8 600 400					5 0000  CAL Stank Filled (No.)  Qualified - Spany Filled (No.)
200					2000 — — Demand (No.)
	2015201520		0152015201520152016201620162016201620162016201620162016		
			Medical Staffing - % Shifts Filled		Nurse Staffing - % Shifts Filled
100					120
80 To 60					50 ————————————————————————————————————
9 80 3 40				X	50 ————————————————————————————————————
20					40 HCA - Agency Filed (%) — Total Filled (%)
0	May Jun 3 201520157	Jul Aug 5	Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Ses 01520152015201520162016201620162016201620162016201	Oct Nov Dec Jan Feb Mar Apr 62016201620162017201720172017	
			Total Filled (%) — Bank Filled (%) — Agency Fill		

### **SQPR**

Data	Data	PAF	Indicator	Measure	Traje	ectory
Source	Quality	FAF	indicator	Measure	Year	Month
			Safeguarding Adults Advanced Training	=> %	85	85
			Safeguarding Children Level 2 Training	=> %	85	85
			Safeguarding Children Level 3 Training	=> %	85	85
			WHO Safer Surgery - Audit - brief and debrief (% lists where complete) - SQPR	=> %	100	100
			Morning Discharges (00:00 to 12:00) - SQPR	=> %	27	27
			ED Diagnosis Coding (Mental Health CQUIN) - SQPR	=> %	90	90
			BMI recorded by 12+6 weeks of pregnancy - SQPR	=> %	90	90
			CO Monitoring by 12+6 weeks of pregnancy - SQPR	=> %	90	90
			Community - Screening For Dementia - SQPR	=> %	100	100
			Community - HV Falls Risk Assessment - SQPR	=> %	100	100


_				-	Previ	ous I	/onti	ns Tr	end (	From	Nov	201	5)					Data	_		Group	7 (		Year To	
N	D	J	F	M	Α	M	J	J	A	S	0	N		J	F	М	Α	Period		M SS W		<b>j</b> [	Month	Date	Trend
-	-	-	-	-	-	-	-	-	-	80	80	81	81	80	79	81	81	Apr 2017					80.98	80.98	
-	-	-	-	-	74	73	73	72	73	71	71	73	75	76	77	77	78	Apr 2017					77.7	77.7	
-	-	-	-	-	71	72	72	75	74	73	73	75	78	78	81	84	85	Apr 2017					84.9	84.9	
-	-	-	-	-	99	99	99	100	99	100	98	97	95	97	99	99	-	Mar 2017	9	9.2 98 10	0		98.7	98.3	
-	-	-	-	-	16	15	17	17	13	16	16	17	17	20	17	16	16	Apr 2017	1:	5.2 9.98 29.	.9		15.7	15.7	<b></b>
-	·	-	-	-	88	88	87	87	87	87	85	86	86	86	86	87	86	Apr 2017					85.5	85.5	
-	-	-	-	-	83	81	79	79	78	87	86	82	81	84	81	77	78	Apr 2017					77.8	77.8	
-	-	-	-	-	79	80	81	82	82	75	76	76	75	73	78	79	76	Apr 2017					75.5	75.5	
-	-	-	-	-	40	37	53	30	37			Dat	a Qua	lity Is:	sues			Aug 2016					37.2	38.4	M
-	-	-	-	-	61	67	56	61	55			Dat	a Qua	lity Is:	sues			Aug 2016					54.8	60.0	M

#### Notes:

- All of the above indicators are subject to formal RAPs (recovery plans) with the CCG and as such groups have to keep focus on improvement.
- Failure to deliver the improvement trajectories will result in another exception report and will be potentially fine-able.

PAGE 17

### Legend



## **Medicine Group**

Section	Indicator	Measure	Trajectory Year Month	Previous Months Trend     N   D   J   F   M   A   M   J   J   A   S   O   N   D   J   F   M   A   M   A   M   J   J   A   S   O   N   D   J   F   M   A   M   A   M   J   J   A   S   O   N   D   J   F   M   A   M   A   M   J   J   A   S   O   N   D   J   F   M   A   M   A   M   J   J   A   S   O   N   D   J   F   M   A   M   A   M   J   J   A   S   O   N   D   J   F   M   A   M   A   M   J   J   A   S   O   N   D   J   F   M   A   M   A   M   J   J   A   S   O   N   D   J   F   M   A   M   A   M   J   J   A   S   O   N   D   J   F   M   A   M   A   M   J   J   A   S   O   N   D   J   F   M   A   M   A   M   J   J   A   S   O   N   D   J   F   M   A   M   A   M   J   J   A   S   O   N   D   J   F   M   A   M   A   M   A   M   J   J   A   S   O   N   D   J   F   M   A   A	Data Period	Directorate  EC   AC   SC	Month	Year To Date	Trend
Patient Safety - Inf Control	C. Difficile	<= No	30 3		Apr 2017	0 0 0	0	0	$\fill \fill \fil$
Patient Safety - Inf Control	MRSA Bacteraemia	<= No	0 0		Apr 2017	0 0 0	0	0	
Patient Safety - Inf Control	MRSA Screening - Elective (%)	=> %	80 80		Apr 2017	90 80 35	68.3		~~~
Patient Safety - Inf Control	MRSA Screening - Non Elective (%)	=> %	80 80		Apr 2017	94 92 93	93.5		M
Patient Safety - Harm Free Care	Number of DOLS raised	No		19 20 14 14 16 9	Apr 2017	6 3 0	9	9	
Patient Safety - Harm Free Care	Number of DOLS which are 7 day urgent	No		19 20 12 14 16 9	Apr 2017	6 3 0	9	9	
Patient Safety - Harm Free Care	Number of delays with LA in assessing for standard DOLS application	No		4 0 0 0 0 0	Apr 2017	0 0 0	0	0	
Patient Safety - Harm Free Care	Number DOLs rolled over from previous month	No		3 14 12 8 8 11	Apr 2017	4 7 0	11	11	~
Patient Safety - Harm Free Care	Number patients discharged prior to LA assessment targets	No		5 6 2 11 5 1	Apr 2017	1 0 0	1	1	
Patient Safety - Harm Free Care	Number of DOLs applications the LA disagreed with	No		1 0 1 1 0 0	Apr 2017	0 0 0	0	0	
Patient Safety - Harm Free Care	Number patients cognitively improved regained capacity did not require LA assessment	No		5 2 1 0 0 1	Apr 2017	1 0 0	1	-	
Patient Safety - Harm Free Care	Falls	<= No	0 0	41 35 40 35 32 44 37 47 39 47 44 34 41 47 50 38 34 36	Apr 2017	20 16 0	36	36	WWV
Patient Safety - Harm Free Care	Falls with a serious injury	<= No	0 0	2 0 0 1 1 0 0 2 1 2 2 0 2 3 3 1 2 1	Apr 2017	0 1 0	1	1	$\bigvee$
Patient Safety - Harm Free Care	Grade 2,3 or 4 Pressure Ulcers (hospital aquired avoidable)	<= No	0 0	3 4 4 6 4 4 3 3 5 5 4 5 7 9 5 5 4 6	Apr 2017	0 6 0	6	6	^~~
Patient Safety - Harm Free Care	Venous Thromboembolism (VTE) Assessments	=> %	95.0 95.0		Apr 2017	92.2 91.8 99.1	95.1		~~~
Patient Safety - Harm Free Care	WHO Safer Surgery Checklist - Audit 3 sections	=> %	100.0 100.0		Mar 2017	100.0 100.0 100.0	100.0		
Patient Safety - Harm Free Care	WHO Safer Surgery Checklist - Audit 3 sections and brief	=> %	100.0 100.0		Mar 2017	100 100 100	100.0		
Patient Safety - Harm Free Care	WHO Safer Surgery Checklist - Audit 3 sections, brief and debrief	=> %	100.0 100.0		Mar 2017	99 99 100	99.2		
Patient Safety - Harm Free Care	Never Events	<= No	0 0		Apr 2017	0 0 0	0	0	
Patient Safety - Harm Free Care	Medication Errors	<= No	0 0	1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Apr 2017	0 0 0	0	0	
Patient Safety - Harm Free Care	Serious Incidents	<= No	0 0		Apr 2017	2 1 0	3	3	<b>/</b>
Clinical Effect - Mort & Read	Mortality Reviews within 42 working days	=> %	100 98		Feb 2017	52 49 52	51		m

				Medicine Group					
Clinical Effect - Mort & Read	Emergency Readmissions (within 30 days) - Overall (exc. Deaths and Stillbirths) month	%		8.6 9.3 9.2 9.4 9.6 9.7 10.0 9.2 9.0 8.6 8.3 10.0 9.7 9.9 9.5 9.4 9.4 -	Mar 2017		9.4		
Clinical Effect - Mort & Read	Emergency Readmissions (within 30 days) - Overall (exc. Deaths and Stillbirths) 12-month cumulative	%		10.3   10.3   10.1   10.1   10.0   9.8   9.8   9.7   9.5   9.3   9.2   10.0   9.3   9.4   9.4   9.4   9.4   -	Mar 2017			9.5	
Section	Indicator		Trajectory Year Month	Previous Months Trend	Data Period	Directorate EC   AC   SC	Month	Year To Date	
Clinical Effect - Stroke & Card	Pts spending >90% stay on Acute Stroke Unit (%)	=> %	90.0 90.0		Mar 2017	95.0	95.0	94.5	
Clinical Effect - Stroke & Card	Pts admitted to Acute Stroke Unit within 4 hrs (%)	=> %	90.0 90.0		Apr 2017	97.1	97.1	97.1	~~
Clinical Effect - Stroke & Card	Pts receiving CT Scan within 1 hr of presentation (%)	=> %	50.0 50.0		Apr 2017	84.2	84.2	84.2	MW
Clinical Effect - Stroke & Card	Pts receiving CT Scan within 24 hrs of presentation (%)	=> %	100.0 100.0		Apr 2017	97.4	97.4	97.4	<b>√</b> √~`
Clinical Effect - Stroke & Card	Stroke Admission to Thrombolysis Time (% within 60 mins)	=> %	85.0 85.0		Apr 2017	75.0	75.0	75.0	<b>~</b> ~~
Clinical Effect - Stroke & Card	Stroke Admissions - Swallowing assessments (<24h) (%)	=> %	98.0 98.0		Apr 2017	100.0	100.0	100.0	
Clinical Effect - Stroke & Card	TIA (High Risk) Treatment <24 Hours from receipt of referral (%)	=> %	70.0 70.0		Apr 2017	100.0	100.0	100.0	VV
Clinical Effect - Stroke & Card	TIA (Low Risk) Treatment <7 days from receipt of referral (%)	=> %	75.0 75.0		Apr 2017	100.0	100.0	100.0	V
Clinical Effect - Stroke & Card	Primary Angioplasty (Door To Balloon Time 90 mins) (%)	=> %	80.0 80.0		Apr 2017	94.1	94.1	94.1	$M \wedge M$
Clinical Effect - Stroke & Card	Primary Angioplasty (Call To Balloon Time 150 mins) (%)	=> %	80.0 80.0		Apr 2017	93.3	93.3	93.3	$\Delta \sim$
Clinical Effect - Stroke & Card	Rapid Access Chest Pain - seen within 14 days (%)	=> %	98.0 98.0		Apr 2017	100.0	100.0	100.0	
Clinical Effect - Cancer	2 weeks	=> %	93.0 93.0		Mar 2017	93.2	93.2		
Clinical Effect - Cancer	31 Day (diagnosis to treatment)	=> %	96.0 96.0		Mar 2017	100.0	100.0		
Clinical Effect - Cancer	62 Day (urgent GP referral to treatment)	=> %	85.0 85.0		Mar 2017	86.1	86.1		
Clinical Effect - Cancer	Cancer = Patients Waiting Over 62 days for treatment	No		2.5   1.5   0.5   6   3   3.5   1.5   3.5   3   4   3.5   1   2.5   2   1.5   3   2.5   -	Mar 2017	2.50	2.50	32	m
Clinical Effect - Cancer	Cancer - Patients Waiting Over 104 days for treatment	No		2 0 0 4.5 0 2 0 1 2 1.5 2 0 0 1 1 1 1 1 -	Mar 2017	1.00	1.00	13	M~
Clinical Effect - Cancer	Cancer - Oldest wait for treatment	No		138 104 98 154 98 175 95 130 113 107 140 75 71 107 111 135 105 -	Mar 2017	105	105		ww/
Clinical Effect - Cancer	Neutropenia Sepsis Door to Needle Time Greater than 1hr	=> No	0.0 0.0	10 8 12 13 5 15 12 12 19 17 8 6 0	Apr 2017	0	0	0	_~~
Pt. Experience - FFT,MSA,Comp	Mixed Sex Accommodation Breaches	<= No	0.0 0.0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 4 21	Apr 2017	21 0 0	21	21	
Pt. Experience - FFT,MSA,Comp	No. of Complaints Received (formal and link)	No		42 32 34 47 39 49 36 28 25 40 23 27 40 35 40 45 42 34	Apr 2017	19 11 4	34	34	$\sim$
Pt. Experience - FFT,MSA,Comp	No. of Active Complaints in the System (formal and link)	No		65 57 50 65 63 72 57 62 46 47 55 56 63 62 66 61 75 79	Apr 2017	40 29 10	79		MM

## **Medicine Group**

Section	Indicator	Measure	Trajectory Year Month	Previous Months Trend	Data Period	Directorate EC AC SC	Month	Year To Date	
Pt. Experience - Cancellations	Elective Admissions Cancelled at last minute for non- clinical reasons	<= %	0.8 0.8		Apr 2017	0.21	0.19		$\mathcal{M}_{\mathcal{M}}$
Pt. Experience - Cancellations	28 day breaches	<= No	0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1	Apr 2017	0.0 0.0 1.0	1	1	
Pt. Experience - Cancellations	Sitrep Declared Late Cancellations	<= No	0 0	1 0 2 1 1 0 3 0 0 6 1 0 6 2 4 6 2 3	Apr 2017	0.0 0.0 3.0	3	3	MM
Pt. Experience - Cancellations	Weekday Theatre Utilisation (as % of scheduled)	=> %	85.0 85.0	35 32 34 32 31 58 56 54 28 32 28 57 44 29 51 37 41 28	Apr 2017	0.0 0.0 28.3	28.3		$\mathcal{M}_{\sim}$
Pt. Experience - Cancellations	Urgent Cancelled Operations	No		0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Apr 2017	0.00 0.00 0.00	0.00	0	
Emergency Care & Pt. Flow	Emergency Care 4-hour waits (%)	=> %	95.0 95.0		Apr 2017	80.3 86.1 Site S/C	83.4	83.4	<b>~~~</b>
Emergency Care & Pt. Flow	Emergency Care 4-hour breach (numbers)	No		1560 1908 1246 1046 1127 1280 1750 1750 1776 1776 1776 1776	Apr 2017	1536 0 126	1662	1662	<u></u>
Emergency Care & Pt. Flow	Emergency Care Trolley Waits >12 hours	<= No	0 0		Apr 2017	0.0 0.0 Site S/C	0	0	
Emergency Care & Pt. Flow (Group Sheet Only)	Emergency Care Timeliness - Time to Initial Assessment (95th centile)	<= No	15.0 15.0		Apr 2017	15.0 15.0 Site S/C	15	15	<u></u>
Emergency Care & Pt. Flow (Group Sheet Only)	Emergency Care Timeliness - Time to Treatment in Department (median)	<= No	60.0 60.0		Apr 2017	68.0 53.0 Site S/C	60	60	<u></u>
Emergency Care & Pt. Flow	Emergency Care Patient Impact - Unplanned Reattendance Rate (%)	<= %	5.0 5.0		Apr 2017	8.1 8.4 Site S/C	8.3	8.3	M
Emergency Care & Pt. Flow	Emergency Care Patient Impact - Left Department Without Being Seen Rate (%)	<= %	5.0 5.0		Apr 2017	4.5 6.1 Site S/C	5.3	5.3	MM
Emergency Care & Pt. Flow	WMAS - Finable Handovers (emergency conveyances) 30 - 60 mins (number)	<= No	0 0	67 1116 116 97 1117 81 1122 1135 1135 1162 1162 1163 1170 1107	Apr 2017	59 51	110	110	$\sim$
Emergency Care & Pt. Flow	WMAS -Finable Handovers (emergency conveyances) >60 mins (number)	<= No	0 0	3 8 10 6 9 2 0 1 8 6 9 16 21 19 11 13 5 0	Apr 2017	0 0	0	0	$\sim$
Emergency Care & Pt. Flow	WMAS - Turnaround Delays > 60 mins (% all emergency conveyances)	<= %	0.02 0.02		Apr 2017	0.00 0.00	0.00	0.00	$\sim$
Emergency Care & Pt. Flow	WMAS - Emergency Conveyances (total)	No		4502 4673 4679 3961 4513 4115 4099 4363 4204 4138 4261 4204 410 4034 410 4137	Apr 2017	2049 2088	4137	4137	M
RTT	RTT - Admitted Care (18-weeks) (%)	=> %	90.0 90.0		Apr 2017	0.0 92.9 83.0	85.5		~~~
RTT	RTT - Non Admittted Care (18-weeks) (%)	=> %	95.0 95.0		Apr 2017	0.0 73.0 86.0	81.3		~~~
RTT	RTT - Incomplete Pathway (18-weeks) (%)	=> %	92.0 92.0		Apr 2017	0.0 92.4 91.1	91.7		~~~
RTT	RTT - Backlog	<= No	0 0	629 587 623 689 725 789 716 674 821 873 1172 1319 1168 1500 1154 897 622 610	Apr 2017	0 236 374	610		
RTT	Patients Waiting >52 weeks	<= No	0 0	1 1 1 3 4 0 0 0 1 0 0 1 2 1 0 0 1 1	Apr 2017	0 0 1	1		<b>-</b>
RTT	Treatment Functions Underperforming	<= No	0 0	8 8 10 8 7 12 11 11 14 13 12 13 10 12 10 10 10 9	Apr 2017	0 3 6	9		~~~

## **Medicine Group**

RTT	Acute Diagnostic Waits in Excess of 6-weeks (%)	<= %	1.0 1.0	Apr 2017 0 4.05 1.69	m
Section	Indicator	Measure	Trajectory Year Mont	Previous Months Trend	
Data Completeness	Open Referrals	No		78, 201 78,	1,,,
Data Completeness	Open Referrals - Awaiting Management	No			
Workforce	WTE - Actual versus Plan	No		214 208 204 201 219 220 207 213 220 229 231 229 231 244 202 194 208 205 Apr 2017 109.4 59 30.67 205	~~~
Workforce	PDRs - 12 month rolling (%)	=> %	95.0 95.0	Apr 2017 84.52 79.94	
Workforce	Medical Appraisal and Revalidation	=> %	95.0 95.0	Apr 2017 73.91 88.89 92.86	<b>^~~</b>
Workforce	Sickness Absence - 12 month rolling (%)	<= %	3.15 3.15	Apr 2017 4.62 4.98 3.84	<u> </u>
Workforce	Sickness Absence - In month	<= No	3.15 3.15	Apr 2017 6.21 4.24 6.52 5.34	M~~
Workforce	Sickness Absence - Long Term - In month	No		57 62 60 49 47 43 45 40 39 39 33 40 53 Apr 2017 23 17 13 53	
Workforce	Sickness Absence - Short Term - In month	No		212 186 195 180 179 162 194 206 243 223 207 182 66 Apr 2017 17 28 21 66	
Workforce	Return to Work Interviews (%) following Sickness Absence	=> %	100 100	Apr 2017 65.5 78.6 68.5	~~
Workforce	Mandatory Training (%)	=> %	95.0 95.0	Apr 2017 83.31 82.28 82.32	~~
Workforce	Mandatory Training - Staff Becoming Out Of Date	%			
Workforce	New Investigations in Month	No		0 1 1 6 4 1 0 0 1 1 0 0 0 0 1 2 0 Apr 2017 0 0 0	Λ~ ^
Workforce	Nurse Bank Fill Rate %	=> %	100 100	41 88 8 8 90 8 8 8 9 9 9 9 9 9 9 9 9 9 9 9	$\mathcal{M}_{\mathcal{A}}$
Workforce	Nurse Bank Shifts Not Filled (number)	<= No	0 0	11	$\bigcap_{i=1}^{n} A_i A_i A_i A_i A_i$
Workforce	Medical Staffing - Number of instances when junior rotas not fully filled	<= No	0 0		
Workforce	Your Voice - Response Rate (%)	No		> 6>>>>>>>>	۸۸
Workforce	Your Voice - Overall Score	No		-> 3.37 -> -> -> -> -> -> -> -> -> -> -> -> ->	۸۸

## **Surgical Services Group**

Section	Indicator	Measure	Traj Year	ectory Month	Previous Months Trend   N   D   J   F   M   A   M   J   J   A   S   O   N   D   J   F   M   A	Data Period	Directorate  GS   SS   TH   An   O	Month	Year To Date	Trend
Patient Safety - Inf Control	C. Difficile	<= No	7	1		Apr 2017	1 0 0 0 0	1	1	<b>/</b>
Patient Safety - Inf Control	MRSA Bacteraemia	<= No	0	0		Apr 2017	0 0 0 0 0	0	0	
Patient Safety - Inf Control	MRSA Screening - Elective	=> %	80	80		Apr 2017	95.07 95.93 0 0 38.46	88.7		my
Patient Safety - Inf Control	MRSA Screening - Non Elective	=> %	80	80		Apr 2017	95.08 94.83 0 100 90.63	94.8		MV
Patient Safety - Harm Free Care	Number of DOLS raised	No			4 0 0 0 2 1	Apr 2017	1 0 0 0 0	1	1	
Patient Safety - Harm Free Care	Number of DOLS which are 7 day urgent	No			4 0 0 0 2 1	Apr 2017	1 0 0 0 0	1	1	
Patient Safety - Harm Free Care	Number of delays with LA in assessing for standard DOLS application	No			0 0 0 0 0 0	Apr 2017	0 0 0 0 0	0	0	
Patient Safety - Harm Free Care	Number DOLs rolled over from previous month	No			0 0 0 0 1	Apr 2017	1 0 0 0 0	1	1	
Patient Safety - Harm Free Care	Number patients discharged prior to LA assessment targets	No			0 0 0 0 1 0	Apr 2017	0 0 0 0 0	0	0	Λ
Patient Safety - Harm Free Care	Number of DOLs applications the LA disagreed with	No				Apr 2017	1 0 0 0 0	1	1	/
Patient Safety - Harm Free Care	Falls	<= No	0	0	8 12 14 7 12 8 9 4 12 12 9 10 12 13 8 6 6 10	Apr 2017	9 0 1 0 0	10	10	~~~
Patient Safety - Harm Free Care	Falls with a serious injury	<= No	0	0	1 0 0 0 0 1 0 1 0 0 0 0 0 0 0	Apr 2017	0 0 0 0 0	0	0	\
	Grade 2,3 or 4 Pressure Ulcers (hospital aquired	<= No	0	0						\_/VV\
Patient Safety - Harm Free Care	avoidable)					Apr 2017			1	~~~
Patient Safety - Harm Free Care	Venous Thromboembolism (VTE) Assessments	=> %	95.0	95.0		Apr 2017	98.32 98.36 0 99.54 98.62	98.5		
Patient Safety - Harm Free Care	WHO Safer Surgery Checklist - Audit 3 sections	=> %	100.0	100.0		Mar 2017	100 100 0 100 100	100.0		
Patient Safety - Harm Free Care	WHO Safer Surgery Checklist - Audit 3 sections and brief	=> %	100.0	100.0		Mar 2017	0 100 100 0 98.16	98.5		
Patient Safety - Harm Free Care	WHO Safer Surgery Checklist - Audit 3 sections, brief and debrief	=> %	100.0	100.0		Mar 2017	0 100 100 0 97.55	98.0		
Patient Safety - Harm Free Care	Never Events	<= No	0	0	0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 0 1	Apr 2017	0 0 0 0 0	0	0	$\Lambda\Lambda\Lambda$
Patient Safety - Harm Free Care	Medication Errors	<= No	0	0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Apr 2017	0 0 0 0 0	0	0	
Patient Safety - Harm Free Care	Serious Incidents	<= No	0	0		Apr 2017	0 0 0 0 0	0	0	wh.
Clinical Effect - Mort & Read	Mortality Reviews within 42 working days	=> %	100	98.0		Feb 2017	83 44 0 0 0	60.0		$\sim$
Clinical Effect - Mort & Read	Emergency Readmissions (within 30 days) - Overall (exc. Deaths and Stillbirths) month	%			6.7 8.2 6.5 6.9 7.1 6.4 6.2 5.5 6.6 5.4 5.9 6.0 5.1 5.9 6.0 6.3 5.7 -	Mar 2017		5.7		~~~
Clinical Effect - Mort & Read	Emergency Readmissions (within 30 days) - Overall (exc. Deaths and Stillbirths) 12-month cumulative	%			6.75 6.92 6.94 6.97 7.05 6.98 6.88 6.76 6.73 6.61 6.5 6.99 6.3 6.11 6 5.95 5.84 -	Mar 2017			6.4	

## **Surgical Services Group**

Section	Indicator	Measure	Traje Year	ectory Month	Previous Months Trend   N   D   J   F   M   A   M   J   J   A   S   O   N   D   J   F   M   A	Data Period	Directorate GS SS TH An O	Month	Year To Date	
Clinical Effect - Cancer	2 weeks	=> %	93.0	93.0		Mar 2017	95.3 - 0.0	95.32		
Clinical Effect - Cancer	2 weeks (Breast Symptomatic)	=> %	93.0	93.0		Mar 2017	93.6	93.62		
Clinical Effect - Cancer	31 Day (diagnosis to treatment)	=> %	96.0	96.0		Mar 2017	100.0 - 0.0	100		
Clinical Effect - Cancer	62 Day (urgent GP referral to treatment)	=> %	85.0	85.0		Mar 2017	97.0 - 0.0	97		
Clinical Effect - Cancer	Cancer = Patients Waiting Over 62 days for treatment	No			3 5 2 2 3 2 9 1 4 7 4 7 4 5 5 8 2 -	Mar 2017		1.5	56	~~~
Clinical Effect - Cancer	Cancer - Patients Waiting Over 104 days for treatment	No			0 4 0 0 1 0 1 0 1 2 2 2 2 0 2 1 -	Mar 2017	0.5 - 0	0.5	12	L
Clinical Effect - Cancer	Cancer - Oldest wait for treatment	No			. 105 193 193 193 193 193 195 245 245 220 273 176 176 178 178 178 178 178 178 178 178 178 178	Mar 2017	105 - 0	105		~~~
Clinical Effect - Cancer	Neutropenia Sepsis Door to Needle Time Greater than 1hr	=> No	0	0	0 0 0 0 0 0 0 0 0 0 0 0 0	Apr 2017	0 - 0	0	0	
Pt. Experience - FFT,MSA,Comp	Mixed Sex Accommodation Breaches	<= No	0	0	0 0 0 0 0 0 0 0 0 0 1 0 8 0 0 0 0	Apr 2017	0 0 0 0 0	0	0	
Pt. Experience - FFT,MSA,Comp	No. of Complaints Received (formal and link)	No			36 28 25 28 38 45 29 27 24 38 30 37 29 26 32 25 36 24	Apr 2017	3 5 1 1 14	24	24	$\sqrt{m}$
Pt. Experience - FFT,MSA,Comp	No. of Active Complaints in the System (formal and link)	No			49 36 32 37 45 49 52 48 41 45 47 51 39 45 62 63 66 78	Apr 2017	27 9 6 5 31	78		<b>~~</b>
Pt. Experience - Cancellations	Elective Admissions Cancelled at last minute for non- clinical reasons	<= %	0.8	0.8		Apr 2017	1.63 4.24 0 0.47 1.42	1.76		~~~
Pt. Experience - Cancellations	28 day breaches	<= No	0	0	0 0 0 0 0 0 0 0 0 0 1 0 3 4 0 0 0	Apr 2017	0 0 0 0 0	0	0	
Pt. Experience - Cancellations	Sitrep Declared Late Cancellations	<= No	0	0	23 27 16 33 20 18 18 22 45 43 32 29 57 31 35 49 45 32	Apr 2017	12 10 0 1 9	32	32	~~~
Pt. Experience - Cancellations	Weekday Theatre Utilisation (as % of scheduled)	=> %	85.0	85.0	76.7 72.8 74.2 75.4 74.9 75.1 75.7 76 70.5 71.6 73.7 75.3 75.7 73 77.1 75.3 75.3 76.4	Apr 2017	77.1 72.3 0.0 89.2 76.2	76.45		WW
Pt. Experience - Cancellations	Urgent Cancelled Operations	No	0	0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Apr 2017	0 0 0 0 0	0	0	
Emergency Care & Pt. Flow	Emergency Care 4-hour breach (%)	%	95.0	95.0	99.8 99.2 98.8 99.6 98.9 98.3 97.9 98.2 98.0 98.6 98.6 99.4 99.4 99.7 99.3 99.3 98.1 97.6	Apr 2017	97.65	-	-	V~~~
Emergency Care & Pt. Flow	Emergency Care 4-hour breach (numbers)	<= No	0	0	62 98 109 82 80 119 121 63 92 76 109 70 68 112 137	Apr 2017	49 40 0 0 48	137	137	
Emergency Care & Pt. Flow	Emergency Care Trolley Waits >12 hours	<= No	0	0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Apr 2017	0	-	-	
Emergency Care & Pt. Flow	Emergency Care Patient Impact - Unplanned Reattendance Rate (%)	<= %	5.0	5.0	7.0 10.9 4.8 3.2 2.3 3.8 4.1 2.8 2.4 3.3 2.2 2.9 3.5 2.6 4.1 3.0 3.3 3.3	Apr 2017	3.3	-	-	<b>\</b>
Emergency Care & Pt. Flow	Emergency Care Patient Impact - Left Department Without Being Seen Rate (%)	<= %	5.0	5.0	1.6 1.5 1.1 1.0 1.7 1.8 2.0 1.1 2.0 1.7 2.5 2.1 1.4 1.1 1.0 1.1 1.7 2.0	Apr 2017	1.99	-	-	<b>√</b>
Emergency Care & Pt. Flow	Emergency Care Timeliness - Time to Initial Assessment (95th centile)	<= No	15	15	15 19 14 25 19 14 41 15 26 14 14 0 0 0 0	Apr 2017	63	0	0	_~^\_
Emergency Care & Pt. Flow	Emergency Care Timeliness - Time to Treatment in Department (median)	<= No	60	60	94 108 115 106 106 121 110 103 107 100 99	Apr 2017	107	-	-	
Emergency Care & Pt. Flow	Hip Fractures BPT (Operation < 36 hours of admissions	=> %	85.0	85.0		Apr 2017		41.4	41.4	<b>~~~</b>

## **Surgical Services Group**

Section	Indicator	Measure	Traj Year	jectory Month	Previous Months Trend   N   D   J   F   M   A   M   J   J   A   S   O   N   D   J   F   M   A	Data Period	Directorate
RTT	RTT - Admitted Care (18-weeks) (%)	=> %	90.0	90.0		Apr 2017	75.6   55.7   0.0   0.0   75.8   72.4
RTT	RTT - Non Admittled Care (18-weeks) (%)	=> %	95.0	95.0		Apr 2017	93.1 94.2 0.0 0.0 96.1
RTT	RTT - Incomplete Pathway (18-weeks) (%)	=> %	92.0	92.0		Apr 2017	93.5 84.4 0.0 0.0 94.4 92.2
RTT	RTT - Backlog	<= No	0	0	1304 1167 1153 1344 1514 1328 1369 1254 1327 1227 1231 1227 1236 1308	Apr 2017	499 464 0 0 341 1304
RTT	Patients Waiting >52 weeks	<= No	0	0	3 1 3 2 3 3 1 2 3 0 1 2 0 1 0 2 2 4	Apr 2017	4 0 0 0 0
RTT	Treatment Functions Underperforming	<= No	0	0	12 14 16 14 13 16 13 14 17 16 16 16 16 14 16 16 16 14 14	Apr 2017	8 5 0 0 1
RTT	Acute Diagnostic Waits in Excess of 6-weeks (%)	<= %	1.0	1.0		Apr 2017	0.6 0.0 7.1 0.0 0.0
Data Completeness	Open Referrals	No			123,687 121,184 1119,262 1116,146 1113,840 1112,897 110,630 109,035 107,435 107,435 107,435 107,435 107,723 98,377 1113,733	Apr 2017	43.132 123687 123687
Data Completeness	Open Referrals - Awaiting Management	No			53,057 51,471 48,985 47,179 445,279 440,451 38,367 36,835 36,835 	Apr 2017	20.679
Workforce	WTE - Actual versus Plan	No			166         173         178         153         149         144         143         151         158         155         152         146         140         151         185         157         166         168	Apr 2017	49.63 34.97 27.09 20.83 30.21
Workforce	PDRs - 12 month rolling	=> %	95.0	95.0		Apr 2017	80.7 86.1 90.3 83.0 77.5
Workforce	Medical Appraisal and Revalidation	=> %	95.0	95.0		Apr 2017	74.19 94.12 0 71.79 73.08
Workforce	Sickness Absence - 12 month rolling (%)	<= %	3.15	3.15		Apr 2017	4.8 5.5 6.9 4.1 2.3
Workforce	Sickness Absence - In Month	<= %	3.15	3.15		Apr 2017	4.7 3.0 6.5 5.9 2.8 4.5
Workforce	Sickness Absence - Long Term - In Month	No			46 52 62 56 46 53 52 50 53 52 33 32 30	Apr 2017	9.0 3.0 8.0 10.0 0.0 30.0 30.0
Workforce	Sickness Absence - Short Term - In Month	No			164 169 161 162 168 169 181 173 181 166 149 138 61	Apr 2017	21.0 10.0 23.0 7.0 0.0 61.0 61.0
Workforce	Return to Work Interviews (%) following Sickness Absence	=> %	100	100		Apr 2017	87.6 75.7 88.8 81.3 86.3 84.3 84.3
Workforce	Mandatory Training	=> %	95.0	95.0		Apr 2017	84.9 86.9 89.6 87.3 84.4
Workforce	Mandatory Training - Staff Becoming Out Of Date	%				Jan-00	
Workforce	New Investigations in Month	No			0 0 1 1 2 0 0 0 2 0 1 3 0 0 2 1 2 0	Apr 2017	0 0 0 0 0 <b>0</b>
Workforce	Nurse Bank Fill Rate	=> %	100.0	100.0	89.5 84.5 83 64.9 86.3 88	Apr 2016	88.03
Workforce	Nurse Bank Shifts Not Filled	<= No	0	0	255 280 233 238 238 238 	Apr 2016	238

				Surgical Services Group
Workforce	Medical Staffing - Number of instances when junior rotas not fully filled	= No 0	0	
Workforce	Your Voice - Response Rate	No		> 22>>>>>>>> -
Workforce	Your Voice - Response Score	%		> 6.94>>>>>>>>>

Section	Indicator	Measure	Trajectory Year Month	N	D	J	F	М	Α			ous Mo				N	D	J	F M A	Data Period	E	Directorate G M P	Month	Year T Date	0	Trend
Patient Safety - Inf Control	C. Difficile	<= No	0 0					•		•	•		•				•	•	• • •	Apr 2017		0 0 0	0	0		
Patient Safety - Inf Control	MRSA Bacteraemia	<= No	0 0				•		•	•	•		•			•		•	• • •	Apr 2017		0 0 0	0	0		
Patient Safety - Inf Control	MRSA Screening - Elective	=> %	80.00 80.00	•			•	•		•	•		•		•	•		•	• • •	Apr 2017		94.7	93.7			~~~~
Patient Safety - Inf Control	MRSA Screening - Non Elective	=> %	80.00 80.00								•		•					•	• • •	Apr 2017		100 100	100.0			<b>\</b>
Patient Safety - Harm Free Care	Number of DOLS raised	No		-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0 0 1	Apr 2017		0 1 0	1	1		
Patient Safety - Harm Free Care	Number of DOLS which are 7 day urgent	No		-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0 0 1	Apr 2017		0 1 0	1	1		
Patient Safety - Harm Free Care	Number of delays with LA in assessing for standard DOLS application	No		-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0 0 0	Apr 2017		0 0 0	0	0		
Patient Safety - Harm Free Care	Number DOLs rolled over from previous month	No		-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0 0 0	Apr 2017		0 0 0	0	0		
Patient Safety - Harm Free Care	Number patients discharged prior to LA assessment targets	No		-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0 0 0	Apr 2017		0 0 0	0	0		
Patient Safety - Harm Free Care	Number of DOLs applications the LA disagreed with	No		-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0 0 0	Apr 2017		0 0 0	0	0		
Patient Safety - Harm Free Care	Number patients cognitively improved regained capacity did not require LA assessment	No		-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0 0 0	Jan-00		0 0 0	0	0		
Patient Safety - Harm Free Care	Falls	<= No	0 0	1	0	2	0	1	0	1	2	1	1	2	3	1	1	2	1 1 0	Apr 2017		0 0 0	0	0		<b>~~</b>
Patient Safety - Harm Free Care	Falls with a serious injury	<= No	0 0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0 0 0	Apr 2017		0 0 0	0	0		
Patient Safety - Harm Free Care	Grade 2,3 or 4 Pressure Ulcers (hospital aquired avoidable)	<= No	0 0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0 0 0	Apr 2017		0 0 0	0	0		
Patient Safety - Harm Free Care	Venous Thromboembolism (VTE) Assessments	=> %	95.0 95.0													•	•	•	• • •	Apr 2017		98.9 93.8	95.4			<b>~~~</b>
Patient Safety - Harm Free Care	WHO Safer Surgery Checklist - Audit 3 sections	=> %	100.0 100.0								•							•		Mar 2017		100 99.4	99.7			
Patient Safety - Harm Free Care	WHO Safer Surgery Checklist - Audit 3 sections and brief	=> %	100.0 100.0							•	•							•	• • -	Mar 2017		100 0	100.0			
Patient Safety - Harm Free Care	WHO Safer Surgery Checklist - Audit 3 sections, brief and debrief	=> %	100.0 100.0	•					•	•	•					•	•	•	• • .	Mar 2017		100 0	100.0			
Patient Safety - Harm Free Care	Never Events	<= No	0 0	•	•		•	•	•		•					•	•	•	• • •	Apr 2017		0 0 0	0	0		
Patient Safety - Harm Free Care	Medication Errors	<= No	0 0	•	•		•	•	•		•	•	•	•		•		•	• • •	Apr 2017		0 0 0	0	0		
Patient Safety - Harm Free Care	Serious Incidents	<= No	0 0	•				•	•		•		•	•		•			• •	Apr 2017		0 1 0	1	1		$\wedge \wedge \wedge$

Section	Indicator	Measure	Trajectory Year Month	N	D	J F	M	A M		ious Mo			N	D .	F	M A	Data Period	Directo G M		Month	Year To Date	
Patient Safety - Obstetrics	Caesarean Section Rate - Total	<= %	25.0 25.0	•	•	•		•	•		•			•		• •	Apr 2017	26.	2	26.2	26.2	<b>~~~</b>
Patient Safety - Obstetrics	Caesarean Section Rate - Elective	%		9	9	8 8	8	10 7	9	8	9	10 8	11	8 7	9	8 9	Apr 2017	8.8	7	8.9	8.9	~W~
Patient Safety - Obstetrics	Caesarean Section Rate - Non Elective	%		16	14	17 15	18	17 15	5 15	19	19	19 23	17	20 1	5 17	17 17	Apr 2017	17.	3	17.3	17.3	~~~
Patient Safety - Obstetrics	Maternal Deaths	<= No	0 0	•	•	•	•	•	•		•	•		•		• •	Apr 2017	0		0	0	
Patient Safety - Obstetrics	Post Partum Haemorrhage (>2000ml)	<= No	48 4		•	•	•	•	•			• •	•	•		• •	Apr 2017	1		1	1	WWY
Patient Safety - Obstetrics	Admissions to Neonatal Intensive Care	<= %	10.0 10.0	•	•	•	•	•	•	•	•	• •	•	•	•	• •	Apr 2017	1.8	3	1.8	1.8	~~~
Patient Safety - Obstetrics	Adjusted Perinatal Mortality Rate (per 1000 babies)	<= Rate1	8.0 8.0	•	•	•	•	•	•		•	•	•	•		• •	Apr 2017	4.0	7	4.1		M
Patient Safety - Obstetrics	Early Booking Assessment (<12 + 6 weeks) (>=%) - SWBH Specific	=> %	90.0 90.0	•	•		•	•				•	•	•		• •	Apr 2017	80.	3	80.8		$\sim$
Patient Safety - Obstetrics	Early Booking Assessment (<12 + 6 weeks) (%) - National Definition	=> %	90.0 90.0	•	•	•	•	• •	•	•	•	• •	•	•	•	• •	Apr 2017	134	1	134.1		M
Clinical Effect - Mort & Read	Mortality Reviews within 42 working days	=> %	100.0 97.0	•	N/A	N/A		•		N/A		N/A		•			Feb 2017	100 0	0	100.0		<b>W_/</b> \
Clinical Effect - Mort & Read	Emergency Readmissions (within 30 days) - Overall (exc. Deaths and Stillbirths) month	%		5.9	4.8 4	1.7 6.7	5.5	4.9 5.0	4.7	4.4	4.2	3.9 5.4	5.9	5.0 4.	0 5.4	4.7 -	Mar 2017			4.7		~~~
Clinical Effect - Mort & Read	Emergency Readmissions (within 30 days) - Overall (exc. Deaths and Stillbirths) 12-month cumulative	%		6.5	6.3	5.1 6.1	5.9	5.8 5.6	5 5.4	5.2	5.2	5.1 5.4	5.0	5.0 5.	0 4.9	4.8 -	Mar 2017				5.2	
Clinical Effect - Cancer	2 weeks	=> %	93.0 93.0		•	•	•	•	•			• •	#DIV/0!	•		•	Mar 2017	90.3	0	90.3		
Clinical Effect - Cancer	31 Day (diagnosis to treatment)	=> %	96.0 96.0	•	•	•	•	•			•	•		•		• .	Mar 2017	90.9		90.9		
Clinical Effect - Cancer	62 Day (urgent GP referral to treatment)	=> %	85.0 85.0	•	•		•	•			•	• •	•				Mar 2017	80.6		80.6		
Clinical Effect - Cancer	Cancer = Patients Waiting Over 62 days for treatment	No		0.5	1.5	3 2	0	3 1	2	0	0.5	0.5 1.5	5 4	3 2	2 4.5	3.5 -	Mar 2017	3.5 -	0	3.5	25.5	M
Clinical Effect - Cancer	Cancer - Patients Waiting Over 104 days for treatment	No		0	0	0 0	0	1 0	1	0	0	0 0	0	0 0.	5 1.5	3.5 -	Mar 2017	3.5 -	0	3.5	7.5	
Clinical Effect - Cancer	Cancer - Oldest wait for treatment	No		89	71 1	04 97	62	149 86	176	62	70	97 76	98	98 12	20 150	162 -	Mar 2017	162 -	0	162		~M~~
Clinical Effect - Cancer	Neutropenia Sepsis Door to Needle Time Greater than 1hr	=> No	0 0	-	-		- [	0 0	0	0	0	0 0	0	0 0	0	0 0	Apr 2017	0 -	0	0	0	

Section	Indicator	Measure	Trajectory Year Month	E	J F M A		Months Trend		J F	M A	Data Period	Directorate G M P	Month	Year To Date	
Pt. Experience - FFT,MSA,Comp	Mixed Sex Accommodation Breaches	<= No	0 0		0 0 0 0	0 0 0	0 0	0 0 0	0 0	0 0	Apr 2017	0	0	0	
Pt. Experience - FFT,MSA,Comp	No. of Complaints Received (formal and link)	No			17 4 13 5	10 9 15	15 15	12 9 12	14 14	12 13	Apr 2017	5 6 2	13	13	<b>~~~</b>
Pt. Experience - FFT,MSA,Comp	No. of Active Complaints in the System (formal and link)	No			20 6 17 9	13 10 19	21 23	23 16 21	24 24	22 19	Apr 2017	0 0 0	19		<b>W</b>
Pt. Experience - Cancellations	Elective Admissions Cancelled at last minute for non- clinical reasons	<= %	0.8 0.8		• • •	• • •	•	• • •	• •	•	Apr 2017	6.49	4.5		<b>W</b>
Pt. Experience - Cancellations	28 day breaches	<= No	0 0		0 0 0 0	0 0 0	0 0	0 0 0	2 0	0 0	Apr 2017	0	0	0	
Pt. Experience - Cancellations	Sitrep Declared Late Cancellations	<= No	0 0		6 7 13 4	10 9 4	6 9	12 6 10	6 12	10 12	Apr 2017	12	12	12	<b>W</b>
Pt. Experience - Cancellations	Weekday Theatre Utilisation (as % of scheduled)	=> %	85.0 85.0		74 71 78 76	73 74 76	76 76	79 79 71	80 83	81 83	Apr 2017	83.1 -	83.1		w~V
Pt. Experience - Cancellations	Urgent Cancelled Operations	No			0 0 0 0	0 0 0	0 0	0 0 0	0 0	0 0	Apr 2017	0 - 0	0	0	
Emergency Care & Pt. Flow	Emergency Care 4-hour breach (numbers)	No			- 15 6 16	5 5 10	7 43	18 38 38	20 23	15 9	Apr 2017	3 0 6	9	9	_~_~
RTT	RTT - Admittted Care (18-weeks)	=> %	90.0 90.0		• • • •	• • •	•		• •	•	Apr 2017	78.7	78.7		~~~
RTT	RTT - Non Admittled Care (18-weeks)	=> %	95.0 95.0		• • •	• • •	•	• •	•	•	Apr 2017	95.8	95.8		<b>~~~</b>
RTT	RTT - Incomplete Pathway (18-weeks)	=> %	92.0 92.0		• • • •	• • •	•	• •	•	• •	Apr 2017	93.4	93.4		~~~
RTT	RTT - Backlog	<= No	0 0		60 70 80 69	92 93 13	121 129	161 161 160	111 96	96 98	Apr 2017	98	98		
RTT	Patients Waiting >52 weeks	<= No	0 0		0 0 0 0	0 1 0	0 0	0 0 0	0 0	1 0	Apr 2017	0	0		
RTT	Treatment Functions Underperforming	<= No	0 0		1 0 1 1	0 1 2	2 2	2 3 3	2 1	2 1	Apr 2017	1	1		<b>~~</b>
RTT	Acute Diagnostic Waits in Excess of 6-weeks	<= %	0.1 0.1		• • • •	• • •	• •	• • •	• •	• •	Apr 2017	0	0.0		

Section	Indicator	Measure	Trajectory Year Month		N	D	J	F	М	A	М		evious I				N	D	J	F	M A	Data Period		torate M P	Month	Year To Date	
Data Completeness Or	open Referrals	No		10,100	29,256	30,745	23,372	23,021	22,929	23,294	24,026	24,973	24,866	25,230	25,985	26,671	27,018	27,523	27,970	28,605	30,091 29,483	Apr 2017	8,048	7,201	30091		1
Data Completeness Op	pen Referrals - Awaiting Management	No									10,041	10,069	10,168	10,770	11,488	11,421	12,342	12,816	13,222	13,822	15,253 14,698	Apr 2017	4,433	1,907	15253		
Workforce	/TE - Actual versus Plan	No		82	82.5	98.9	96.9	94.7	91.8	87.3	3 101	99.	.2 97.	1 11	8 116	6 107	109	126	119	111	116 119	Apr 2017	6.16 8	1.6 31.1	118.9		~~
Workforce	DRs - 12 month rolling	=> %	95.0 95.0									•										Apr 2017	93.8 8	7.8 91.7		89.8	<b>^</b>
Workforce Me	ledical Appraisal and Revalidation	=> %	95.0 95.0							•												Apr 2017	94.1 6	6.7 66.7		77.3	<b>~~</b> ~
Workforce Sig	ickness Absence - 12 month rolling	<= %	3.15 3.15																			Apr 2017	4.67 5.	.05 3.02	4.5	4.5	<u></u>
Workforce Sie	ickness Absence - in month	<= %	3.15 3.15						•					•								Apr 2017	3.72 5.	.23 3.12	4.5	4.5	~~~
Workforce Sie	ickness Absence - Long Term - in month	No			-	-	-	-	-	40	36	34	4 39	43	3 44	43	43	30	30	23	29 27	Apr 2017	5 1	18 4	27.0	27.0	
Workforce Sie	ickness Absence - Short Term - in month	No			-	-	-	-	-	99	105	94	4 111	96	5 106	6 113	125	114	142	83	105 50	Apr 2017	8 2	26 16	50.0	50.0	
	eturn to Work Interviews (%) following Sickness bsence	=> %	100.0 100.0	•					•												•	Apr 2017	90.1 8	4.4 81.6	84.25	84.25	
Workforce Ma	landatory Training	=> %	95.0 95.0																		•	Apr 2017	87 8	9.3 89.2		88.9	~~~
Workforce Ma	landatory Training - Staff Becoming Out Of Date	%			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		Jan-00	-			-	
Workforce Ne	lew Investigations in Month	No			1	0	0	1	0	1	0	0	1	1	0	0	0	0	0	0	1 1	Apr 2017	0	1 0	1		\M/\/
Workforce Ad	dmin & Clerical Bank Use (shifts)	<= No	0 0								-	-	-	-	-	-	-	-	-	-		Apr 2016			98	98	$\sqrt{}$
Workforce Ad	dmin & Clerical Agency Use (shifts)	<= No	0 0	•					•		-	-	-	-	-	-	-	-	-	-	-	Apr 2016			40	40	<b>M</b>
	ledical Staffing - Number of instances when junior rotas ot fully filled	0	0																								
Workforce Yo	our Voice - Response Rate	No			>	11	>	>	>	>	>	>	>>	>	>>	>	>	>	13	>	>	Jan 2017	17	10 20	13		٨٨.
Workforce Yo	our Voice - Overall Score	No		-	>	3.63	>	>	>	>	>	>	>>	>	>>	>	>	>	3.66	>	>	Jan 2017	3.54 3.	.72 3.6	3.7		ΛΛ.

Section	Indicator	Measure	Trajectory Year Month	Previous Months Trend     N   D   J   F   M   A   M   J   J   A   S   O   N   D   J   F   M   A   M   A   M   D   D   D   D   D   D   D   D   D	Data Period	Directorate G M P	Month	Year To Date	
WCH Group Only	HV (C1) - No. of mothers who receive a face to face AN contact with a HV at =>28 weeks of pregancy	No		159 167 207 193 159 207 198 244 253 219 255 119 131 109 126	Jan 2017	126	126	1861	~~~
WCH Group Only	HV (C2) - % of births that receive a face to face new birth visit by a HV =<14 days	=> %	95.0 95.0	88.9 88.2 87.6 91.9 89 86.9 88.6 86.7 92.4 86.1 87.6 85.3 84.6 95.7 90.5 88.3	Feb 2017	88.3	88.25	88.5	
WCH Group Only	HV (C3) - % of births that receive a face to face new birth visit by a HV >days	%		9.19 8.82 7.69 6.68 9.33 12.8 11.4 11.8 8.76 12.3 10.5 7.71 1117 3.23 7.22 9.56 4.81 -	Mar 2017	4.81	4.81	18.29	
WCH Group Only	HV (C4) - % of children who received a 12 months review by 12 months	=> %	95.0 95.0	93.3 91.9 97.5 90.3 94.4 98.2 97.7 94.8 98.6 96.6 95.8 90.1 93.9 94.6 95.6 97.2 96.2 -	Mar 2017	96.2	96.23	95.74	
WCH Group Only	HV (C5) - % of children who received a 12 months review by the time they were 15 months	%		94.5 96.2 99.8 97.9 96.2 99.7 99.5 97.1 100 100 99.5 98.8 98.4 98.5 99.3 1.29 95.8 -	Mar 2017	95.8	95.82	90.93	$\overline{}$
WCH Group Only	HV (C6i) - % of children who received a 2 - 2.5 year review	=> %	95.0 95.0	93 94.5 95.8 88.9 95.6 99 97.5 96.6 96 96 94.3 91.5 95.4 94.1 93 92.1 90.1 -	Mar 2017	90.1	90.07	94.55	
WCH Group Only	HV (C6ii) - % of children who receive a 2 - 2.5 year review using ASQ 3	%		84.4 80.5 90.2 84.2 81.6 89.2 81.9 86 88.7 88.3 91.5 92.8 89.4 89.2 89.7 82.5 84.2 -	Mar 2017	84.2	84.16	87.69	
WCH Group Only	HV (C7) - No. of Sure Start Advisory Boards / Children's Centre Boards witha HV presence	=> No	100 100	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Mar 2017	1	1	12	
WCH Group Only	HV (C8) - % of children who receive a 6 - 8 week review	=> %	95.0 95.0	97.1 93.9 97.9 93.6 96 97.9 92.8 94.9 97.8 99.2 97 95 95.9 93.9 96.9 - 95.5 -	Mar 2017	95.6	95.55	96.16	M
WCH Group Only	HV - % of infants for whom breast feeding status is recorded at 6 - 8 week check	=> %	100 100	84.7 91.9 98.6 99.3 99.4 99.8 99.4 99.7 99.8 99.5 99.3 94 93.6 87.9 98.6 - 86.1 -	Mar 2017	86.1	86.13	96.22	
WCH Group Only	HV - % of infants being breastfed at 6 - 8 weeks	%		30.7 36.8 37.9 35.6 43.9 42.8 39.4 41.7 49.3 40.6 39.6 40.7 37.6 43.5 43.5 - 42.2 -	Mar 2017	42.3	42.25	41.99	$\overline{}$
WCH Group Only	HV - % HV staff who have completed mandatory training at L1,2 or 3 in child protection in last 3 years	=> %	95.0 95.0	100 100 100 100 100 100 100 100 10	Feb 2017	100	100	100	
WCH Group Only	HV - No. of babies from 0 - 1 year who have a conclusive newborn bloodspot status documented at the 10 - 14 day developmental check	No		358 353 335 391 341 382 400 391 391 365 413 313 132 306 377 - 357 -	Mar 2017	357	357	3827	
WCH Group Only	HV - % of babies from 0 - 1 year who have a conclusive newborn bloodspot status documented at the 10 - 14 day developmental check	=> %	100 100	98.6 97.2 96.3 100 100 100 98.8 98.7 101 97.3 96.3 92.4 91.3 93.5 97.2 - 91.3 -	Mar 2017	91.3	91.3	96.27	$\overline{}$
WCH Group Only	HV - No. of babies from 0 - 1 year who have a conclusive newborn bloodspot status documented at the 6 - 8 week developmental check	No		337 376 366 322 358 411 322 369 393 376 409 347 330 310 342 - 322 -	Mar 2017	322	322	3931	$\sim$
WCH Group Only	HV - % of babies from 0 - 1 year who have a conclusive newborn bloodspot status documented at the 6 - 8 week developmental check	=> %	100 100	91.8 98.2 99.7 98.8 100 99.8 99.4 99.7 95.4 96.7 94.9 89.4 86.6 86.5 88.6 - 97.9 -	Mar 2017	97.9	97.87	94.05	$\bigvee$
WCH Group Only	HV - No. of babies from 0 - 1 year who have a conclusive newborn bloodspot status documented at the 9 - 12 months developmental check	No		257 316 352 294 339 290 341 355 393 375 346 347 339 323 343	Jan 2017	343	343	3452	
WCH Group Only	HV - % of babies from 0 - 1 year who have a conclusive newborn bloodspot status documented at the 9 - 12 months developmental check	=> %	100 100	83.4 92.4 89.6 92.2 91.6 91.2 90.9 92 91.4 85.6 86.3 83.6 86.7 82.4 89.8	Jan 2017	89.8	89.79	87.88	

			W	on	ne	n	&	<b>C</b>	<b>;</b> h	lii	d	Н	ea	alt	th		<b>3</b> r	Ol	uķ	)									
WCH Group Only	HV - movers into provider <1 year of age to be checked =<14 d following notification to HV service	No			56	51 4	12	39	39	51	60	42	42	38	45	41	34	3	1 6	3	-	-	-	Jan 2017	6	63	63	447	$\sim$
WCH Group Only	HV - all untested babies <1 year of age will be offered NBBS screening & results to HV.	No			-	-	-	-	-	-	-	-	-	-	-	-	-	-		-	-	-	-	Jan-00		-	-	-	

## **Pathology Group**

Section	Indicator	Measure	Trajectory Year Month	Previous Months Trend	Data Period	Directorate HA HI B M I	Month	Year To Date	Trend
Patient Safety - Harm Free Care	Never Events	<= No	0 0		Apr 2017	0 0 0 0 0	0	0	
Clinical Effect - Cancer	Cancer = Patients Waiting Over 62 days for treatment	No			Mar 2017		-	-	
Clinical Effect - Cancer	Cancer - Patients Waiting Over 104 days for treatment	No			Mar 2017		-	-	
Clinical Effect - Cancer	Cancer - Oldest wait for treatment	No			Mar 2017		-		
Pt. Experience - FFT,MSA,Comp	No. of Complaints Received (formal and link)	No		2 0 2 4 2 3 4 2 1 2 1 2 3 2 4 1 2 1	Apr 2017	1 0 0 0 0	1	1	<b>/////</b>
Pt. Experience - FFT,MSA,Comp	No. of Active Complaints in the System (formal and link)	No		2 1 1 4 3 3 5 4 2 2 2 3 3 1 3 4 4 3	Apr 2017	3 0 0 0 0	3		$\sim$
Pt. Experience - Cancellations	Urgent Cancelled Operations	No			Apr 2017		-	-	
Data Completeness	Open Referrals	No		6,601 6,495 6,387 6,284 6,140 6,140 6,051 5,631 3,639 3,572 3,639 3,572 3,420 3,294 3,312 3,318	Apr 2017	2,480 0 2,190 0	6,601		
Data Completeness	Open Referrals - Awaiting Management	No		2,846 2,791 2,685 2,685 2,478 2,477 2,275 2,206 1,510 1,510 1,500	Apr 2017	912 0 1,024 0 909	2,845		-
Workforce	WTE - Actual versus Plan	No		39.2 38.2 32.5 22.9 30.3 25.7 31.6 35.2 39 39.8 38.4 40 37 31 34.7 30.3 23.7 18.7	Apr 2017	9.9 4.8 0.8 2.6 -2.8	19		$\bigvee$
Workforce	PDRs - 12 month rolling	=> %	95.0 95.0		Apr 2017	100 94 95 98 92		95.65	5
Workforce	Medical Appraisal and Revalidation	=> %	95.0 95.0		Apr 2017	0 75 100 100 100		87.5	
Workforce	Sickness Absence - 12 month rolling	<= %	3.15 3.15		Apr 2017	3.2 3.6 5.5 2.9 2.7	4.05	4.05	<b>~</b>
Workforce	Sickness Absence - In Month	<= %	3.15 3.15		Apr 2017	0.9 0.9 3.1 3.7 4.6	2.8	2.8	<b>^</b>
Workforce	Sickness Absence - Long Term - In Month	No		10 12 14 14 15 13 12 14 6 5 6 8 6	Apr 2017	0.0 0.0 3.0 1.0 1.0	6	6	~~
Workforce	Sickness Absence - Short Term - In Month	No		47 45 38 35 36 30 43 49 41 36 35 45 30	Apr 2017	1.0 1.0 15.0 8.0 2.0	30	30	<u></u>
Workforce	Return to Work Interviews (%) following Sickness Absence	=> %	100.0 100.0		Apr 2017	90 94 71 98 96	83.9	83.9	~~/
Workforce	Mandatory Training	=> %	95.0 95.0		Apr 2017	92 91 93 91 99		92.8	\h^
Workforce	Mandatory Training - Staff Becoming Out Of Date	%			Jan-00			-	
Workforce	New Investigations in Month	No		1 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0	Apr 2017	0 0 0 0 0	0		M 1.A.
Workforce	Admin & Clerical Bank Use (shifts)	<= No	0 0		Apr 2016		265	265	
Workforce	Admin & Clerical Agency Use (shifts)	<= No	0 0		Apr 2016		0	0	
Workforce	Your Voice - Response Rate	No		-> 19 -> -> -> -> -> -> -> -> ->	Jan 2017	24 21 17 27 55	22		٨ ٨
Workforce	Your Voice - Overall Score	No		> 3.79>>>>>>>>>	Jan 2017	3.5 3.3 3.9 4 3.9	3.82		٨ ٨

### **Imaging Group**

March   Marc			ı	Trainstan	Previous Months Trend Data Directorate Year To	
The contract of the contract	Section	Indicator	Measure	Trajectory Year Month	Previous Months Trend Data Data Drectorate Month N D J F M A M J J A S O N D J F M A Period DR R NM BS  Year To Date	Trend
Part	Patient Safety - Harm Free Care	Never Events	<= No	0 0	Apr 2017 0 0 0 0	
March   Contract   C	Patient Safety - Harm Free Care	Medication Errors	<= No	0 0	Apr 2017 0 0 0 0 0 0	
Control   Cont	Clinical Effect - Mort & Read	Emergency Readmissions (within 30 days) - Overall (exc. Deaths and Stillbirths) month	<= No	0 0	1.0 2.0 - 2.0 1.0 2.0 1.0 3.0 1.0 - 2.0 2.0 1.0 - 1.0 - Mer 2017	<b>√</b> √√
Section   Sect	Clinical Effect - Mort & Read	Emergency Readmissions (within 30 days) - Overall (exc. Deaths and Stillbirths) 12-month cumulative	=> %	0 0	14.0 11.0 11.0 12.0 12.0 14.0 13.0 13.0 13.0 12.0 14.0 13.0 15.0 17.0 17.0 15.0 16.0 - Mer 2017	
Contract Classes   Contract Prisons (Contract	Clinical Effect - Stroke & Card	Pts receiving CT Scan within 1 hr of presentation (%)	=> %	50.0 50.0	Apr 2017 84.21	MM
Company   Comp	Clinical Effect - Stroke & Card	Pts receiving CT Scan within 24 hrs of presentation (%)	=> %	100.0 100.00	97.37 97.37 97.37	
Contraction   Contract   Contra	Clinical Effect - Cancer	Cancer = Patients Waiting Over 62 days for treatment	No		Mar 2017	
Part	Clinical Effect - Cancer	Cancer - Patients Waiting Over 104 days for treatment	No			
The Security	Clinical Effect - Cancer	Cancer - Oldest wait for treatment	No		Mar 2017	
The Sequence of the Companies in the Cympanies in the Cym	Pt. Experience - FFT,MSA,Comp	Mixed Sex Accommodation Breaches	<= No	0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
Fire Expenses Canadarian Jugari Control Contro	Pt. Experience - FFT,MSA,Comp	No. of Complaints Received (formal and link)	No		2 1 3 6 5 2 0 1 1 2 1 1 4 5 4 1 1 4 Apr 2017 3 1 0 0 4	^~^
	Pt. Experience - FFT,MSA,Comp	No. of Active Complaints in the System (formal and link)	No		2 0 3 6 5 2 1 2 2 2 0 1 4 9 3 2 2 1 Apr 2017 1 0 0 0 1	$\sim$ $\land$
### Access   Comprehension   C	Pt. Experience - Cancellations	Urgent Cancelled Operations	No			
Des Completeress   Copen Returns   Annual Management   No	Emergency Care & Pt. Flow	Emergency Care 4-hour breach (numbers)	No		49 62 36 67 69 86 66 54 55 60 55 66 54 100 102 Apr 2017	~~~
Completer   Comp	RTT	Acute Diagnostic Waits in Excess of 6-weeks (%)	<= %	1.0 1.0	0.57 O.57	M
Wilderse   WTE - Actual versus Plan   No     44   60   64   65   65   65   65   65   65   65	Data Completeness	Open Referrals	No		21 24 25 71 86 88 88 88 88 88 88 88 88 88 88 88 88	
Workforce   FCRs 12 morth rolling   2-5 %   95.0   95.0   96.0   9   9   9   9   9   9   9   9   9	Data Completeness	Open Referrals - Awaiting Management	No			
Modulate Appressial and Revolutions	Workforce	WTE - Actual versus Plan	No		45 40 44 44 46 49 51 44 45 47 45 41 40 38 32 31 32 35 Apr 2017	~~,
Nontroce   Schress Absence - 12 morth rolling   C = %   3.15   3.15   3.15   0   0   0   0   0   0   0   0   0	Workforce	PDRs - 12 month rolling	=> %	95.0 95.0	Apr 2017 82.2 50 77.8 91.2	<b>~~</b>
Monkforce   Sickness Absence - in morth   No	Workforce	Medical Appraisal and Revalidation	=> %	95.0 95.0	Apr 2017 E7 0 100 75	_/\
Workforce   Sickness Absence - Long Term - in month   No	Workforce	Sickness Absence - 12 month rolling	<= %	3.15 3.15	Apr 2017 32 7.9 2.6 47	$\sim$
Nondiscre   Sickness Absence - Short Term - in month   No	Workforce	Sickness Absence - in month	<= %	3.15 3.15	Apr 2017 A3 12.1 1.5 0.8 3.51	$\sim$
Northdore   Return to Work Interviews (%) following Sickness   >> %   100.0   100.0	Workforce	Sickness Absence - Long Term - in month	No		10 10 8 8 7 6 7 13 10 15 13 9 6 Apr 2017	~~
April   Apri	Workforce	Sickness Absence - Short Term - in month	No		33 39 38 31 23 26 29 41 40 53 36 32 29 Apr 2017	~~
Workforce         Mandatory Training - Staff Becoming Out Of Date         %	Workforce		=> %	100.0 100.0	Apr 2017 ESS 53.6 94.9 52.4 70.8	
Workforce   New Investigations in Month   No     0   0   0   0   0   0   0   0   0	Workforce	Mandatory Training	=> %	95.0 95.0	Apr 2017	~
Vour Vaice - Response Rate	Workforce	Mandatory Training - Staff Becoming Out Of Date	%			
Vour Voice - Overall Score	Workforce	New Investigations in Month	No		0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Λ
Imaging Group Only Unreported Tests / Scans No	Workforce	Your Voice - Response Rate	No		-> 21 -> -> -> -> -> -> -> -> -> -> -> -> ->	Λ
Imaging Group Only Outsourced Reporting No	Workforce	Your Voice - Overall Score	No		-> 3.40 -> -> -> -> -> -> -> -> -> -> -> -> ->	Λ
	Imaging Group Only	Unreported Tests / Scans	No			
Imaging Group Only IRMA Instances No	Imaging Group Only	Outsourced Reporting	No			
	Imaging Group Only	IRMA Instances	No			

## **Community & Therapies Group**

Section	Indicator	Measure	Tra	jectory	) Г								Previ	ous Mo	onths 1	rend							Data		irectorate	7	Month		ar To	Trend
Section	maicator	Weasure	Year	Month		N	D	J	F	М	Α	M	J	J	Α	S	0	N	D	J	F N	ΙΑ	Period	AT	IB IC		Wonth	D	ate	Trend
Patient Safety - Inf Control	MRSA Screening - Elective	=> %	80.0	80.0																	•	•	Apr 2017	0	0 0		0			
Patient Safety - Harm Free Care	Number of DOLS raised	No				-	-	-	-	-	-	-	-	-	-	-	-	2	2	1	0 5	4	Apr 2017	0	4 0		4		4	
Patient Safety - Harm Free Care	Number of DOLS which are 7 day urgent	No				-	-		-	-	-	-	-	-	-	-	-	2	2	2	0 5	4	Apr 2017	0	4 0		4		4	
Patient Safety - Harm Free Care	Number of delays with LA in assessing for standard DOLS application	No				-	-	-	-	-	-	-	-	-	-	-	-	2	0	0	0 0	0	Apr 2017	0	0 0		0		0	
Patient Safety - Harm Free Care	Number DOLs rolled over from previous month	No				-	-	-	-	-	-	-	-	-	-	-	-	1	1	2	0 0	3	Apr 2017	0	3 0		3		3	
Patient Safety - Harm Free Care	Number patients discharged prior to LA assessment targets	No				-	-	-	-	-	-	-	-	-	-	-	-	1	0	0	0 0	2	Apr 2017	0	2 0		2		2	
Patient Safety - Harm Free Care	Number of DOLs applications the LA disagreed with	No				-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0 0	0	Apr 2017	0	0 0		0		0	
Patient Safety - Harm Free Care	Number patients cognitively improved regained capacity did not require LA assessment	No				-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0 0	2	Apr 2017	0	2 0		2		2	
Patient Safety - Harm Free Care	Falls	<= No	0	0		21	26	31	23	20	22	38	31	29	31	29	33	30	27	20	19 3	23	Apr 2017	1	21 1		23		23	<b>√</b> ~√
Patient Safety - Harm Free Care	Falls with a serious injury	<= No	0	0		0	1	2	1	1	0	0	1	0	0	1	0	0	0	0	0 0	0	Apr 2017	0	0 0		0		0	<b>/</b>
Patient Safety - Harm Free Care	Grade 3 or 4 Pressure Ulcers (avoidable)	<= No	0	0		2	0	3	0	4	2	4	2	3	1	1	0	1	3	2	2 1	6	Apr 2017	-	6 -		6		6	<b>~~~</b>
Patient Safety - Harm Free Care	Never Events	<= No	0	0		•				•										•	•	•	Apr 2017	0	0 0		0		0	
Patient Safety - Harm Free Care	Medication Errors	<= No	0	0						•	•		•					•		•	•	•	Apr 2017	0	0 0		0		0	
Patient Safety - Harm Free Care	Serious Incidents	<= No	0	0																	•		Apr 2017	0	0 0		0		0	<b>/</b> _M_
Pt. Experience - FFT,MSA,Comp	Mixed Sex Accommodation Breaches	<= No	0	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0 0	0	Apr 2017	0	0 0		0		0	
Pt. Experience - FFT,MSA,Comp	No. of Complaints Received (formal and link)	No				4	2	3	6	7	3	5	5	4	5	4	3	8	4	6	1 1	4	Apr 2017	1	3 0		4		4	<b>/</b>
Pt. Experience - FFT,MSA,Comp	No. of Active Complaints in the System (formal and link)	No				5	5	3	6	7	11	7	9	8	9	7	5	5	6	6	6 6	9	Apr 2017	2	6 1		9			<b>////</b>

## **Community & Therapies Group**

Section	Indicator	Measure	Tra Year	jectory Month	] E	Pre	evious Months		N D J F M A	Data Period	Directorate AT IB IC	Month	Year To Date	
Workforce	WTE - Actual versus Plan	No				94.7 100 106 102 123 126	8 154 152	135 104	109 122 115 112 118 128	Apr 2017	22.9 68.8 35.9	127.5		-~~
Workforce	PDRs - 12 month rolling	=> %	95.0	95.0		• • • • •			• • • • •	Apr 2017	98 95.7 97.3		96.8	./\/
Workforce	Sickness Absence - 12 month rolling	<= %	3.15	3.15						Apr 2017	3.25 4.6 4.1	4.02	4.02	
Workforce	Sickness Absence - in month	<= %	3.15	3.15		• • • • •				Apr 2017	2.33 5.28 3.73	3.87	3.87	$\sim$
Workforce	Sickness Absence - Long Term - in month	No				26 25 26	6 24 27	29 22	23 29 32 24 24 24	Apr 2017	2	24	24	
Workforce	Sickness Absence - Short Term - in month	No				65 59 81	1 80 83	53 74	104 101 102 93 82 57	Apr 2017	4 22 31	57	57	
Workforce	Return to Work Interviews (%) following Sickness Absence	=> %	100.0	100.0						Apr 2017	69.9 80.8 82.1	78.64	78.64	
Workforce	Mandatory Training	=> %	95.0	95.0				•		Apr 2017	95.2 89.5 93.3		92.1	<b>/</b>
Workforce	Mandatory Training - Staff Becoming Out Of Date	%								Jan-00			-	
Workforce	New Investigations in Month	No				0 2 0 0 0 2	0 1	0 0	0 1 0 0 0 0	Apr 2017		0		\\\.\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
Workforce	Nurse Bank Fill Rate	=> %	100	100	g	88.4 78.3 89.3 87.9				Apr 2016		87.87	87.87	<b>—</b>
Workforce	Nurse Bank Shifts Not Filled	<= No	0	0		90 78 86 87				Apr 2016		87	87	
Workforce	Your Voice - Response Rate	No				>>>>	>>	>	> 29>>	Jan 2017	29 31 28	29		۸۸.
Workforce	Your Voice - Overall Score	No				>>>>>	>>	>	>> 3.83>>	Jan 2017	3.72 3.72 3.96	3.83		ΛΛ

## **Community & Therapies Group**

Section	Indicator	Measure	Traje Year	ctory Month	} [	N	I D	D J	J F	- M	1 A	M		us Mon	ths Trer		N	D	J F	F M A	Data Period	rectorate IB IC	Month	Year T Date		
Community & Therapies Group Only	DVT numbers	=> No	730	61	] [	0	24	4 47	7 65	5 51	53	55	74	-	-   -	-	-	-	-   -		Jun 2016		74	182		$\mathcal{M}$
Community & Therapies Group Only	Adults Therapy DNA rate OP services	<= %	9	9	] [	11	10.	0.5 11.3	.3 9	8.00	9.9	8.82	9.6	8.85	.01 9.2	<b>2</b> 7.88	7.37	12.2 1	12.2 8.9	97 8.04 8.47	Apr 2017		8.5	8.5		
Community & Therapies Group Only	Therapy DNA rate Paediatric Therapy services	<= %	9	9	] [	_	-	Ι-	-	-	-	1.58	1.58	1.58 1	.58 1.2	9 0	1.42	0.87 3	3.94 1.1	15	Feb 2017		1.2	1.4		
Community & Therapies Group Only	Therapy DNA rate S1 based OP Therapy services	<= %	9	9	] [	-	-	Ι-	-	-	-	-	-	-	-   -	-	-	-	-   -		Jan-00		-	-		
Community & Therapies Group Only	STEIS	<= No	0	0	] [	0	1	1 2	1	1	0	0	2	0	0 2	1	1	0	0 0	0 0	Apr 2017		0	0		$\Lambda\Lambda\Lambda$
Community & Therapies Group Only	Green Stream Community Rehab response time for treatment (days)	<= No	11.0	11.0	] [	17	7 17	7 16	6 24	4 24	4 23	17	17	-	-   -	-	-	-	-   -		Jun 2016		17	57		<b>~</b>
Community & Therapies Group Only	DNA/No Access Visits	%			] [	1	1	1 1	1	0	1	1	2	3	2 2	2	2	2	1 2	2	Feb 2017		2.1			
Community & Therapies Group Only	Baseline Observations for DN	=> %	100	100	] [	-	-		-   -	-	-	-	38.5	42.4 4	1.5 60	1 36.8	53	57.3 5	55.8 59	0.2 56.3 66.8	Apr 2017		66.8	66.8		
Community & Therapies Group Only	Falls Assessments - DN Intial Assessments only	%			] [	41	I 46	6 52	2 55	5 54	4 61	161	70	61	55 6	42	77	69	60 63	2 58 69	Apr 2017		68.84			_/
Community & Therapies Group Only	Pressure Ulcer Assessment - DN Intial Assessments only	%			] [	33	3 48	8 54	4 56	6 58	64	67	75	65	63 7 <sup>-</sup>	47	80	71	63 6	5 63 77	Apr 2017		76.73			\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
Community & Therapies Group Only	MUST Assessments - DN Intial Assessments only	%			] [	23	3 26	28	8 32	2 32	2 37	35	40	36	32 3	26	52	46	48 3	6 46 58	Apr 2017		57.69			~~~
Community & Therapies Group Only	Dementia Assessments - DN Intial Assessments only	%			] [	50	29	9 28	8 31	1 21	1 40	37	11	30	37 4	14	53	53	52 6	2 44 55	Apr 2017		55			~~~
Community & Therapies Group Only	48 hour inputting rate - DN Service Only	%			] [	94	1 94	4 93	3 94	4 94	93	91	90	90	92 80	94	93	93	69 9	3 94 92	Apr 2017		91.84			
Community & Therapies Group Only	Making Every Contact (MECC) - DN Intial Assessments only	%			] [	-	-	-   -	-	7	-	-	200	222 2	222 27	0 177	251	369 3	308 38	32 460 488	Apr 2017		66.39	66.39	•	
Community & Therapies Group Only	Avoidable Grade 2,3 or 4 Pressure Ulcers (DN Caseload acquired)	No			] [	-	-	Ι-	-	3	3	2	1	4	3 2	0	2	5	6 8	3 6 6	Apr 2017		6	6		~~~
Community & Therapies Group Only	Avoidable Grade 2 Pressure Ulcers (DN caseload acquired)	No			] [	-	-	Ι-	-	3	3	2	1	3	1 1	0	2	2	4 6	3 5	Apr 2017		5	5		~~~
Community & Therapies Group Only	Avoidable Grade 3 Pressure Ulcers (DN caseload acquired)	No			] [	_	-		-	0	0	0	0	1	1 1	0	0	3	2 2	2 2 1	Apr 2017		1	1		
Community & Therapies Group Only	Avoidable Grade 4 Pressure Ulcers (DN caseload acquired)	No			] [	-	-	Ι-	-	0	0	0	0	0	1 0	0	0	0	0 0	1 0	Apr 2017		0	0		ΛΛ

## **Corporate Group**

Section	Indicator	Measure	Traje Year	ectory Month	Previous Months Trend   N   D   J   F   M   A   M   J   J   A   S   O   N   D   J   F   M   A	Data Period	Directorate  SG F W M E N O	Month	Year To Date	Trend
Pt. Experience - FFT,MSA,Comp	No. of Complaints Received (formal and link)	No			8 5 4 5 8 8 10 12 4 13 8 13 11 12 11 11 14 3	Apr 2017	0 0 0 0 0 0 3	3	3	~~~
Pt. Experience - FFT,MSA,Comp	No. of Active Complaints in the System (formal and link)	No			9 8 4 4 7 8 9 12 9 17 10 13 18 13 12 17 19 16	Apr 2017	1 0 0 0 2 5 8	16		,
Workforce	WTE - Actual versus Plan	No			89.3 97.8 81.9 83.2 96.4 102 128 101 106 130 146 123 118 133 98.6 94.5 105 99.5	Apr 2017	13.7 1.14 -15.9 16.9 -4.24 24.6 63.2	99.48		,.M
Workforce	PDRs - 12 month rolling	=> %	95.0	95.0		Apr 2017	91 80 91 89 91 95 90		91.8	~\~
Workforce	Medical Appraisal and Revalidation	=> %	95.0	95.0		Apr 2017	95	50.0	50	$\mathcal{M}_{\mathcal{L}}$
Workforce	Sickness Absence - 12 month rolling	<= %	3.15	3.15		Apr 2017	2.13 2.92 3.50 2.78 3.83 5.14 4.85	4.37	4.37	\ <u></u>
Workforce	Sickness Absence - in month	<= %	3.15	3.15		Apr 2017	0.52 1.17 3.25 2.32 3.53 5.63 4.76	4.30	4.30	<b>^</b>
Workforce	Sickness Absence - Long Term - in month	No			51 53 52 59 62 65 64 64 79 0 1 0 2	Apr 2017	1.00 0.00 0.00 0.00 0.00 1.00 0.00	2.00	2.00	M.
Workforce	Sickness Absence - Short Term - in month	No			192 176 173 153 160 181 203 224 191 7 8 8 3	Apr 2017	3.00 0.00 0.00 0.00 0.00 0.00 0.00	3.00	3.00	M
Workforce	Return to Work Interviews (%) following Sickness Absence	=> %	100.0	100.0		Apr 2017	89.0 78.7 71.4 79.9 76.1 83.7 79.9	81.1	81.1	
Workforce	Mandatory Training	=> %	95.0	95.0		Apr 2017	0 96 96 91 98 86 91	89.8	90	<b>~</b> ~~
Workforce	Mandatory Training - Staff Becoming Out Of Date	%				Jan-00		-	-	
Workforce	New Investigations in Month	No			0 1 2 2 2 4 4 1 4 1 1 0 0 2 1 1 4 0	Apr 2017	0 0 0 0 0 0	0		$\mathcal{N}_{\mathcal{N}}$
Workforce	Your Voice - Response Rate	No			-> 15 -> -> -> -> -> -> ->	Jan 2017	51 45 39 30 19 6 17	18		۸۸.
Workforce	Your Voice - Overall Score	No			> 3.58>>>>>>>>> 3.64>>>	Jan 2017	3.83 3.61 3.98 3.55 3.52 3.62 3.37	3.64		۸۸.

## Sandwell and West Birmingham Hospitals

**NHS Trust** 

### TRUST BOARD

DOCUMENT TITLE:	Financial performance – P01 April 2017
SPONSOR (EXECUTIVE DIRECTOR):	Tony Waite – Finance Director
AUTHOR:	Tim Reardon – Associate Director of Finance
DATE OF MEETING:	1 June 2017

#### **EXECUTIVE SUMMARY:**

#### **Headlines**

This report deals with the financial performance for P01 April 2017/18 and indications for the performance in relation to statutory duties for the full year.

#### **Key messages:**

- P01 headline performance reported as plan but reliant on significant unplanned technical support. Requires remediation through delivery of cornerstone P&L improvement.
- Significant unidentified savings requirement requiring remediation through FIP2 process.
- STF income assumed earned for P01. Requires consistent P&L delivery to plan and ED 4hr remediation to 90% by June for performance component.
- Capex programme being pursued as plan. CRL remains to be confirmed by NHSi. Dialogue on-going.
- Cash borrowing requirements subject to routine assessment. Loan review & application meeting scheduled with NHSI 7<sup>th</sup> June 2017.
- Planned care activity exceeds plan with consequent income over-recovery on SLA income. Theatre efficiency remains biggest opportunity for improvement.
- Reduced agency spend in P01 but remains above plan trajectory. Requires mobilisation & delivery of plan to secure first £10m of spend reduction.

### **Key actions:**

- Confirmation and execution of step reduction in costs through focus on bed reduction, pay & workforce change & procurement cost savings. Delivery of demand & capacity plan to secure income
- Delivery of capital programme to time & revised plan consistent with enabling programme for MMH
- Monitoring and delivery of liquidity / cash improvement plan.
- Resolution of 2017.18 contract discussion with SWBCCG.
- Manage application process for DH loan/s.
- Secure land sale to maximise H1 cash in-flow.

#### **Key numbers:**

- Month deficit £(1.6)m being £7k favourable compared to plan
- Underlying deficit £(3.5)m being £(1)m adverse to plan.
- STF of £0.5m assumed earned for the month
- Pay bill £26.4m (vs. £26.5m last month); Agency spend £1.6m (vs. £1.9m).
- o Capital spend at £0.4m is £2.7m behind plan to date.
- Cash at 30<sup>th</sup> April £19.9m being above plan by £6.2m.

### **REPORT RECOMMENDATION:**

The Board is recommended to note the report and to REQUIRE those actions necessary to secure the required plan out-turn for FY 2017/18.

ACTION REQUIRED (Indicate The receiving body is asked					
Accept		Approve the recommendation	n	Discuss	
х		x		X	
KEY AREAS OF IMPACT (Ind	dicate w	rith 'x' all those that apply):			
Financial	Х	Environmental		Communications & Media	
Business and market share		Legal & Policy	х	Patient Experience	
Clinical		Equality and Diversity		Workforce	X
Comments:	•		•		

### ALIGNMENT TO TRUST OBJECTIVES, RISK REGISTERS, BAF, STANDARDS AND PERFORMANCE METRICS:

Excellence in the use of resources Excellence in governance including effective grip & control

### PREVIOUS CONSIDERATION:

FIC 31.05.17

# **Finance Report**

Period 01 2017/18 April 2017

Trust Board 1 June 2017

#### **Contents**

### Page Title

- 1. Title & contents
- 2. Summary, key financial targets and recommendations
- 3. Performance to date I&E and cash
- 4. Trust I&E
- 5. Income analysis
- 6. Pay bill & workforce
- 7. FY prospective view P1+11
- 8. Capital
- 9. SOFP
- 10. Working capital metrics

## Finance Report

## **Summary & Recommendations**

Period 01 2017/18

Statutory Financial Duties	Value	Outlook	Note
I&E control total deficit	£9.9m	TBC	1
Live within Capital Resource Limit	£46.6m	٧	2
Live within External Finance Limit	£93.0m	٧	3

- 1. Forecast surplus £9.9m formally reported. Downside risk.
- 2. CRL as plan submission and remains to be confirmed by NHSi.
- 3. EFL based on £9.9m surplus and opening cash of £14.4m. Compliance risk from P&L downside. Accelerated surplus asset disposal provides mitigation.

#### Outlook

- NHSI P01 return reports forecast surplus £9.9m. This reflects control total value agreed in 30<sup>th</sup> March NHSI plan submission.
- Achievement requires development of production planning and roster management as core competences.
- Required opex run rate change also depends on CIP delivery and additional efficiency delivery.
- Key risks to plan known and confirmed by external review.
   FIP2 process to support accelerated financial improvement.

### P01 key issues & remedial actions

- P01 headline performance reported as plan but reliant on significant unplanned technical support. Requires remediation through delivery of cornerstone P&L improvement.
- Significant unidentified savings requirement requiring remediation through FIP2 process.
- STF income assumed earned for P01. Requires consistent P&L delivery to plan and ED 4hr remediation to 90% by June for performance component.
- Capex programme being pursued as plan. CRL remains to be confirmed by NHSi. Dialogue on-going.
- Cash borrowing requirements subject to routine assessment. Loan review & application meeting scheduled with NHSI 7<sup>th</sup> June 2017.
- Planned care activity exceeds plan with consequent income over-recovery on SLA income. Theatre efficiency remains biggest opportunity for improvement.
- Reduced agency spend in P01 but remains above plan trajectory. Requires mobilisation of plan to secure first £10m of spend reduction.

#### Recommendation

- Challenge and confirm:
  - reported P01 position
  - plausible route to control total and require mitigating actions to reduce costs to be expedited.

## Performance to date - I&E and cash

Period 01 2017/18

#### Financial Performance to Date

For the period to the end of April 2017 the Trust is reporting:

- Headline I&E deficit of £1,638k being £7k favourable to plan;
- Underlying I&E deficit £3.5m being £1.0m adverse to plan
- Capital spend of £387k being £2,693k below plan;
- Cash at the end of February is £19,919k being £6,168k more than plan.

#### I&E

P01 reported as delivering to plan but dependent on the benefits from £1.0m of unplanned contingencies and flexibility.

There are significant reported variances on Patient Related Income and non-pay and which reflect in large part matters of phasing in the original financial plan. The impact of a more refined and robust phasing shall be recognised from P02.

P01 includes £0.5m STF and £0.25m of taper relief income on a presumption that these will be secured. STF requires consistent delivery to headline financial plan and improvement in ED performance to key milestones.

#### **Savings**

Progress reported through the Trust's savings management system TPRS indicates c£19m of identified schemes of which £3.59m of schemes have been signed off. The initial focus of attention is on the confirmation and delivery of £20m of schemes. The residual savings requirement of £13m is the subject of opportunity identification through the FIP2 work.

#### **Use of Resources Rating**

Consistent with the downside scenario analysis the plan use of resources (UoR) rating for the Trust is 3 for the month and year.

#### Cash

The cash position is £6.2m above plan at 30<sup>th</sup> April. This is due to the I&E position being more than offset by capital underspending in April.

The key issue for the Trust is the impact of both prior year underlying deficits on the cash position. P01 financials and P02 lead measures indicate that current year I&E performance is not making good these shortfalls.

Achievement of EFL is based on I&E recovery and securing STF in full.

Bed closures and income were both below the plan level required in April. Cash support will be required from the NHSI the exact timing of this shortage will depend on the net impact of any delay in I&E recovery and slower rate of capital spend than plan.

#### **Better Payments Practice Code**

Performance in April improved when measured by value and was maintained when measured by volume. However, this was below the target of 95%. It is expected that this target will not be achieved in FY 2017/18 given the cash position and the resulting extension of creditor terms that will be maintained.

An ongoing issue with BPPC remains the lack of timely receipting of orders by Groups.

#### Capital

Capital expenditure to date stands at £0.4m against a full year plan of £46.6m. A rate of monthly spend in excess of £3m is expected per the plan.

## **I&E Performance - Full Year**

Period 01 2017/18

Period 01	CP Plan £'000s	CP Actual £'000s	CP Variance £'000s	FY Plan £'000s	FY Forecast £'000s	FY Variance £'000s
Patient Related Income	35,310	31,894	(3,416)	424,405	424,405	0
Other Income	3,899	4,969	1,070	59,706	59,706	0
Income total	39,209	36,863	(2,346)	484,111	484,111	0
Pay	(26,068)	(26,426)	(358)	(300,666)	(300,666)	0
Non-Pay	(12,713)	(10,011)	2,702	(148,580)	(148,580)	0
Expenditure total	(38,781)	(36,437)	2,344	(449,246)	(449,246)	0
EBITDA	428	426	(2)	34,865	34,865	0
Non-Operating Expenditure	(2,087)	(2,083)	4	(25,144)	(25,144)	0
Technical Adjustments	14	19	5	212	212	0
DH Surplus/(Deficit)	(1,645)	(1,638)	7	9,933	9,933	0
Add back STF	(524)	(524)	0	(10,483)	(10,483)	0
Adjusted position	(2,169)	(2,162)	7	(550)	(550)	0
Technical Support (inc. Taper Relief)	(250)	(1,283)	(1,033)	(3,000)	(3,000)	0
Underlying position	(2,419)	(3,445)	(1,026)	(3,550)	(3,550)	0

The trust reported a headline deficit of £1.6m for P01 being in line with plan.

This was reliant on the benefit of £1m of unplanned contingency and support.

The level of technical support utilised is £1.8m including STF received. This included £0.6m of taper relief funding against which there may be calls in future months.

The underlying deficit in P01 is therefore recorded as £3.4m. This is £1m adverse compared with the plan underlying deficit of £2.4m.

## **Income Analysis**

Period 01 2017/18

	Year to Date		e Against SLA	by Patient Typ			
-		Activity			Finance		Straight
	Planned	Actual	Variance -	Planned £000	Actual £000	Variance £000	Forecast £000
A&E	18,311	18,823	512	C4 050	52.024	£73	604.004
	•	•	_	£1,950	£2,024		£24,284
Emergencies	3,802	3,512	-290	£7,270	£7,203	-£67	£86,442
Emergency Short Stay	1,081	689	-392	£841	£534	-£307	£6,409
Excess bed days	1,177	1,262	85	£324	£349	£26	£4,192
Urgent Care				£10,386	£10,111	-£275	£121,327
OP New	10,916	13,286	2,370	£1,659	£1,954	£295	£23,451
OP Procedures	4,167	5,543	1,376	£693	£878	£185	£10,535
OP Review	25,953	26,145	192	£1,805	£1,813	£8	£21,761
OP Telephone	945	1,308	363	£22	£25	£3	£302
DC	2,688	2,884	195	£2,109	£2,141	£32	£25,689
EL	444	482	38	£1,053	£1,153	£100	£13,841
Planned Care				£7,341	£7,965	£624	£95,579
Maternity	1,678	1,633	-45	£1,588	£1,602	£14	£19,222
Renal dialysis	37	64	27	£4	£8	£3	£92
Community	40,620	51,329	10,709	£2,572	£2,680	£108	£32,161
Cot days	964	1,047	83	£506	£540	£35	£6,485
Other contract lines	301,538	317,379	15,841	£7,697	£7,798	£101	£93,579
Unbundled activity	4,127	5,725	1,599	£420	£691	£271	£8,296
Other				£12,787	£13,319	£533	£159,834
Grand Total				£30,514	£31,395	£881	£376,740

This table shows the Trust's year to date SLA income performance by point of delivery as measured against the draft contract price & activity schedule.

Work on the production plan appears to have impacted on elective work with the favourable variance for planned care this must now be maintained throughout the financial year. Outpatient activity was the main driver of this performance. With the RTT backlog being mainly elective (>60%) theatre performance is critical to both the income and RTT targets that underpin the Trust's recovery trajectory.

The variance on total Patient Related Income to date is £3,416k adverse. The difference compared to SLA income shown above is primarily related to phasing differences between NHSI plan and now determined operational plans. This will be reflected in P02 reporting.

## Pay bill & Workforce

Period 01 2017/18

#### **Paybill & Workforce**

- Total workforce of 6,952 WTE [being 176 above plan] including 243 WTE of agency staff.
- Total pay costs (including agency workers) were £26.4m in April being £0.4m over plan.
- Significant reduction in temporary pay costs required to be consistent with FY 2017/18 plan assumptions. Focus on reduction in capacity and improved roster management.
- The Trust did not comply with national agency framework guidance for agency suppliers in April. Shifts procured outside of this are subject to COO approval and is driven by strict commitment to maintaining safe staffing.
- The Trust continues to exceed the national agency rate caps. Trust implementation and compliance is subject to granular assurance that there is no compromise to securing safe staffing levels.
- Target have been set for locum spend reduction in FY 2017/18. For SWBH the target is a spend reduction of £544,770 compared to FY 2016/17.

			Change in	n period
Pay and Workforce	Current Period	Previous Period	Value	%
Pay - total spend	26,426	26,495	(69)	0%
Pay - substantive	22,102	21,662	440	2%
Pay - agency spend	1,605	1,908	(303)	-16%
Pay - bank (inc. locum) spend	2,719	2,924	(205)	-7%
WTE - total	6,952	7,120	(168)	-2%
WTE - substantive	6,058	6,090	(32)	-1%
WTE - agency	243	269	(26)	-10%
WTE - bank (inc. locum)	651	760	(109)	-14%

Locum Target	£'000s
Spend 2016/17	6,852
Savings Target	545
Target 2017/18	6,307

Throughout 2016/17 NHSI monitored agency expenditure. Caps were introduced and they have reported savings. For 2017/18 a similar approach has been announced for Locum spend.

The Trust has been notified that a savings target has been set of £545k in relation to Locum expenditure.

## **Prospective View - P01+11**

Period 01 2017/18

Reported Position	Apr-16 Act £'000s	May-16 Plan £'000s	Jun-16 Plan £'000s	Jul-16 Plan £'000s	Aug-16 Plan £'000s	Sep-16 Plan £'000s	Oct-16 Plan £'000s	Nov-16 Plan £'000s	Dec-16 Plan £'000s	Jan-17 Plan £'000s	Feb-17 Plan £'000s	Mar-17 Plan £'000s	2017/18 FY 1+11 £'000s
Patient Related Income	31,894	35,336	35,336	35,436	35,436	35,436	35,336	35,336	35,336	35,369	35,369	35,369	420,989
Other Income	4,969	3,882	3,882	4,057	4,057	4,057	4,406	4,406	4,406	4,581	4,581	13,492	60,776
Income total	36,863	39,218	39,218	39,493	39,493	39,493	39,742	39,742	39,742	39,950	39,950	48,861	481,765
Pay	(26,426)	(26,072)	(26,072)	(25,560)	(25,560)	(25,560)	(25,048)	(25,048)	(25,048)	(24,567)	(24,567)	(21,496)	(301,024)
Non-Pay	(10,011)	(12,721)	(12,721)	(12,566)	(12,567)	(12,567)	(12,398)	(12,398)	(12,398)	(12,184)	(12,184)	(11,164)	(145,878)
Expenditure total	(36,437)	(38,793)	(38,793)	(38,126)	(38,127)	(38,127)	(37,446)	(37,446)	(37,446)	(36,751)	(36,751)	(32,660)	(446,902)
EBITDA	426	425	425	1,367	1,366	1,366	2,296	2,296	2,296	3,199	3,199	16,201	34,863
Non-Operating Expenditure	(2,083)	(2,083)	(2,083)	(2,099)	(2,099)	(2,099)	(2,099)	(2,099)	(2,099)	(2,099)	(2,099)	(2,099)	(25,140)
Technical Adjustments	19	18	18	18	18	18	18	18	18	18	18	18	217
Reported DH Surplus/(Deficit)	(1,638)	(1,640)	(1,640)	(714)	(715)	(715)	215	215	215	1,118	1,118	14,120	9,940

The current I&E forecast for FY 2017/18 at £9,932k is consistent with plan.

This table combines the actual I&E position for April and the plan I&E position for the coming months. This reflects the impact of the technical support utilised in April. It can be seen that there are key numbers within the plan the I&E that need to change to deliver this plan.

Income level are where the biggest increase is required based on April. However, working days were low due to the number of bank holidays and so, subject to theatre efficiency, increased working days in May should lead to increased income levels.

Pay numbers need to reduce by £0.3m in May and a further £0.5m in July followed by a further £0.5m in October and a further £0.5m in January. Based on the bed numbers reported in May previously referred to this outcome has some risk attached to it.

Non-pay incorporates the technical support utilised by the Trust.

# Capital Period 01 2017/18

Programme	Flex Plan £'000s	Year to Date Actual £'000s	Gap £'000s	Orders Placed £'000s
Estates	1,181	240	(941)	8,347
Information	1,826	41	(1,785)	1,885
Medical equipment / Imaging	0	43	43	0
Contingency	0	0	0	0
Sub-Total	3,007	324	(2,683)	10,232
Technical schemes	63	63	(0)	0
Donated assets	7	0	(7)	0
Total Programme	3,077	387	(2,690)	10,232

	Full Yea	ar	
NHSI Plan £'000s	Flex Plan £'000s	Outlook £'000s	Variance £'000s
20,624	20,624	20,624	0
10,572	10,572	10,572	0
5,006	5,006	5,006	0
0	0	0	0
36,202	36,202	36,202	0
10,386	10,386	10,386	0
84	84	84	0
46,672	46,672	46,672	0

The above table shows the status of the capital programme, analysed by category, at the end of Period 01. The technical schemes include MES and BTC against which £0.06m and nil items have been capitalised respectively. In addition to the YTD spend £10.2m of commitments have been made. The £46.7m outlook reflects the capital element of the plan submitted to NHSI on  $30^{th}$  March 2017. Forecast capital spend is consistent with this plan.

The £46,672k CRL includes £34,720k of anticipated adjustments NHSI have yet to confirm the full CRL.

This reflects the re-phasing of the capital programme that was undertaken in 2016/17 and which moved £9m capex into 2017.18. This was managed without compromise to the critical path strategic investment plan and supports near term cash remediation. A reduced capital programme may be required if the outlook on I&E surpluses deteriorates or medium term cash remediation is compromised.

## **SOFP**

Period 01 2017/18

	Balance as at 31st March 2017	Balance as at 30th April 2017	TDA Planned Balance as at 30th April 2017	Variance to plan as at 30th April 2017	TDA Plan as at 31st March 2018	Forecast 31st March 2018
	£000	£000	£000	£000	£000	£000
Non Current Assets						
Property, Plant and Equipment	207,434	206,504	209,253	(2,749)	242,166	242,166
Intangible Assets	166	160	239	(79)	239	
Trade and Other Receivables	43,017	46,453	48,799	` /	92,045	
Current Assets						
Inventories	5,268	5,268	4,179	1,089	4,177	4,177
Trade and Other Receivables	25,151	24,832	20,946	3,886	20,946	20,946
Cash and Cash Equivalents	23,902	19,919	13,751	6,168	309	309
Current Liabilities						
Trade and Other Payables	(68,516)	(63,452)	(65,144)	1,692	(38,646)	(38,646)
Provisions	(1,138)	(1,114)	(1,196)	82	(1,196)	(1,196)
Borrowings	(903)	(903)	(903)	0	(3,353)	(3,353)
DH Capital Loan	0	0	0	0	0	0
Non Current Liabilities						
Provisions	(3,404)	(3,370)	(2,960)	(410)	(3,012)	(3,012)
Borrowings	(33,954)	(33,880)	(26,586)	(7,294)	(50,077)	(50,077)
DH Capital Loan	0	0	0	0	0	0
	197,023	200,417	200,378	39	263,598	263,598
Financed By						
Taxpayers Equity						
Public Dividend Capital	205,362	210,412	210,412	0	252,540	252,540
Retained Earnings reserve	(24,972)	(26,628)	(26,375)		(5,822)	,
Revaluation Reserve	7,575	7,575	7,606	(31)	7,822	7,822
Other Reserves	9,058	9,058	9,058	0	9,058	9,058
	197,023	200,417	200,701	(284)	263,598	263,598

The table opposite is a summarised SOFP for the Trust including the actual and planned positions at the end of April and the full year.


Variance from plan for cash is due to the reduced cash out flows arising from lower levels of capital expenditure. The impact of the underlying has been mitigated by this.


The Receivables variance from plan relates to the prepayment associated with the MES contract. Analysis and commentary in relation to working capital is available on the next slide.


A task & finish group initiated a cash remediation plan in 2016/17. The actions of this are reflected in the favourable variance on cash. This plan is the subject of a separate paper.

### Aged Receivables, Aged Payables, BPPC and Cash Forecast

Period 01 2017/18







#### Note

- The April debt position reduced as aged NHS debt was recovered following the end of the year. However, the Non NHS debt and the over 90 Day element, increased as local government debt and Overseas Patient income aged further.
- The overall Payables position has decreased during April as the Trust utilised the cash balances from 31st March 2017 to settle debt. The overall levels remain high as the Trust continues to manage cash pressures. The overall level of over 90 days liability reduced as NHS debts were settled.
- BPPC is below target of 95% by volume and value as the Trust looks to effectively manage cash. Underlying performance remains the subject of improvement work with finance and procurement teams.

### **TRUST BOARD**

DOCUMENT TITLE:	Planned Care Production Plan 2017.18 – P01 update & outlook
SPONSOR (EXECUTIVE DIRECTOR):	Tony Waite, Finance Director
AUTHOR:	Yasmina Gainer, Head of Performance Management
DATE OF MEETING:	1 June 2017

### **EXECUTIVE SUMMARY:**

#### **Purpose**

Delivery of planned care to time and budget is a cornerstone of the trust's financial plan for 2017.18. A detailed production plan has been established to deliver that and this is overseen by the Planned Care PMO which meets on a weekly basis and which is underpinned by respective GPOs.

#### Governance - Board 'tests'

An updated position against the four tests set by the Board is set out in the table below:

Board 'test'	Position statement
The Production Plan to be returned to the April Trust Board meeting with all specialities and confirmation of the outpatients position	There are no specialties with production plans outstanding. There is a residual £700k to be resolved such that the aggregate value of production plans aligns to the contract and financial plan target value. This is being resolved through the weekly PMO led by the COO and is mitigated through current over performance which will be forecast where anticipated to continue over the year. This will fully close the planned gap.
Consultants to agree and sign up to the production plan. Those who do not sign the plan are to meet with Mr Lewis and Dr Stedman to discuss their position.	Specialty production plans agreed with respective clinical directors and consultants for all specialties with the exception of orthopaedics.  Orthopaedics The orthopaedic CD has confidence in a majority of the plan but the team are unable to provide numerical assurance in the productivity step up and alignment to scheduling in theatres. There are workforce challenges in registrar cover with 40% vacancies of which the mitigation plan is not finalised. The team are representing the numerical analysis and recruitment plans wc 29.5.17
Confirmation to be provided that general surgery and ophthalmology are able to meet their activity projections.	Both specialties have production plans which align with their annual targets. There is on-going work to finalise the granular level phasing and

	which is not expected to compromise the full year plan.
Confirmation to be provided that the elective access arrangements are fit for purpose.	Further improvement noted and necessary but not sufficient. A proposal for a revised and fit for purpose booking structure and procedures has been developed and is with the new DCOO for planned care for finalisation and delivery.

#### **Results**

This report provides three things:

- 1. Final results for P01 April 2017 activity & expected SLA income
- 2. May forecast for P02 May 2017 activity & anticipated SLA income
- 3. June early predictions P03

#### April results Planned Care:

- Delivered activity ahead of plan [46,428 delivered units vs 44,927 planned 1,501 ahead ]
- Delivered income ahead of plan [£7.604m vs £7.481m £123k ahead]
- Daycase and IP activity is below plan, propped up by OP news, follow ups in line with plan (see appendix for performance by speciality and trust level graphical presentation by POD vs plan)

#### May flash results Planned Care:


- Anticipated activity ahead of plan [56,130 anticipated delivery vs 50,427 planned] calculating presently a forecast £0.6m positive variance to plan.
- We are still in May so this projection may change if slots are cancelled, assumed walk-ins do not happen.

#### June early projections:

- c25,000 units of activity with value c£4.7m remain to be booked.
- This reinforces that further improvement is required in booking on a timely and complete basis including better compliance with the 8/6/4/2/0 discipline for theatre activity

#### **Supporting information**

### Working Day Profiles 2017/18



**Note**: that June has a significant increase in working days countering the EPR downtime in Oct& Nov (June standard working days available 22, adjusted to 26.3). The working days activity profile below has been used in the production plan.

#### Governance – end to end production plan data assurance

Work has progressed and prima facie confirmed the coherence of end to end governance of the production plan process – from contract through production planning to booking to delivery to the reporting of actual results achieved. Further work is being undertaken on the back of P01 actual results to re-confirm that coherence and to close out any residual issues including specifically the £700k [0.5%] gap between production plan and contract value.

Specific work has been on-going to validate:

- the activity & income plans used in the production plan match and are comparable to the CCG activity & income plan on an annual level. The validation has identified a small gap of £0.7m between the two plans, which can be mitigated as we go through the year and fine-tune the differences. This reassures that we are tracking the right targets. There are small, monthly phasing differences and this will be worked through to ensure that it matches fully the service delivery phasing.
- The production plan is appropriately uplifted by a service specific DNA rate to stimulate over-booking therefore and as a minimum the plans are delivered.
- The production plan counts 'activity' retrospectively and prospectively. For weeks which have completed, attended patients are counted, for weeks ahead booked patients + walk-ins + cancer 2WW assumed are counted.
- Ongoing meetings with the service to support their contractual management are in place supported by the Deputy COO, Planned Care.

#### Attachments:

April final results Planned Care - summary

#### **REPORT RECOMMENDATION:**

The Board is recommended to note the report and to require that results are reported routinely to the Finance & Investment Committee until such time as it is assured as to the robustness of production plan

& delivery.

<b>ACTION REQUIRED</b> (Indicate The receiving body is aske				
Accept		Approve the recommendation	Discuss	
			X	
KEY AREAS OF IMPACT (Inc	dicate w	ith 'x' all those that apply):		
Financial	Х	Environmental	Communications & Media	
Business and market share	Х	Legal & Policy	Patient Experience	
Clinical		Equality and Diversity	Workforce	Х
Comments:		·		

### ALIGNMENT TO TRUST OBJECTIVES, RISK REGISTERS, BAF, STANDARDS AND PERFORMANCE METRICS:


Excellence in the use of resources.


Sustainable finances

### **PREVIOUS CONSIDERATION:**

Production plan development & plan considered at FIC, Board







Group Name	Spec Group Description	POD Group Code 12	Activity Plan	Activity Actual Ac	tivity Diff	Price Plan Inc MFF	Price Actual Inc	Price Diff Inc
Imaging	Interventional Radiology	DC	21	29	8	£17,265	<b>MFF</b> £20,529	MFF £3,2
magmg	interventional Radiology	EL	1	0	-1			
		OP New	5		-3			
wasing Tatal		OP Review	1	0	-1			
maging Total Medicine & Emergency Care	Cardiac Rehabilitation	OP New	28 130		-15	•		
		OP Review	1,537		101			
		OP Telephone	21		-21			
	Cardiology	DC	127		-23			
		EL OP New	14 401		1 52			
		OP Review	1,015		109			
		OP Telephone	16		35			
	Cardiothoracic Surgery	DC OR Navy	-0		0			
		OP New OP Review	6		C			
	Clinical Haematology	DC	293		22			
		EL	17		2	· · · · · · · · · · · · · · · · · · ·		
		OP New	127		-6	,		
		OP Review OP Telephone	672 57		-11			
	Clinical Neuro-Physiology	OP New	164		114			
		OP Review	9		-3		£846	5 -£1
	Clinical Pharmacology	EL	3		3	,		
		OP New	0		-0			
	Gastroenterology	OP Review DC	10 75		23			
	Custi center ology	EL	7		2			
		OP New	760		89	· · · · · · · · · · · · · · · · · · ·		£21,1
		OP Review	401		-28			
	Geriatric Medicine	OP Telephone DC	86		10			
	Genatric Medicine	EL	-0		0			
		OP New	36		-4			
		OP Review	60	45	-15			
	Nephrology	DC	5		-2			
		EL OP New	27		-0 9			
		OP Review	75		C			
	Neurology	DC	7		-7			
		EL	0		1			
		OP New	252		36			
	Respiratory Medicine	OP Review DC	321 28		-20 -24	,		
	nespiratory meaning	EL	2		1			
		OP New	241		127			
		OP Review	440		-20			
Medicine & Emergency Care Total athology	Allergy	OP New	<b>7,455</b>		<b>629</b>			
athology	Allergy	OP Review	10		-4			
	Anticoagulant Service	DC	3		-3			
		OP New	25		3			
	Chamical Bath slam.	OP Review	3,573		-175			
	Chemical Pathology	DC EL	11	9				
		OP New	69		4			
		OP Review	108	216	108			
	Clinical Immunology	DC	91		12			
		EL OP New	85		-0 23			
		OP New OP Review	63		3			
		OP Telephone	0		10			
athology Total			4,054		-14			
urgical Services	Anaesthetics	OP New	44		11			
	Audiology	OP Review OP New	0 1,948		-0 185			
		OP Review	562		62			
	Breast Surgery	DC	69		-28	£119,207	7 £83,829	
		EL	7		-2			
		OP New	335		135			
	Clinical Psychology	OP Review OP New	370		18 5			
		OP Review	1		3			
	Critical Care Medicine	OP New	4		-2	£264	4 £208	3 -
		OP Review	0		1			
	ENT	DC	86		-33	£85,692	£49,851	L -£35,
		FI.		~-	-	004 400	\	
		EL OP New	750		-97			

OP New

OP New

OP New

OP New

OP Review

OP Telephone

DC

 $\mathsf{EL}$ 

OP Review

OP Review

OP Telephone

OP Telephone

DC

EL

**General Surgery** 

Ophthalmology

**Medical Ophthalmology** 

OP Review

750

624

143

66

689

728

6

15

47

17

571

30

5

2,769

7,786

653

516

160

73

806

774

1

7

70

5

579

53

51

2,799

8,226

-97

-108

17

7

117

46

-5

-8

23

-12

8

23

30

440

46

£85,571

£43,159

£189,472

£189,698

£120,543

£46,017

£147

£1,450

£4,374

£462,758

£45,882

£418,549

£497,853

£104

£380

-£10,058

-£9,065

£10,279

£7,466

£29,407

-£877

-£50

-£649

£1,094

-£106

£9,475

£19,359

£48,337

£3,983

£517

£75,513

£34,094

£199,751

£197,164

£149,951

£45,140

£96

£800

£274

£5,467

£472,233

£65,241

£422,532

£546,190

£621

Columnity	Group Name	Spec Group Description	POD Group Code 12	Activity Plan	Activity Actual	Activity Diff	Price Plan Inc MFF	Price Actual Inc MFF	Price Diff Inc MFF
Post Sergery		Optometry	OP New	57	39	-18			
B.   1.   1.   1.   1.   1.   1.   1.				390	428	38	£19,274		£564
Prince		Oral Surgery							
OP Notes									
Community   Comm									
Principle   Company   Co		Orthoptics							
Pain Monogenees    C		Orthotics							
Pan Moragement CC 277 210 32 52 5297 111,1279 127,126		Orthotics							
Plant Surgery		Pain Management							
Plantic Surgery   CC									
El		Plastic Surgary							
Prison B. Composedics		riastic Surgery							
Frame & Orthopereiro				138	32	-106			
File									
### OP New   598   1,398   10,		Trauma & Orthopaedics							
Verlage									
Cl.   82   71   11   \$13,488   \$128,379   \$45,579   \$15,679   \$1									
OF Process		Urology							
March   Marc									
Vaccular Surgery									
Corner		Vascular Surgery							
Suggest Services Total									
Surgical Stories Total  Women's & Child Health  Gentila-Urinary Medicine  OP New  OP N									
Manual   Community pendiatris   OP New   S   22   10	Surgical Services Total		O. Neview						
Genito Urhany Medicine		Community Paediatrics		5	21	16	£1,128	£2,630	£1,502
Gynaecological Oncology		Cariba Hainama Madiaina							
Cyasecological Oncology		Genito-Urinary Medicine							
OP New		Gynaecological Oncology							
OP Review   117   143   26									
Priespone   15									
Primary Care, Community and Therape   Fig. 1   1   558,435   613,495   613,695   612,005									
OP New		Gynaecology	·						
Principal									
MIV									
HIV									
Neonatology   DC		HIV	·						
EL									
Price		Neonatology							
Pediatric Diabetic Medicine   OP New   1   2   1   £216   £559   £213   £149     OP New   1   2   1   £216   £559   £213     OP New   31   39   8   £6,647   £71,320   £672     OP New   31   39   8   £6,647   £71,320   £672     OP Review   97   103   6   £12,716   £12,851   £138     OP Review   97   103   6   £12,716   £12,851   £138     OP New   24   25   3   £12,715   £17,851   £14,936     OP New   26   25   3   £12,715   £17,851   £4,936     OP New   26   25   45   5,767   £55,069   £45,577     OP Review   56   486   40   £73,272   £67,131   £45,171     OP New   56   486   40   £73,272   £11,131   £13,571     OP New   56   486   40   £73,272   £11,131   £13,571     OP New   56   486   40   £73,272   £11,131   £13,571     OP New   57   57   £13,574   £13,574     OP New   57   57   £13,574   £13,574   £13,574     OP New   57   57   £13,574   £13,574   £13,574     OP New   57   57   £13,574   £13,574   £13,574     OP New   57   72   4   £15,877   £13,514   £13,574     OP New   57   72   £114   £125   £114   £125   £114     OP New   57   72   £114   £125   £145   £1									
Pediatric Neuro-Disability									
Paediatric Neuro-Disability		Paediatric Diabetic Medicine							
Paediatrics    Paediatrics   C		Pandiatric Neuro Disability							
Paediatrics   C		raediatric Neuro-Disability							
OP New		Paediatrics				3			
OP Review   566   486   480   £73,2772   £67,131   £6,141									
Momen's & Child Health Total									
Women's & Child Health Total   C									
EL	Women's & Child Health Total			3,099	3,333		£693,224	£825,153	£131,929
OP New	Primary Care, Community and The	era <sub>l</sub> Dermatology							
Diabetic Medicine									
OP Review   346   344   -2   £28,398   £24,709   -£3,689     OP Telephone   5   7   2   £114   £125   £111     Dietetics   OP New   10   27   17   £680   £1,158   £479     OP Review   22   17   -5   £1,067   £969   -£98     Endocrinology   OP New   61   64   3   £13,311   £14,875   £1,563     OP Review   213   197   -16   £20,049   £18,120   £1,553     OP Review   934   946   12   £45,734   £45,870   £137     OP Review   934   946   12   £45,734   £45,870   £137     OP Review   934   946   12   £45,734   £45,870   £137     OP Review   4   0   -4   £252   £148   £103     OP Review   16   0   -16   £802   £477   £325     OP Review   88   41   -47   £4,324   £3,395   £924     OP Review   88   41   -47   £4,324   £3,395   £924     OP Telephone   4   0   -4   £87   £52   £35     Rheumatology   DC   106   110   4   £42,867   £48,621   £5,755     EL   1   1   0   £493   £4,262   £3,759     OP New   155   181   26   £39,497   £45,677   £6,179     OP Review   991   934   -57   £104,722   £88,769   £15,953     OP Review   991   993   993   59				1,340	1,400				
Dietetics		Diabetic Medicine		76	72		£15,877	£13,014	-£2,863
Dietetics   OP New   10   27   17   f680   f1,158   f479									
Properties		Dietetics							
Endocrinology				_					
Physiotherapy         OP New         17         269         252         £1,212         £8,355         £7,143           OP Review         934         946         12         £45,734         £45,870         £137           Physiotherapy - FES         OP New         4         0         -4         £252         £148         -£103           Podiatry         OP New         16         0         -16         £802         £477         -£32           Podiatry         OP New         4         1         -3         £281         £188         -£94           OP Review         88         41         -47         £4,324         £3,395         -£929           OP Telephone         4         0         -4         £87         £52         -£35           Rheumatology         DC         106         110         4         £42,867         £48,621         £5,755           EL         1         1         1         0         £493         £4,662         £3,769           OP New         155         181         26         £39,497         £45,677         £6,179           OP Review         991         934         -57         £104,722         £88,769<		Endocrinology		_			£13,311		
OP Review   934   946   12   £45,734   £45,870   £137		Physiotherapy							
Physiotherapy - FES         OP New         4         0         -4         £252         £148         -£103           OP Review         16         0         -16         £802         £477         -£325           Podiatry         OP New         4         1         -3         £281         £188         -£94           Podiatry         OP New         88         41         -47         £4,324         £3,395         -£929           OP Telephone         4         0         -4         £87         £52         -£35           Rheumatology         DC         106         110         4         £42,867         £48,621         £5,755           EL         1         1         0         £493         £42,62         £3,769           Po Review         991         934         -57         £104,722         £88,769         £15,953           OP Review         991         934         -57         £104,722         £88,769         £15,953           Speech And Language Therapy         OP New         1         16         15         £52         £481         £429           OP Review         48         59         11         £2,350         £2,565		Physiotherapy							
Podiatry         OP New         4         1         -3         £281         £188         -£94           OP Review         88         41         -47         £4,324         £3,395         -£929           OP Telephone         4         0         -4         £87         £52         -£35           Rheumatology         DC         106         110         4         £42,867         £48,621         £5,755           EL         1         1         0         £493         £4,262         £3,769           OP New         155         181         26         £39,497         £45,677         £6,179           OP Review         991         934         -57         £104,722         £88,769         -£15,953           OP Telephone         626         702         76         £14,392         £15,079         £687           Speech And Language Therapy         OP New         1         16         15         £52         £481         £429           OP Review         48         59         11         £2,350         £2,565         £215           Clinical Genetics         OP New         7         0         -7         £4,169         £2,501         -£1,667 <td></td> <td>Physiotherapy - FES</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>		Physiotherapy - FES							
OP Review         88         41         -47         £4,324         £3,395         -£929           Primary Care, Community and Therapies Total         OP Review         88         41         -47         £4,324         £3,395         -£929           OP Telephone         4         0         -4         £87         £52         -£35           Rheumatology         DC         106         110         4         £42,867         £48,621         £5,755           EL         1         1         0         £493         £4,662         £3,769           OP New         155         181         26         £39,497         £45,677         £6,179           OP Review         991         934         -57         £104,722         £88,769         -£15,953           OP Telephone         626         702         76         £14,392         £15,079         £687           Speech And Language Therapy         OP New         1         16         15         £52         £481         £429           Clinical Genetics         OP New         7         0         -7         £4,169         £2,501         -£1,667				1					
Primary Care, Community and Therapies Total   Fast   Fas		Podiatry							
Rheumatology         DC         106         110         4         £42,867         £48,621         £5,755           EL         1         1         0         £493         £42,662         £3,769           OP New         155         181         26         £39,497         £45,677         £6,179           OP Review         991         934         -57         £104,722         £88,769         -£15,953           OP Telephone         626         702         76         £14,392         £15,079         £687           Speech And Language Therapy         OP New         1         16         15         £52         £481         £429           OP Review         48         59         11         £2,350         £2,565         £215           Clinical Genetics         OP New         7         0         -7         £4,169         £2,501         -£1,667           Primary Care, Community and Therapies Total         5,748         6,057         309         £588,085         £608,264         £20,179									
EL         1         1         0         £493         £4,262         £3,769           OP New         155         181         26         £39,497         £45,677         £6,179           OP Review         991         934         -57         £104,722         £88,769         -£15,953           OP Telephone         626         702         76         £14,392         £15,079         £687           Speech And Language Therapy         OP New         1         16         15         £52         £481         £429           OP Review         48         59         11         £2,350         £2,565         £215           Clinical Genetics         OP New         7         0         -7         £4,169         £2,501         -£10,677           Primary Care, Community and Therapies Total         5,748         6,057         309         £588,085         £608,264         £20,179		Rheumatology							
OP Review         991         934         -57         £104,722         £88,769         -£15,953           OP Telephone         626         702         76         £14,392         £15,079         £687           Speech And Language Therapy         OP New         1         16         15         £52         £481         £429           OP Review         48         59         11         £2,350         £2,565         £215           Clinical Genetics         OP New         7         0         -7         £4,169         £2,501         -£1,667           Primary Care, Community and Therapies Total         5,748         6,057         309         £588,085         £608,264         £20,179				1	1		£493	£4,262	£3,769
OP Telephone         626         702         76         £14,392         £15,079         £687           Speech And Language Therapy         OP New         1         16         15         £52         £481         £429           OP Review         48         59         11         £2,350         £2,565         £215           Clinical Genetics         OP New         7         0         -7         £4,169         £2,501         -£1,667           Primary Care, Community and Therapies Total         5,748         6,057         309         £588,085         £608,264         £20,179									
Speech And Language Therapy         OP New         1         16         15         £52         £481         £429           OP Review         48         59         11         £2,350         £2,565         £215           Clinical Genetics         OP New         7         0         -7         £4,169         £2,501         -£1,667           Primary Care, Community and Therapies Total         5,748         6,057         309         £588,085         £608,264         £20,179									
Clinical Genetics         OP New         7         0         -7         £4,169         £2,501         -£1,667           Primary Care, Community and Therapies Total         5,748         6,057         309         £588,085         £608,264         £20,179		Speech And Language Therapy		1	16				
Primary Care, Community and Therapies Total         5,748         6,057         309         £588,085         £608,264         £20,179									
	Primary Care Community and The		OP New						
		CIAPICO I ULAI							
				,,,,,	.5,.20	_,501		,	





TRUST BOARD				
DOCUMENT TITLE:	2016/17 Never Events: action plan review			
SPONSOR (EXECUTIVE DIRECTOR):	Kam Dhami, Director of Governance			
AUTHOR:	Allison Binns, Assistant Director of Governance			
DATE OF MEETING:	1st June 2017			

#### **EXECUTIVE SUMMARY:**

This report provides the Board with a reminder of the Trust's response to the four Never Events which occurred between April 2016 and March 2017, in Maternity, Trauma & Orthopaedics, Ophthalmology and Gynaecology. In all four incidents no harm resulted for the patients and full disclosure was made to them immediately in line with 'duty of candour' obligations. Where relevant additional information has been included in relation to the delivery of the agreed actions.

On-going monitoring will continue through various ways, including clinical audit reviews, inhouse inspections, KPIs, observations, patient feedback, to ensure sustained delivery.

#### **REPORT RECOMMENDATION:**

**RECEIVE and NOTE** updates from Executive Directors for Never Events which occurred between 2016 and 2017.

### **ACTION REQUIRED** (*Indicate with 'x' the purpose that applies*):

The receiving body is asked to receive, consider and:

Accept

		,		✓	
KEY AREAS OF IMPACT (Indicate	te with	'x' all those that a	pply):		
Financial	✓	Environmental	✓	Communications & Media	
Business and market share		Legal & Policy	✓	Patient Experience	✓
Clinical	~	Equality and Diversity	<b>√</b>	Workforce	<b>✓</b>
Comments:					

Approve the recommendation

#### ALIGNMENT TO TRUST OBJECTIVES, RISK REGISTERS, BAF, STANDARDS AND PERFORMANCE METRICS:

Safe High Quality care

#### **PREVIOUS CONSIDERATION:**

Never Event investigation reports, including actions plans, have previously been received by the Board.

### Trust Response to Never Events occurring in 2016/17

## 1. Retained item at surgery

Incident date	Department/Ward	Lead Investigator
08.06.16	Maternity Labour Ward	Dr J Bleasdale, Anaesthetist

#### **Incident synopsis:**

A retained vaginal pack was discovered on delivery suite at City hospital on the 08.06.16 when the patient self-referred 3 days post emergency lower segment caesarean section.

#### **Incident investigation synopsis:**

There were a number of opportunities to avert this incident. Problems with the supply of large packs meant these were not available necessitating the use of an alternative. It is also unusual practice but not uncommon to use more than one vaginal pack following obstetric operations. Despite correctly documenting that there were two retained vaginal packs in situ on both the white board in theatre and in the theatre care plan, this did not translate onto the operation notes, the electronic patient record or verbally during handovers.

#### What have we done to prevent the incident from occurring again?

- All throat packs from Maternity theatres were removed immediately. The requirement for large pack availability was escalated to the Specialty Theatre Manager & Stores immediately and actioned.
- Reflections and learning from the incident was discussed at the Obstetric QIHD, attended by a multi-disciplinary group of 62 staff. Additionally, an instruction was issued by the Clinical Director at the Consultants' Forum that midwives and medical staff MUST access documentation at the time of pack removal.
- 3. Following a successful trial of the use of fluorescent wristbands in gynaecology and maternity (1 wristband per vaginal pack) as a visual alert to ensure all packs are removed when relevant, these have been introduced and are being used in all theatre specialties.
- 4. A process for completion of the operation sign-out was developed and introduced, so staff document when packs, balloons etc are to be removed, in conjunction with use of wristbands. As part of the new guidance, if more than 1 pack is used it MUST be tied together.
- 5. The incident was discussed and highlighted at various meetings and forums over a month to highlight documentation and handover issues and a standardised process for handover (i.e. use of SBAR) was discussed with all staff

#### Further local actions re contributory factors:

- 6. A system for notifying theatre leads when there is a supply issue and approved alternatives was agreed with the Specialty Theatre lead. All bar codes for maternity theatre stock have been provided and 'packs' are bar-coded. They now also state what the packs are so it is clearly visible. This system is working well and there is an earlier point in the stocking process which flags when supplies are running short, together with an effective communication book.
- 7. Further training has been provided to both doctors and midwives within Obstetrics and standard operating procedures (SOP) developed for correct completion of Badgernet (maternity electronic patient record) for intra-partum and triage stages.

### 2. Retained item at surgery

Incident date	Department/Ward	Lead Investigator
01.09.16	Trauma & Orthopaedic Theatres	Mr A Tyagi, Ophthalmologist

#### **Incident synopsis:**

A retained drill guide used as part of an open reduction internal fixation (ORIF) of the left humerus operation in Theatre 4, Sandwell General Hospital on 29.6.16 was left in situ.

#### **Incident investigation synopsis:**

Although the operation was straight forward it was recognised that the fracture was large and that the drill guide became obscured by the muscle. The instrument count did not identify that there was an item missing which led to it being left in the patient when it should have been removed. As the drill guide is made from the same material as the 'plate', there should not be any adverse complication from leaving it place until the fracture has healed.

#### What have we done to prevent the incident from occurring again?

- A surgical pause introduced for the operating team to thoroughly review x-ray images and
  positively identify that the images are for the correct patient is now part of the WHO
  checklist during 'time-out'. It has been cascaded to all Directorates, all surgeons and all
  theatre staff directly. This is audited on a monthly basis as part of the WHO surgical
  checklist audit. Data for April 2017 shows 100% compliance with the snapshot done.
- 2. The scrub nurses that complete the instrument count visually confirm each item during the count.
- 3. All basic trays have been standardised. Some of the more complex trays have not been standardised due to costs and remain on the risk register.
- 4. The next patient on the operating list will not be sent for until the final count is completed. Process clarified to ALL the surgeons, anaesthetists and theatre staff directly.
- 5. The case was discussed at the September 2016 Theatre QIHD for shared learning where 43 members of theatre staff attended.

### 3. Wrong site surgery

Incident date	Department/Ward	Lead Investigator
03/11/16	Ophthalmology	Dr J Bleasdale, Anaesthetist

#### **Incident synopsis:**

On 3 November 2016 during an afternoon session, two patients with similar names and dates of birth attended the Birmingham and Midlands Eye Hospital (BMEC) Outpatients.

Patient 1 was attending an outpatient's review clinic and patient 2 required Lucentis injections in each eye.

When Patient 2 was called for their injection Patient 1 stood up and went into the room. The operator in the room had a temporary copy of the notes for Patient 2. Patient 1 was consented for the procedure, using the details of Patient 2, and bilateral injections were performed in accordance with normal procedure – including WHO checklist and pause for procedure confirmation and SOP stamp. Following the injections Patient 1 was sent home.

At about the same time Patient 1 was called for visual acuity tests and Patient 2 stood up and went into the room. Patient 2 then had a visual acuity test and eye drops and was sent for, and had, an OCT scan, none of which were necessary.

At approx. 5.30pm, Patient 2 notified the nurse in charge that they had been waiting for their injections. The nurse explained that the injection list had finished, apologised and said they would be contacted with another date for their injection.

#### **Incident investigation synopsis:**

This incident occurred following an accumulation of environmental (timing, co-location and busy clinic) and human (distraction and pressure error) factors. However, the fundamental error was a failure to positively identify Patients 1 and 2 at any stage during their visit to BMEC Outpatients.

### What have we done to prevent the incident from occurring again?

- 1. The process for correct positive patient identification has been reinforced to all staff.
- 2. A process whereby staff retrieving patients from a waiting area positively identify patients has been implemented and is monitored through observational audits on a monthly basis. Results show 100% compliance to date.
- 3. Develop a process whereby patients undergoing an invasive procedure (injections or laser treatment) in outpatients are issued with a patient identification wristband at clinic registration.
- 4. The Injection Clinic Waiting Room has been isolated from the other waiting areas and patients for injections are directed straight to that area.
- 5. The consent process has been strengthened so that:
  - No consent is taken on the day for patients having their first injection
  - For patients having subsequent injections consent can be on the day only after confirmation with a Consultant.
- 6. The Injection Clinic SOP has been updated and the checking process shared with learning from main BMEC theatres serious incidents.

NB: The feasibility of the electronic self-check-in system recognising two patients with the same surname attending outpatients for the same session has been assessed and is not possible.

### 4. Retained item at surgery

Incident date	Department/Ward	Lead Investigator
11.01.2017	Gynaecology	Dr J Bleasdale, Anaesthetist

#### **Incident synopsis:**

A patient returned to the Gynaecology clinic following emergency surgery five weeks previously at which point a retained ribbon gauze pack was identified that should have been removed prior to discharge from hospital following surgery.

#### **Incident investigation synopsis:**

Actions were taken following the last retained swab Never event (July 2016) including a change in policy and procedures to include the use of coloured wrist bands to indicate deliberately retained swabs following surgery. In this instance that policy change was fully followed by the surgical team – the nature and position of the retained swab was documented in the notes and the wrist band was in place. The staff member that prepared the patient for discharge removed the wrist band when she believed the pack to have either already fallen out or been removed.

#### The investigation identified a number of factors that contributed to this human error:

- Practice regarding the use of retained packs in this particular procedure varies between practitioners and also depending on clinical circumstances – therefore the use of ribbon gauze in this procedure is not consistent
- The member of staff that made the error was aware of the policy change however was not fully briefed regarding the detail, due to being a regular night shift worker. This led to overlooking policy detail including the requirement for 2 staff members to be involved in removing packs.
- The changes to the 'Safer Surgery Policy' had been ratified by the Theatres Board however the new policy had not been uploaded onto the intranet.

#### What have we done to prevent the incident from occurring again?

- 1. Introduced a policy that clearly demonstrates the number of packs intentionally left in the patient at the end of a surgical procedure that will need to be removed at a later time. The key stages of the revised process are:
- <u>During the procedure</u>: the surgeon and the scrub nurse or midwife discuss and confirm that pack/packs will be left in situ at the end of the procedure and the number of packs involved.
- At "Sign Out": the team agree the number of packs left in situ and then a member of staff attaches a luminous wrist band to the patient's arm for EACH and EVERY pack left in situ and that number of band (s) is confirmed with the scrub nurse/midwife once attached. The number must then be recorded in both the theatre care plan and the operation note. Each and every pack is recorded even if tied together. The date of removal of the packs must be recorded by the operative surgeon on the operation note and post-op plan. Their sole purpose is to have an external record of the number of packs in situ.
- At removal of the pack(s): as each pack is removed they must be counted as "1" then one band cut and kept with the pack. "2" and the second band cut and kept with the pack etc. until all the packs have been removed and checked with the number of wrist bands. The number removed and checked should be recorded on the operation note and scrub count record. The packs must always be removed with two people present one person to remove the pack and one person to remove the band and put with the pack. The number removed and by whom must be recorded in the notes and countersigned.
- If the band(s) are removed for venous access they must be immediately replaced on the other arm and the numbers re-confirmed.

- No patient is allowed to leave the hospital with the luminous wrist bands still in place.
- 2. Permitted the use of ribbon gauze as clinically indicated but stopped use of Jelonet and blue gauze.

TRUST BOARD				
DOCUMENT TITLE:	Improving A&E performance			
SPONSOR (EXECUTIVE DIRECTOR):	Rachel Barlow Chief Operating Officer			
AUTHOR:	Rachel Barlow Chief Operating Officer			
DATE OF MEETING:	24 <sup>th</sup> May 2017			

#### **EXECUTIVE SUMMARY:**

In April 2017 the Trust ED performance as measured against the 4 hour standard was 84.95%. May to date performance has deteriorated to 81.21%; the scale of improvement challenge has increased. The trajectory to reach that includes a marked step up in performance in July 2017 to 90% as measured against the 4 hour standard which is equivalent to 60 fewer breaches a day compared to the first 3 weeks of May.

The scale of challenge is related in the main to the patient discharge outflow and internal professional standards. The improvement design is complete for our first of 2 urgent care challenge weeks which will specifically focus internal ED and speciality professional standards practiced consistently.

The paper provides an update on progress and preparedness for improvement and show how the team will measure success. A supportive coaching rota of senior clinical and non-clinical leaders will support the behavioural and cultural changes over implementation.

#### **REPORT RECOMMENDATION:**

The Trust Board are asked to note and discuss

- progress
- risks and mitigation
- the role of trust board members in the improvement approach

#### **ACTION REQUIRED** (*Indicate with 'x' the purpose that applies*):

The receiving body is asked to receive, consider and:

Accept	Approve the recommendation	Discuss			
		x			
KEY AREAS OF IMPACT (Indicate with 'x' all those that apply):					

KEY AREAS OF IMPACT (Indicate with 'x' all those that apply):						
Financial	Х	Environmental		Communications & Media	Х	
Business and market share		Legal & Policy		Patient Experience	Х	
Clinical	v	Equality and		Workforce	v	
Cillical	^	Diversity			^	

#### Comments:

### ALIGNMENT TO TRUST OBJECTIVES, RISK REGISTERS, BAF, STANDARDS AND PERFORMANCE METRICS:

Accessible and responsive care objective,

#### PREVIOUS CONSIDERATION:

Previous Trust Boards

#### **Improving A&E performance**

#### 1.0 Introduction

In April 2017 the Trust ED performance as measured against the 4 hour standard was 84.95%. May to date performance has deteriorated to 81.21%, the scale of improvement challenge has increased. By March 2018 the Trust ED performance is required to be at 95% measured against the 4 hour target, which is equivalent to 90 fewer breaches a day pan Trust compared to the first 3 weeks of May. The trajectory to reach that includes a marked step up in performance in July 2017 to 90% as measured against the 4 hour standard which is equivalent to 60 fewer breaches a day compared to the first 3 weeks of May.

The scale of challenge is related in the main to the patient discharge outflow and internal professional standards; whilst attendances and admissions over the course of a week and month are stable, discharges from our wards have decreased by 6 a day across our medical bed base compared to March. Specialties report high acuity and the number of frail patients requiring in-patient therapy treatment prior to a transfer to intermediate care has increased by circa 30%. In week ambulance and overall attendance activity variances remains a challenge with up to 30% above prediction on occasions being challenging. However, we must remain focussed on the internal opportunity of improvement in our ED's, speciality responsiveness and address the shortfall in discharge flow.

This paper updates the board on progress in our improvement activities;

**2.0** The **new ophthalmology urgent care pathway** has been put in place which diverts appropriate patients to booked urgent care clinics, facilitating patient pathways to the right clinical teams. The decrease in reportable ED patient activity has had an impact of 2% on Trust level 4 hour ED performance and is the second contributory factor to the decrease in performance since April. The ophthalmology urgent care pathway is now in its 3<sup>rd</sup> week of implementation; clinics have >95% utilisation, no patients are transferred from ED to the ward out of hours for continued assessment and treatment which is a significant improvement in patient experience. Initial teething problems identified during implementation include a mismatch in pre-triage capacity and triage staff, causing a delay in this first stage of the pathway at peak times. There have been some 4 hour breaches in the ED pathway that resulted from a misalignment in demand, acuity and failure to reallocate staff to ED stream. The multi professional leadership team have a daily PMO (in a patient facing environment) where they analyse key measurable standards of success. Where these have fallen short, there has been a PDSA (plan, do, study, act) approach to refining how the team work and initiating incremental improvements. We will formally evaluate this implementation in July.

### 3.0 July 2017: Achieving 90% 4 hour performance – 60 fewer patients waiting over 4 hours from arrival in ED

There are 8 main improvement areas to be delivered in advance on July 2017:

An Urgent Care Challenge week led by Deputy COO Phil Holland starts week commencing 29<sup>th</sup> May which will oversee implementation.

Improvement area	Progress				
1.Increasing the substantive workforce by June 2017	On track with 2 of the 3 consultants already in post.				
2.Increase capacity in ED through different use of space in May 2017 – 20% increase in capacity at Sandwell from mid-May through using space differently	, ,				
The combination of 1 and 2 will contribute to a reduction of 10 breaches a day.					
3.Enact consistent professional standards in ED in June	Under the leadership of Phil Holland Deputy COO				

**2017**— this requires the role of consultant and shift leader to be practiced with consistency.

This improvement focus will contribute to a reduction of 10 breaches a day.

for Urgent Care, implementation of these standards will be during urgent care challenge week commencing 29/5/17. Situational coaching will be in place with a regular PMO measuring how we are performing for each standard from 10am-10pm daily to oversee implementation and improvement. There will also be a daily learning event with staff.

In preparedness the following is completed:

- Rapid assessment and treatment model agreed.
- Evidence of staffing rotas to support 10am-10pm service.
- KPIs agreed for all professional standards see appendix 1.
- Comms' and engagement sessions in place with individual members of staff in ED and the Out of Hours site team.
- Visual management boards in place in all EDs.

**4.Enact consistent professional standards within specialities in June 2017** – speciality doctors should always respond to referral request within 30 minutes and accept the ED decision to admit to specialty. The patient should be admitted within 20 minutes of that decision

This improvement focus will contribute to a reduction of 10 breaches a day.

Implementation will be led through the same urgent care challenge week.

- All surgical pathways reviewed and reaffirmed with clinical and operational teams.
- These pathways are published and key ones visible within the ED.
- KPIs agreed for all pathways see appendix 1 which will be measured through a regular PMO activity.

**5.Strengthening ambulatory care in June 2017** to avoid admission and reduce demand in ED

This improvement focus will contribute to a reduction of 10 breaches a day.

Project team in place with defined improvement scope using the Trust improvement approach. Engagement with Primary Care in redesign.

Project on track to try out improvement end of June in a second improvement week.

**6.** Implement a 'pull admitting model in June 2017 'from the assessment units to the wards.

This improvement focus will contribute to a reduction of 10 breaches a day.

Modelling complete and project group forming.

Engagement with clinical leads ongoing and theme at leadership conference.

Next step – complete design process to pilot end of June

7.Focus on discharge planning and length of stay Call to arms for clinical ward teams to meet discharge

7.Focus on discharge planning and length of stay reduction

This improvement will contribute to a reduction of 11 breaches a day.

Call to arms for clinical ward teams to meet discharge goals across the week and focus on red to green improvement activities to reduce LOS.

Support through buddy system to be commissioned to support local ward level improvement with concentration on older people's wards.

7 day and 14 day LOS reviews and pilot new approach to weekend discharges with TTO doctor.

Consistency of care programme underpins team development to lead improvement.

Next steps – review 7 day ADAPT joint health and social care pathway.

Seek assurance on transport availability which contribute to failed discharges

8.Incoming key leadership appointments will increase

New starters in post:

the capacity to implement and sustain improvement.	Michelle Harris - Director of Operations for Medicine
	and Emergency Care
	Phil Holland - Deputy COO for Urgent Care
	Liz Miller - Directorate General Manager Emergency
	Care

## 4.0 March 2018: Achieving 95% 4 hour performance –92 fewer patients waiting over 4 hours from arrival in ED

There are 7 further improvement themes over Quarter 2 and Quarter 3:

- 1. Workforce create a high performing team by March we aim to fully recruit to a substantive workforce and ensure clinical leadership is right for the future. This is about ensuring the right clinicians are in the right jobs and situational leaders have the competence to step up to the scale of MMH ED which will be one of the largest EDs in the country.
- 2. Rightsizing community and social care bed base this accounts for 28% of the improvement required to meet the 95% standard. It involves successful commissioning of community beds to meet demand including non-weight bearing and neuro rehabilitation beds and social care beds including nursing homes and enhanced assessment beds.
- **3.** Continued improvement focus on internal patient pathways through going from red to green reducing length of stay; this will include expansion of the hot clinic model to support discharge ahead of winter
- 4. Additional primary care appointments across a 7 day profile with direct booking for 111 and the Trust.
- 5. A reduction in ambulance conveyances (5 a day on each site) through additional no conveyance pathways.
- 6. Mental health diversion from ED through crisis care planning improvement to be fully scoped.
- 7. Reduction in FTB long waits escalation required and improvement approach to be fully scoped.

Progress will be tracked through the external A&E delivery group as 5/7 improvement areas rely on partners to deliver.

#### 5.0 Risks are known and mitigated where possible

- Failure to recruit clinical staff remains an ongoing risk given the national market, but recent recruitment and the midland metropolitan hospital will input into the future recruitment and marketing strategy.
- Impact on ED performance during EPR goes live it is inevitable that ED performance will be temporarily impacted during EPR go live. Training and workforce plans will be in place to mitigate this impact as much as possible.
- Lack of community and social care beds to meet demand- this is in scope of the improvement approach though system wide A&E delivery group.
- Lack of engagement of key partners to deliver to be managed through A&E delivery group, Commissioners and other external assurance meetings with regulators.

Rachel Barlow - Chief Operating Officer

24.5.17

Category	Core Indicators	Current Baseline	Metric	Target	29-May	30-May	31-May	01-Jun	02-Jun	Cumulative for Week
	% Within 15 minutes	TBC	%	100%						
	Number of patients with an initial assessment within 15 minutes		Number							
	Number of patients with an initial assessment over 15 minutes		Number							
Initial Assessment within 15 minutes	Number of patients streamed to appropriate ED Dept		Number							
within 13 minutes	Number of patients referred directly to specialty assessment area (SAU, AMAA, PAU, EGAU, Urology or ENT)		Number							
	Number of patients deflected to another healthcare provider (Malling Health, GP, Pharmacy etc)		Number							
	Number of GP Referrals to ED		Number							
GP Referrals	Number of GP Referrals to ED transferred out or seen in ED within 30 minutes		Number							
Of Referrals	Number of GP Referrals to ED transferred out or seen in ED over 30 minutes		Number							
	% of patients having RAT within 30 minutes	TBC	%	100%						
followed for all Major			Number							
patients 10am to 10pm	Number of patients having RAT over 30 minutes		Number							
	Number of patients with no RAT completed		Number							
Patients seen by a	% of patients seen within 60 minutes	45%	%	80%						
	Number of patients seen within 60 minutes		Number							
a muit val	Number of patients seen over 60 minutes		Number							
	% of patients admitted with red dot within 2 hours		%	100%						
Clinical Plan and Decision to admit	Number of patients admitted		Number							
within 2 hours	Number of DTAs within 2 hours arrival		Number							
	Number of DTAs after 2 hours from arrival % of patients treated and discharged within 2		Number	0.504		<u> </u>				
Minors patients treated and	hours  Number of patients treated and discharged		%	95%						
discharged within 2	over 2 hours		Number							
hours	Number of minor patients that breached % of minor breaches		Number %	0%						
4 hour standard	Compliance against the 4 hour standard, and trajectory to 95%	83%	%	95%						
	% of patients referred to specialty seen within 30 minutes		%	100%						
Specialty review within 30 minutes of	Number of patients seen by specialty within 30 minutes of referral		Number							
referral	Number of patient seen between 30 and 60 minutes after referral		Number							
	Number of patients seen more than 60 minutes after referral		Number							
Urology Pathway - diagnostics within 1 hour	% of patients CTKUB within 1 hour of request		%							
Head Injury Pathway	% of CT positive patients admitted to T&O ward		%	100%						
	% of CT negative patients admitted to AMU		%	100%						
Pathway	Number of Gynae patients attending ED		Number	0						
Critical Care/Multi Specialty pathway	TBC									
Mental Health Pathway	% of mental health patients seen by Psychiatric team within 60 minutes		%	100%						
	Number of mental health patients seen by Psychiatric team in 60 minutes		Number							
	Number of mental health patients seen by Psychiatric team in over 60 minutes		Number							
Adherence to SOP	Regular departmental reviews held between Lead Consultant and Shift Coordinator		Y/N							
	Escalation triggers used as appropriate in alignment with SOP		Y/N							

## Sandwell and West Birmingham Hospitals NES



**NHS Trust** 

### **TRUST BOARD**

DOCUMENT TITLE:	Complaints & PALS report: 2016/17 Annual
SPONSOR (EXECUTIVE DIRECTOR):	Kam Dhami, Director of Governance
AUTHOR:	Karen Wood, Head of PALS & Complaints
DATE OF MEETING:	1 <sup>st</sup> June 2017

#### **EXECUTIVE SUMMARY:**

This report sets out details of Complaints and PALS enquiries received between 1 April 2016 and 31 March 2017.

The report provides high level data on PALS and Complaints, the reasons those complaints were made and work underway to improve complaints management.

In this year, it is reported that the complaints activity has increased, from 935 to 1026, and also shows that 81% (at the time of reporting) of complaints have been managed within their target date. Themes and outcomes remain consistent with previous quarters and show a continued focus on lessons learned, and quality responses that are caring, transparent, timely and responsive to the needs of complainants.

#### **REPORT RECOMMENDATION:**

The Trust Board is recommended to **DISCUSS** and **NOTE** the review of complaints handling in 2016/17.

#### **ACTION REQUIRED** (*Indicate with 'x' the purpose that applies*):

The receiving body is asked to receive, consider and:

Accept		Approve the recommendation	n	Discuss			
✓				✓			
KEY AREAS OF IMPACT (Indicate with 'x' all those that apply):							
Financial		Environmental		Communications & Media			
Business and market share		Legal & Policy	✓	Patient Experience	✓		
Clinical	<b>√</b>	Equality and Diversity		Workforce			
C		·					

Comments:

### ALIGNMENT TO TRUST OBJECTIVES, RISK REGISTERS, BAF, STANDARDS AND PERFORMANCE METRICS:

Safe, high quality care

Improve and heighten awareness of the need to report and learn from complaints.

#### PREVIOUS CONSIDERATION:

None



SWBTB (06/17) 18a

## **Complaints and PALS**

2016/17 Annual Report

#### WITH THANKS

#### Q1 2016/7

My purpose in writing to you now is to inform you that the matter I raised has been satisfactorily resolved. However, I would like to place on record my sincere thanks to Jo Werhun, of your Patient Advice and Liaison Service, who dealt with the matter on your behalf.

Jo maintained regular contact with me throughout and displayed a kind, sincere, courteous and professional approach and at no time did I feel that I was being regarded as troublesome. Simply put, Jo is a credit to the National Health Service and one of the many reasons why right minded people hold it in such high regard. During my contact with her Department, I also spoke briefly to a lady called Norma, whose courtesy should not go unmentioned.

#### Q2 2016/17

Dear Kan Dhami, I would like to thank you for your feedback on my complaint of 14th June

concerning the behaviour of the phlabotomist at Rodey Regis Hospital.

your letter showed me that you have dealt with our complaint in a sympathetic, positive and considerate manner. Although my write's blood test was a routine one, it could have keen in connection with a serious illness and the phlabotomist's attitude could have had more serious consequences. This consideration was the overviding reason for bringing the complaint for both my write and myself.

Could you also pass on our thanks to

Carled you also pass on our Thanks to Sukhvinder for her efforts and Arita Trushove for her input.

your sincerely



Thanks very much Helena, I'm emailing because as I said on the phone I really don't want to waste any more NHS time and money but just felt that it was important to give feedback on this occasion. Ironically, I was very impressed with how easy it was to provide the feedback — I had been delaying getting in touch as I was expecting to get drawn into an onerous bureaucratic system, but it was very ease to deal with you, and I thought you received my comments in a helpful and professional way

### Q4 2016/17



I have received the most exceptional advice and assistance from your staff; Norma Bayliss and Trina Massi . They have been able to contact both the Ward Managers and Matrons for D26 and D16 as it is imperative that they are aware of the horrendous circumstances. Without Trina and Norma it would have been so difficult especially as I really thought I'd lost my Mom to incompetence. They are a real credit to your department and deserve the utmost praise. They made direct contact with the senior staff involved in order that I could speak with them and arrange meetings which has now been done.

I forward this for your attention and in this day and age when it is so easy to complain I know as a Police Officer how hard it is and we rarely get praise. I thank both Norma and Trina from the bottom of my heart for their care, compassion and complete professionalism which together have made a very difficult situation more bearable.

### **COMPLAINTS AND PALS: 2016/17**

### **Annual data highlights**

- 1. The total number of PALS concerns registered was 2592 compared to 2136 from the previous year, up by 456 from the previous year. Whilst many Groups saw a slight decrease, the most notable increase was in Medicine, with a 12% (83) increase in PALS concerns.
- 2. The total number of Complaints logged was 1176 compared to 1062, an increase of 114 complaints across the year compared to 2015/16. 149 of these were withdrawn by the complainant at some point during the year leaving 1027 to manage, compared to 158 withdrawn in 2015/16 leaving 904 to manage.
- 3. The average number of days taken to resolve complaints was 31.05 days, compared to 38.12 in the previous year. Q1 and Q2 of this year saw this average drop to 26 and 28 respectively with Q3 and Q4 performance no as strong.
- **4. Complaints per 1000 bed days to 3.0.** The highest rate was in Surgery at 5.6 and the lowest was 2.3 for Women and Child Health.
- **5. The complaints rate per 1000 FCE was 7.0.** Surgery were the Group with the highest rate at 17.2 and Women and Child Health are the lowest at 4.0.
- 6. The average number of days to respond to a complaint was 31.05 in 2016/17 compared to 38.12 in 2015/16. This is against a Trust performance measure of 30 days and although the year average was over this, quarters 1 and 2 results were both below 30 at 28.73 and 28.66 respectively.
- 7. The three themes that emerged out of complaints this quarter remain as in previous years and are Clinical Care Outpatient appointments and Attitude of Staff. Traditionally in that order, in Q4 2016/17 the Trust received more complaints about the attitude of staff, than they did about outpatient appointments.
- 8. 'Not Upheld' complaints made up 32% of closed complaints with 68% either upheld, or partially upheld. This compares to 28% not upheld and 72% either upheld, or partially upheld in 205/16
- **9.** Reopened cases totalled 168 in 2016/17, compared to 191 in 2015/16. 7 of the cases that were reopened were because the Trust had failed to answer all of the issues covered in the complaint. The main reason why complaints were reopened in 2016/17 was that the response was disputed at 75% of cases.
- **10.** There were **34** new PHSO enquiries of the Trust in this quarter, and 22 were closed. Of those 22, 77% (17 were not upheld).
- 11. The fluctuation in the proportionality of how complaints split across the ethnicity of patients has continued this year. 3% of complaints came from the Pakistani community against 11% demographic population and 9% patient population. A higher rate of complaints for the Black Caribbean community is again seen at 13% complaints, against a demographic population of 4% and a patient population of 6%.

### **COMPLAINTS AND PALS: 2016/17 ANNUAL REPORT**

### Index

			Page						
Introd	lucti	on							
Comp	laint	s							
1.	Cor	mplaints management							
1.1		mplaints received	6						
1.2		mplaints by Clinical Group	6						
1.3		mplaints by 1000 FCE	7						
1.4		mplaints by 1000 Bed days	8						
1.5	Tim	neliness of responses	9						
1.6	Cor	nplaints resolution meetings	10						
1.7	Cor	nplaint satisfaction survey	11						
2.	Cor	mplaints in detail							
2.1	Pro	file of subjects of complaints	12						
2.2	For	mal complaints by theme	13						
2.3	For	mal complaints by severity	14						
2.4	For	mal complaints by profession	14						
3.	For	mal complaint outcomes							
3.1	Resolved complaints								
3.2		mal complaints upheld	16						
3.3		opened complaints	17						
3.4	Par	liamentary and Health Service Ombudsman enquiries	18						
4.	PAI	LS	18						
5.	Key	areas for focus in Quarter 2017/18	20						
6.	Cor	nclusion	20						
Appendi	x 1a	Complaints received by Clinical Group and Corporate Directorate							
Appendi	x 1b	Complaints received by Ward							
Appendi	x 2a	Complaints rate per Group by 1000 FCE							
Appendix 2b Comple		Complaints rate per Group by 1000 Bed Days							
Appendi	х 3	Complaints turn around by Clinical Group							
Appendix 4a A breakdown of all m		A breakdown of all meetings held							
Appendi	x 4b	A breakdown of all meetings held by complaint type							
Appendix 5a		Breakdown of ethnicity of complainant, ethnicity by local population and by patient population.							
Appendix 5b		Breakdown of subject of complaint by age and gender.							
Appendix 6a		Complaints breakdown by theme							
Appendix 6b		Complaints breakdown of attitude of staff theme, by profession.							
Appendix 6c		Declining trend of complaints about appointments							
Appendi		Distribution of complaints by severity							
Appendi	x 8	Complaints split by profession							
Appendi		No of complaints where action/ learning has been taken as a result							
Appendi	x 10	Reopened complaints							
Annendi	v 11	PALS by Group							

#### INTRODUCTION

Concerns and complaints raised by patients and visitors must be viewed positively as an unsolicited form of feedback. These are opportunities to improve our services and the care we provide based on user experience.

This report sets out and provides commentary on the complaints, PALS enquiries, local departmentally resolved concerns and compliments, the way they were managed, who they were made against and what about. The important learning opportunities are evidenced and the subjects of the complaints are also profiled.


#### **COMPLAINTS**

### 1. Complaints Management

#### 1.1 Total received

The total number of complaints received by the Trust for this year is 1137, compared to 1052 in 2015/16. This includes 111 complaints that were withdrawn, leaving 1026 to manage in 2016/17 compared to 925 in 2015/16.


#### 2016/17 complaints received by month



#### 1.2 Complaints by Clinical Group

When analysing the complaints received in 2016/17, by Clinical Group and Corporate Directorate, Medicine continue to receive the most complaints. **Appendix 1a** shows how these figures compare over the last 4 quarters. **Appendix 1b** shows how this is broken down by ward (where applicable).


2016/17 complaints received by Clinical Group/ Corporate Direcotrate



#### 1.3 Complaints received per 1000 FCE (Finished Consultant Episodes)

To more accurately compare which Clinical Group is receiving the most complaints, it is important to represent these not just as numbers of complaints and 1000 bed days, but also as a proportion of the patients that have received care in these areas. This then puts these numbers into context. By comparing the numbers of complaints against FCE we can gauge better whether one service or another is attracting more dissatisfaction and once understood, drill down further into what aspect of that service needs to improve. This analysis was only applied to the largest of the Clinical Groups, as they contributed to 81% of the complaints for the year.

Complaints received per 1000 FCE (Finished Consultant Episodes) 2015/16 and 2016/17




Although the majority of complaints received are still made about Medicine, it is again Surgery that has the highest number of complaints per 1000 FCE. Surgery (and in particular Birmingham and Midland Eye Centre- BMEC) has been working closely with the Elective Access Team to improve the way that

appointments are managed and utilised across the Group. This work has been the focus of the elective access team all year, and in Q4 there was a noticeable decrease in complaints about appointments.

Reference is also made to the theme of complaints in section 2.2 in order to better understand the types of complaints made against Surgery. **Appendix 2a and 2b** show the breakdown of complaints rates for both 1000 Bed days and 1000 FCEs by group.


#### Complaint rate per 1000 FCE for 2016/17 by Clinical Group




### 1.4 Complaints by 1000 bed days

The complaints rate, calculated as complaints per 1000 bed days for 2016/17 is 3.0 with Surgery again showing a higher rate than Medicine and Emergency Care and Women and Child Health.

#### Complaint rate over last 6 quarters showing trend and average



#### Complaint rate per 1000 bed days for 2016/17 by Clinical Group



It is worth noting that many patients in this group do not occupy a bed therefore the more accurate measure for this Group is the FCE rate.

#### 1.5 Timeliness of Responses

Since Q1 2015/16 there has been a steady decrease in the number of days taken to resolve a complaint, and as cases were managed within their target date, and renewed focus being given to accurate target dates, as opposed to a default 30 day turnaround. This resulted in the rate reducing to 29.48 in Q3 2015/16 and further to 26.75 in Q4 2015/16. At the start of the financial year, some cases had started to take longer to complete, some because of their complexity, and some because of notable issues with resourcing (complaints team, and investigation leads). There has been an increase in the number of cases that were not managed with their target date, and this has also had an impact on the average days to complete cases. This rose to 28.73 in Q1 2016/17, and then steadily (see graph below) finishing on 33.98 in Q4 2016/17. This took the result overall for the year to 31.05.

In 2015/16 the Trust kept 93% of cases in their target date, this year this reduced to 81% (as at the time of reporting, with some 2016/17 complaints still to finalise). The complaints team have revisited the principles and practices that led to the improvement of case management in 2015/16 (daily reporting, stringent escalation) to ensure that this standard is improved upon for 2017/18.

Of the 905 complaints resolved (new and reopened as at the time of reporting), 212 breached their target date. This equates to 81% of the cases that were resolved in this period being managed within their target date.

The cases that breached have done so largely in relation to a failure to keep up to date with the responses due, as opposed to a system or process failure. An evaluation has taken place as to how to ensure that complaints that are still yet to be resolved from 2016/17 will be quickly but thoroughly completed early into 2017/18. Escalation processes, and database reporting have been revisited in order to get cases back on track. The complaints team are meeting regularly with Investigation Leads (for devolved complaints) and complaints managers are working to new case deadlines in order to ensure that older cases are completed without defaulting on new 2017/18 cases.

#### Average days to respond by quarter in Q1 2016/17




**Appendix 3** shows a further breakdown of this data by Clinical Group. It should be noted that this is the total time that the complaint took to resolve and includes all stages of the process.

#### 1.6 Complaints managed by resolution meeting

It is recognised that for some complaints, a resolution meeting, as opposed to a written response can be more effective in addressing concerns. Complainants whose concerns relate to a patient who has died are always offered a meeting. It has become apparent that many complainants will express a wish to receive a written response first, before agreeing to meet with the Trust whilst others prefer a meeting. The take up rate of complaints resolution meetings is monitored. In 2016/17 the rate at which complaints were resolved as a meeting was 8%, compared to 8.75% in 2015/16.

% of complaints that were managed by a resolution meeting as opposed to a written response. Q2016/17



#### 1.7 Complaint satisfaction survey

Complaints survey response rates have traditionally been low and in 2015/16 the timing of the sending of the surveys was changed, to encourage greater take up of the survey. This led to a further decline, and reducing the data to levels that was meaningless in terms of its use to help improve the complaints service. Whilst surveys are now sent out with complaint responses again (timing from previous years) the response rate has not improved and results have not been monitored consistently. In 2017/18 there are plans for the Head of Complaints to work with the Head of Patient Experience, running focus groups and joint initiatives relating to service user feedback.

#### **KEY POINTS**


- BMEC had the highest complaint rate, with a large number relating to appointment management, but in Q4 2016/17 this started to show signs that this was decreasing.
- In Q4, there was a shift in the number of complaints received in the three most popular categories, Clinical Treatment, Outpatient Appointments and Attitude of Staff.
- 81% (693) of complaints resolved in this quarter were sent within their target date. This is a decreased number of cases compared to previous and whilst this is still improved when compared to the previous year, work is now underway to ensure that the total result for 2016/17 is improved on 2015/16, not worse.
- The average turn around has also increased, largely due to the number of cases that have breached, and a smaller number of cases that were 'fast tracked'. The result achieved this year was 31.05 compared to 38.12 in 2015/16.

# 2. Complaints in detail


#### 2.1 Profile of the subject of complaints

In order to check that our complaints process is accessible to all, it is important to understand the profile of complainants by certain protected characteristics. Gender, age and ethnicity are recorded and then compared to our hospital population and also the population of the geographic area that we serve in **Appendix 6**.

Subject of complaint by % Ethnicity 2016/17 (of 670 of complaints where ethnicity stated)



Subject of complaint by total number- Ethnicity 2016/17 (of 254 of complaints where ethnicity stated, minus British White)




The disproportionality around complaint rates for the Pakistani and Black Caribbean communities has continued this year, as in previous years.

Despite a meeting with Black Community Leaders, no real conclusive explanation was reached. This year, Complaints and Patient Experience will be working much closer together to look at improving our understanding of how to improve the experience of all patients and visitors to the Trust. This will include what complainants experience when they make a complaint, and how effective the service is, and how satisfied they were with the response.

#### 2.2 Formal complaints by theme

#### Broad themes that complaints fell into in 2016/17




When analysing the top three themes complained about, these remain 'all aspects of clinical treatment', 'appointment delays', and 'staff attitude'. In Q4 2016/17, there was a shift in the number of complaints about staff attitude and outpatient appointments. **Appendix 6a** compares these topics for complaint over the previous 2 years by Group. **Appendix 6b and 6c** the breakdown of complaints logged about of staff (where small increases are highlighted in the staff groups of admin staff, nursing, ambulance workers, it is the decrease in complaints about outpatient appointments in Q4 2016/17 that has seen these two topics swap ranking in order of most complained about.

#### 2.3 Formal complaints by severity

The following is a breakdown of the 1026 actively managed complaints by severity and shows that once again complaints considered high or significant (Levels 3 and 4) remain in the minority. Appendix 7 splits this data by quarters where a relatively steady pattern of distribution across each severity category can be seen.


#### A breakdown the severity grade of complaint for 2016/17



# 2.4 Formal complaints by profession

It has been previously reported that there were no significant changes in the number of complaints received across the seven professional groups. Toward the end of 2015/16 there was a notable increase in the number of complaints about administrative and managerial staff. Whilst this came down slightly throughout 2016/17, this increased again in quarter 4 of 2016/17.

#### Complaints by staffing group Q1 2016/17 compared to previous 4 quarters



#### **KEY POINTS**

- There has been a drop in the number of complaints about the management of outpatient appointments, resulting in this moving from the second most complained about topic, to the third.
- Level 4 complaints (rated the most serious) have returned to the expected low number following a spike in the year.
- The increase in complaints about admin and management staff toward the end of last quarter has
  not continued throughout the year, there being an even split across professions when compared to
  the previous year. see Appendix 8

# 3. Formal complaints outcomes

#### 3.1 Resolved complaints

905 complaints were resolved from 2016/17 (at the time of producing the report) 693 (81%) were responded to on or prior to their target date. This compares to 881 complaints resolved in 2015/16 and 818 (93%) were responded to on or prior to their target date in 2015/16.

#### 3.2 Formal complaints upheld.

At the conclusion of a complaint, we categorise the outcome as one of the following three categories.


**Upheld** – we agreed that the complainant was found to have experienced poor care/ treatment/ customer service.

Partially upheld- elements of the complaint were found to be the case, but not all.


Not upheld- The investigation did not uncover any failings on behalf of the Trust.

The outcome of complaint responses remain mostly either upheld or partially upheld, at 70% (630) of complaint responses sent (totalling 905) in 2016/17. This is consistent with the outcomes on average over all 4 quarters of this year, and the result for 2015/16 which at 72% (635) of complaints responded to (totalling 881).


#### Q1 2016/17 no. of complaint by outcomes



Q1 2015/16 no. of complaint by outcomes



#### Complaints outcome 2016/17 compared to 2015/16 Q3 2015/16




#### **Learning from complaints**

Complaints provide an important opportunity to improve services, learn from mistakes and identify systemic flaws in order to improve the patient experience, and in some cases patient safety. The database used in the complaints process has an action tracker, and records any recommendations that are made for individual complaints.

Of the 905 complaints closed in 2016/17 145 (16%) recommended an action or learning as a result of the complaint. Most of the actions or learning came from those complaints that were either partially or wholly upheld. Reported is a breakdown of all complaints by outcome, where recommendations for action were made. **Appendix 9a** shows how these complaints split across the three resolution outcomes (upheld, partially upheld or not upheld.) **Appendix 9b** gives examples of learning from complaints across the year.

#### **Reopened cases**

Reopened cases in 2016/17 totalled 168, with 11 (7%) case reopened because not all questions were answered. This compares to 191 in 2015/16 with 17 (9%) case reopened because not all questions were answered.




**Appendix 10** shows all reopened complaints by Group and Grade, and continues to show that it is the medium grade (Level 2) complaints that are most likely to be reopened.

#### 3.4 Parliamentary and Health Services Ombudsman enquiries.

When the local complaints process is exhausted, any complainant who remains dissatisfied can have their complaint reviewed independently by the Parliamentary and Health Services Ombudsman (PHSO).

20 new PHSO complaints were logged in 2016/17, and 17 enquiries were concluded. Of those closed, 17 cases were not upheld (77%).



The trend in receiving a high number of new complaints from the PHSO has slowed down this year, with 25 complaints being referred to the PHSO in 2015/16. The percentage of cases not upheld in 2015/16 was 66%.


### 4. PALS

The Patient Advice and Liaison Service (PALS) continue to play a vital role in providing patients with a local advocate who can investigate concerns. During 2016/17, work began to integrate the work that the PALS team do, with the complaints team. The aim of this more streamlined approach to enquiries is set to see complainants to the Trust managed in a more streamlined way, 'fast tracked' enquiries are encouraged where a complaint might not be complex in nature, and double handling of PALS enquiries that turn into complaints will be eradicated as they will all be handled in just one team.

This new structure was implemented from 1 April 2017/18 and the success, achievements and improved service to users is being closely monitored and will be reported over 2017/18.

The total number of PALS enquiries received in 2016/17 was 2592, compared to 2136 in 2015/16.

#### Graph shows the number of enquiries of PALS by quarter over the past since 2013/14



**Appendix 10** reports all PALS enquiries compared to the last 4 quarters, and is also broken down by Clinical Group and theme.

#### **Compliments**

There is still no consistent method across the Trust for collecting all compliments. PALS implemented a collection method but this was not taken up consistently across all wards. Those that have been counted this year total 2445. Already highlighted are plans to work with the Head of Patient Experience and the challenge of collection of compliments will be discussed in this forum in 2017/18.

# 5. Key areas for focus in 2017/18


- 5.1 19% of the cases logged this year (at the time of reporting) breached their target dates. In order to ensure that increase of breached cases does not continue into 2017/18, work is underway throughout the complaints team and the key complaints leads within the clinical groups, to refocus on timely responses, senior managers have been sited on deadlines and the methods of daily reporting have been re-implemented to ensure that 2017/18 sees a return to the results of 2015/16, and indeed exceeds them, aiming for a 97% compliant to target date.
- 5.2 It became apparent that in order to improve the experience of those using the services of both PALS and Complaints, there is a need to develop a more streamlined service. 2017/18 sees the launch of the creation of a service that does not differentiate between the two types of enquiry (for the complainant; the two types of enquiry will still be reported separately) will improve user experience, reduce double handling, and use the resources of the team much more efficiently. This work has started, with a redesign of the department, to be fully implemented from April 2017 in line with the Workforce review currently underway. Bespoke solutions, local resolution and proactive, preventative actions will be encouraged within the newly formed complaints team.
- 5.3 Working in conjunction with the newly restructured team, and in recognition for the need to improve access to support services for those with concerns, an exciting inpatient hospital based telephone system will be implemented which will provide patients and relatives with a fast face to face response. Whilst primarily managed by the complaints team, this line will be available 24 hours a day, 7 days per week. Most of the enquiries will be managed through the channels being established though the complaints team, but it is recognised that there will be some enquiries that will need immediate attention, and senior executive action. This will be referred to as the 'Purple Phone' initiative.
- 5.4 It is recognised that the previous survey method used for complaint service feedback is not effective, and does not provide data that identifies service improvement opportunities. There is a need to engage with Healthwatch further to work with them on ways of involving their service users, and our complainants in providing feedback. This could include the use of focus groups, and user feedback meetings held in partnership with Healthwatch. There are also plans of the Complaints team to work closely with the new Head of Patient Experience. Discussions are underway to explore if intel that is gleaned from patient groups working with Patient Experience, and patient focus groups can be shared with the Complaints team.

#### 6. Conclusion


Complaints management and the handling of PALS enquires in 2016/17 has remained effective and patient focused, albeit with a slippage in the number of queries that were managed within their target date. The number of complaints and concerns have again risen, although there are no significant spikes or trends in one clinical Group of complaint theme. Enquiries and complaints about appointment management have started to show signs of decreasing albeit only in the last quarter of the year. The team have completed the initial stages of a restructure to ensure that concerns and complaints are managed together in one team, offering efficiencies, and more bespoke outcomes for enquirers and complainants.

2017/18 is set to improve on previous years' results, aiming for a 97% compliance to target dates. This will be achieved by building on the new structure, using new standard operating procedures to glean efficient and LEAN ways of managing complaints, and by launching the new initiative, the purple phone, aimed at achieving local resolution, and timely and immediate solutions before they become complaints.


#### Complaints received by Clinical Group and Corporate Directorate for 2016/17 broken down by quarters.



Appendix 1b Complaints received by Ward (where applicable) for Q1 2016/17 compared to Q4 2015/16, Q3 2015/16, Q2 2015/16, Q1 2014/15- (same time last year.)




# Complaints rates by 1000 FCE for 2016/17 and 2015/16 (by the top four Clinical Groups, that became three Groups when Surgery A and B merged.)




**Appendix 2b** 

# Complaints rates by 1000 Bed days for 2016/17 and 2015/16 (by the top four Clinical Groups, that became three Groups when Surgery A and B merged.)




# **Appendix 3**

# Complaints turn around by Clinical Group for 2016/17 compared to 2015/16.




# Appendix 4a

# Break down of the % of meetings (against total complaints) held across the 4 quarters of 2016/17




Total % of meetings for 2016/17 split by type of complaint (new or reopened).




# Appendix 5a

Ethnicity split by Sandwell and West Birmingham Population as taken from the 2011 census and quoted out to the Local Demography report prepared by the Trusts Equality and Diversity team in 2013.




# Ethnicity split of patient population

# **Ethnicity**







Ethnicity split by Sandwell and West Birmingham Population as taken from the 2011 census and quoted out to the Local Demography report prepared by Equality and Diversity in 2013, without White British.



# Breakdown of respondents by age (where specified)


# Breakdown of respondents by gender (where specified)






## Appendix 6a

A breakdown of the top three themes complained about, broken down by Clinical Group or Corporate Directorate for 2016/17 compared to 2015/16. Where there were no complaints for this theme for a Clinical Group or Corporate Directorate, then they are not featured in this breakdown.




The number of complaints received about attitude of staff over the 4 quarters of 2016/17 highlighting those staff groups that increased in Q4




**Appendix 6c** 

The number of complaints received about outpatient appointment over the 4 quarters of 2016/17 highlighting the decrease in Q4





# The distribution of complaint severity categories in 2016/17



**Appendix 8** 

# The split of complaints across professions from 2016/17 compared to 2015/16





#### 2016/17 number of complaints where action has been taken as a result of the complaint

#### Examples of learning from complaints in 2016/17

- The management of the patient's pressure sores, by district nurses were questioned, by the family. They felt that they had not been fully aware of the care that was being provided by the nurses in their absence. As a result, a communication sheet has been developed by the team. This sheet is left with the patient after a visit, with updates on care, or concerns, allowing the family to be more involved in the visits when they are not present.
- An urgent outpatient appointment was misinterpreted by the booking team, and managed as a non- urgent booking. This resulted in a potential 9 week wait for this appointment so the patient paid privately. At this private appointment, she was diagnosed with cancer of the optic nerve. As a result of this complaint, and the underlying theme of concerns around appointment bookings, the contact centre responsible for these bookings are all undergoing a competency based training programme to ensure that all staff have the appropriate knowledge and skills to manage this important aspect of their roles.
- Communication between the District Nursing team, and a patient's family was criticised and as a result, a "Communication Sheet" is being trialled, where detail is left by the DN on a record that is left for family to read (with patients permission), so that they can be more involved in their family members care.
- The unit of weight was not specified on a paediatric prescription (Kgs vs pounds) and as a result the
  dosage dispensed was incorrect. Whilst the dosage that was subsequently given to the patient was
  incorrect, there were no adverse effects and no harm was done as a result. New guidance has
  been issued that specifies that all weight on prescriptions must be written in Kgs. Pharmacists

should check baby weights with the child's red health booklet or by contacting the clinic to obtain confirmation from the medical notes. The source of the weight must be clearly documented on the prescription and signed and dated by the person confirming the weight.


If there are any queries on prescriptions concerning weight, dosages, formulation or administration the prescriber must be contacted to clarify the prescription before it is issued to the patient and the outcome clearly documented on the prescription and signed and dated.

The patient (when appropriate as this may be a child) and their family or representative must be kept fully informed at all times of any possible delays due to the need to clarification of any details on the prescription which may need to be discussed with the prescriber.


- When discharged from a long stay in hospital, the patient was taken home in a hospital arranged taxi. The patient had four carry bags and a suitcase with him, but received no support getting into his home from the taxi driver. In future, when booking a hospital arranged taxi in future, we will alert the taxi company to the fact that a patient may have several items with them or if for any other reason they may need assistance. This information will either be provided by the ward when they book a taxi directly or to Patient Transport if they are requested to book a taxi on the wards' behalf.
- When the patient got undressed to be x-rayed, they were distressed that there were students in attendance and they were not made aware of this. As well as acknowledging that they should have been introduced, there are now several posters that clearly state that there are students within the areas that patients may be examined and x-rayed and that if this does cause concern then this should be raised with staff at the time.

#### Appendix 10


#### 2016/17 number of reopened complaints by Group



### PALS enquiries for 2016/17 by group split by quarter



## PALS enquiries for 2016/17 by group split by quarter



# Sandwell and West Birmingham Hospitals **MHS**

NHS Trust

TRUST BOARD		
DOCUMENT TITLE:	Research and Development Plan 2017 - 2020	
SPONSOR (EXECUTIVE DIRECTOR):	Dr Roger Stedman	
AUTHOR:	Professor Karim Raza, Dr Jocelyn Bell	
DATE OF MEETING:	Thursday 1 <sup>st</sup> June 2017	

#### **EXECUTIVE SUMMARY:**

This paper lays out our objectives and approach to delivering a key pillar of our 2020 vision – The R&D Plan. The Board will be aware that we have been working to the 2014 – 2017 R&D Plan and that it was time to take that plan to the next level. The first R&D plan has delivered an R&D function operating on a stable financial platform and a growth of activity that has seen us deliver more research than has ever taken place at this Trust before. The plan did not however deliver the stretching ambition it set out from the outset to treble trial recruitment.

This plan outlines both the actions we will take to address this over the next 3 years as well as modelling a number of growth scenarios and the impact this will have on resources in the context of the capped income model that is currently operated by the local CRN.

The R&D team have further elaborated two preferred models of activity growth and carried out analysis of both the required input (staff) costs and the resultant opportunity (unfunded activity) costs in both scenarios. One scenario delivers the ambition over five years and covers its costs within the current funding model, the other scenario delivers the ambition over three years – but generates a funding gap that cannot be closed by current means in the order of £900k over three years.

#### **REPORT RECOMMENDATION:**

The board are asked to consider the following questions:

- Are the actions proposed in the plan considered sufficient and appropriate to deliver the ambition?
- Of the two modelled growth propositions to debate the merits and risks of each.
- In particular is the plan sufficiently aligned to other strategic objectives of the organisation?
- What more can we do as a board to engage patients and stakeholders in the R&D mission of the organisation?

#### **ACTION REQUIRED** (Indicate with 'x' the purpose that applies): The receiving body is asked to receive, consider and: Approve the recommendation Accept Discuss Χ **KEY AREAS OF IMPACT (Indicate with 'x' all those that apply):** Financial Environmental Communications & Media X Business and market share X Legal & Policy Patient Experience X **Equality** and Workforce Clinical Χ X Diversity Comments:

# ALIGNMENT TO TRUST OBJECTIVES, RISK REGISTERS, BAF, STANDARDS AND PERFORMANCE METRICS:

R&D Plan Quality & Safety Plans People Plan Digital Plan

# PREVIOUS CONSIDERATION:

R&D Committee

# Template for Pillar Plans

# Contents

Contents	1
Version Control	1
Purpose	2
Aim	2
Objectives	2
R&D Activity	3
Scope	
Current State	
Future State	4
Scenario modelling	
Organisation and governance	5
Steering Group	6
Programme Board	6
Delivery Group	7
Group Engagement	7
RACI	7
Schedule	8
Communications plan	8
Stakeholder Analysis	8
Benefit analysis1	1
Risks, Assumptions, I <mark>ssu</mark> es and Dependencies 1	1
Risks1	
Assumptions	1
Issues1	2
Dependencies1	2
Schedule1	2

# **Version Control**

Date	Ver	Changes	Released to	Authorised

# **Purpose**

The Trust vision is that we are recognised as a centre of national and international research excellence, delivering high-quality research across all service lines, affording staff and patients ready access to research opportunities. The R&D strategy is closely aligned with the Trust 2020 vision, focusing on embedding innovation and research for improved safety and quality of care. This reinforces research as core Trust business and will raise awareness of the value of research that underpins practice.

#### Aim


The 2017–2020 SWBH Research & Development (R&D) Plan provides a framework through which R&D will become integral to the culture of clinical practice at SWBH. The aim is to deliver an enhanced quality and quantity of research and development that translates into safer clinical care and better patient outcomes. This will in turn promote the profile of SWBH as a centre of outstanding R&D, attract clinical and non-clinical talent to SWBH, and improve staff motivation, workplace satisfaction and retention rates.

## **Objectives**

The 2017 – 2020 R&D Plan will be achieved through the following objectives:

	R&D Plan Objectives		
1	Translating research and development into better/safer clinical care		
2	Promoting national and international excellence and leadership in		
	research and development		
3	Increasing the breadth of research and development		
4	Increasing involvement of non-medical healthcare professionals in		
	research and development		
5	Developing the research and development workforce and capabilities		
	through redesign and new ways of working		
6	Empowering patients to influence research and development		
7	Enhancing alignment with the Trust's academic and other research		
	partners		
8	Enhancing alignment with the Trust's strategy for integrated care		
9	Ensuring rigorous research and development governance processes		
10	Ensuring that the future estate for research and development supports		
	the planned growth in activity		
11	Increasing Research & Development activity (number of recruits)		

#### **R&D Activity**



# Scope

Assignment of the objectives is set through the R&D Committee and whilst some objectives are speciality specific others are cross cutting over several specialties.

### **Current State**


The outcomes of SWBH based research has been used to inform national and international guidelines to improve the management and care of patients with diseases such as Atrial fibrillation, Early arthritis, Pregnancy and rheumatic diseases, Parkinson's disease, Gyane-oncology. Our researchers have successfully secured national and international grant funding for research across a range of disease areas including Inflammatory arthritis, Corneal scarring, Atrial fibrillation, Behçet's disease and Faecal incontinence.

Since 2014 we have expanded the breath of our clinical portfolio with research activity taking place in a number of new specialties including Respiratory Medicine, Orthopaedics and Clinical Immunology. We have also seen an increase in the number of Allied Health Professionals involved in and leading research studies most notably our Physiotherapists. Growth to date is shown below.

Year	Research recruits	% growth
2013-2014	2015	
2014-2015	2092	4% (+77)
2015-2016	2629	26% (+537)
2016-2017	3200	22% (+571)

(2014 - 2017 = growth of 53% over the 3 years)

To continue growth in numbers three things need to be aligned.



#### **Future State**

In the future we will see:

- growth in research and development activity in areas where little or no research has been undertaken previously
- growth in research & development activity in two disease areas that are already active in delivery
- promotion of research in clinical nursing and midwifery with nurses/midwives in two areas being actively involved in research & development delivery
- expansion of the portfolio of research & development supported by physiotherapists
- expansion of research & development activity into new AHP areas e.g. optometrists, orthoptists, podiatrists, pharmacists, biomedical scientists, Medical Laboratory Scientific Officers
- delivery of research & development supported by high specification digital technologies
- our patients become more aware of and involved in research & development
- the development of new joint academic posts with local Universities
- the development of an integrated care model across the primary / secondary care interface supporting the delivery of research & development
- the development of a programme to support staff to obtain grant funding for research & development ideas
- SWBH working with CLAHRC-WM to institute changes in clinical practice resulting from research & development delivery

- health care professionals being encouraged to work with Specialty Advisory Groups and National (NICE) and international bodies to facilitate SWBH research & development being integrated into clinical guidelines
- our research & development workforce will being supported by a fully developed career structure with clear role definitions, career progression opportunities and training programmes and secondment opportunities for other Trust staff to experience research & development
- research & development being promoted across the Trust including dedicated R&D exhibition in the foyer of MMH, promotional materials available on other areas, a fully developed R&D section on the Trust website and a Trust R&D Twitter account

## **Scenario modelling**


To understand the relationship between recruitment growth and income growth several scenarios have been developed (see appendix 1). A summary of these is detailed in Appendix 2.

Scenario 7 is considered to be the most suitable model taking into account delivery of growth, capacity and sustainability. Other alternative options with a steeper trajectory to achieve growth in numbers over a shorter period of time would result in a shortfall in income due to the capping of income growth by the West Midlands Clinical Research Network (WMCRN). The table below shows the growth that would be achieved if this model was adopted.

Voor	FY	Growth
Year	FI	+560/year
0	16-17	3200
1	17-18	3760
2	18-19	4320
3	19-20	4880
4	20-21	5440
5	21-22	6000

# **Organisation and governance**

The R&D plan governance structure will use a programme board to define the R&D Plan improvements and working groups in each group will deliver the R&D objectives, supported by the Project Lead, Responsible Officers and Project Management Office (PMO).



## **Steering Group**

The Research & Development Committee, chaired by the Medical Director, will act as the Steering Group to oversee the delivery of the Plan and hold the project SRO, Project Lead and Responsible Officers to account to deliver on time and to budget. This will be the forum for involving all parties impacted by the project. It will authorise the Plan, provide corporate direction as required, receive periodic updates on and advise on issues with progress.

#### **Programme Board**

The Programme Board is responsible for defining, planning and ensuring the delivery of the R&D Plan through:

- Sponsor (Exec SRO) senior executive who champions the plan, and is the initial source for determining the plan's scope and objectives. The sponsor keeps the executive team informed of overall progress and upward escalation of issues for executive decision
- Responsible Officers (RO) Director and Deputy Director of R&D who champion the plan, and are co-responsible for determining the plan's scope and objectives with SRO and fostering an environment within the groups for plan delivery
- Project Lead Author and owner of the master R&D Plan on behalf of the Exec SRO. Works closely with ROs and working groups to:
  - Facilitate planning within working groups to enable groups to deliver objective projects

- Collate corporate oversight of rollout, project progress and exceptions to enable periodic reporting to the Steering Group
- Operational Delivery Responsibility for delivery of the R&D Plan lies with the groups. This will be enabled by oversight through group directors of operations and directorate governance.
- Change Delivery Individual Project Leads will provide the oversight to projects ensuring they add value to research & development

#### **Delivery Group**

The Delivery Group is a subset of the Programme Board with corporate responsibility for assuring the delivery of the plan through regular liaisons with the groups and directorates to ensure they:

- Understand process
- Develop credible delivery plans
- o Regularly monitors feedback on progress of plans
- Provides feedback to exec PMO, R&D Committee and any other relevant committees

#### **Group Engagement**

The responsibility for delivering the R&D Plan objectives lies with the individual groups. This will require:

- A focus at group level to assure delivery of quality research & development –
  to be undertaken through group performance meetings. This can be an
  existing group meeting.
- A focus at directorate level to ensure engagement in the project. This will be led by the individual Project Leads who will be required to report progress to group performance meetings and to R&D Plan SRO, ROs and R&D Project Lead.
- Project Teams will be formed at group

level and will be accountable for the implementation of the change and completion of the project. The team should be led by the individual Project Lead.

#### **RACI**

- Responsible Groups are responsible for the implementation and management of projects to realise the Trust R&D Plan.
- Accountable The Medical Director as SRO is accountable to the CEO for successfully designing, communicating, monitoring and controlling the overall Trust R&D Plan benefits, trajectories, targets and engagement with groups.
- Consulted Initially discussed at R&D Committee meetings and with stakeholders at R&D QIHD in February 2017.
- Informed A standard Trust wide communications mechanism will be used to keep all staff / groups in the Trust aware of the outline benefits, outcomes and activities associated with the R&D Plan.

#### **Schedule**

The objectives will be developed into projects in conjunction with the ROs, R&D Project Lead and individual Project Leads who will be supported by the PMO. Key areas of activity will be:

- Stakeholder identification who is required to deliver objective/project
- Subject development how can objective be delivered
- Development of project plan detail of plan including timescales, KPIs, governance
- Signoff and implementation SRO/R&D Committee

# **Communications plan**

# **Stakeholder Analysis**


To ensure all appropriate parties are informed of the R&D activity and are able to contribute towards the 2017–2020 R&D plan, the following stakeholders will be part of the communications plan.



Stakeholder	Messages	Delivery Methods
Clinicians	Every clinician, whatever their job role or grade, can play a role in the	R&D pages on Connect
	Trust's research activities	R&D agenda item on QIHDs
	There are an enormous range of different research activities to get	Grand Rounds
	involved with – research is not just about drug trials	Departmental Away days
	Involvement in research is an excellent way to broaden experience	R&D Investigator meetings
	and to build a portfolio	MDT meetings
	Patients involved in clinical trials are still patients – and clinicians are	
	still clinicians. Those involved in research will find that their clinical	MMH foyer R&D exhibition
	skills are highly valued.	R&D promotional information around the Trust
		Social media – SWBH R&D Twitter account
		R&D training courses
Nursing /	All patient facing staff, whatever their job role or grade, can play a role	R&D pages on Connect
Midwifery / AHP's	in the Trust's research activities	R&D agenda item on QIHDs
	There are an enormous range of different research activities to get	Grand Rounds
	involved with – research is not just about drug trials	Departmental Away days
	Involvement in research projects is a route to career development and	R&D Investigator meetings
	greater job satisfaction	MDT meetings
	Ward and clinics staff have unrivalled patient knowledge and are in the	R&D page in Heartbeat magazine
	front line when it comes to identifying potential recruits for research	MMH foyer R&D exhibition
	studies	R&D promotional information around the Trust
		Social media – SWBH R&D Twitter account
		R&D training courses
Patients	Patient care is at the heart of everything we do – including our	Trust website
	research, which is expected to deliver real patient benefits, every time	MMH foyer R&D exhibition
	The key to providing better patient care now and in the future depends	R&D promotional information around the Trust

	on the Trust's involvement in clinical research.	Social media – SWBH R&D Twitter account
	The Trust is already a world leader in many areas of clinical research –	External communications e.g. Newspaper
	and patients directly benefit	articles, radio and TV interviews
	·	·
	There are an enormous range of different research activities to get	
	involved with – research is not just about drug trials	H <mark>os</mark> pital radio
	Patients are always welcome to volunteer to join research st <mark>udies –</mark> and	Patient and Public Involvement
	they can be proud that they're making a real contribution to the	
	progress of medicine	
	Patients are never 'guinea pigs' – they are partners, whose health and	
	wellbeing always come first	
	Patients can join groups to champion research activity within Trust	
General Public	The public we serve can take pride in the fact that their hospitals are	Trust website
	world leaders in medical research.	MMH foyer R&D exhibition
	The Trust's research makes a real difference to people's lives.	R&D promotional information around the Trust
	Every Trust research project is carried out for the benefit of patients,	Social media – SWBH R&D Twitter account
	now and in the future. It is about real people in the real world, not	External communications e.g. Newspaper
	'science for its own sake'.	articles, radio and TV interviews
	Clinical research is an integral part of the Trust's role	International Clinical Trials Day
		Patient and Public Involvement
•		

# **Benefit analysis**



# Risks, Assumptions, Issues and Dependencies

#### Risks

- Studies to recruit to not available
- Investigators not having sufficient time in job plans to carry out research
- R&D dedicated estate not well structured to enable the efficiencies required to facilitate the growth plan within the planned cost model
- Staff retention in light of neighbouring organisations competing for skilled R&D resources
- Transition to new estates locations, during MMH transition, will impact delivery against the plan
- Non engagement of stakeholders to deliver the plan

#### **Assumptions**

- NIHR funding model for research activity remains consistent with the existing model
- R&D has sufficient estate on all Trust sites to facilitate the growth and delivery of the R&D plan

## Issues

## **Dependencies**

- EPR system will provide efficiencies in patient identification and tracking
- Imaging, pharmacy and Labs will have sufficient capacity and technology to support growth in research
- Growth is reliant on required increase in staff


# Schedule

	R&D Plan Objectives	Schedule
1	Translating research and development into better/safer clinical care	Work with CLAHRC-WM to institute changes in maternity and educating mothers in choice of birth place.  Work with Speciality Advisory Groups and National (NICE) and international bodies to facilitate SWBH research being integrated into clinical guidelines. E.g. in Atrial Fibrillation, Rheumatoid Arthritis, Lupus, Sjogens Syndrome, Parkinson's and Diabetes
2	Promoting national and international excellence and leadership in research and development	Expand the portfolio of research by further developing research within the Endobarrier programme e.ginto Sleep Apnoea Expand the portfolio of research by further developing research within Bechet's e.g. microbial makeup of faeces linked to inflammatory disease Expand the portfolio of research by further developing research within Sjogren's syndrome and myositis
3	Increasing the breadth of research and development	Develop new research activity in three new disease areas and recruit the numbers stipulated within the study Expand the research activity in at least two areas already research active and recruit the numbers stipulated within the study Using the implementation of the new EPR to identify potential recruits for existing research programmes and identifying new research opportunities.
4	Increasing involvement of non- medical healthcare professionals	Promote active research within nursing with the support of the Chief Nurse

	in research and development	New CNS actively involved in research delivery with delegated activities in two research areas  Expand research activity in to other AHP areas  Maintain profile of R&D in physiotherapy with a target of a minimum of 1 new study by April 2018  Expand research activity in two new AHP areas e.g. Optometry / Orthoptics / Podiatry / Biomedical Scientists / Clinical Pharmacists/Medical Laboratory Scientific Officers with a target of a minimum of 2 new studies
5	Developing the research and development workforce and capabilities through redesign and new ways of working	Development of a career structure that provides role definition, career progression, retains experienced staff and offers secondment opportunities for Trust staff to experience R&D Development of training packages to support new and existing roles Identify and develop research mentors to support trainees in their new roles Maintain full complement of staff to manage the planned increase in recruits Review best practice working to develop and implement new ways of working throughout R&D
6	Empowering patients to influence research and development	Working with MMH commissioning team to develop R&D advertising space in the MMH Foyer Develop a new R&D Patient and Public Involvement group in one disease area Developing the R&D website Working with EPR team to develop a flag system that identifies patients who have indicated an interest in research electronically
7	Enhancing alignment with the Trust's academic and other research partners	Development and recruitment to a post in integrated care with a partner the University of Birmingham Establish links with Aston University to develop and recruit to a joint post in e.g. Obstetrics, Cardiology, Ophthalmology Ensuring SWBH is integrated into the arthritis accelerated trials programme between Birmingham and Oxford

		Enhance collaborative working within the
		BCA e.g. FINCH
8	Enhancing alignment with the	Develop a new forum, with
	Trust's strategy for integrated	representation from Primary and
	care	Secondary care, to support R&D activities
		at the interfaces of care. In addition, the
		R&D group will develop a strategy for the
		forum
		Develop a structured working method
		with local GP's and other health
		professionals, to support studies and
		patient recruitment, for new research
		activity focussed on integrated care
		Using population health informatics and
		the Heal <mark>th information exchange to</mark>
		identify potential areas of research and
		collaboration across the health economy.
9	Ensuring rigorous research and	Develop a formal feasibility assessment
	development governance	process for new research studies to
	processes	ensure deliverability prior to
		confirmation of capacity and capability
		by the SWBH R&D Office
		Develop research governance and
		management Standard Operating
		Procedures (SOP's) approved and
		released in the Trust
		Integrate the new UK Policy Framework
		for Health and Social Care Research
		Monitor and implement any changes
		linked to the EU Regulations, planned for
		October 2018, and Brexit
10	Ensuring that the future estate for	Work with MMH, Estates and Capital
	research and development	Projects teams to understand future
	supports the planned growth in	configuration of R&D services
	activity	Future OPD accommodation & R&D's
		access particularly at STC
		Available space and accommodation for
		R&D across all sites
11	Increasing Research &	Increase to xxxx participants recruited to
	Development activity (number of	research studies – Year 1
	recruits)	Increase to xxxx participants recruited to
		research studies – Year 2
		Increase to xxxx participants recruited to
		research studies – Year 3

# R&D | Income and Recruits | SCENARIO 1:INCOME + 10% and Band 1 +10%, Band 2 +10%, Band 3 +10%, Non-





#### PURPOSE

To Illustrate the effect of different scenarios on the R&D study recruit and Income totals each year with the aim to hit a target of 6000 study recruits within a financial year whilst staying within Income constraints.

#### METHOD

Use current year April to Sept totals and forecasted actuals.

APPLY an increase to the income and also increase study recruits across bands 1,2,3 and Non-Portfolio.

CALCULATE Time(t) to achieve target using formula:

t = (LN(x)-LN(y))/LN(1+(z/100))

#### where:


- x = target
- y = current recruits
- z = % increase

#### RESULTS

7 Years to hit Study recruit target of 5862 with an Income increase of 10% year on year without doing any unfunded studies.



## R&D | Income and Recruits | SCENARIO 2 (PESSIMISTIC) - INCOME + 5% and Band 1,2,3 +5%, NON-PORTFOLIO+10%



#### PURPOSE

To illustrate the effect of different scenarios on the R&D study recruit and income totals each year with the aim to hit a target of 6000 study recruits within a financial year whilst staying within income constraints.

#### METHOD

Use current year April to Sept totals and forecasted actuals.

APPLY an increase to the income and also increase study recruits across bands 1,2,3 and Non-Portfolio.

CALCULATE Time(t) to achieve target using formula:

t = (LN(x)-LN(y))/LN(1+(z/100))


#### where:

- x = target
- y = current recruits
- z = % increase

#### RESULTS

12 Years to hit Study recruit total of 5987 with an Income increase of 5% year on year without doing any unfunded studies.

# R&D | Income and Recruits | SCENARIO 2a (LOW INCOME % ALLOWANCE) - INCOME + 2% and Band 1,2,3 +5%, NON-PORTFOLIO+30%





#### PURPOSE

To illustrate the effect of different scenarios on the R&D study recruit and Income totals each year with the aim to hit a target of 6000 study recruits within a financial year whilst staying within income constraints.

#### METHOD

Use current year April to Sept totals and forecasted actuals.

APPLY an increase to the income and also increase study recruits across bands 1,2,3 and Non-Portfolio.

CALCULATE Time(t) to achieve target using formula:

t = (LN(x)-LN(y))/LN(1+(z/100))


#### where:

- x = target
- y = current recruits
- z = % increase

#### RESULTS

5 Years to hit Study recruit total of 4901 with an Income increase of 2% year on year with doing unfunded studies.

# R&D | Income and Recruits | SCENARIO 3 (OPTIMISTIC) - INCOME + 10% and Band1 + 20%, Band 2 + 10%, Band 3 + 9%, NON-PORTFOLIO + 33%.





#### PURPOSE

To illustrate the effect of different scenarios on the R&D study recruit and income totals each year with the aim to hit a target of 5000 study recruits within a financial year whilst staying within income constraints.

#### METHOD

Use current year April to Sept totals and forecasted actuals.

APPLY an increase to the income and also increase study recruits across bands 1,2,3 and Non-Portfolio.

CALCULATE Time(t) to achieve target using formula:

t = (LN(x)-LN(y))/LN(1+(z/100))


## where:

- x = target
- y = current recruits
- z = % increase

### RESULTS

5 Years to hit Study recruit total of 5946 with an Income increase of 10% year on year without doing any unfunded studies.

# R&D | Income and Recruits | SCENARIO 4 (RACE TO 6000) - FUNDED INCOME + 10% and Band1 + 100%, Band 2 + 15%, Band 3 + 15%, NON-PORTFOLIO + 50%.





#### PURPOSE

To illustrate the effect of different scenarios on the R&D study recruit and income totals each year with the aim to hit a target of 6000 study recruits within a financial year whilst staying within income constraints.

#### METHOD

Use current year April to Sept totals and forecasted actuals.

APPLY an increase to the income and also increase study recruits across bands 1,2,3 and Non-Portfolio.

CALCULATE Time(t) to achieve target using formula:

t = (LN(x)-LN(y))/LN(1+(z/100))


#### where:

- x = target
- y = current recruits
- z = % increase

#### RESULTS

3 Years to hit Study recruit total of 5995 FUNDED Income increase of 10% year on year with doing some unfunded studies for first 3 years.

# R&D | Income and Recruits | SCENARIO 5 (RACE TO 6000) - FUNDED INCOME + 5% and Band1 + 100%, Band 2 + 15%, Band 3 + 15%, NON-PORTFOLIO + 50%.





#### PURPOSE

To illustrate the effect of different scenarios on the R&D study recruit and Income totals each year with the aim to hit a target of 6000 study recruits within a financial year whilst staying within income constraints.

#### METHOD

Use current year April to Sept totals and forecasted actuals.

APPLY an increase to the income and also increase study recruits across bands 1.2,3 and Non-Portfolio.

CALCULATE Time(t) to achieve target using formula:

t = (LN(x)-LN(y))/LN(1+(z/100))

#### where:

x = target

v = current recruits


z = % increase

#### RESULTS

3 Years to hit Study recruit total of 5995 FUNDED Income increase of 5% year on year with doing some unfunded studies for first 3 years and this unfunded work carries on until funded allowance catches up with work undertaken.

## R&D | Income and Recruits | SCENARIO 7 (25% recruits EXTRA Each Year) - FUNDED INCOME + 10%





#### PURPOSE

To illustrate the effect of different scenarios on the R&D study recruit and Income totals each year with the aim to hit a target of 6000 study recruits within a financial year whilst staying within income constraints.

#### METHOD

Use current year April to Sept totals and forecasted actuals.

APPLY an increase to the income and also increase study recruits across bands 1,2,3 and Non-Portfolio.

CALCULATE Time(t) to achieve target using formula:

t = (LN(x)-LN(y))/LN(1+(z/100))

#### where:


- x = target
- y = current recruits
- z = % increase

#### RESULTS

## R&D | Income and Recruits | SCENARIO 7 (560 recruits EXTRA Each Year) - FUNDED INCOME + 10%

Author: Martin Chadderton , Produced: 5" January 2017, Document: R&D-INCOME-RECRUITS-SCENARIO6-560extra.doc





#### PURPOSE

To illustrate the effect of different scenarios on the R&D study recruit and income totals each year with the aim to hit a target of 6000 study recruits within a financial year whilst staying within income constraints.

#### METHOD

Use current year April to Sept totals and forecasted actuals.

APPLY an increase to the income and also increase study recruits across bands 1.2.3 and Non-Portfolio.

CALCULATE Time(t) to achieve target using formula:

t = (LN(x)-LN(y))/LN(1+(z/100))

#### where:

- x = target
- y = current recruits
- z = % increase

#### RESULTS

# APPENDIX 2 – Scenario Modelling Summary

	Allowed Income	Band 1	Band 2	Band 3	Non-	Years to	Chargeable	Unfunded	Unfunded	CHARGEABLE
	Increase %	increase%	increase%	increase% Portfolio r		reach target	Income after	Activity 1 <sup>st</sup>	Activity after	MINUS
							5 years £M	Year £	5 years £M	UNFUNDED
										£M AFTER 5
										YEARS
1	10%	10%	10%	10%	10%	7	4.94	0	0	4.94
2	5%	5%	5%	5%	10%	12	4.27	0	0	4.27
2a	2%	5%	5%	5%	30%	9	3.9	22,076	0.36	3.54
3	10%	20%	10%	9%	33%	5	4.94	0	0	4.94
4	10%	100%	15%	15%	50%	3	4.94	36,793	0.3	4.64
5	5%	100%	15%	15%	50%	3	4.27	73,587	0.98	3.29
6	10%	25%	25%	25%	25%	3	4.94	110,381	1.44	2.83
7	10%	560 extra re		r split using curr	ent ratio of	5	4.94	66,228	0.70	4.24
			bands and n	on-portfolio						



# Master Schedule \_ Research and Development - 2017 - 2020 - DRAFT v11



Matter Matter	Ster Concadi		-		•	2017-18		<b>-</b> P			••				'	2018-19										2019-20			
		April May	June	luly	Aug Si	ept Oct	Nov	Dec	Jan	Feb	Mar /	April May	June	July .	Aug Si	ept Oct	Nov	Dec	Jan	Feb Ma	ar A	pril May	June	July Au	ug Sr	ept Oct	Nov Dec	Jan	Feb Mar
d	Resp																												
1 Translating research and development onto better / safer care			1 1											1			1		l I		1	<u> </u>	4	<u> </u>		<u> </u>		_	
Work with CLAHRC-WM to institute changes in maternity and educating mothers in choice of birth place	Lydia Nestor																												
2 Promoting national and international excellence and leadership in	esearch and development																L				<u> </u>								
Expand the portfolio of research by further developing research within the Endobarrier Programme e.g. Sleep Apnoea	Bob Ryder																												
Expand the portfolio of research by further developing research within rheumatology - e.g.Sjogren's syndrome and myositis	Francesca Barone																												
Expand the portfolio of research by further developing research within Bechet's e.g microbial makeup of faeces linked to inflammatory disease	Saaeha Rauz	•										·				Duration of	4 years			·									
3 Increasing the breadth of research and development																													
Develop new research activity in Critical Care and recruit the numbers stipulated within the study	JB/Jonathon Hulme		ng of porto			ort																							
Develop new research activity in the disease tbc and recruit the numbers stipulated within the study	JB/Study lead							oping of po		nical supp	oort and	patient																	
Develop new research activity in the disease tbc and recruit the numbers stipulated within the study	JB/Study lead											Scoping of po populatin mat		ical supp	port and p	patient													
Develop new research activity in the disease tbc and recruit the numbers stipulated within the study	JB/Study lead																					Scoping of populatin ma		nical suppo	rt and p	oatient			
Develop new research activity in Orthopaedics and recruit the numbers stipulated within the study	JB/Kanthan Theivendran		ng of porto			ort																							
Utilise the implementation of the new EPR to identify potential recruits for existing research programmes and identifying new research opportunities.	JB																												
4 Increasing involvement of non-medical health care professionals in r	esearch and development												_								I								
Promote active research within nursing and understand barriers to be overcome - engage with Chief Nurse to understand timelines	Chief Nurse																												
New CNS actively involved in research delivery with delegated duties in disease area 1	ТВС																												
New CNS actively involved in research delivery with delegated duties in disease area 2	ТВС																												
Expand research activity into a new AHP area: e.g  Optometry/Orthoptics/Podiatry/Pharmacists with a minimum of one study	ТВС											Scoping of po		ical supp	port and p	oatient													
Expand research activity into a new AHP area - e.g Biomedical Scientists and Medical Laboratory Scientific Officers (MSLOs) with a minumum of one study	твс																												
Maintain profile of research in physiotheraphy with a minimum of one new study - GRASP study	ТВС																												
5 Developing the research and development workforce and capabilitie	s through redesign and ne	ew ways of v	working															-								<u> </u>			
Develop a career structure that provides role definition, career progression, retains experienced staff and offers secondment opportunities for Trust staff to experience R&D	JB																												
Develop training packages to support new and existing roles	JB																												
Identify and develop research mentors to support trainees in their new roles	JB																												
Maintain full complement of staff to manage the planned increase in recruits	JB																												
Review best practise working to develop and implement new ways of working throughout R&D	JB																												
6 Empowering patients to influence research and development																		•											
Work with MMH commissioning team to develop R&D advertising space in the MMH Foyer	KG / KR																												
Develop a new R&D Patient and Public Involvement groups in one disease area	JB																												
Develop the R&D website	KG																												

Work with EPR team to develop a flag system that identifies patients who have indicated an interest in research electronically	JB																
7 Enhancing alignment with the Trust's acaedemic and other research p	partners.																
Develop and recruit to a post in integrated care with the University of Birminham	KR																
Ensure SWBH is integrated into the arthritis accelerated trials programme between Birmingham and Oxford	KR	$\Rightarrow$	*														
As part of the M40 alliance participate in the arthritis acceleration programme (ATP)	KR																
Develop links with Aston University to develp and recruit to a joint post in e.g. Maternity, Cardiology, Ophthalmology	ТВС																
Enhance collaborative working within the BCA e.g FINCH	KG / KR		F	FINCH													
8 Enhancing alignment with the Trust's strategy for integrated care						<del>                                     </del>	1 1	<del>                                     </del>		<u> </u>			1		<u> </u>		
Develop a new forum with representations from primary and secondary care to support R&D activities at the interfaces of care	Roger Stedman																
Develop a structured working method with local GP's and other health professions to support studies and patient recruitment for new research activity focussed on integrated care	Roger Steadman																
Develop a research strategy for the forum	Roger Stedman																
Utilise population health informatics and the Health information exchange to identify potential areas of research and collaboration across the health economy.	ТВС																
9 Ensuring rigorous research and development governance processes																	
Develop a formal feasibility assessment process for new research studies to ensure deliverability prior to approval by SWBH R&D office	JB																
Develop research governance and managements SOP's approved and released in the Trust	JB																
Integrate the new UK Policy Framework in Health and Social Care	JB																
Monitor and implement any changes linked to the EU regulations, planned for October 2018, and Brexit	JB																
Expand core members of Research Management and Governance Team and the Research Delivery Team	JB/KR																
Deliver CIP target of £200k of additional income	JB																
Develop an expenditure plan for speciality/sub speciality funds	JB																
10 Ensuring that future estate for research and development supports	the planned growth in a	ctivity							1		1 1					1	
Work with MMH, Estates and Capital Projects teams to understand future configuration of services:	JB																
- OPD accommodation & R&D access particularly at STC	JB																
- available space and accommodation for R&D across all sites	JB																
11. Increasing research and development activity (number of recruits)											1					,	
Increase to xxxx patients recruited to research studies	JB																
Increase to xxxx patients recruited to research studies	JB																
Increase to xxxx patients recruited to research studies	JB																
Increase to xxxx patients recruited to research studies 2020-2021	JB																

Scenario		16-17	17-18	18-19	19-20	20-21	21-22
560 extra recruits per year	Income by year	£735,870	£809,457	£890,403	£979,443	£1,077,387	£1,185,126
	Unfunded Activity (Ic	£0	£66,228	£151,663	£260,615	£162,671	£54,932
		£735,870	£875,685	£1,042,066	£1,240,058	£1,240,058	£1,240,058
	Staff Costs	£1,526,556	£1,544,658	£1,803,299	£1,949,255	£2,116,129	£2,346,821
25% extra recruits per year	Income by year	£735,870	£809,457	£890,403	£979,443	£1,077,387	£1,185,126
	Unfunded Activity (Ic	£0	£110,381	£259,394	£457,803	£359,859	£252,120
		£735,870	£919,838	£1,149,797	£1,437,246	£1,437,246	£1,437,246
	Staff Costs	£1,526,556	£1,544,658	£2,040,673	£2,366,821	£2,346,826	£2,346,821
Difference	Income	£0	£0	£0	£0	£0	£0
	Unfunded Activity (Ic	£0	-£44,153	-£107,731	-£197,188	-£197,188	-£197,188
	Staff Costs	£0	£0	-£237,374	-£417,566	-£230,697	£0

-£743,448 -£885,637

PAY COSTS 2016-2017	WTE growth Recruit grow T		WTE cost	2017-2018 2017-2018 RECRUITS 3760	+/-	2018-2019 2018-2019 RECRUITS 0 4320	+/-	20	<b>19-2020</b> <b>19-2020</b> CRUITS 4880		2020-2021 2020-2021 RECRUITS 5440	+/-	factor	2021-2022 2021-2022 RECRUITS 6000	+/-
PAY COS1S 2016-2017	WTE			3760	50	0 4320	,	300	4880	500	5440	500		6000	500
C1 C1 DDV				14/75	C C	WTE			WTE	C C	WTE	C1 C		WTE	C C
Cost Centre : RDV	(Actual)	60272	60272.00		Cost £		Cost £	60.272		Cost £		Cost £	4.00		Cost £
Senior Manager - Band 8a	1	60372	60372.00					60,372	1.0	60,372	1.0	60,372		1.0	60,372
Admin and Clerical - Band 7	1	40393.8	40393.80		-,			40,394	1.0	40,394	1.0	40,394		1.0	40,394
Admin and Clerical - Band 6	1	37728	37728.00		- ,			75,456	2.0	75,456	2.0	75,456		2.0	75,456
Admin and Clerical - Band 5	2	61100.4	30550.20		. ,			91,651	3.0	91,651	3.0	91,651		4.0	122,201
Admin and Clerical - Band 4	1	26716.75	26716.75		26,71			53,434	2.0	53,434	2.0	53,434		2.0	53,434
Admin and Clerical - Band 3	0	0	23636.10			0.0	)	0	0.0	0	0.0	0		0.0	0
Admin and Clerical - Band 2	1	21242.4	21242.40	1.0	21,24	2 0.0	)	0	0.0	0	0.0	0	1.00	0.0	0
	7	247,553.35		8.0	278,10	4 9.0	)	321,306	9.0	321,306	9.0	321,306		10.0	351,856
Cost Centre : RSN															
Nursing & Midwifery Qual - Band 8a	1	60386.28	60372.00												_
RN/CTP - Band 7	3	143815.92	47938.64	4.00	191,75	5 4.00	)	191,755	4.00	191,755	5.00	239,693	1.00	5.0	239,693
RN/CTP - Band 6	17.87	674199.36	37728.00	17.87	674,19	9 22.00	)	830,016	23.00	867,744	24.00	905,472	1.00	25.0	943,200
RN/CTP - Band 5	4.27	130449.35	30550.20	4.27	130,44	9 6.00	)	183,301	7.00	213,851	8.00	244,402	1.00	10.0	305,502
Admin and Clerical - Band 4	3	81062.64	27020.88	3.00	81,06	3 5.00	)	135,104	7.00	189,146	8.00	216,167	1.00	10.0	270,209
Admin and Clerical - Band 3	8	189088.8	23636.10	8.00	189,08	9 6.00	)	141,817	7.00	165,453	8.00	189,089	1.00	10.0	236,361
	37.14	1,279,002.35		37.1	1,266,55	<b>5</b> 43.0	)	1,481,993	48.0	1,627,949	53.0	1,794,823		60.0	1,994,965
BASELINE (2016-2017)	3008 F	RECRUITS													
				2017			2018-201			9-2020	2020-			-	-2022
				RECRUITS		0 RECRUITS		4320 RE			RECRUITS	5440		RECRUITS	6000
					COST £	WTE	COST £	W <sup>*</sup>				COST £			COST £
				45.1	1,544,65	<b>8</b> 52.0	)	1,803,299	57.0	1,949,255	62.0	2,116,129		70.0	2,346,821

 SCENARIO
 INCREASE IN RECRUITS FROM
 3200
 TO
 AFTER 5 YEARS

 7
 WTE COMPLIMENT INCREASE FROM PAY COST PAY

r

	WTE growth Recruit grov			2017-2018 2017-2018		2018-2019 2018-2019		20	019-2020 019-2020		2020-2021 2020-2021		Adjustment factor	2021-2022 2021-2022	
PAY COSTS 2016-2017			1 WTE cost	RECRUITS 3765		RECRUITS 4700	+/-	25%	ECRUITS 5875	+/-	RECRUITS 5875	+/-		RECRUITS 5875	+/-
PAT CO313 2010-2017	WTE			3/03	23%	4700	,	2370	30/3		3073	,		36/3	U
Cost Centre : RDV		TD Actual		WTE	Cost £	WTE	Cost £		WTE	Cost £	WTE	Cost £		WTE (	Cost £
Senior Manager - Band 8a	(Actual) 1	60372	60372.00	1.0		1.0		60,372	1.0				1.00	1.0	60,372
Admin and Clerical - Band 7	1	40393.8				1.0		40.394	1.0				1.00	1.0	40,394
Admin and Clerical - Band 7	1	37728		1.0	-,	2.0		75.456	2.0	.,				2.0	75,456
Admin and Clerical - Band 5	2	61100.4				3.0		91,651	4.0	-, -			1.00	4.0	122,201
Admin and Clerical - Band 4	1	26716.75				2.0		53,434	2.0			, ,	1.00	2.0	53,434
Admin and Clerical - Band 3	0	20/10./3				0.0		33,434	0.0		) 0.0		1.00	0.0	33,434
Admin and Clerical - Band 2	1	21242.4	21242.40			0.0		0	0.0		0.0		1.00	0.0	0
Admin and Ciencal - Band 2	7	247,553.35		8.0		9.0		321,306	10.0					10.0	351,856
Cost Centre : RSN						-		,				,			,
Nursing & Midwifery Qual - Band 8a	1	60386.28	60372.00												Ų
RN/CTP - Band 7	3	143815.92		4.00	191,755	5.00	1	239,693	5.00	239,69	3 5.00	239,693	1.00	5.0	239,693
RN/CTP - Band 6	17.87	674199.36		17.87	- ,	22.00		830,016	25.00	943,20		,	1.00	25.0	943,200
RN/CTP - Band 5	4.27	130449.35		4.27	. ,	8.00		244.402	10.00	305,50			1.00	10.0	305,502
Admin and Clerical - Band 4	3	81062.64		3.00	,	8.00		216,167	10.00	270,20				10.0	270,209
Admin and Clerical - Band 3	8	189088.8	23636.10		. ,	8.00		189,089	10.00	236,36			1.00	10.0	236,361
Admin and Ciencal - Band 3	37.14	1,279,002.35		37.1	•	51.0		1,719,367	60.0					60.0	1,994,965
								_,:,:		_,					_,
BASELINE (2016-2017)	3008 F	RECRUITS												L	
,				2017	7-2018		2018-2019	)	20	19-2020	2020	0-2021		2021-	2022
				RECRUITS	3765	RECRUITS		4700 RE			RECRUITS	5875		RECRUITS	5875
				WTE	COST £	WTE	COST £	W	/TE	COST £	WTE	COST £		WTE (	COST £
				45.1	1,544,658	60.0	)	2,040,673	70.0	2,346,82	L 70.0	2,346,821		70.0	2,346,821
														Ī	

 SCENARIO
 INCREASE IN RECRUITS FROM
 3200
 TO
 5875

 7
 WTE COMPLIMENT INCREASE FROM PAY COST FROM PAY

r



	TRUST BOARD
DOCUMENT TITLE:	Diversity Pledges 2017
SPONSOR (EXECUTIVE DIRECTOR):	Raffaela Goodby Director of Organisation Development
AUTHOR:	Raffaela Goodby Director of Organisation Development
DATE OF MEETING:	1 <sup>st</sup> June 2017

## **EXECUTIVE SUMMARY:**

The Trust is fully committed to being an inclusive organisation for our staff and our patients. The 2014-2017 Public Health plan includes a clear and consistent commitment to equality and diversity, with 9 pledges that are monitored each month at the Public Trust Board.

This report sets out the staff and patient pledges for the coming 2 years, and the early draft that will denote success. The Staff pledges form projects and actions of Theme 2 of The People Plan, sponsored by the Director of OD. The patient pledges need further expansion and will be sponsored by clinical executives and monitored through the Public Health Committee and the Public Trust Board.

## REPORT RECOMMENDATION:

Recommend that the Trust Board discuss the attached pledges, in particular the patient pledges and make suggestions for improvements or additions.

## **ACTION REQUIRED** (Indicate with 'x' the purpose that applies):

The receiving body is asked to receive, consider and:

Accept	Approve the recommendation	Discuss
		X
KEY AREAS OF IMPACT (Indicate with '	x' all those that apply):	

Financial	Environmental		Communications & Media	
Business and market share	Legal & Policy		Patient Experience	Χ
Clinical	Equality and	Х	Workforce	V
Cillical	Diversity			^

## Comments:

## ALIGNMENT TO TRUST OBJECTIVES, RISK REGISTERS, BAF, STANDARDS AND PERFORMANCE METRICS:

## PREVIOUS CONSIDERATION:

Public Health, Community Development and Equality Committee

# Inclusion and Diversity. Proposed Pledges for 2017/18

1	<ul> <li>Increase recognition and knowledge of the value of inclusion within the leader and manager population</li> <li>Develop training module, using an interactive story telling approach, through e-learning platform.</li> <li>Deliver one QIHD corporate learning module on Inclusion and diversity</li> <li>Develop module of 'SWBH Chartered Line Manager' on inclusion and diversity</li> <li>Design and deliver a managers development workshop on inclusive leadership, as part of the 2017/19 leadership development offer.</li> <li>Executive team and board development on inclusion to be delivered</li> <li>Develop a photo exhibition / poster campaign to celebrate and acknowledge the diversity of staff and role model diverse leadership at different levels</li> </ul>
2	Review and redesign recruitment and selection processes  Inclusion and diversity to be included as a key aspect of all recruitment and selection training  Deliver unconscious bias training for recruiting managers  Run CV and interview skills workshops for staff groups with protected characteristics  Implement diverse recruitment panels (gender and ethnicity)  Work closely with external recruitment partners stating Trust values on inclusion and diversity  Monitor data of applicants through the WRES  Intensive training for Organisation Development team  Monitor protected characteristics data of PDR completion and scoring
3	<ul> <li>Develop and support Staff Network Groups</li> <li>Support newly established staff networks, including executive sponsorship</li> <li>Support network chairs and vice chairs and others involved with time, efforts, events and communicating outcomes</li> <li>Executive sponsor meet with network at least 4 times a year</li> <li>Support each network in terms of personal development, mentorship</li> <li>Support networks for campaigning, networking, education, advocacy or social purposes</li> </ul>
4	Creating a culture where it is safe to be 'out' at SWBH as a staff member or a patient  Raise awareness and support LGBT network

## Inclusion and Diversity. Proposed Pledges for 2017/18

- Attend Birmingham Pride 2017 for recruitment and awareness raising
- Join Stonewall and take part in regional conferences and workshops
- Train staff in supporting LGBT patients sensitively and appropriately
- Create a 'Safe Space' for LGBT colleagues
- Work with Birmingham LGBT and other external partners to ensure best practice is being implemented
- Work with Staffside, and RCN to support LGBT staff at work
- Celebrate LGBT History Month with events and support in Feb 2018
- Implement 'Allies' programme for non LGBT staff communicated and visible
- Increase sexual orientation declaration to at least 20% in two years
- Independent review and audit by Stonewall UK of Trust, ready to enter 'Top 100' in 2018

## 5 To ensure a safe and inclusive environment for transgender people.

- Support clinical groups with clear guidance on the implementation of the public sector Equality Duty, which includes gender reassignment as one of the pc's.
- Work with members of SWBH staff to develop a programme to raise awareness of the challenges transgender people may face.
- Develop and re-launch trans policy
- Develop and launch supportive guidance for staff on welcoming trans patients
- Celebrate national Trans Day of remembrance in November 2017

## Review the use of EDS 2 and develop and implement a 'Trust EDS'

EDS measures 1) Better Health Outcomes 2) Improved Patient Access and Experience 3) A representative & inclusive workforce 4) Inclusive Leadership

- Senior support of EDS action plans in hot spot areas
- Deliver 2 work programmes (TBC) to improve patient access and experience and better health outcomes
- Communication and engagement with EDS both internally and externally
- Inclusion of revised EDS in annual equality report
- Work with Local Interest Group to change focus of EDS to Trust Wide

# Inclusion and Diversity. Proposed Pledges for 2017/18

	Even and mambarabin of Local Intercet Croup to be mare diverse
	Expand membership of Local Interest Group to be more diverse
7	To ensure a safe and inclusive working environment for BME Staff
	Annual review of access to training for BME Staff
	Develop clear action plan to respond to the 2016 WRES using best practise from the WRES report released on 18 <sup>th</sup> April
	Analyse via group and take any appropriate remedial action
	Support BME Staff network group to have a visible presence in organisation
	<ul> <li>Release staff to the 'Stepping Up' BME Leadership Programme - Bands 5/6 and Bands 7</li> </ul>
	<ul> <li>Monitor 'First Line Leadership Attendance' of BME Staff to ensure it does not drop below 30%</li> </ul>
	Direct contact with BME staff to advertise leadership programmes and management development
	Direct contact with BME staff to advertise and encourage 'Middle Manager' Leadership Programme
	Inclusive communications across organisation in branding, photographs, videos and other media
9	In addition we will further add to our portfolio of leadership development activities a series of structured development and mentorship programmes for people with PC
	Annual review of data and analysis, will be brought to the board
	Continue LGBT Leadership Programme in partnership with Birmingham LGBT
	Access and support for 'Stonewall UK' mentoring scheme
	Case studies, posters, videos and marketing that is inclusive and accesses staff with PC.
10.	Run communications campaigns each month with emphasis on protected characteristics (PC) based on CIPD Diversity Calendar and with visible support from employee network groups e.g
	February LGBT History Month
	October Black History Month
	Religious Celebrations
	International Women's Day
	Mental Health Awareness
	•

# Inclusion and Diversity. Proposed Patient Pledges for 2017/18

1				
	Widening access to services for our transgender or transitioning patients.			
	<ul> <li>Identifying and improving 2 patient pathways for transitioned patients</li> </ul>			
	Develop and relaunch transgender policy for patients			
	<ul> <li>Develop a partnership with community to explore issues facing trans patients and their carers or families</li> </ul>			
2	Increase offer to deaf or partially deaf patients in our hospital			
	Train staff in sign language			
	Deaf Awareness Campaign with front line staff			
3	Widening offer for parents who are looking after their children in hospital			
	<ul> <li>Expand on work of 'John's Campaign' for parents</li> </ul>			
	<ul> <li>Offer food options and expand offer to parents who are looking after their child</li> </ul>			
	Develop support for parents and overnight / morning support			
4	Review friends and family comments and complaints / compliments to identify trends or issues			
	Explore issues raised by patients with protected characteristics			
	Review measures for improvements			
5	Enhance our offering to older people's patient experience in our hospital			
	Launch 'end PJ Paralysis' campaign			
	<ul> <li>Work with partners to offer support for stay in hospital e.g. Sandwell College on massage and therapies</li> </ul>			
	•			



TRUST BOARD		
DOCUMENT TITLE:	Reducing Agency Spend	
SPONSOR (EXECUTIVE DIRECTOR):	Raffaela Goodby – Director of OD	
SPONSOR (EXECUTIVE DIRECTOR).	Elaine Newell – Chief Nurse	
AUTHOR:	Raffaela Goodby – Director of OD	
AOTHOR.	Kirsten Moon – Improvement Team	
DATE OF MEETING:	1 <sup>st</sup> June 2017	

## **EXECUTIVE SUMMARY:**

The Trust People Plan – theme one – outlines the target to reduce temporary spend by £10m during 2016/17. This is an agreed NHSI target.

The following report outlines four main areas of focus to achieve this target, and the governance and KPI's being used to tightly monitor the delivery through the clinical group programme management offices (PMO) on a regular basis..

- Productive Rostering
- Reduce Open 'Hard to Fill' Vacancies
- Manage and Reduce Owed Hours
- Improve Attendance

The delivery chain is through a combination of finance, OD & operational support (through the improvement team) to support the clinical group boards. The executive PMO will monitor the delivery overall on a monthly basis.

## REPORT RECOMMENDATION:

The Trust board are asked to note the plan and the governance, and receive regular updates

## **ACTION REQUIRED** (*Indicate with 'x' the purpose that applies*):

The receiving body is asked to receive, consider and:

Accept	Approve the rec	Approve the recommendation	
Х			
KEY AREAS OF IMPACT (Indicate	with 'x' all those that apply):		
Financial	Environmental	Communicat	ions & Media
Business and market share	Legal & Policy	Patient Expe	rience
Clinical	Equality and Diversity	Workforce	

## Comments:

ALIGNMENT TO TRUST OBJECTIVES, RISK REGISTERS, BAF, STANDARDS AND PERFORMANCE METRICS:

## PREVIOUS CONSIDERATION:

# Aim: Reduce agency spend by £10m by 31st March 2018

## **Purpose of Report**

The purpose of this report is to provide an update to the Trust Board on progress of planned measures to reduce agency spend by £10m durng 2017/18, the plans for monitoring and the tracking of performance and the proposed governance and reporting framework. This falls in to theme one of the People Plan.

### Objective: Reduce Temporary Pay Spend by £10M

The Trust has adopted a four-pronged approach to achieve the key objective, which is to 'Reduce Temporary Pay Spend by £10M by 31 March 2018'. These objectives will be broken down in to group level targets, and managed weekly, at a group level, in their PMO.

- **Productive Rostering** Improved rostering practices, in particular compliance to completion 6 weeks in advance, to ensure that bank/agency use is significantly reduced. This is a nurse led objective sponsored by the Chief Nurse.
- **Reduce Open 'Hard to Fill' Vacancies** Reduce open nursing vacancies within a Group to reduce bank/agency usage to cover the vacant posts.
- Manage and Reduce Owed Hours Reduce the level of owed hours in a Group at Ward level to reduce bank/agency use and review flexible working arrangements.
- Improve Attendance Halve short term sickness rates in hotspot areas to reduce reliance and usage of bank/agency to cover gaps in shifts

To support the above, the Trust has implemented a total ban on the use of the Thornbury agency as follows:

Ban on the use of Thornbury (and other agencies) from 1<sup>st</sup> June 2017

A ban on the use of Thornbury (and other agencies) for HCA's has been already been implemented. This ban will extend to nursing staff as of 1<sup>st</sup> June.

Application of a wholesale agency ban has been slow to embed, however no Thornbury agency has been used for HCAs since the beginning of April 2017. Overall agency usage has reduced significantly in May 2017.

## **Focussed Delivery**

The following actions are being implemented across all Groups to achieve reduced temporary pay spend and to support the ban of Thornbury and significantly reduce agency use.

## **Productive Rostering**

The aim is to achieve more productive rostering to resolve poor practice, in particular, late requisition of shifts. The objective is to ensure rostering gaps are requisitioned with a minimum of six weeks' notice to allow sufficient time for fill with bank staff prior to submission to tier one / two agencies. This programme is being jointly led by Nursing and OD (Bank Office and Deputy HR Director)

A series of KPI's have been developed to track compliance with good rostering practice:

KPI		Measures		
•	Are Rosters Safe?	<ul> <li>% of shifts staffed to agreed safe staffing parameters i.e. numbers and mix of qualified and unqualified.</li> <li>% of shifts with more than 30% temporary staff.</li> </ul>		
•	Are Rosters Within Budget?	Variance to budget		
•	Roster Effectiveness:	<ul> <li>Roster sign off six weeks (42 days) prior to the commencement of the shift.</li> <li>Requisition of temporary cover – cover notice period to be six weeks for 80% of predicted demand.</li> <li>Bank and agency use above vacancy levels.</li> <li>Use of contractual (owed) hours.</li> <li>Annual leave management – within agreed tolerance for the ward calculated target.</li> </ul>		

To monitor and track rostering performance and compliance, Group Directors of Nursing (GDoNs) meet weekly with matrons and ward managers to ensure there is proactive oversight of the planning and production of rotas and to provide coaching as required. The purpose is to ensure that staff have the necessary rostering skills, training, mentoring and coaching required.

Those areas who fail to produce rosters which are complaint with the agreed KPI's will require weekly meetings with the GDoN who will facilitate an agreed 4 week improvement plan. Persistent non-compliance will result in a more formal improvement conversation in line with established Trust disciplinary policies.

### Ensure wards are staffed appropriately.

In addition to all actions detailed in this report, it is critical to ensure all wards are staffed appropriately. A month long staffing review is in progress, led by the Chief Nurse, to assess staffing requirements using recognised acuity based scoring tools.

Results will be analysed and published in early July. It is not anticipated that a significant uplift of staff will be required – rather that staff will be realigned and the skill mix adjusted.

## **Manage and Reduce Owed Hours**

The objective is to ensure the use of owed hours as an alternative to Thornbury and agency use. Barnacles reports indicate that there are a significant amount of 'owed hours' which have accrued since March 2016. Staff are currently agreeing personal contracts with their ward managers to pay back this time over a reasonable period of 3 months. Going forward, managers will be required to ensure that no more than 10 hours per employee per month is carried forward or owed to employees.

In addition the Group monitors the payback of owed hours on a monthly basis via the Group Programme Office (GPO).

## **Reduce Open Vacancies**

Substantive recruitment of both nursing and HCA staff continues to progress, although there has been an anticipated seasonal lull in nurse staffing recruitment. Targeted work is being undertaken to support the ongoing substantive recruitment process:

- A nursing and HCA celebration event on the 12<sup>th</sup> May generated significant interest from HCA's currently
  working within the private sector all of whom are being actively followed up. 2 offers were made on the day
- Local and regional recruitment events are planned over the next 6 months in London, Liverpool and Nottingham.
- Trust Bank increased have increased the number of its HCA's by proactively promoting and recruiting to the internal staffing bank. To date, 28 staff have been appointed scheduled to start in June 2017. A further 26 are scheduled for interviews in late May. The Staffside have requested a specific recruitment event for facilities staff who want to become HCA's this is currently being organised.

### Improving attendance

The aim is to reduce sickness in hotspot areas will support the reliance on bank/agency. Groups will plan and deliver the following:

- Series of actions to identify and resolve reasons for high sickness within hotspot areas
- Identify opportunities to plan in advance to manage short term sickness operational gaps, e.g. implement a HIT team (floating bank support pre-booked and planned.)
- Monitor the hot spot areas at the Group PMO

## NHS Improvement (NHSI) – Bank/Agency Reduction Plan

The Trust has agreed a profile of reduced bank/agency spend for the coming year with NHSI.

Finance have translated the NHSI targets and plan into hours; broken down by Group and staffing type. The aim has been to provide a realistic measure for Groups to understand to ensure targeted approach to monitoring and driving down their bank and agency use. The annual profile aims for a 43% reduction across all Groups and staffing type by 31 March 2018. The allocation per Group has been pro-rated based on their 2016/17 use.

Group performance of actual bank/agency hours to the maximum target NHSI hours will be monitored weekly as part of the GPO process, starting June 2017.

This will be closely monitored each week in the group PMO, with the Group Management Board being accountable for delivery.

## **Monitoring Performance and Activity**

The importance of regular and timely monitoring is recognised by the Executive team to ensure compliance to the Agency and Thornbury ban, and progression towards reduced £10M Temporary Pay Spend by 31 March 2018.

The following performance and finance monitoring is undertaken on a weekly and fortnightly basis:

### A. Productive Rostering / Compliance to the Thornbury and Agency HCA ban:

- The Rostering system, Barnacles, now produces a weekly report that details compliance against Productive Rostering KPI's.
- Daily breach reports and weekly bank and agency usage reports will be generated by the Trust Bank and monitored by the Chief Nurse and GDoNs.
- Agency requests are now agreed by the Group Director of Nursing and any Thornbury requests will require authorisation by the CEO.
- Heat maps demonstrating high use areas are being produced and will enable focused support and where necessary performance management measures.

# B. NHSI Targets/Reduced Temporary Pay Spend/Management and Reduction of Owed Hours/reduce Open Vacancies

The Group Programme Offices (GPO) will play a critical role in weekly monitoring and tracking of the following:

- Weekly monitoring of performance of agency/bank to NHSI maximum target hours
- Ward by ward performance to hours and also compliance to key rostering KPIs
- Monthly management and reduction of owed hours above agreed level
- Monitoring of planned and agreed actions to address issues
- Number of band 5 nursing vacancies
- Number of HCA vacancies
- Substantive recruitment to ED, Ophthalmology & Lyndon 5.

## **Governance**

To oversee and monitor performance, a Project Board will be established in June 2017. Membership will include the Chief Nurse, OD Lead, Trust Bank Lead, Finance Lead, and a GDoN and GDoP representative.

The Board will report to the Executive Programme Office (PMO) on the following:

- Progress against reduced hours NHSI agreed targets
- Reduction in spend aligned to reduced bank/agency hours
- Revised forecast profile of reduced hours per month and spend per month as required.

In addition to the Project Board, oversight will be provided by the Group Management Boards and Executive Group reviews.

The GPO forum will be used to support GDoNs and GDoPs to monitor performance, plan corrective actions and further the embedding of new practices at Group level. Successful delivery will require weekly executive oversight, and corporate and clinical teams working together closely to ensure that temporary pay spend is reduced by a minimum of £10M and in line with the NHSI plan.

Raffaela Goodby - Director of Organisation Development Kirsten Moon – Improvement Team

23<sup>rd</sup> May 2017

## <u>Appendix A – Progress on Specific Directives to Reduce Spend</u>

## **Nursing Agency Spend – Chief Nurse**

Directives to reduce spend	
<ul> <li>Efficient Rostering, measured and monitored against agreed KPI's - including time owing to Trust</li> <li>Recruit substantively to nursing vacancies</li> <li>Ban of Thornbury from 1<sup>st</sup> June 2017</li> <li>Substantively staff Lyndon 5</li> <li>Halve sickness in Ophthalmology Theatres</li> <li>Tighter escalation for approvals via prompt cards</li> <li>Bed reduction programme delivered by 31<sup>st</sup> May</li> <li>Staffing review commencing 1<sup>st</sup> May</li> <li>Review heat maps for agency spend / sickness with a view to focussed support</li> </ul>	Underway  Underway – monitored in GPO On Track for 1 <sup>st</sup> June 2017 Recruitment underway ?  Implemented ?  Available and hotspots being monitored in GPOs.

## **HCA Agency Spend – Chief Nurse**

Directives to Reduce Spend	
<ul> <li>Focussed care reduction across the Trust</li> <li>Ban on all agency HCA's effective 1<sup>st</sup> April 2017</li> <li>Substantive recruitment to HCA 100 WTE vacancies through recruitment drive (84 are in recruitment process)</li> <li>Growth of HCA numbers on Trust Bank</li> </ul>	Being implemented Implemented and actively monitored weekly Underway

## (Medical Agency, AHP & Corporate) – Chief Executive & Chief Operating Officer

Dire	ectives to Reduce (draft)	Assumed Im	pact
		Q1	Up to Mar 18
- - -	Fill medical vacancies substantively Medical Break glass process to be agreed by CEX A&E medical plan to be implemented Direct engagement of medical locums	£0	

Ophthalmology) - Minimise junior - Implementation - Radiographer ag	doctor gaps (known in May 2017)		£400k per month  (£4.5m 1 <sup>st</sup> July 17  – 31 <sup>st</sup> March 18)
Totals		£0.5m	£9.5m

# Sandwell and West Birmingham Hospitals MHS

JHS Trust

## **TRUST BOARD**

DOCUMENT TITLE:	Financial Statements for the Year Ended 31 <sup>st</sup> March 2017	
SPONSOR (EXECUTIVE DIRECTOR):	Tony Waite (Director of Finance and Performance Management)	
AUTHOR:	Tim Reardon (Associate Director of Finance – Compliance)	
DATE OF MEETING:	1 June 2017	

## **EXECUTIVE SUMMARY:**

This report presents the Trust's financial statements for the year ended 31<sup>st</sup> March 2017.

Those financial statements demonstrate the following performance in respect of key financial duties for the financial year 2016/17:

Financial duty	Delivery	Comment
Compliance with annual control total	Х	£11.9m deficit recorded versus a plan target of
		£6.6m surplus
Compliance with External Finance Limit	٧	£46.9m relevant net cash outflow against a
		£56.4m EFL.
Compliance with Capital Resource Limit	٧	£19.0m capital expenditure against a £19.0m
		CRL
Statutory break-even taking one year	٧	£25.8m cumulative break-even for the
with another		purposes of statutory duty measurement

The financial statements and related documents have been subject to review by the Trust's external auditors. KPMG have indicated their intention to issue the following opinions:

Financial statements	Unqualified opinion
Use of resources	'Except for' qualified opinion
Quality account (content)	Clean opinion
Quality account (indicators)	Clean opinion

The auditors have confirmed that there are no matters of concern that they are required to report in respect of the trust's probity and stewardship of public funds or matters of significant public interest.

The ISA260 report issued by the auditors to those charged with governance draws attention to three specific matters:

- 1. An unadjusted audit difference of £0.4m in respect of a provision for credit notes on SLA income. This is not material to the audit opinion.
- 2. The application of a general hospital approach to the MEA valuation of current land and buildings and appropriate recognition of surplus assets. This is consistent with that approach taken in 2015.16.
- 3. The completeness of provisions in respect of obligations arising from workforce changes. Due consideration has been given to the trust's record of success in redeployment.

The Audit Committee has challenged and confirmed its contentment with the trust's accounting judgements in respect of items 2. and 3. above.

The auditors are seeking appropriate management representations in this regard.

The ISA260 report has been considered by the Audit Committee. The report has been made available to all members of the Board in support of its consideration of the financial statements.

The Trust is requested to provide a Letter of Representation in support of the financial statements and which is attached for the Board's consideration.

The Audit Committee has challenged and confirmed its contentment with those proposed representations.

## **REPORT RECOMMENDATION:**

The Board is recommended to

- 1. accept the Audit Committee's recommendation to adopt the financial statements
- 2. authorise the CEO & FD to sign relevant certificates in regard to those financial statements
- 3. review the draft Letter of Representation and to challenge and confirm that
  - a) The proposed representations are fair & complete
  - b) There are no significant events occurring between 31.03.16 and 01.06.17 which are material to the financial statements as presented
  - c) All relevant related parties are disclosed in the financial statements

ACTION REQUIRED (Indicate with 'x' the purpose that applies): The receiving body is asked to receive, consider and:					
Accept		Approve the recommendation		Discuss	
		X			
KEY AREAS OF IMPACT (Indicate with 'x' all those that apply):					
Financial	Х	Environmental		Communications & Media	
Business and market share		Legal & Policy	Х	Patient Experience	
Clinical		Equality and Diversity		Workforce	

## Comments:

## ALIGNMENT TO TRUST OBJECTIVES, RISK REGISTERS, BAF, STANDARDS AND PERFORMANCE METRICS:

Good governance and transparency in financial reporting

## **PREVIOUS CONSIDERATION:**

Audit & Risk Management Committee on 24 May 2017

Sandwell and West Birmingham Hospitals NHS Trust - Annual Accounts 2016-17

# Statement of Comprehensive Income for year ended 31 March 2017

31 Warch 2017			
		2016-17	2015-16
	NOTE	2000s	£000s
Gross employee benefits	8.1	(311,043)	(295,516)
Other operating costs	6	(148,908)	(145,715)
Revenue from patient care activities	3		
		411,619	405,531
Other operating revenue	4	48,578	38,167
Operating surplus/(deficit)		246	2,467
Investment revenue	10	66	136
Other gains and (losses)	11	0	50
, ,		-	
Finance costs	12	(2,191)	(2,057)
Surplus/(deficit) for the financial year		(1,879)	596
Public dividend capital dividends payable		(5,117)	(4,850)
Transfers by absorption - gains		0	0
Transfers by absorption - (losses)		0	0
Net Gain/(loss) on transfers by absorption	-	0	0
Retained surplus/(deficit) for the year	-	(6,996)	(4,254)
, , , , , , , , , , , , , , , , , , ,		(0,000)	( -,== -,
Other Comprehensive Income		2016-17	2015-16
Other Comprehensive Income			
		20003	£000s
		0.54	(00.000)
Impairments and reversals taken to the revaluation reserve		654	(36,230)
Net gain/(loss) on revaluation of property, plant & equipment		0	0
Net gain/(loss) on revaluation of intangibles		0	0
Net gain/(loss) on revaluation of financial assets		0	0
Other gain /(loss) (explain in footnote below)		0	0
Net gain/(loss) on revaluation of available for sale financial			
assets		0	0
Net actuarial gain/(loss) on pension schemes		0	0
Other pension remeasurements		Ō	0
Reclassification adjustments		•	ŭ
On disposal of available for sale financial assets		0	0
Total comprehensive income for the year	-	(6,342)	(40,484)
rotal comprehensive income for the year		(0,342)	(40,464)
Financial newformers for the year			
Financial performance for the year			
Retained surplus/(deficit) for the year		(6,996)	(4,254)
Prior period adjustment to correct errors and other			
performance adjustments		0	0
IFRIC 12 adjustment (including IFRIC 12 impairments)		0	1,368
Impairments (excluding IFRIC 12 impairments)		(5,161)	7,022
Adjustments in respect of donated gov't grant asset reserve		,	• •
elimination		224	(279)
		224	, ,
Adjustment re absorption accounting	-	(11.000)	0
Adjusted retained surplus/(deficit)		(11,933)	3,857

A Trust Reported NHS financial performance position is derived from its Retained Surplus/ (Deficit), but adjusted for the following:-

- a) The revenue cost of bringing PFI assets onto the balance sheet (due to the introduction of International Financial Reporting Standards (IFRS) accounting in 2009/10) NHS Trusts' financial performance measurement needs to be aligned with the guidance issued by HM Treasury measuring Departmental expenditure. Therefore, the incremental revenue expenditure resulting from the application of IFRS to PFI, which has no cash impact and is not chargeable for overall budgeting purposes, should be reported as technical. Where there is a positive financial consequence, the performance figures are not adjusted.
- b) The Trust is required to revalue its Land and Buildings on a regular basis as a result of the IFRS implementation and in 2016-17 this has resulted in an increase to Asset Values. The increase is represented in the accounts as a reversal of previous impairments of Buildings of £5.9m, £0.6m of which was carried through the Revaluation Reserve which reverses impairments charged from prior years. The remaining reversal of impairment of £5.2m has been recognised as a credit to the SOCI. In addition the Trust impaired intangible assets of £0.05m. Impairments and Reversals are specifically excluded from measurement of the Trust's financial performance.
- c) Due to change in accounting requirement, elimination of donated and government grant reserve has resulted in the Trust recording income of £0.62m. Income resulting from the application of this change which has no cash impact and is not chargeable for overall budgeting purposes is removed as a technical adjustment. In addition the revenue impact of depreciation, £0.286m, relating to Donated assets was previously offset by a release from the Donated Asset Reserve. Following revision to the reporting manuals this cost is charged to the Trusts expenditure without any offset. This is therefore not considered part of the Trusts operating position and is adjusted. The net impact of these two adjustments is reported above as a technical adjustment to the Financial Performance of the Trust of (£0.224m)

The notes on pages 6 to 41 form part of this account.

# Statement of Financial Position as at 31 March 2017

		31 March 2017	31 March 2016
	NOTE	£000s	£000s
Non-current assets:			
Property, plant and equipment	14	207,430	196,381
Intangible assets	15	166	386
Investment property		0	0
Other financial assets		0	0
Trade and other receivables	19.1	43,017	846
Total non-current assets	_	250,613	197,613
Current assets:			
Inventories	18	5,268	4,096
Trade and other receivables	19.1	17,100	16,308
Other financial assets		0	0
Other current assets		8,043	0
Cash and cash equivalents	20	23,902	27,296
Sub-total current assets	-	54,313	47,700
Non-current assets held for sale	_	0	0
Total current assets	-	54,313	47,700
Total assets	-	304,926	245,313
Ourse and High History	_	_	
Current liabilities	0.1	(00.540)	(54.441)
Trade and other payables	21	(68,512)	(54,144)
Other liabilities	0.4	0	0 (4.470)
Provisions	24	(1,147)	(1,472)
Borrowings	22	(903)	(1,306)
Other financial liabilities		0	0
DH revenue support loan	22	0	0
DH capital loan	22	0	0 (50.000)
Total current liabilities	-	(70,562)	(56,922)
Net current assets/(liabilities)	-	(16,249)	(9,222)
Total assets less current liabilities	-	234,364	188,391
Non-current liabilities			
Trade and other payables	21	0	0
Other liabilities		0	0
Provisions	24	(3,396)	(3,095)
Borrowings	22	(33,953)	(25,591)
Other financial liabilities		0	0
DH revenue support loan	22	0	0
DH capital loan	22	0	0
Total non-current liabilities	_	(37,349)	(28,686)
Total assets employed:	-	197,015	159,705
FINANCED BY:			
Public Dividend Capital		205,362	161,710
Retained earnings		(24,979)	(17,993)
Revaluation reserve		7,574	6,930
Other reserves		9,058	9,058
Total Taxpayers' Equity:	-	197,015	159,705
- 1-1 41-	-	,	

The notes on pages 6 to 41 form part of this account.

The financial statements on pages 1 to 5 were approved by the Board on 1st June 2017 and signed on its behalf by

Chief Executive: Date:

# Statement of Changes in Taxpayers' Equity For the year ending 31 March 2017

For the year ending 31 March 2017	Public Dividend capital	Retained earnings	Revaluation reserve	Other reserves	Total reserves
	£000s	2000s	2000s	£000s	£000s
Balance at 1 April 2016	161,710	(17,993)	6,930	9,058	159,705
Changes in taxpayers' equity for 2016-17 Retained surplus/(deficit) for the year		(6,996)			(6,996)
Net gain / (loss) on revaluation of property, plant,		(0,000)	0		(0,000)
equipment					_
Net gain / (loss) on revaluation of intangible assets			0		0
Net gain / (loss) on revaluation of financial assets			0		0
Net gain / (loss) on revaluation of available for sale			0		0
Impairments and reversals			654		654
Other gains/(loss) (provide details below)			(1.5)	0	0
Transfers between reserves		10	(10)	0	0
Reclassification Adjustments	0	0	0	0	•
Transfers between Reserves in respect of assets transferred under absorption	0	U	0	0	0
On disposal of available for sale financial assets			0		0
Reserves eliminated on dissolution		0	0	0	0
Originating capital for Trust established in year	0				Ö
Temporary and permanent PDC received - cash	43,652				43,652
Temporary and permanent PDC repaid in year	0				0
PDC written off	0	0			0
Transfer due to change of status from Trust to Foundation	0	0	0	0	0
Other movements	0	0	0	0	0
Net actuarial gain/(loss) on pension		0		0	0
Other pensions remeasurement		0		0	0
Net recognised revenue/(expense) for the year	43,652	(6,986)	644	0	37,310
Balance at 31 March 2017	205,362	(24,979)	7,574	9,058	197,015
Balance at 1 April 2015	162,210	(13,758)	43,179	9,058	200,689
Changes in taxpayers' equity for the year ended 31	102,210	(10,750)	40,173	3,030	200,003
March 2016					
Retained surplus/(deficit) for the year		(4,254)			(4,254)
Net gain / (loss) on revaluation of property, plant,			0		0
equipment					
Net gain / (loss) on revaluation of intangible assets			0		0
Net gain / (loss) on revaluation of financial assets			0		0
Net gain / (loss) on revaluation of assets held for sale			0		0
Impairments and reversals			(36,230)		(36,230)
Other gains / (loss)		19	(19)	0	0
Transfers between reserves  Reclassification Adjustments		19	(19)	U	U
Transfers between revaluation reserve & retained		0	0		0
earnings reserve in respect of assets transferred under		Ū	· ·		Ü
On disposal of available for sale financial assets			0		0
Originating capital for Trust established in year	0				0
New PDC received - cash	0				0
PDC repaid in year	(500)				(500)
Other movements	0	0	0	0	0
Net actuarial gain/(loss) on pension				0	0
Other pension remeasurement	(E00)	(4.005)	(26.040)	0	(40.094)
Net recognised revenue/(expense) for the year	(500)	(4,235)	(36,249)	0.059	(40,984)
Balance at 31 March 2016	161,710	(17,993)	6,930	9,058	159,705

#### Information on reserves

#### 1 Public dividend capital

Public dividend capital (PDC) is a type of public sector equity finance based on the excess of assets over liabilities. Additional PDC may also be issued to NHS trusts by the Department of Health. A charge, reflecting the cost of capital utilised by the NHS foundation trust, is payable to the Department of Health as the public dividend capital dividend.

### 2 Income and expenditure reserve

The balance of this reserve is the accumulated surpluses and deficits of the NHS trust.

#### 3 Revaluation Reserve

Increases in asset values arising from revaluations are recognised in the revaluation reserve, except where, and to the extent that, they reverse impairments previously recognised in operating expenses, in which case they are recognised in operating income. Subsequent downward movements in asset valuations are charged to the revaluation reserve to the extent that a previous gain was recognised unless the downward movement represents a clear consumption of economic benefit or a reduction in service potential.

#### 4 Other reserves

The Other Reserve reflects the differences between the value of the fixed assets taken over by the Trust at inception and the corresponding figure in its originating debt

# Statement of Cash Flows for the Year ended 31 March 2017

Cash Flows from Operating Activities         2,46         2,47           Operating surpliks/deficity         6         14,015         12,946           Impairments and reversals         16         6,5161         8,398           Other gains/(losses) on foreign exchange         11         0         0           Obmated Assets received credited to revenue but non-cash         4         662         0           Release of PEriderred credit         0         0         0           Release of PEriderred credit         (1,172)         (629)           (Increase)/Decrease in Inventories         (42,773)         864           (Increase)/Decrease in Other Current Assets         0         0           Increase/Decrease in Other Current Liabilities         0         0           Provisions utilised         0         0         0           Increase/Decrease in movement in non cash provisions         84         199           Net Cash Inflow/(Outitiow) from Operating Activities         (22,510)         30.341           Increase (Decrease) in Trade and Cupiement         (56         13           Interest Received         6         6         13           Interest Received         6         6         13           Interest Received         6		NOTE	2016-17 £000s	2015-16 £000s
Depreciation and amortisation   6   14,015   12,946   10,938   1	Cash Flows from Operating Activities			
Impairments and reversals   16   (5,161)   8.390   10   10   10   10   10   10   10	Operating surplus/(deficit)		246	2,467
Orber gains/(losses) on foreign exchange         11         0         0         (527)           Covernment Granted Assets received credited to revenue but non-cash         4         (62)         (527)           Release of PFIddeferred credit         0         0         0           (Increases)/Decrease in Trade and Other Receivables         (42,773)         864           (Increases)/Decrease in Trade and Other Payables         12,463         10,277           (Increase)/Decrease in Trade and Other Payables         12,463         10,270           (Increase)/Decrease in Trade and Other Payables         9         0         0           (Increase)/Decrease in Trade and Other Payables         9         0         0         0           (Increase)/Decrease in Trade and Other Payables         9         0	Depreciation and amortisation		14,015	12,946
Donated Assets received credited to revenue but non-cash	Impairments and reversals		(5,161)	8,390
Government Granted Assets received credited to revenue but non-cash   0			-	
Release of PFI/deferred credit (Increase)   Decrease in Inventories (1,172) (629) (Increase)   Decrease in Inventories (1,172) (629) (Increase)   Decrease in Inventories (1,172) (629) (Increase)   Decrease in Other Current Assets (1,172) (1,172		4		
(Increase)/Decrease in Inventories         (1,172)         (623)           (Increase)/Decrease in Inventories         (2,773)         864           (Increase)/Decrease in Intrade and Other Payables         12,463         10,270           (Increase)/Decrease in Intrade and Other Payables         12,463         10,270           (Increase)/Decrease in Intrade and Other Payables         910         0           (Increase)/Decrease in Intrade Tournet Liabilities         0         0           Provisions utilised         (910)         (3,139)           Net Cash Inflow/(Outflow) from Operating Activities         844         199           Interest Received         66         136           (Payments) for Investing Activities         0         66           Interest Received         66         136           (Payments) for Investinents with DH         0         0           (Payments) for Other Financial Assets         0         0           (Payments) for Investments with DH         0         0           (Payments) for Investments with DH         0         0           (Payments) for Investment with DH         0         0           Proceeds of disposal of assets held for sale (PPE)         0         0           Proceeds from Disposal of Investment with DH <t< td=""><td></td><td></td><td>-</td><td></td></t<>			-	
(Increase)/Decrease in Trade and Other Receivables         (42,773)         864           (Increase)/Cecrease in Other Current Assets         0         0           (Increase)/Decrease in Other Current Liabilities         0         0           (Increase)/Decrease in Other Current Liabilities         9(10)         (3,139)           (Increase)/Decrease in Other Current Liabilities         (910)         (3,339)           (Increase)/Decrease in Other Current Liabilities         (910)         (3,384)           Provisions utilised         (910)         (3,384)           Net Cash Inflow(Outflow) from Operating Activities         (25,510)         30,841           Cash Flows from Investing Activities         66         136         (66)         136         (22,925)         (22,929)         (22,929)         (22,929)         (22,929)         (22,929)         (22,929)         (22,929)         (23,921)         (23,921)         (23,921)         (23,921)         (23,921)         (23,921) <td></td> <td></td> <td>-</td> <td></td>			-	
(Increase)/Decrease) in Other Current Assets         0         0           Increases/(Decrease) in Trade and Other Payables         12,463         10,270           (Increase)/Decrease in Other Current Liabilities         0         0           Increases/(Decrease) in increase (Increase)         (910)         (3,339)           Increases/(Decrease) in movement in non cash provisions         844         199           Net Cash Inflow/(Outflow) from Operating Activities         (22,510)         30,841           Cash Flows from Investing Activities         (66         136           Interest Received         66         136           (Payments) for Property, Plant and Equipment         0         0           (Payments) for Investments with DH         0         0           (Payments) for Interngible Assets         0         0           (Payments) for Other Financial Assets (LIFT)         0         0           Proceeds of disposal of assets held for sale (Intangible)         0         0           Proceeds from Disposal of Investment with DH         0         0           Proceeds from Disposal of Investment with DH         0         0           Proceeds from the disposal of Financial Assets (LIFT)         0         0           Loans Repaid in Respect of LIFT         0         0				, ,
Increase/ Decrease in Other Current Liabilities   12,463   10,270   (Increase)/Decrease in Other Current Liabilities   9   10   (3,139)   Increase/(Decrease) in movement in non cash provisions   844   199   (3,139)   Increase/(Decrease) in movement in non cash provisions   844   199   (3,139)   Increase/(Decrease) in movement in non cash provisions   844   199   (3,139)   Increase/(Decrease) in movement in non cash provisions   844   199   (3,139)   Increase/(Decrease) in movement in non cash provisions   844   199   (3,139)   (	,		• • •	
(Increase)/Decrease in Other Current Liabilities         0         0         0         7         0         (910)         (3,139)         Increases/(Decrease) in movement in non cash provisions         844         199         Net Cash Inflow/(Outflow) from Operating Activities         (22,510)         30,841         198         Net Cash Inflow/(Outflow) from Operating Activities         (25,510)         30,841         28,841         199         Activities         198         (26,325)         (26,325)         (26,925)         (26,925)         (26,925)         (26,925)         (26,925)         (26,925)         (26,925)         (26,925)         (26,925)         (26,925)         (26,925)         (26,925)         (26,925)         (26,925)         (26,925)         (27,925)         (26,925)         (27,925)         (26,925)         (26,925)         (27,925)         (26,925)         (27,925)         (27,925)         (26,925)         (27,925)	,		-	_
Provisions utilised   (910)	· · · · · · · · · · · · · · · · · · ·		· · · · · · · · · · · · · · · · · · ·	
Increase/(Decrease) in movement in non cash provisions   244   199   30,841   30,8			-	
Net Cash Inflow/(Outflow) from Operating Activities         (22,510)         30,841           Cash Flows from Investing Activities         136         66         136           Interest Received         66         136         136           (Payments) for Property, Plant and Equipment         (16,718)         (22,925)           (Payments) for Intangible Assets         0         (53)           (Payments) for Intancial Assets         0         0           (Payments) for Financial Assets (LIFT)         0         0           Proceeds of disposal of assets held for sale (Intangible)         0         0           Proceeds of disposal of assets held for sale (Intangible)         0         0           Proceeds from Disposal of Investment with DH         0         0           Proceeds from Disposal of Investment with DH         0         0           Proceeds from Disposal of LIFT         0         0           Loans Radei in Respect of LIFT         0         0           Loans Repaid in Respect of LIFT         0         0           Loans Repaid in Respect of UFF         0         0           Net Cash Inform / (outflow) before Financing         (39,162)         2,792           Net Cash Inform / (outflow) before Financing         (39,362)         0			, ,	* *
Cash Flows from Investing Activities   Interest Received   166   136   136   (Payments) for Property, Plant and Equipment   (16,718)   (22,925)   (22,925)   (22,925)   (23,92				
Interest Received	net dash fillow/(outflow) from operating Activities		(22,310)	30,041
(Payments) for Property, Plant and Equipment (Payments) for Intangible Assets (Payments) for Intengible Assets (Payments) for Investments with DH (Payments) for Investments with DH (Payments) for Cither Financial Assets (LIFT) (Payments) for Financial Assets (LIFT) (Proceeds of disposal of assets held for sale (Intangible) (Payments) for Disposal of Investment with DH (Proceeds from Disposal of Financial Assets (LIFT) (Proceeds from Disposal Assets (LIFT) (LIFT) (LIFT) (LIFT) (LIFT) (LIFT) (LIFT) (LIFT) (LI			66	136
(Payments) for Intangible Assets         0         (53)           (Payments) for Other Financial Assets         0         0           (Payments) for Other Financial Assets         0         0           (Payments) for Financial Assets (LIFT)         0         50           Proceeds of disposal of assets held for sale (Intangible)         0         0           Proceeds from Disposal of Investment with DH         0         0         0           Proceeds from Disposal of Other Financial Assets         0         0         0           Proceeds from Disposal of Other Financial Assets         0         0         0           Proceeds from Disposal of Financial Assets (LIFT)         0         0         0           Loans Repaid in Respect of LIFT         0         0         0           Loans Repaid in Respect of LIFT         0         0         0           Loans Repaid in Respect of LIFT         0         0         0           Net Cash Inflow/(Outflow) from Investing Activities         (16,652)         (22,792)           Net Cash Inform / (outflow) before Financing         (39,162)         8,049           Cash Flows from Financing Activities         0         0         (500)           Gross Temporary and Permanent PDC Received         43,652         0				
(Payments) for Investments with DH         0         0           (Payments) for Other Financial Assets         0         0           (Payments) for Financial Assets         0         0           (Payments) for Financial Assets (LIFT)         0         50           Proceeds of disposal of assets held for sale (Intangible)         0         0           Proceeds from Disposal of Investment with DH         0         0           Proceeds from Disposal of Other Financial Assets         0         0           Proceeds from the disposal of Financial Assets (LIFT)         0         0           Loans Made in Respect of LIFT         0         0           Loans Repaid in Respect of LIFT         0         0           Loans Repaid in Respect of LIFT         0         0           Loans Inflow(Outflow) from Investing Activities         (16,652)         (22,792)           Net Cash Inflow(Outflow) before Financing         (39,162)         8,049           Cash Flows from Financing Activities         (16,652)         (22,792)           Net Cash Inflow (Outflow) before Financing         (39,162)         8,049           Cash Flows from Financing Activities         (16,652)         (22,792)           Net Cash Inflow (Fourth of Permanent PDC Received         43,652         0			• • •	
(Payments) for Other Financial Assets (LIFT)     0     0       (Payments) for Financial Assets (LIFT)     0     0       Proceeds of disposal of assets held for sale (Intangible)     0     0       Proceeds from Disposal of Investment with DH     0     0       Proceeds from Disposal of Other Financial Assets     0     0       Proceeds from the disposal of Financial Assets (LIFT)     0     0       Loans Made in Respect of LIFT     0     0       Loans Repaid in Respect of LIFT     0     0       Loans Repaid in Respect of LIFT     0     0       Net Cash Inflow/(Outflow) from Investing Activities     (16,652)     (22,792)       Net Cash Inform / (outflow) before Financing     3,162)     8,049       Cash Flows from Financing Activities     (16,652)     (22,792)       Gross Temporary and Permanent PDC Received     43,652     0       Gross Temporary and Permanent PDC Received     43,652     0       Gross Temporary and Permanent PDC Repaid     0     0       Loans received from DH - New Capital Investment Loans     0     0       Loans repaid to DH - Working Capital Loans/Revenue Support Loans     0     0       Cash transferred to NHS Foundation Trusts or on dissolution     0     0       Cash transferred to NHS Foundation Trusts or on dissolution     0     0			-	
(Payments) for Financial Assets (LIFT)         0         0           Proceeds of disposal of assets held for sale (Intangible)         0         50           Proceeds of disposal of assets held for sale (Intangible)         0         0           Proceeds from Disposal of Investment with DH         0         0           Proceeds from Disposal of Other Financial Assets         0         0           Proceeds from the disposal of Financial Assets         0         0           Loans Made in Respect of LIFT         0         0           Loans Repaid in Respect of LIFT         0         0           Loans Repaid in Respect of LIFT         0         0           Rental Revenue         0         0           Net Cash Inflow/(Outflow) from Investing Activities         (16,652)         (22,792)           Net Cash Inform / (outflow) before Financing         (39,162)         8,049           Cash Flows from Financing Activities         (16,652)         (22,792)           Net Cash Inform / (outflow) before Financing         (39,162)         8,049           Cash Flows from Financing Activities         (16,652)         (22,792)           Net Cash Inform / (outflow) before Financing         (39,162)         0           Gross Temporary and Permanent PDC Repaid         0         (50      <				
Proceeds of disposal of assets held for sale (PPE)         0         50           Proceeds of disposal of assets held for sale (Intangible)         0         0           Proceeds from Disposal of Investment with DH         0         0           Proceeds from Disposal of Other Financial Assets         0         0           Proceeds from the disposal of Financial Assets (LIFT)         0         0           Loans Made in Respect of LIFT         0         0           Loans Repaid in Respect of LIFT         0         0           Rettal Revenue         0         0           Net Cash Inflow/(Outflow) from Investing Activities         (16,652)         (22,792)           Net Cash Inform / (outflow) before Financing         (39,162)         8,049           Cash Flows from Financing Activities         (16,652)         0         6           Gross Temporary and Permanent PDC Received         43,652         0         0           Gross Temporary and Permanent PDC Received         43,652         0         0           Loans received from DH - New Capital Investment Loans         0         0         0           Loans received from DH - New Revenue Support Loans         0         0         0           Cother Loans Received         0         0         0           C			0	
Proceeds from Disposal of Investment with DH Proceeds from Disposal of Other Financial Assets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0			0	50
Proceeds from Disposal of Other Financial Assets Proceeds from the disposal of Financial Assets (LIFT) O Coans Made in Respect of LIFT O Rental Revenue Respect of LIFT O Rental Revenue Ret Cash Inflow/(Outflow) from Investing Activities  Cash Flows from Financing Activities  Cash Flows from Financing Activities  Cross Temporary and Permanent PDC Received Asset Temporary And Permanent PDC Positivities And Permanent PDC Positivities And Cash Legility Alexenter Positivities Asset Temporary And Permanent PDC Positivities And Cash Legility Alexenter Positivities Positivities Asset Temporary And Permanent PDC Positivities Period Asset Temporary And Permanent PDC Positivities Period Asset Temporary And Permanent PDC Positivities Period Asset Temporary And Permanent PDC Positivities Positivities Positivities Positivities Positivities Positivities Positivities P	Proceeds of disposal of assets held for sale (Intangible)		0	0
Proceeds from the disposal of Financial Assets (LIFT) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Proceeds from Disposal of Investment with DH		0	0
Loans Made in Respect of LIFT Loans Repaid in Respect of LIFT Rental Revenue Rota Repaid in Respect of LIFT Rental Revenue Rotash Inflow/(Outflow) from Investing Activities (16,652) Ret Cash Inflow/(Outflow) before Financing (39,162) Ret Cash Inflom/ (outflow) before Financing Rorss Temporary and Permanent PDC Received Rorss Temporary and Permanent PDC Repaid Rorss Temporary and Permanent PDC Received Rorss Temporary and Permanent PDC Repaid Rorss Temporary and Permanent PDC Roporary and Perm	Proceeds from Disposal of Other Financial Assets		0	0
Loans Repaid in Respect of LIFT 0 0 0 Rental Revenue 0 0 0 Net Cash Inflow/(Outflow) from Investing Activities (16,652) (22,792)  Net Cash Inform / (outflow) before Financing (39,162) 8,049  Cash Flows from Financing Activities Gross Temporary and Permanent PDC Received 43,652 0 Gross Temporary and Permanent PDC Repaid 0 (500) Loans received from DH - New Capital Investment Loans 0 0 0 Coans received from DH - New Revenue Support Loans 0 0 0 Other Loans Received 0 0 0 0 Loans repaid to DH - Capital Investment Loans Repayment of Principal 0 0 (1,000) Loans repaid to DH - Capital Investment Loans Repayment of Principal 0 0 0 Cash transferred to NHS Foundation Trusts or on dissolution 0 0 0 Cash transferred to NHS Foundation Trusts or on dissolution 0 0 0 Capital Element of Payments in Respect of Finance Leases and On-SoFP PFI and LIFT (84) (2,145) LIFT (84) (2,145) LIFT (84) (2,145) PDC Dividend (paid)/refunded (5,655) (4,607) Capital grants and other capital receipts (excluding donated / government granted cash receipts) 0 0 Net Cash Inflow/(Outflow) from Financing Activities 35,768 (9,135) NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS (3,394) (1,086)  Effect of exchange rate changes in the balance of cash held in foreign currencies 0 0	Proceeds from the disposal of Financial Assets (LIFT)		0	0
Rental Revenue 0 0 0 Net Cash Inflow/(Outflow) from Investing Activities (16,652) (22,792)  Net Cash Inform / (outflow) before Financing (39,162) 8,049  Cash Flows from Financing Activities  Gross Temporary and Permanent PDC Received 43,652 0 Gross Temporary and Permanent PDC Repaid 0 0 (500) Loans received from DH - New Capital Investment Loans 0 0 0 Other Loans Received 10 0 0 0 Other Loans Received 10 0 0 0 Loans repaid to DH - Capital Investment Loans Repayment of Principal 0 0 (1,000) Loans repaid to DH - Working Capital Loans/Revenue Support Loans 0 0 0 Other Loans Repaid 0 0 0 0 0 Cash transferred to NHS Foundation Trusts or on dissolution 0 0 0 Capital Element of Payments in Respect of Finance Leases and On-SoFP PFI and LIFT (84) (2,145) (2,011) PDC Dividend (paid)/refunded (5,655) (4,607) Capital grants and other capital receipts (excluding donated / government granted cash receipts) 0 0 Net Cash Inflow/(Outflow) from Financing Activities 33,768 (9,135) NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS (3,394) (1,086)  Effect of exchange rate changes in the balance of cash held in foreign currencies 0 0 0	Loans Made in Respect of LIFT		0	0
Net Cash Inflow/(Outflow) from Investing Activities       (16,652)       (22,792)         Net Cash Inform / (outflow) before Financing       (39,162)       8,049         Cash Flows from Financing Activities       8         Gross Temporary and Permanent PDC Received       43,652       0         Gross Temporary and Permanent PDC Repaid       0       (500)         Loans received from DH - New Capital Investment Loans       0       0         Loans received from DH - New Revenue Support Loans       0       0         Other Loans Received       0       0         Loans repaid to DH - Capital Investment Loans Repayment of Principal       0       0         Loans repaid to DH - Working Capital Loans/Revenue Support Loans       0       0         Other Loans Repaid       0       0       0         Capital Element of Payments in Respect of Finance Leases and On-SoFP PFI and LIFT       (84)       (1,017)         Interest paid       (2,145)       (2,011)       (2,011)         PDC Dividend (paid)/refunded       (5,655)       (4,607)         Capital grants and other capital receipts (excluding donated / government granted cash receipts)       0       0         Net Cash Inflow/(Outflow) from Financing Activities       35,768       (9,135)         Net INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS <td>Loans Repaid in Respect of LIFT</td> <td></td> <td>0</td> <td>0</td>	Loans Repaid in Respect of LIFT		0	0
Net Cash Inform / (outflow) before Financing(39,162)8,049Cash Flows from Financing Activities8,049Gross Temporary and Permanent PDC Received43,6520Gross Temporary and Permanent PDC Repaid0(500)Loans received from DH - New Capital Investment Loans00Loans received from DH - New Revenue Support Loans00Other Loans Received00Loans repaid to DH - Capital Investment Loans Repayment of Principal0(1,000)Loans repaid to DH - Working Capital Loans/Revenue Support Loans00Other Loans Repaid00Cash transferred to NHS Foundation Trusts or on dissolution00Capital Element of Payments in Respect of Finance Leases and On-SoFP PFI and LIFT(84)(1,017)Interest paid(2,145)(2,011)PDC Dividend (paid)/refunded(5,655)(4,607)Capital grants and other capital receipts (excluding donated / government granted cash receipts)00Net Cash Inflow/(Outflow) from Financing Activities35,768(9,135)NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS(3,394)(1,086)Cash and Cash Equivalents (and Bank Overdraft) at Beginning of the Period27,29628,382Effect of exchange rate changes in the balance of cash held in foreign currencies00	Rental Revenue		0	0
Cash Flows from Financing Activities Gross Temporary and Permanent PDC Received 43,652 0 Gross Temporary and Permanent PDC Repaid 0 (500) Loans received from DH - New Capital Investment Loans 0 0 Coans received from DH - New Revenue Support Loans 0 0 Cother Loans Received 0 0 0 Coans repaid to DH - Capital Investment Loans Repayment of Principal 0 (1,000) Loans repaid to DH - Working Capital Loans/Revenue Support Loans 0 0 Cother Loans Repaid 0 0 0 Cother Loans Repaid 0 0 0 Cash transferred to NHS Foundation Trusts or on dissolution 0 0 Capital Element of Payments in Respect of Finance Leases and On-SoFP PFI and LIFT (84) (1,017) Interest paid (2,145) (2,011) PDC Dividend (paid)/refunded (5,655) (4,607) Capital grants and other capital receipts (excluding donated / government granted cash receipts) Net Cash Inflow/(Outflow) from Financing Activities 35,768 (9,135)  NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS (3,394) (1,086)  Effect of exchange rate changes in the balance of cash held in foreign currencies 0 0	Net Cash Inflow/(Outflow) from Investing Activities		(16,652)	(22,792)
Gross Temporary and Permanent PDC Received Gross Temporary and Permanent PDC Repaid Const Temporary and Permanent PDC Received Const Temporary and Permanent PDC Received Const Temporary and Permanent PDC Repaid Const Temporary and Permanent PDC Const Temporary and Const Te	Net Cash Inform / (outflow) before Financing		(39,162)	8,049
Gross Temporary and Permanent PDC Received Gross Temporary and Permanent PDC Repaid Const Temporary and Permanent PDC Received Const Temporary and Permanent PDC Received Const Temporary and Permanent PDC Repaid Const Temporary and Permanent PDC Const Temporary and Const Te	Cash Flows from Financing Activities			
Loans received from DH - New Capital Investment Loans  Loans received from DH - New Revenue Support Loans  Other Loans Received  Loans repaid to DH - Capital Investment Loans Repayment of Principal  Loans repaid to DH - Capital Investment Loans Repayment of Principal  Loans repaid to DH - Working Capital Loans/Revenue Support Loans  Other Loans Repaid  Other Loans Repaid  Cash transferred to NHS Foundation Trusts or on dissolution  Capital Element of Payments in Respect of Finance Leases and On-SoFP PFI and  LIFT  (84)  (1,017)  Interest paid  Capital grants and other capital receipts (excluding donated / government granted cash receipts)  Net Cash Inflow/(Outflow) from Financing Activities  NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS  Cash and Cash Equivalents (and Bank Overdraft) at Beginning of the Period  Effect of exchange rate changes in the balance of cash held in foreign currencies  0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	<del>-</del>		43,652	0
Loans received from DH - New Revenue Support Loans Other Loans Received Loans Received Loans Repaid to DH - Capital Investment Loans Repayment of Principal Other Loans Repaid to DH - Working Capital Loans/Revenue Support Loans Other Loans Repaid Other Loans Repayment of Principal Other Loans Repaid Other Loans Repaid Other Loans Repayment of Principal Other Loans Repaid Other Loans Other Loans Repaid Other Loans Other Loans Other Loans Repaid Other Loans Ot	Gross Temporary and Permanent PDC Repaid		0	(500)
Other Loans Received  Loans repaid to DH - Capital Investment Loans Repayment of Principal  Loans repaid to DH - Working Capital Loans/Revenue Support Loans  Other Loans Repaid  Other Lo	Loans received from DH - New Capital Investment Loans		0	0
Loans repaid to DH - Capital Investment Loans Repayment of Principal  Loans repaid to DH - Working Capital Loans/Revenue Support Loans  Other Loans Repaid  Cash transferred to NHS Foundation Trusts or on dissolution  Capital Element of Payments in Respect of Finance Leases and On-SoFP PFI and LIFT  Interest paid  PDC Dividend (paid)/refunded  (apid)/refunded  (	Loans received from DH - New Revenue Support Loans		0	0
Loans repaid to DH - Working Capital Loans/Revenue Support Loans  Other Loans Repaid  Other Loans Repaid  Cash transferred to NHS Foundation Trusts or on dissolution  Capital Element of Payments in Respect of Finance Leases and On-SoFP PFI and LIFT  (R4)  (I,017)  Interest paid  (PDC Dividend (paid)/refunded  (Capital grants and other capital receipts (excluding donated / government granted cash receipts)  Net Cash Inflow/(Outflow) from Financing Activities  NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS  Cash and Cash Equivalents (and Bank Overdraft) at Beginning of the Period  Effect of exchange rate changes in the balance of cash held in foreign currencies  0  0  0  0  0  0  0  0  0  0  0  0  0	Other Loans Received		0	0
Other Loans Repaid 0 0 0 Cash transferred to NHS Foundation Trusts or on dissolution 0 0 Capital Element of Payments in Respect of Finance Leases and On-SoFP PFI and LIFT (84) (1,017) Interest paid (2,145) (2,011) PDC Dividend (paid)/refunded (5,655) (4,607) Capital grants and other capital receipts (excluding donated / government granted cash receipts) 0 0 Net Cash Inflow/(Outflow) from Financing Activities 35,768 (9,135)  NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS (3,394) (1,086)  Cash and Cash Equivalents (and Bank Overdraft) at Beginning of the Period 27,296 28,382  Effect of exchange rate changes in the balance of cash held in foreign currencies 0 0	Loans repaid to DH - Capital Investment Loans Repayment of Principal			(1,000)
Cash transferred to NHS Foundation Trusts or on dissolution Capital Element of Payments in Respect of Finance Leases and On-SoFP PFI and LIFT Interest paid PDC Dividend (paid)/refunded Capital grants and other capital receipts (excluding donated / government granted cash receipts) Net Cash Inflow/(Outflow) from Financing Activities NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS  Cash and Cash Equivalents (and Bank Overdraft) at Beginning of the Period  27,296 28,382 Effect of exchange rate changes in the balance of cash held in foreign currencies 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0			-	
Capital Element of Payments in Respect of Finance Leases and On-SoFP PFI and LIFT (84) (1,017) Interest paid (2,145) (2,011) PDC Dividend (paid)/refunded (5,655) (4,607) Capital grants and other capital receipts (excluding donated / government granted cash receipts) Net Cash Inflow/(Outflow) from Financing Activities (9,135) NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS (3,394) (1,086)  Cash and Cash Equivalents (and Bank Overdraft) at Beginning of the Period 27,296 28,382  Effect of exchange rate changes in the balance of cash held in foreign currencies 0 0	•		-	
LIFT Interest paid Interest pa			0	0
Interest paid  PDC Dividend (paid)/refunded  Capital grants and other capital receipts (excluding donated / government granted cash receipts)  Net Cash Inflow/(Outflow) from Financing Activities  NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS  Cash and Cash Equivalents (and Bank Overdraft) at Beginning of the Period  27,296  28,382  Effect of exchange rate changes in the balance of cash held in foreign currencies  0 0 0 0 2,394)  28,382	·		(0.4)	(1.017)
PDC Dividend (paid)/refunded (5,655) (4,607)  Capital grants and other capital receipts (excluding donated / government granted cash receipts) 0 0  Net Cash Inflow/(Outflow) from Financing Activities 35,768 (9,135)  NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS (3,394) (1,086)  Cash and Cash Equivalents (and Bank Overdraft) at Beginning of the Period 27,296 28,382  Effect of exchange rate changes in the balance of cash held in foreign currencies 0 0			. ,	
Capital grants and other capital receipts (excluding donated / government granted cash receipts)  Net Cash Inflow/(Outflow) from Financing Activities  NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS  Cash and Cash Equivalents (and Bank Overdraft) at Beginning of the Period  27,296  28,382  Effect of exchange rate changes in the balance of cash held in foreign currencies  0 0	•		. , ,	
cash receipts)  Net Cash Inflow/(Outflow) from Financing Activities  NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS  Cash and Cash Equivalents (and Bank Overdraft) at Beginning of the Period  27,296  28,382  Effect of exchange rate changes in the balance of cash held in foreign currencies  0 0			(3,033)	(4,007)
Net Cash Inflow/(Outflow) from Financing Activities       35,768       (9,135)         NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS       (3,394)       (1,086)         Cash and Cash Equivalents (and Bank Overdraft) at Beginning of the Period       27,296       28,382         Effect of exchange rate changes in the balance of cash held in foreign currencies       0       0			0	0
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS  (3,394) (1,086)  Cash and Cash Equivalents (and Bank Overdraft) at Beginning of the Period 27,296 28,382  Effect of exchange rate changes in the balance of cash held in foreign currencies 0 0	• /		35.768	(9.135)
Cash and Cash Equivalents (and Bank Overdraft) at Beginning of the Period 27,296 28,382  Effect of exchange rate changes in the balance of cash held in foreign currencies 0 0	, ,		(3.394)	
Effect of exchange rate changes in the balance of cash held in foreign currencies0			(0,00.)	(.,000)
	Cash and Cash Equivalents (and Bank Overdraft) at Beginning of the Period		27,296	28,382
	Effect of exchange rate changes in the balance of cash held in foreign currencies		n	n
		20	23,902	

#### 1. Accounting Policies

The Secretary of State for Health has directed that the financial statements of NHS trusts shall meet the accounting requirements of the Department of Health Group Manual for Accounts, which shall be agreed with HM Treasury. Consequently, the following financial statements have been prepared in accordance with the DH Group Manual for Accounts 2016-17 issued by the Department of Health. The accounting policies contained in that manual follow International Financial Reporting Standards to the extent that they are meaningful and appropriate to the NHS, as determined by HM Treasury, which is advised by the Financial Reporting Advisory Board. Where the Manual for Accounts permits a choice of accounting policy, the accounting policy which is judged to be most appropriate to the particular circumstances of the trust for the purpose of giving a true and fair view has been selected. The particular policies adopted by the trust are described below. They have been applied consistently in dealing with items considered material in relation to the accounts.

#### 1.1 Accounting convention

These accounts have been prepared under the historical cost convention modified to account for the revaluation of property, plant and equipment, intangible assets, inventories and certain financial assets and financial liabilities.

#### Going Concern

These accounts have been prepared on a going concern basis

NHS organisations are required to produce financial statements in line with International Accounting & Financial Reporting Standards. The NHS also has the benefit of additional guidance in the group accounting manual (GAM). The impact of this is that Trusts should prepare financial statements on a going concern basis unless management concludes that the entity is not a going concern. IAS 1 requires this conclusion to be based on a management assessment of an entity's ability to continue as a going concern.

### **Management Assessment of Going Concern**

In line with financial forecasts SWBH Trust has reported a deficit position for 2016/17 which, following the underlying deficit generated in 2015/16, is expected to result in a shortage of internally generated cash in 2017/18. The underlying deficit for 2016/17 is £25.8m which is carried forward into 2017/18

SWBH Trust has developed two year financial plans that address the current underlying deficit and secure underlying break even over that period. These recognise a delay in recovery and consequent short-term cash requirements and, through DH loan, secure liquidity in the short and medium term. This financing facility also implicitly recognises and addresses the risk of further delay to financial recovery and the sensitivity of the liquidity position to the assumptions about financial recovery.

The Black Country Sustainability and Transformation Plan involves SWBH Trust as a partner. The Trust's existing contribution to the health economy is recognised and appears to remain an integral component over the course of the planning cycle.

The Trust's Commissioners' intentions indicate that SWBH Trust services are required to deliver the CCG's plans for serving the needs of the local population.

Based on this evidence it is clear that SWBH Trust has financial plans which address the liquidity risks and secure the Trust's ability to make good liabilities as they fall due. In addition published documents indicate a requirement for the services currently provided by the Trust. SWBH Trust meets the criteria to be considered a going concern and the financial statements for the period 2016/17 have been prepared on that begin

## 1.2 Acquisitions and discontinued operations

Activities are considered to be 'acquired' only if they are taken on from outside the public sector. Activities are considered to be 'discontinued' only if they cease entirely. They are not considered to be 'discontinued' if they transfer from one public sector body to another.

## 1.3 Movement of assets within the DH Group

"Transfers as part of reorganisation fall to be accounted for by use of absorption accounting in line with the Treasury FReM. The FReM does not require retrospective adoption, so prior year transactions (which have been accounted for under merger accounting) have not been restated. Absorption accounting requires that entities account for their transactions in the period in which they took place, with no restatement of performance required when functions transfer within the public sector. Where assets and liabilities transfer, the gain or loss resulting is recognised in the SOCI, and is disclosed separately from operating costs.

Other transfers of assets and liabilities within the Group are accounted for in line with IAS 20 and similarly give rise to income and expenditure entries."

### 1.4 Charitable Funds

Under the provisions of IAS 27 Consolidated and Separate Financial Statements, those Charitable Funds that fall under common control with NHS bodies are consolidated within the entity's financial statements. In accordance with IAS 1 Presentation of Financial Statements, restated prior period accounts are presented where the adoption of the new policy has a material impact. The Board of Sandwell and West Birmingham Hospitals NHS Trust acts as a corporate Trustee for the Charitable Funds, however it has confirmed that the Charitable Funds are not material to the Trust accounts and has therefore not consolidated.

## Notes to the Accounts - 1. Accounting Policies (Continued)

### 1.5 Critical accounting judgements and key sources of estimation uncertainty

In the application of the NHS trust's accounting policies, management is required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from those estimates and the estimates and underlying assumptions are continually reviewed. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

### 1.5.1 Critical judgements in applying accounting policies

The following are the critical judgements, apart from those involving estimations (see below) that management has made in the process of applying the NHS trust's accounting policies and that have the most significant effect on the amounts recognised in the financial statements.

#### Charitable Funds

Following Treasury's agreement to apply IAS 27 to NHS Charities from 1 April 2013, the Trust has established that as it is the corporate trustee of the Sandwell and West Birmingham Hospitals NHS Trust Charities, charity number 1056127, it effectively has the power to exercise control so as to obtain economic benefits.

Total donations received during 2016 / 2017 were £1.2m and total resources expended were £2.1m which represent 0.27% of the Trust's Exchequer Funds.

IAS 1, Presentation of Financial Statements, says that specific disclosure requirements set out in individual standards or interpretations need not be satisfied if the information is not material and this guidance is reiterated in the Department of Health Group Accounting Manual for 2016 17

Thus, In line with IAS 1, charitable funds are not consolidated into Sandwell and West Birmingham Hospitals NHS Trust's accounts on grounds of materiality.

#### PFI Asset Valuation

From 1st April 2015, the Trust has accounted for the Valuation of its PFI Hospital (BTC) on the basis of Depreciated Replacement Cost excluding VAT.

#### Managed Equipment Scheme

On 1/05/16 the trust entered into a Managed Service Contract for the provision and maintenance of imaging equipment. The contract is for a period of 10 years with an option to extend for a further 2 years. The estimated value of the contract is £30m and anticipated capital value of equipment to be provided under the contract is £18m. The accounting treatment for the scheme was determined to be considered as an IFRIC12 Service concession and included within 'on SOFP' PFI schemes included in Note 27.

## 1.5.2 Key sources of estimation uncertainty

### **Property Valuation**

Assets relating to land and buildings were subject to a formal valuation at 1st April 2015, completed on an 'alternate MEA' basis. An Existing Use Value alternative MEA approach was used which assumes the asset would be replaced with a modern equivalent, i.e. not a building of identical design - but with the same service potential as the existing assets. The alternative modern equivalent asset may well be smaller (reduced Gross Internal Area) than the existing asset which reflects the challenges Healthcare Providers face when utilising historical NHS Estate. A subsequent annual valuation is performed at 31st March to ensure a true and fair view was reflected.

## Notes to the Accounts - 1. Accounting Policies (Continued)

#### 1.6 Revenue

Revenue in respect of services provided is recognised when, and to the extent that, performance occurs, and is measured at the fair value of the consideration receivable. The main source of revenue for the trust is from commissioners for healthcare services. Revenue relating to patient care spells that are part-completed at the year end are apportioned across the financial years on the basis of costs incurred to date compared to total expected costs.

Where income is received for a specific activity that is to be delivered in the following year, that income is deferred.

The NHS trust receives income under the NHS Injury Cost Recovery Scheme, designed to reclaim the cost of treating injured individuals to whom personal injury compensation has subsequently been paid e.g. by an insurer. The NHS trust recognises the income when it receives notification from the Department of Work and Pension's Compensation Recovery Unit that the individual has lodged a compensation claim. The income is measured at the agreed tariff for the treatments provided to the injured individual, less a provision for unsuccessful compensation claims and doubtful debts.

#### 1.7 Employee Benefits

### Short-term employee benefits

Salaries, wages and employment-related payments are recognised in the period in which the service is received from employees\*. The cost of leave earned but not taken by employees at the end of the period is recognised in the financial statements to the extent that employees are permitted to carry forward leave into the following period.

#### Retirement benefit costs

Past and present employees are covered by the provisions of the NHS Pension Schemes. These schemes are unfunded, defined benefit schemes that cover NHS employers, General Practices and other bodies, allowed under the direction of the Secretary of State in England and Wales. The schemes are not designed to be run in a way that would enable NHS bodies to identify their share of the underlying scheme assets and liabilities. Therefore, the schemes are accounted for as though they were defined contribution schemes: the cost to the NHS body of participating in a scheme is taken as equal to the contributions payable to the scheme for the accounting period.

For early retirements other than those due to ill health the additional pension liabilities are not funded by the scheme. The full amount of the liability for the additional costs is charged to expenditure at the time the NHS trust commits itself to the retirement, regardless of the method of payment.

#### 1.8 Other expenses

Other operating expenses are recognised when, and to the extent that, the goods or services have been received. They are measured at the fair value of the consideration payable.

### 1.9 Property, plant and equipment

### Recognition

Property, plant and equipment is capitalised if:

- $\bullet$  it is held for use in delivering services or for administrative purposes;
- it is probable that future economic benefits will flow to, or service potential will be supplied to the NHS trust;
- it is expected to be used for more than one financial year;
- the cost of the item can be measured reliably; and either
- the item cost at least £5,000; or
- Collectively, a number of items have a total cost of at least £5,000 and individually have a cost of more than £250, where the assets are functionally interdependent, they had broadly simultaneous purchase dates, are anticipated to have simultaneous disposal dates and are under single managerial control.

Where a large asset, for example a building, includes a number of components with significantly different asset lives, the components are treated as separate assets and depreciated over their own useful economic lives.

#### Notes to the Accounts - 1. Accounting Policies (Continued)

#### Valuation

All property, plant and equipment are measured initially at cost, representing the cost directly attributable to acquiring or constructing the asset and bringing it to the location and condition necessary for it to be capable of operating in the manner intended by management. Assets that are held for their service potential and are in use are measured subsequently at their current value in existing use. Assets that were most recently held for their service potential but are surplus are measured at fair value where there are no restrictions preventing access to the market at the reporting date.

Revaluations of property, plant and equipment are performed with sufficient regularity to ensure that carrying amounts are not materially different from those that would be determined at the end of the reporting period. Current values in existing use are determined as follows:

- Land and non-specialised buildings market value for existing use.
- Specialised buildings depreciated replacement cost, modern equivalent asset basis.

HM Treasury has adopted a standard approach to depreciated replacement cost valuations based on modern equivalent assets and, where it would meet the location requirements of the service being provided, an alternative site can be valued.

Properties in the course of construction for service or administration purposes are carried at cost, less any impairment loss. Cost includes professional fees and, where capitalised in accordance with IAS 23, borrowing costs. Assets are revalued and depreciation commences when they are brought into use.

IT equipment, transport equipment, furniture and fittings, and plant and machinery that are held for operational use are valued at depreciated historic cost where these assets have short useful economic lives or low values or both, as this is not considered to be materially different from current value in existing use.

An increase arising on revaluation is taken to the revaluation reserve except when it reverses an impairment for the same asset previously recognised in expenditure, in which case it is credited to expenditure to the extent of the decrease previously charged there. A revaluation decrease that does not result from a loss of economic value or service potential is recognised as an impairment charged to the revaluation reserve to the extent that there is a balance on the reserve for the asset and, thereafter, to expenditure. Impairment losses that arise from a clear consumption of economic benefit should be taken to expenditure. Gains and losses recognised in the revaluation reserve are reported as other comprehensive income in the Statement of Comprehensive Income.

#### Subsequent expenditure

Where subsequent expenditure enhances an asset beyond its original specification, the directly attributable cost is capitalised. Where subsequent expenditure restores the asset to its original specification, the expenditure is capitalised and any existing carrying value of the item replaced is written-out and charged to operating expenses.

### 1.10 Intangible assets

### Recognition

Intangible assets are non-monetary assets without physical substance, which are capable of sale separately from the rest of the trust's business or which arise from contractual or other legal rights. They are recognised only when it is probable that future economic benefits will flow to, or service potential be provided to, the trust; where the cost of the asset can be measured reliably, and where the cost is at least £5000.

Intangible assets acquired separately are initially recognised at cost. Software that is integral to the operation of hardware, for example an operating system, is capitalised as part of the relevant item of property, plant and equipment. Software that is not integral to the operation of hardware, for example application software, is capitalised as an intangible asset. Expenditure on research is not capitalised: it is recognised as an operating expense in the period in which it is incurred. Internally-generated assets are recognised if, and only if, all of the following have been demonstrated:

- the technical feasibility of completing the intangible asset so that it will be available for use;
- the intention to complete the intangible asset and use it;
- the ability to sell or use the intangible asset;
- how the intangible asset will generate probable future economic benefits or service potential
- the availability of adequate technical, financial and other resources to complete the intangible asset and sell or use it; and
- the ability to measure reliably the expenditure attributable to the intangible asset during its development

### Measurement

The amount initially recognised for internally-generated intangible assets is the sum of the expenditure incurred from the date when the criteria above are initially met. Where no internally-generated intangible asset can be recognised, the expenditure is recognised in the period in which it is incurred.

Following initial recognition, intangible assets are carried at current value in existing use by reference to an active market, or, where no active market exists, at the lower of amortised replacement cost (modern equivalent assets basis) and value in use where the asset is income generating. Internally-developed software is held at historic cost to reflect the opposing effects of increases in development costs and technological advances.

Notes to the Accounts - 1. Accounting Policies (Continued)

#### 1.11 Depreciation, amortisation and impairments

Freehold land, assets under construction or development, and assets held for sale are not depreciated/amortised.

Otherwise, depreciation or amortisation is charged to write off the costs or valuation of property, plant and equipment and intangible noncurrent assets, less any residual value, on a straight line basis over their estimated useful lives. The estimated useful life of an asset is the period over which the NHS trust expects to obtain economic benefits or service potential from the asset. This is specific to the NHS trust and may be shorter than the physical life of the asset itself. Estimated useful lives and residual values are reviewed each year end, with the effect of any changes recognised on a prospective basis. Assets held under finance leases are depreciated over the shorter of the lease term and the estimated useful lives.

At each financial year-end, the NHS trust checks whether there is any indication that its property, plant and equipment or intangible noncurrent assets have suffered an impairment loss. If there is indication of such an impairment, the recoverable amount of the asset is estimated to determine whether there has been a loss and, if so, its amount. Intangible assets not yet available for use are tested for impairment annually at the financial year end.

A revaluation decrease that does not result from a loss of economic value or service potential is recognised as an impairment charged to the revaluation reserve to the extent that there is a balance on the reserve for the asset and, thereafter, to expenditure. Impairment losses that arise from a clear consumption of economic benefit are taken to expenditure. Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of the recoverable amount but capped at the amount that would have been determined had there been no initial impairment loss. The reversal of the impairment loss is credited to expenditure to the extent of the decrease previously charged there and thereafter to the revaluation reserve.

#### 1.12 Donated assets

Donated non-current assets are capitalised at current value in existing use, if they will be held for their service potential, or otherwise at value on receipt, with a matching credit to income. They are valued, depreciated and impaired as described above for purchased assets. Gains and losses on revaluations, impairments and sales are treated in the same way as for purchased assets. Deferred income is recognised only where conditions attached to the donation preclude immediate recognition of the gain.

### 1.13 Government grants

Government grant funded assets are capitalised at current value in existing use, if they will be held for their service potential, or otherwise at fair value on receipt, with a matching credit to income. Deferred income is recognised only where conditions attached to the grant preclude immediate recognition of the gain.

#### 1.14 Non-current assets held for sale

Non-current assets are classified as held for sale if their carrying amount will be recovered principally through a sale transaction rather than through continuing use. This condition is regarded as met when the sale is highly probable, the asset is available for immediate sale in its present condition and management is committed to the sale, which is expected to qualify for recognition as a completed sale within one year from the date of classification. Non-current assets held for sale are measured at the lower of their previous carrying amount and fair value less costs to sell. Fair value is open market value including alternative uses.

The profit or loss arising on disposal of an asset is the difference between the sale proceeds and the carrying amount and is recognised in the Statement of Comprehensive Income. On disposal, the balance for the asset on the revaluation reserve is transferred to retained earnings.

Property, plant and equipment that is to be scrapped or demolished does not qualify for recognition as held for sale. Instead, it is retained as an operational asset and its economic life is adjusted. The asset is de-recognised when it is scrapped or demolished.

### 1.15 Leases

Leases are classified as finance leases when substantially all the risks and rewards of ownership are transferred to the lessee. All other leases are classified as operating leases.

## The trust as lessee

Property, plant and equipment held under finance leases are initially recognised, at the inception of the lease, at fair value or, if lower, at the present value of the minimum lease payments, with a matching liability for the lease obligation to the lessor. Lease payments are apportioned between finance charges and reduction of the lease obligation so as to achieve a constant rate of interest on the remaining balance of the liability. Finance charges are recognised in calculating the trust's surplus/deficit.

Operating lease payments are recognised as an expense on a straight-line basis over the lease term. Lease incentives are recognised initially as a liability and subsequently as a reduction of rentals on a straight-line basis over the lease term.

Contingent rentals are recognised as an expense in the period in which they are incurred.

Where a lease is for land and buildings, the land and building components are separated and individually assessed as to whether they are operating or finance leases.

### Notes to the Accounts - 1. Accounting Policies (Continued)

#### The NHS trust as lessor

Amounts due from lessees under finance leases are recorded as receivables at the amount of the NHS trust's net investment in the leases. Finance lease income is allocated to accounting periods so as to reflect a constant periodic rate of return on the trust's net investment outstanding in respect of the leases.

Rental income from operating leases is recognised on a straight-line basis over the term of the lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised on a straight-line basis over the lease term.

### 1.16 Private Finance Initiative (PFI) transactions

HM Treasury has determined that government bodies shall account for infrastructure PFI schemes where the government body controls the use of the infrastructure and the residual interest in the infrastructure at the end of the arrangement as service concession arrangements, following the principles of the requirements of IFRIC 12. The NHS trust therefore recognises the PFI asset as an item of property, plant and equipment together with a liability to pay for it. The services received under the contract are recorded as operating expenses.

The annual unitary payment is separated into the following component parts, using appropriate estimation techniques where necessary:

- a) Payment for the fair value of services received;
- b) Payment for the PFI asset, including finance costs; and
- c) Payment for the replacement of components of the asset during the contract 'lifecycle replacement'.

#### Services received

The fair value of services received in the year is recorded under the relevant expenditure headings within 'operating expenses'

#### PFI Asset

The PFI assets are recognised as property, plant and equipment, when they come into use. The assets are measured initially at fair value or, if lower, at the present value of the minimum lease payments, in accordance with the principles of IAS 17. Subsequently, the assets are measured at current value in existing use.

#### PFI liability

A PFI liability is recognised at the same time as the PFI assets are recognised. It is measured initially at the same amount as the initial value of the PFI assets and is subsequently measured as a finance lease liability in accordance with IAS 17.

An annual finance cost is calculated by applying the implicit interest rate in the lease to the opening lease liability for the period, and is charged to 'Finance Costs' within the Statement of Comprehensive Income.

The element of the annual unitary payment that is allocated as a finance lease rental is applied to meet the annual finance cost and to repay the lease liability over the contract term.

An element of the annual unitary payment increase due to cumulative indexation is allocated to the finance lease. In accordance with IAS 17, this amount is not included in the minimum lease payments, but is instead treated as contingent rent and is expensed as incurred. In substance, this amount is a finance cost in respect of the liability and the expense is presented as a contingent finance cost in the Statement of Comprehensive Income.

## Lifecycle replacement

Components of the asset replaced by the operator during the contract ('lifecycle replacement') are capitalised where they meet the NHS trust's criteria for capital expenditure. They are capitalised at the time they are provided by the operator and are measured initially at their fair

The element of the annual unitary payment allocated to lifecycle replacement is pre-determined for each year of the contract from the operator's planned programme of lifecycle replacement. Where the lifecycle component is provided earlier or later than expected, a short-term accrual or prepayment is recognised respectively.

Where the fair value of the lifecycle component is less than the amount determined in the contract, the difference is recognised as an expense when the replacement is provided. If the fair value is greater than the amount determined in the contract, the difference is treated as a 'free' asset and a deferred income balance is recognised. The deferred income is released to operating income over the shorter of the remaining contract period or the useful economic life of the replacement component.

## Assets contributed by the NHS trust to the operator for use in the scheme

Assets contributed for use in the scheme continue to be recognised as items of property, plant and equipment in the NHS trust's Statement of Financial Position.

## Other assets contributed by the NHS trust to the operator

Assets contributed (e.g. cash payments, surplus property) by the NHS trust to the operator before the asset is brought into use, which are intended to defray the operator's capital costs, are recognised initially as prepayments during the construction phase of the contract. Subsequently, when the asset is made available to the NHS trust, the prepayment is treated as an initial payment towards the finance lease liability and is set against the carrying value of the liability.

### Notes to the Accounts - 1. Accounting Policies (Continued)

#### 1.17 Inventories

Inventories are valued at the lower of cost and net realisable value using the [first-in first-out/weighted average] cost formula. This is considered to be a reasonable approximation to fair value due to the high turnover of stocks.

#### 1.18 Cash and cash equivalents

Cash is cash in hand and deposits with any financial institution repayable without penalty on notice of not more than 24 hours. Cash equivalents are investments that mature in 3 months or less from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

In the Statement of Cash Flows, cash and cash equivalents are shown net of bank overdrafts that are repayable on demand and that form an integral part of the NHS trust's cash management.

#### 1.19 Provisions

Provisions are recognised when the NHS trust has a present legal or constructive obligation as a result of a past event, it is probable that the NHS trust will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The amount recognised as a provision is the best estimate of the expenditure required to settle the obligation at the end of the reporting period, taking into account the risks and uncertainties. Where a provision is measured using the cash flows estimated to settle the obligation, its carrying amount is the present value of those cash flows using HM Treasury's discount rates.

Early retirement provisions are discounted using HM Treasury's pension discount rate of positive 0.24% (2015-16: positive 1.37%) in real terms. All other provisions are subject to three separate discount rates according to the expected timing of cashflows from the Statement of Financial Position date:

- A short term rate of negative 2.70% (2015-16: negative 1.55%) for expected cash flows up to and including 5 years
- A medium term rate of negative 1.95% (2015-16: negative 1.00%) for expected cash flows over 5 years up to and including 10 years
- A long term rate of negative 0.80% (2015-16: negative 0.80%) for expected cash flows over 10 years.

All percentages are in real terms.

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, the receivable is recognised as an asset if it is virtually certain that reimbursements will be received and the amount of the receivable can be measured reliably

A restructuring provision is recognised when the NHS trust has developed a detailed formal plan for the restructuring and has raised a valid expectation in those affected that it will carry out the restructuring by starting to implement the plan or announcing its main features to those affected by it. The measurement of a restructuring provision includes only the direct expenditures arising from the restructuring, which are those amounts that are both necessarily entailed by the restructuring and not associated with ongoing activities of the entity.

## 1.20 Clinical negligence costs

The NHS Litigation Authority (NHSLA) operates a risk pooling scheme under which the trust pays an annual contribution to the NHSLA, which in return settles all clinical negligence claims. The contribution is charged to expenditure. Although the NHSLA is administratively responsible for all clinical negligence cases the legal liability remains with the NHS trust. The total value of clinical negligence provisions carried by the NHSLA on behalf of the trust is disclosed at Note 24.

### 1.21 Non-clinical risk pooling

The NHS trust participates in the Property Expenses Scheme and the Liabilities to Third Parties Scheme. Both are risk pooling schemes under which the NHS trust pays an annual contribution to the NHS Litigation Authority and, in return, receives assistance with the costs of claims arising. The annual membership contributions, and any excesses payable in respect of particular claims are charged to operating expenses as and when they become due.

## 1.22 Carbon Reduction Commitment Scheme (CRC)

CRC and similar allowances are accounted for as government grant funded intangible assets if they are not expected to be realised within twelve months, and otherwise as other current assets. They are valued at open market value. As the NHS trust makes emissions, a provision is recognised with an offsetting transfer from deferred income. The provision is settled on surrender of the allowances. The asset, provision and deferred income amounts are valued at fair value at the end of the reporting period.

## 1.23 Contingencies

A contingent liability is a possible obligation that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the NHS trust, or a present obligation that is not recognised because it is not probable that a payment will be required to settle the obligation or the amount of the obligation cannot be measured sufficiently reliably. A contingent liability is disclosed unless the possibility of a payment is remote.

A contingent asset is a possible asset that arises from past events and whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the NHS trust. A contingent asset is disclosed where an inflow of economic benefits is probable.

Where the time value of money is material, contingencies are disclosed at their present value.

### Notes to the Accounts - 1. Accounting Policies (Continued)

#### 1.24 Financial assets

Financial assets are recognised when the NHS trust becomes party to the financial instrument contract or, in the case of trade receivables, when the goods or services have been delivered. Financial assets are derecognised when the contractual rights have expired or the asset has been transferred.

Financial assets are classified into the following categories: financial assets at fair value through profit and loss; held to maturity investments; available for sale financial assets, and loans and receivables. The classification depends on the nature and purpose of the financial assets and is determined at the time of initial recognition.

#### Financial assets at fair value through profit and loss

Embedded derivatives that have different risks and characteristics to their host contracts, and contracts with embedded derivatives whose separate value cannot be ascertained, are treated as financial assets at fair value through profit and loss. They are held at fair value, with any resultant gain or loss recognised in calculating the NHS trust's surplus or deficit for the year. The net gain or loss incorporates any interest earned on the financial asset.

#### Held to maturity investments

Held to maturity investments are non-derivative financial assets with fixed or determinable payments and fixed maturity, and where there is a positive intention and ability to hold to maturity. After initial recognition, they are held at amortised cost using the effective interest method, less any impairment. Interest is recognised using the effective interest method.

#### Available for sale financial assets

Available for sale financial assets are non-derivative financial assets that are designated as available for sale or that do not fall within any of the other three financial asset classifications. They are measured at fair value with changes in value taken to the revaluation reserve, with the exception of impairment losses. Accumulated gains or losses are recycled to surplus/deficit on de-recognition.

### Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments which are not quoted in an active market. After initial recognition, they are measured at amortised cost using the effective interest method, less any impairment. Interest is recognised using the effective interest method.

Financial assets are initially recognised at fair value. Fair value is determined by reference to quoted market prices where possible, otherwise by valuation techniques.

The effective interest rate is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset, to the initial fair value of the financial asset.

At the end of the reporting period, the NHS trust assesses whether any financial assets, other than those held at 'fair value through profit and loss' are impaired. Financial assets are impaired and impairment losses recognised if there is objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset and that have an impact on the estimated future cash flows of the

For financial assets carried at amortised cost, the amount of the impairment loss is measured as the difference between the asset's carrying amount and the present value of the revised future cash flows discounted at the asset's original effective interest rate. The loss is recognised in expenditure and the carrying amount of the asset is reduced directly.

If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognised, the previously recognised impairment loss is reversed through expenditure to the extent that the carrying amount of the receivable at the date of the impairment is reversed does not exceed what the amortised cost would have been had the impairment not been recognised.

### 1.25 Financial liabilities

Financial liabilities are recognised on the statement of financial position when the NHS trust becomes party to the contractual provisions of the financial instrument or, in the case of trade payables, when the goods or services have been received. Financial liabilities are derecognised when the liability has been discharged, that is, the liability has been paid or has expired.

Loans from the Department of Health are recognised at historic cost. Otherwise, financial liabilities are initially recognised at fair value.

### Financial guarantee contract liabilities

Financial guarantee contract liabilities are subsequently measured at the higher of:

- The amount of the obligation under the contract, as determined in accordance with IAS 37 Provisions, Contingent Liabilities and Contingent Assets; and
- The premium received (or imputed) for entering into the guarantee less cumulative amortisation.

### Notes to the Accounts - 1. Accounting Policies (Continued)

#### Financial liabilities at fair value through profit and loss

Embedded derivatives that have different risks and characteristics to their host contracts, and contracts with embedded derivatives whose separate value cannot be ascertained, are treated as financial liabilities at fair value through profit and loss. They are held at fair value, with any resultant gain or loss recognised in the NHS trust's surplus/deficit. The net gain or loss incorporates any interest payable on the financial liability.

#### Other financial liabilities

After initial recognition, all other financial liabilities are measured at amortised cost using the effective interest method, except for loans from Department of Health, which are carried at historic cost. The effective interest rate is the rate that exactly discounts estimated future cash payments through the life of the asset, to the net carrying amount of the financial liability. Interest is recognised using the effective interest method.

#### 1.26 Value Added Tax

Most of the activities of the trust are outside the scope of VAT and, in general, output tax does not apply and input tax on purchases is not recoverable. Irrecoverable VAT is charged to the relevant expenditure category or included in the capitalised purchase cost of fixed assets. Where output tax is charged or input VAT is recoverable, the amounts are stated net of VAT.

#### 1.27 Foreign currencies

The NHS trust's functional and presentational currency is sterling. Transactions denominated in a foreign currency are translated into sterling at the exchange rate ruling on the dates of the transactions. At the end of the reporting period, monetary items denominated in foreign currencies are retranslated at the spot exchange rate on 31 March. Resulting exchange gains and losses for either of these are recognised in the trust's surplus/deficit in the period in which they arise.

#### 1.28 Third party assets

Asset's belonging to third parties (such as money held on behalf of patients) are not recognised in the accounts since the trust has no beneficial interest in them. Details of third party assets are given in Note 34 to the accounts.

#### 1.29 Public Dividend Capital (PDC) and PDC dividend

Public dividend capital represents taxpayers' equity in the NHS trust. At any time the Secretary of State can issue new PDC to, and require repayments of PDC from, the trust. PDC is recorded at the value received. As PDC is issued under legislation rather than under contract, it is not treated as an equity financial instrument.

An annual charge, reflecting the cost of capital utilised by the trust, is payable to the Department of Health as public dividend capital dividend. The charge is calculated at the real rate set by HM Treasury (currently 3.5%) on the average carrying amount of all assets less liabilities (except for donated assets and cash balances with the Government Banking Service). The average carrying amount of assets is calculated as a simple average of opening and closing relevant net assets.

In accordance with the requirements laid down by the Department of Health (as the issuer of PDC), the dividend for the year is calculated on the actual average relevant net assets as set out in the "pre-audit" version of the annual accounts. The dividend thus calculated is not revised should any adjustment to net assets occur as a result the audit of the annual accounts.

### 1.30 Losses and Special Payments

Losses and special payments are items that Parliament would not have contemplated when it agreed funds for the health service or passed legislation. By their nature they are items that ideally should not arise. They are therefore subject to special control procedures compared with the generality of payments. They are divided into different categories, which govern the way that individual cases are handled.

Losses and special payments are charged to the relevant functional headings in expenditure on an accruals basis, including losses which would have been made good through insurance cover had the NHS trust not been bearing its own risks (with insurance premiums then being included as normal revenue expenditure).

## 1.31 Subsidiaries

Material entities over which the NHS trust has the power to exercise control are classified as subsidiaries and are consolidated. The NHS trust has control when it is exposed to or has rights to variable returns through its power over another entity. The income and expenses; gains and losses; assets, liabilities and reserves; and cash flows of the subsidiary are consolidated in full into the appropriate financial statement lines. Appropriate adjustments are made on consolidation where the subsidiary's accounting policies are not aligned with the NHS trust or where the subsidiary's accounting date is not co-terminus.

Subsidiaries that are classified as 'held for sale' are measured at the lower of their carrying amount or 'fair value less costs to sell'.

### 1.32 Associates

Material entities over which the NHS trust has the power to exercise significant influence so as to obtain economic or other benefits are classified as associates and are recognised in the NHS trust's accounts using the equity method. The investment is recognised initially at cost and is adjusted subsequently to reflect the NHS trust share of the entity's profit/loss and other gains/losses. It is also reduced when any distribution is received by the NHS trust from the entity.

Associates that are classified as 'held for sale' are measured at the lower of their carrying amount or 'fair value less costs to sell'

## 1.33 Joint arrangements

Material entities over which the NHS trust has joint control with one or more other entities are classified as joint arrangements. Joint control is the contractually agreed sharing of control of an arrangement. A joint arrangement is either a joint operation or a joint venture.

A joint operation exists where the parties that have joint control have rights to the assets and obligations for the liabilities relating to the arrangement. Where the NHS trust is a joint operator it recognises its share of, assets, liabilities, income and expenses in its own accounts.

A joint venture is a joint arrangement whereby the parties that have joint control of the arrangement have rights to the net assets of the arrangement. Joint ventures are recognised as an investment and accounted for using the equity method.

## Notes to the Accounts - 1. Accounting Policies (Continued)

### 1.34 Research and Development

Research and development expenditure is charged against income in the year in which it is incurred, except insofar as development expenditure relates to a clearly defined project and the benefits of it can reasonably be regarded as assured. Expenditure so deferred is limited to the value of future benefits expected and is amortised through the SOCI on a systematic basis over the period expected to benefit from the project. It should be revalued on the basis of current cost. The amortisation is calculated on the same basis as depreciation, on a quarterly basis.

## 1.35 Accounting Standards that have been issued but have not yet been adopted

The HM Treasury FReM does not require the following Standards and Interpretations to be applied in 2016-17. These standards are still subject to HM Treasury FReM interpretation, with IFRS 9 and IFRS 15 being for implementation in 2018-19, and the government implementation date for IFRS 16 still subject to HM Treasury consideration.

- IFRS 9 Financial Instruments Application required for accounting periods beginning on or after 1 January 2018, but not yet adopted by the FReM: early adoption is not therefore permitted
- IFRS 15 Revenue from Contracts with Customers Application required for accounting periods beginning on or after 1 January 2018, but not yet adopted by the FReM: early adoption is not therefore permitted
- IFRS 16 Leases Application required for accounting periods beginning on or after 1 January 2019, but not yet adopted by the FReM: early adoption is not therefore permitted.

### 1.36 Gifts

Gifts are items that are voluntarily donated, with no preconditions and without the expectation of any return. Gifts include all transactions economically equivalent to free and unremunerated transfers, such as the loan of an asset for its expected useful life, and the sale or lease of assets at below market value.

## 2. Operating segments

The Board, as 'Chief Operating Decision Maker', has determined that the Trust operates in one material segment which is the provision of healthcare services. The segmental reporting format reflects the Trust's management and internal reporting structure.

The provision of healthcare (including medical treatment, research and education) is within one main geographical segment, the United Kingdom, and materially from Departments of HM Government in England.

The Trust has only one business segment which is provision of healthcare. A segmental analysis is therefore not applicable.

## 3. Revenue from patient care activities

	2016-17 £000s	2015-16 £000s
NHS Trusts	284	629
NHS England	51,239	53,199
Clinical Commissioning Groups	343,930	338,649
Foundation Trusts	3,276	3,449
Department of Health	0	196
NHS Other (including Public Health England and Prop Co)	1,070	1,303
Additional income for delivery of healthcare services	0	500
Non-NHS:		
Local Authorities	9,008	5,640
Private patients	172	159
Overseas patients (non-reciprocal)	1,100	192
Injury costs recovery	1,283	1,283
Other Non-NHS patient care income	257	332
Total Revenue from patient care activities	411,619	405,531

# 4. Other operating revenue

	2016-17 £000s	2015-16 £000s
Recoveries in respect of employee benefits	0	0
Patient transport services	135	166
Education, training and research	20,351	20,028
Charitable and other contributions to revenue expenditure - NHS	0	0
Charitable and other contributions to revenue expenditure -non- NHS	0	0
Receipt of charitable donations for capital acquisitions	62	527
Support from DH for mergers	0	0
Receipt of Government grants for capital acquisitions	0	0
Non-patient care services to other bodies	5,190	6,595
Sustainability & Transformation Fund Income	5,297	0
Income generation (Other fees and charges)	9,893	6,544
Rental revenue from finance leases	0	0
Rental revenue from operating leases	0	0
Other revenue *	7,650	4,307
Total Other Operating Revenue	48,578	38,167
Total operating revenue	460,197	443,698

<sup>\*</sup> Other Revenue includes £3m that the Trust received for non recurrent funding in support of the development and transition to the Midland Metropolitan Hospital (MMH). That funding is part of a total of £22.3m which the trust expects to receive over the period 2016-2020. Such funding is in line with national arrangements for supporting large scale infrastructure projects such as MMH

### 5. Overseas Visitors Disclosure

	2016-17 £000s	2015-16 £000s
Income recognised during 2016-17 (invoiced amounts and accruals)	1,100	192
Cash payments received in-year (re receivables at 31 March 2016)	143	98
Cash payments received in-year (iro invoices issued 2016-17)	166	33
Amounts added to provision for impairment of receivables (re receivables at 31 March 2016)	0	0
Amounts added to provision for impairment of receivables (iro invoices issued 2016-17)	735	162
Amounts written off in-year (irrespective of year of recognition)	123	86

# Operating expenses

	2016-17 £000s	2015-16 £000s
Services from other NHS Trusts	1,782	1,020
Services from CCGs/NHS England	0	0
Services from other NHS bodies	507	2,146
Services from NHS Foundation Trusts	6,947	7,434
Total Services from NHS bodies*	9,236	10,600
Purchase of healthcare from non-NHS bodies	3,397	1,596
Purchase of Social Care	0	0
Trust Chair and Non-executive Directors	64	66
Supplies and services - clinical	79,133	71,033
Supplies and services - general	6,950	6,485
Consultancy services	930	852
Establishment	4,518	3,884
Transport	1,839	1,527
Service charges - ON-SOFP PFIs and other service concession arrangements	2,166	863
Service charges - On-SOFP LIFT contracts	0	0
Total charges - Off-SOFP PFIs and other service concession arrangements	0	0
Total charges - Off-SOFP LIFT contracts	0	0
Business rates paid to local authorities	1,597	1,299
Premises	17,429	16,207
Hospitality	0	0
Insurance	90	110
Legal Fees	97	49
Impairments and Reversals of Receivables	1,382	515
Inventories write down	8	57
Depreciation	13,853	12,714
Amortisation	162	232
Impairments and reversals of property, plant and equipment	(5,219)	8,278
Impairments and reversals of intangible assets	58	112
Impairments and reversals of financial assets [by class]	0	0
Impairments and reversals of non current assets held for sale	0	0
Internal Audit Fees	220	197
Audit fees **	91	91
Other auditor's remuneration	14	27
Clinical negligence	7,577	6,476
Research and development (excluding staff costs)	242	242
Education and Training	1,111	1,206
Change in Discount Rate	388 0	(23)
Capital Grants in Kind Other	1,575	0 1,020
Total Operating expenses (excluding employee benefits)	148,908	145,715
Total Operating expenses (excluding employee benefits)	140,900	145,715
Employee Benefits		
Employee benefits excluding Board members	309,639	294,183
Board members	1,404	1,333
Total Employee Benefits	311,043	295,516
Total Operating Expenses	459,951	441,231

<sup>\*</sup> Services from NHS bodies does not include expenditure which falls into a category below \*\* Audit Fees - External Audit fees are disclosed inclusive of VAT. (The contract for 2016/17 was £75,380 plus VAT)

# 7. Operating Leases

# 7.1. Sandwell and West Birmingham Hospitals NHS Trust as lessee

			2016-17		
	Land	Buildings	Other	Total	2015-16
	£000s	£000s	£000s	£000s	£000s
Payments recognised as an expense					
Minimum lease payments				44	138
Contingent rents				0	0
Sub-lease payments				0	0
Total			_	44	138
Payable:			•		
No later than one year	18	0	25	43	131
Between one and five years	73	0	47	120	216
After five years	127	0	24	151	146
Total	218	0	96	314	493
Total future sublease payments expected to be received:			-	0	0

## 8. Employee benefits

### 8.1. Employee benefits

	2016-17	2015-16
	Total	Total
	£000s	£000s
Employee Benefits - Gross Expenditure		
Salaries and wages	262,812	253,134
Social security costs	23,743	18,800
Employer Contributions to NHS BSA - Pensions Division	27,185	26,766
Other pension costs	0	0
Termination benefits	0	0
Total employee benefits	313,740	298,700
Employee costs capitalised	2,697	3,184
Gross Employee Benefits excluding capitalised costs	311,043	295,516

### 8.2. Retirements due to ill-health

	2016-17	2015-16
	Number	Number
Number of persons retired early on ill health grounds	9	4
	£000s	£000s
Total additional pensions liabilities accrued in the year	323	201

### 8.3. Pension costs

Past and present employees are covered by the provisions of the two NHS Pension Schemes. Details of the benefits payable and rules of the Schemes can be found on the NHS Pensions website at www.nhsbsa.nhs.uk/pensions. Both are unfunded defined benefit schemes that cover NHS employers, GP practices and other bodies, allowed under the direction of the Secretary of State in England and Wales. They are not designed to be run in a way that would enable NHS bodies to identify their share of the underlying scheme assets and liabilities. Therefore, each scheme is accounted for as if it were a defined contribution scheme: the cost to the NHS body of participating in each scheme is taken as equal to the contributions payable to that scheme for the accounting period.

In order that the defined benefit obligations recognised in the financial statements do not differ materially from those that would be determined at the reporting date by a formal actuarial valuation, the FReM requires that "the period between formal valuations shall be four years, with approximate assessments in intervening years". An outline of these follows:

## a) Accounting valuation

A valuation of scheme liability is carried out annually by the scheme actuary (currently the Government Actuary's Department) as at the end of the reporting period. This utilises an actuarial assessment for the previous accounting period in conjunction with updated membership and financial data for the current reporting period, and are accepted as providing suitably robust figures for financial reporting purposes. The valuation of scheme liability as at 31 March 2017, is based on valuation data as 31 March 2016, updated to 31 March 2017 with summary global member and accounting data. In undertaking this actuarial assessment, the methodology prescribed in IAS 19, relevant FReM interpretations, and the discount rate prescribed by HM Treasury have also been used.

The latest assessment of the liabilities of the scheme is contained in the scheme actuary report, which forms part of the annual NHS Pension Scheme (England and Wales) Pension Accounts. These accounts can be viewed on the NHS Pensions website and are published annually. Copies can also be obtained from The Stationery Office.

## b) Full actuarial (funding) valuation

The purpose of this valuation is to assess the level of liability in respect of the benefits due under the schemes (taking into account their recent demographic experience), and to recommend contribution rates payable by employees and employers.

The last published actuarial valuation undertaken for the NHS Pension Scheme was completed for the year ending 31 March 2012. The Scheme Regulations allow for the level of contribution rates to be changed by the Secretary of State for Health, with the consent of HM Treasury, and consideration of the advice of the Scheme Actuary and appropriate employee and employer representatives as deemed appropriate.

The next actuarial valuation is to be carried out as at 31 March 2016. This will set the employer contribution rate payable from April 2019 and will consider the cost of the Scheme relative to the employer cost cap. There are provisions in the Public Service Pension Act 2013 to adjust member benefits or contribution rates if the cost of the Scheme changes by more than 2% of pay. Subject to this 'employer cost cap' assessment, any required revisions to member benefits or contribution rates will be determined by the Secretary of State for Health after consultation with the relevant stakeholders.

# 9. Better Payment Practice Code

# 9.1. Measure of compliance

	2016-17 Number	2016-17 £000s	2015-16 Number	2015-16 £000s
Non-NHS Payables				
Total Non-NHS Trade Invoices Paid in the Year	107,147	255,483	112,909	157,420
Total Non-NHS Trade Invoices Paid Within Target	56,239	204,246	99,996	138,820
Percentage of NHS Trade Invoices Paid Within Target	52.49%	79.95%	88.56%	88.18%
NHS Payables Total NHS Trade Invoices Paid in the Year Total NHS Trade Invoices Paid Within Target	2,141 1,011	31,490 16,038	2,022 1,449	28,228 18,762
Percentage of NHS Trade Invoices Paid Within Target	47.22%	50.93%	71.66%	66.47%

The Better Payment Practice Code requires the NHS body to aim to pay all valid invoices by the due date or within 30 days of receipt of a valid invoice, whichever is later.

# 9.2. The Late Payment of Commercial Debts (Interest) Act 1998

,	2016-17 £000s	2015-16 £000s
Amounts included in finance costs from claims made under this legislation Compensation paid to cover debt recovery costs under this legislation <b>Total</b>	1 0 1	2 0 2
10. Investment Revenue	2016-17 £000s	2015-16 £000s
Bank interest Total investment revenue	66 66	136 136
11. Other Gains and Losses	2016-17 £000s	2015-16 £000s
Gain/(Loss) on disposal of assets other than by sale (PPE) Gain/(Loss) on disposal of assets other than by sale (intangibles) Total	0 0 0	50 0 50

## 12. Finance Costs

	2016-17	2015-16
	£000s	£000s
Interest		
Interest on loans and overdrafts	0	4
Interest on obligations under finance leases	0	0
Interest on obligations under PFI contracts:		
- main finance cost	1,332	1,391
- contingent finance cost	813	618
Interest on late payment of commercial debt	1	2
Total interest expense	2,146	2,015
Other finance costs	0	0
Provisions - unwinding of discount	45	42
Total	2,191	2,057
13. Auditor Remuneration		
13.1. Other auditor remuneration		
	2016-17	2015-16
	£000s	£000s
Other auditor remuneration paid to the external auditor:		
Audit of accounts of any associate of the trust	0	0
Audit-related assurance services	10	19
Taxation compliance services	0	0
4. All taxation advisory services not falling within item 3 above	4	8
5. Internal audit services	0	0
6. All assurance services not falling within items 1 to 5	0	0
7. Corporate finance transaction services not falling within items 1 to 6 above	0	0
8. Other non-audit services not falling within items 2 to 7 above	0	0
Total	14	27

# 14.1. Property, plant and equipment

14.1. Property, plant and equipment	Land	Buildings excluding dwellings	Dwellings	Assets under construction & payments on account	Plant & machinery	Transport equipment	Information technology	Furniture & fittings	Total
2016-17	£000's	£000's	£000's	£000's	£000's	£000's	£000's	£000's	£0003
Cost or valuation:	£000 S	£000 S	£000 S	£000 S	£000 S	£000 S	£000 S	£000 S	£000 S
At 1 April 2016	16,640	140,725	0	10,283	101,531	3,833	31,689	1,997	306,698
Additions of Assets Under Construction				3,540					3,540
Additions Purchased	0	4,732	0		1,805	0	6,193	0	12,730
Additions - Non Cash Donations (i.e. physical assets)	0	0	0	0	49	0	13	0	62
Additions - Purchases from Cash Donations & Government Grants	0	0	0	0	0	0	0	0	0
Additions Leased (including PFI/LIFT)	0	105	0		2,592	0	0	0	2,697
Reclassifications	0	0	0	0	0	0	0	0	0
Reclassifications as Held for Sale and reversals Disposals other than for sale	0	0	0	0	(694)	0	(35)	0	(729)
Revaluation	0	(1,149)	0	0	(094)	0	(33)	0	(1,149)
Impairments/reversals charged to operating expenses	0	(1,110)	0	0	0	0	0	0	(1,110)
Impairments/reversals charged to reserves	0	654	0	0	0	0	0	0	654
Transfers to NHS Foundation Trust on authorisation as FT	0	0	0	0	0	0	0	0	0
Transfers (to)/from Other Public Sector Bodies under Absorption Accounting	0	0	0	0	0	0	0	0	0
At 31 March 2017	16,640	145,067	0	13,823	105,283	3,833	37,860	1,997	324,503
Depreciation									
At 1 April 2016	0	0	0		82,000	3,295	23,461	1,561	110,317
Reclassifications	0	0	0		0	0	0	0	0
Reclassifications as Held for Sale and reversals	0	0	0		0	0	0	0	0
Disposals other than for sale	0	0	0		(694)	0	(35)	0	(729)
Revaluation	0	(1,149)	0		0	0	0	0	(1,149)
Impairment/reversals charged to reserves	0	0 (5.010)	0		0	0	0	0	0 (5.040)
Impairments/reversals charged to operating expenses	0	(5,219)	0		0 4,533	0 170	0 2.710	0 71	(5,219) 13,853
Charged During the Year Transfers to NHS Foundation Trust on authorisation as FT	0	6,369 0	0		4,533	0	2,710	0	13,653
Transfers (to)/from Other Public Sector Bodies under Absorption Accounting	0	0	0		0	0	0	0	0
At 31 March 2017			0		85,839	3,465	26,136	1,632	117,073
Net Book Value at 31 March 2017	16,640	145,066	0	13,823	19,444	368	11,724	365	207,430
Asset financing: Owned - Purchased	16,640	104 001	0	13,823	10.000	368	11,712	364	178,414
Owned - Purchased Owned - Donated	16,640	124,681 329	0	13,823	10,826 769	368	11,712	364 0	1,110
Owned - Government Granted	0	861	0	0	769	0	0	0	861
Held on finance lease	0	0	0	0	0	0	0	0	0
On-SOFP PFI contracts	0	19,195	0	0	7,849	0	0	1	27,045
PFI residual interests	0	0	0	0	0	0	0	0	0
Total at 31 March 2017	16,640	145,066	0	13,823	19,444	368	11,724	365	207,430

Sandwell and West Birmingham Hospitals NHS Trust - Annual Accounts 2016-17

# Revaluation Reserve Balance for Property, Plant & Equipment

	Land	Buildings	Dwellings	Assets under construction & payments on account	Plant & machinery	Transport equipment	Information technology	Furniture & fittings	Total
At 1 April 2016	<b>£000's</b> 4,684	<b>£000's</b> 2,239	£000's	<b>£000's</b>	<b>£000's</b>	2000's	<b>£000's</b>	<b>£000's</b>	£000's 6,930
Movements (specify)	0	644		) 0	0	Č	0 0	0	644
At 31 March 2017	4,684			0	7		0 0	0	7,574
Additions to Assets Under Construction in 2016-17									
Land				0					
Buildings excl Dwellings				3,540					
Dwellings				0					
Plant & Machinery				0.540	-				
Balance as at YTD				3,540	_				

# 14.2. Property, plant and equipment prior-year

14.2. Property, plant and equipment prior-year	Land	Buildings excluding dwellings	Dwellings	Assets under construction & payments on account	Plant & machinery	Transport equipment	Information technology	Furniture & fittings	Total
2015-16	£000's	£000's	£000's	£000's	£000's	£000's	£000's	£000's	£000's
Cost or valuation:		2000 0		2000 0	2000 0	2000 0	2000 0	2000 0	2000 0
At 1 April 2015	37,740	160,654	922	6,303	101,421	3,833	27,362	1,997	340,232
Additions of Assets Under Construction		5.050		5,855	0.155		4.007		5,855
Additions Purchased Additions - Non Cash Donations (i.e. Physical Assets)	0	5,958	0	0	3,155 527	0	4,327	0	13,440 527
Additions - Non Cash Donations (i.e. Friysical Assets)  Additions - Purchases from Cash Donations & Government Grants	0	0	0	0	527 0	0	0	0	52 <i>1</i> 0
Additions Leased (including PFI/LIFT)	0	472	0	0	0	0	0	0	472
Reclassifications	0	2,797	(922)	(1,875)	0	0	0	0	0
Reclassifications as Held for Sale and Reversals	0	0	` ó	Ó	0	0	0	0	0
Disposals other than for sale	0	0	0	0	(3,572)	0	0	0	(3,572)
Revaluation	(7,446)	(6,580)	0	0	0	0	0	0	(14,026)
Impairment/reversals charged to reserves	0	0	0	0	0	0	0	0	0
Impairments/reversals charged to operating expenses	(13,654)	(22,576)	0	0	0	0	0	0	(36,230)
Transfers to NHS Foundation Trust on authorisation as FT Transfers (to)/from Other Public Sector Bodies under Absorption Accounting	0	0	0	0	0	0	0	0	0
At 31 March 2016	16,640	140,725	0	10,283	101,531	3,833	31,689	1,997	306,698
Depreciation									
At 1 April 2015	0	0	0		80,792	3,119	21,552	1,460	106,923
Reclassifications	0	0	0		0	0	0	0	0
Reclassifications as Held for Sale and Reversals	0	0	0		0	0	0	0	0
Disposals other than for sale	0	0	0		(3,572)	0	0	0	(3,572)
Revaluation	(7,446)	(6,580)	0		0	0	0	0	(14,026)
Impairment/reversals charged to reserves	7 110	0	0		0	0	0	0	0
Impairments/reversals charged to operating expenses Charged During the Year	7,446 0	832 5,748	0		0 4,780	176	1,909	101	8,278 12,714
Transfers to NHS Foundation Trust on authorisation as FT	0	3,748	0		4,760	0	1,909	0	12,714
Transfers (to)/from Other Public Sector Bodies under Absorption Accounting	0	0	0		0	0	0	0	Ö
At 31 March 2016			0	0	82,000	3,295	23,461	1,561	110,317
Net Book Value at 31 March 2016	16,640	140,725	0	10,283	19,531	538	8,228	436	196,381
Asset financing:									
Owned - Purchased	16,640	120,940	0	10,283	18,563	538	8,227	436	175,627
Owned - Donated	0	325	0	0	968	0	1	0	1,294
Owned - Government Granted	0	842	0	0	0	0	0	0	842
Held on finance lease	0	0	0	0	0	0	0	0	0
On-SOFP PFI contracts	0	18,618	0	0	0	0	0	0	18,618
PFI residual interests	0	0	0	0	0	0	0	0	0
Total at 31 March 2016	16,640	140,725	0	10,283	19,531	538	8,228	436	196,381

## 14.3. (cont). Property, plant and equipment

The Trust's property assets (land and buildings) were revalued during the year by the District Valuation Service and using Modern Equivalent Asset valuation techniques with a valuation date of 31st March 2016. Valuation was undertaken with reference to the size, location and Service Potential of existing buildings and the basis on which they would be replaced by Modern Equivalent Assets.

The Trust owns Non Operational Land assets which are currently held as surplus assets. These assets are required to be valued at 'Fair Value' in accordance with IFRS13. The valuation technique applied by the appointed Valuer in respect of all the Fair Value figures contained in his assessment was the market approach using prices and other relevant information generated by market transactions involving identical or comparable assets.

Asset lives for currently held assets are as follow:-

Transport Equipment 1 to 5 Information Technology 1 to 10		Ye	ears
Transport Equipment 1 to 5 Information Technology 1 to 10 Furniture and Fittings 1 to 10 Software Licences 1 to 4	Buildings excl Dwellings	12	to 50
Information Technology 1 to 10 Furniture and Fittings 1 to 10 Software Licences 1 to 4	Plant & Machinery	1	to 10
Furniture and Fittings 1 to 10 Software Licences 1 to 4	Transport Equipment	1	to 5
Software Licences 1 to 4	Information Technology	1	to 10
	Furniture and Fittings	1	to 10
Licences and Trademarks 1 to 1	Software Licences	1	to 4
	Licences and Trademarks	1	to 1

# 15. Intangible non-current assets

# 15.1. Intangible non-current assets

2016-17	IT - in-house & 3rd party software	Computer Licenses	Licenses and Trademarks	Patents	Development Expenditure - Internally Generated	Total
2010-17	£000's	£000's	£000's	£000's	£000's	£000's
At 1 April 2016	0	2,954	101	0	0	3,055
Additions of Assets Under Construction						0
Additions Purchased	0	0	0	0	0	0
Additions Internally Generated	0	0	0	0	0	0
Additions - Non Cash Donations (i.e. physical assets)	0	0	0	0	0	0
Additions - Purchases from Cash Donations and Government Grants	0	0	0	0	0	0
Additions Leased (including PFI/LIFT)	0	0	0	0	0	0
Reclassifications Reclassified as Held for Sale and Reversals	0	0	0	0	0	0
Disposals other than by sale	0	0	0	0	0	0
Upward revaluation/positive indexation	0	0	0	0	0	0
Impairments/reversals charged to operating expenses	0	0	(58)	0	0	(58)
Impairments/reversals charged to reserves	0	0	0	0	0	0
Transfers to NHS Foundation Trust on authorisation as FT	0	0	0	0	0	Ō
Transfer (to)/from Other Public Sector bodies under Absorption	0	0	0	0	0	0
At 31 March 2017	0	2,954	43	0	0	2,997
Amortisation						
At 1 April 2016	0	2,669	0	0	0	2,669
Reclassifications	0	0	0	0	0	0
Reclassified as Held for Sale and Reversals	0	0	0	0	0	0
Disposals other than by sale	0	0	0	0	0	0
Upward revaluation/positive indexation	0	0	0	0	0	0
Impairment/reversals charged to reserves	0	0	0	0	0	0
Impairments/reversals charged to operating expenses	0	0	0	0	0	0
Charged During the Year	0	162	0	0	0	162
Transfers to NHS Foundation Trust on authorisation as FT	0	0	0	0	0	0
Transfer (to)/from Other Public Sector bodies under Absorption  At 31 March 2017	0	2,831		0	0	2,831
Net Book Value at 31 March 2017	0	123	43	0	0	166
Asset Financing: Net book value at 31 March 2017 comprises:						
Purchased	0	123	43	0	0	166
Total at 31 March 2017		123	43	0	0	166
10.01.01.01.101.2017		120				
Revaluation reserve balance for intangible non-current assets						
	£000's	s'0003	s'0003	s'0003	£000's	£000's
At 1 April 2016	0	0	0	0	0	0
Movements (specify)	0	0	0	0	0	0
At 31 March 2017	0	0	0	0	0	0

Sandwell and West Birmingham Hospitals NHS Trust - Annual Accounts 2016-17

## 15.2. Intangible non-current assets prior year

2015-16	IT - in-house & 3rd party software	Computer Licenses	Licenses and Trademarks	Patents	Development Expenditure - Internally Generated	Total
	£000's	£000's	£000's	£000's	£000's	£000's
Cost or valuation:						
At 1 April 2015	0	2,901	0	213	0	3,114
Additions - purchased	0	53	0	0	0	53
Reclassifications	0	0	213	(213)	0	0
At 31 March 2016	0	2,954	213	0	0	3,167
Amortisation						
At 1 April 2015	0	2,437	0	0	0	2,437
Impairments/reversals charged to reserves	0	0	0	0	0	_,
Charged during the year	0	232	0	0	0	232
At 31 March 2016	0	2,669	112	0	0	2,781
Net book value at 31 March 2016	0	285	101	0	0	386
Net book value at 31 March 2016 comprises:						
Purchased		285	101			386
Total at 31 March 2016	0	0	0	0	0	0

# 15.3. Intangible non-current assets

Asset lives for intangible assets (purchased computer software) range from 0 to 5 years. Assets are initially recognised at cost and amortised over the expected life of the asset. They have not been revalued.

An intangible asset in respect of Carbon Emission Credits is included in the Trust's accounts to reflect the receipt and consumption of these credits. They are valued at market price at 31st March 2017.

# 16. Analysis of impairments and reversals recognised in 2016-17

16. Analysis of impairments and reversals recognised in 2016-17	
	2016-17 Total
Property, Plant and Equipment impairments and reversals taken to SoCI	2000s
Loss or damage resulting from normal operations	0
Over-specification of assets	0
Abandonment of assets in the course of construction	0
Total charged to Departmental Expenditure Limit	0
Unforeseen obsolescence	0
Loss as a result of catastrophe	0
Other	0
Changes in market price Total charged to Annually Managed Expenditure	(5,219) (5,219)
Total charged to Annually Managed Expenditure	(3,219)
Total Impairments of Property, Plant and Equipment changed to SoCI	(5,219)
Intangible assets impairments and reversals charged to SoCI	
Loss or damage resulting from normal operations	0
Over-specification of assets  Abandonment of assets in the course of construction	0
Total charged to Departmental Expenditure Limit	<u>0</u>
	•
Unforeseen obsolescence	58
Loss as a result of catastrophe	0
Other Changes in market price	0
Total charged to Annually Managed Expenditure	58
Total Impairments of Intangibles charged to SoCI	58
Financial Assets charged to SoCI	0
Loss or damage resulting from normal operations  Total charged to Departmental Expenditure Limit	<u>0</u>
	-
Loss as a result of catastrophe	0
Other Total charged to Annually Managed Expanditure	<u>0</u>
Total charged to Annually Managed Expenditure	
Total Impairments of Financial Assets charged to SoCI	0
Non-current assets held for sale - impairments and reversals charged to SoCI.	
Loss or damage resulting from normal operations	0
Abandonment of assets in the course of construction  Total charged to Departmental Expenditure Limit	<u>0</u>
Total charged to Departmental Experiordire Limit	· ·
Unforeseen obsolescence	0
Loss as a result of catastrophe	0
Other Changes in market price	0
Changes in market price Total charged to Annually Managed Expenditure	<u>0</u>
Total impairments of non-current assets held for sale charged to SoCI	0
Total Impairments charged to SoCI - DEL	0
Total Impairments charged to SoCI - AME	(5,161)
Overall Total Impairments	(5,161)
Donated and Government Granted Assets, included above	
PPE - Donated and Government Granted Asset Impairments: amount charged to SOCI - DEL	0
Intangibles - Donated and Government Granted Asset Impairments: amount charged to SOCI - DEL	0

# 16. Analysis of impairments and reversals recognised in 2016-17

	Property Plant and Equipment	Intangible Assets	Financial Assets	Non- Current Assets Held for Sale	Total £000s
Impairments and reversals taken to SoCI					
Loss or damage resulting from normal operations	0	0	0	0	0
Over-specification of assets	0	0	0	0	0
Abandonment of assets in the course of construction	0	0	0	0	0
Total charged to Departmental Expenditure Limit	0	0	0	0	0
Unforeseen obsolescence	0	58	0	0	58
Loss as a result of catastrophe	0	0	0	0	0
Other	0	0	0	0	0
Changes in market price	(5,219)	0	0	0	(5,219)
Total charged to Annually Managed Expenditure	(5,219)	58	0	0	(5,161)
Total Impairments of Property, Plant and Equipment changed	(5,219)	58	0	0	(5,161)

## Donated and Government Granted Assets, included above

2000s

PPE - Donated and Government Granted Asset Impairments: amount charged to SOCI - DEL Intangibles - Donated and Government Granted Asset Impairments: amount charged to SOCI - DEL

0

# 17. Commitments

## 17.1. Capital commitments

Contracted capital commitments at 31 March not otherwise included in these financial statements:

	31 March	31 March
	2017	2016
	£000s	£000s
Property, plant and equipment	2,659	2,177
Intangible assets	0	0
Total	2,659	2,177

### 18. Inventories

	Drugs	Consumables	Work in Progress	Energy	Loan Equipment	Other	Total	Of which held at NRV
	£000s	£000s	£000s	£000s	£000s	£000s	£000s	£000s
Balance at 1 April 2016	1,761	2,217	0	118	0	0	4,096	0
Additions Inventories recognised as an expense in the	37,831	1,336	0	74	0	0	39,241	0
period	(38,061)	0	0	0	0	0	(38,061)	0
Write-down of inventories (including losses) Reversal of write-down previously taken to	(8)	0	0	0	0	0	(8)	0
SOCI Transfers to NHS Foundation Trust on	0	0	0	0	0	0	0	0
authorisation as FT Transfers (to)/from Other Public Sector	0	0	0	0	0	0	0	0
Bodies under Absorption Accounting	0	0	0	0	0	0	0	0
Balance at 31 March 2017	1,523	3,553	0	192	0	0	5,268	0

The value of Consumables Inventories "Additions" and "recognised as an expense during the year" is not separable for the purpose of this note and shown as a net movement, however the value of adjustments to Consumable Inventory items is included within total expenditure in Note 6 of these Accounts

### 19.1. Trade and other receivables

	Current		Non-c	urrent
	31 March 2017 £000s	31 March 2016 £000s	31 March 2017 £000s	31 March 2016 £000s
NHS receivables - revenue	9,462	10,372	0	0
NHS receivables - capital	0	0	0	0
NHS prepayments and accrued income	0	0	0	0
Non-NHS receivables - revenue	5,415	3,665	0	0
Non-NHS receivables - capital	0	0	0	0
Non-NHS prepayments and accrued income	1,090	1,310	0	0
PDC Dividend prepaid to DH	190	0	0	0
Provision for the impairment of receivables	(3,134)	(1,819)	(156)	(238)
VAT	2,003	1,115	0	0
Current/non-current part of PFI and other PPP arrangements prepayments and accrued income				
excluding PFI lifecycle	0	0	0	0
Interest receivables	0	0	0	0
Finance lease receivables	0	0	0	0
Operating lease receivables	0	0	0	0
Other receivables	2,074	1,665	43,173	1,084
Total	17,100	16,308	43,017	846
Total current and non current	60,117	17,154		
Included in NHS receivables are prepaid pension contributions:	0			

The great majority of trade is with NHS Clinical Commissioning Groups (CCG's) . As CCG's are funded by Government to buy NHS patient care no credit scoring of them is considered necessary.

19.2. Receivables past their due date but not impaired	31 March 2017 £000s	31 March 2016 £000s
By up to three months By three to six months By more than six months Total	860 1,454 2,708 5,022	1,038 1,323 2,013 4,374
19.3. Provision for impairment of receivables	2016-17 £000s	2015-16 £000s
Balance at 1 April 2016 Amount written off during the year Amount recovered during the year (Increase)/decrease in receivables impaired Transfers to NHS Foundation Trust on authorisation as FT	(2,057) 149 0 (1,382) 0	(1,644) 102 0 (515)
Transfers (to)/from Other Public Sector Bodies under Absorption Accounting  Balance at 31 March 2017	(3,290)	(2,057)

Impairment of receivables is based on an assessment of individual amounts receivable taking into account the age of the debt and other known circumstances regarding the debt or the debtor.

# 20. Cash and Cash Equivalents

20. Cash and Cash Equivalents		
	31 March	31 March
	2017	2016
	£000s	£000s
Opening balance	27,296	28,382
Net change in year	(3,394)	(1,086)
Closing balance	23,902	27,296
Made up of		
Cash with Government Banking Service	23,873	27,272
Commercial banks	0	0
Cash in hand	29	24
Liquid deposits with NLF	0	0
Current investments	0	0
Cash and cash equivalents as in statement of financial position	23,902	27,296
Bank overdraft - Government Banking Service	0	0
Bank overdraft - Commercial banks	0	0
Cash and cash equivalents as in statement of cash flows	23,902	27,296
Third Party Assets - Bank balance (not included above) See Note 34	1	2
Third Party Assets - Monies on deposit	0	0

# 21. Trade and other payables

	Current		Non-c	urrent
	31 March 2017 £000s	31 March 2016 £000s	31 March 2017 £000s	31 March 2016 £000s
NHS payables - revenue	13,774	10,203	0	0
NHS payables - capital	0	0	0	0
NHS accruals and deferred income	2,652	2,406	0	0
Non-NHS payables - revenue	12,896	3,841	0	0
Non-NHS payables - capital	7,218	4,965	0	0
Non-NHS accruals and deferred income	25,836	26,966	0	0
Social security costs	3,408	2,746		
PDC Dividend payable to DH	0	347		
Accrued Interest on DH Loans	0	0		
VAT	0	0	0	0
Tax	2,728	2,670		
Payments received on account	0	0	0	0
Other	0	0	0	0
Total	68,512	54,144	0	0
Total payables (current and non-current)	68,512	54,144		
Included above:				
to Buy Out the Liability for Early Retirements Over 5 Years	0	0		
number of Cases Involved (number)	0	0		
outstanding Pension Contributions at the year end	3,762	1,158		

22. Borrowings				
	Cur	rent	Non-c	urrent
	31 March 2017 £000s	31 March 2016 £000s	31 March 2017 £000s	31 March 2016 £000s
Bank overdraft - Government Banking Service	0	0		
Bank overdraft - commercial banks	0	0		
Loans from Department of Health	0	0	0	0
Loans from other entities	0	0	0	0
PFI liabilities - main liability	903	1,306	33,953	25,591
LIFT liabilities - main liability	0	0	0	0
Finance lease liabilities	0	0	0	0
Other (describe)	0	0	0	0
Total	903	1,306	33,953	25,591
Total other liabilities (current and non-current)	34,856	26,897		
0-1 Years 1 - 2 Years 2 - 5 Years Over 5 Years TOTAL		DH £000s 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	31 March 2017 Other £000s 903 2,188 5,791	Total £000s 903 2,188
		0	25,974 <b>34,856</b>	5,791 25,974 34,856
23. Deferred income				25,974
23. Deferred income		rent	34,856 Non-c	25,974 34,856
23. Deferred income	Cur 31 March 2017 £000s		34,856	25,974 34,856
23. Deferred income  Opening balance at 1 April 2016	31 March 2017	rent 31 March 2016	34,856 Non-c 31 March 2017	25,974 34,856 urrent 31 March 2016
	31 March 2017 £000s	rent 31 March 2016 £000s	34,856 Non-c 31 March 2017 £000s	25,974 34,856 urrent 31 March 2016 £000s
Opening balance at 1 April 2016	31 March 2017 £000s 4,707	rent 31 March 2016 £000s 4,858	34,856 Non-c 31 March 2017 £000s 0	25,974 34,856 urrent 31 March 2016 £000s 0
Opening balance at 1 April 2016 Deferred revenue addition	31 March 2017 £000s 4,707 5,040	rent 31 March 2016 £000s 4,858 4,707	34,856 Non-c 31 March 2017 £000s 0	25,974 34,856 urrent 31 March 2016 £000s 0
Opening balance at 1 April 2016 Deferred revenue addition Transfer of deferred revenue	31 March 2017 £000s 4,707 5,040 (4,707)	rent 31 March 2016 £000s 4,858 4,707 (4,858)	34,856 Non-c 31 March 2017 £000s 0 0	25,974 34,856 urrent 31 March 2016 £000s 0 0

Sandwell and West Birmingham Hospitals NHS Trust - Annual Accounts 2016-17

#### 24. Provisions

		Comprising:				
		Early	Legal Claims	Restructuring	Other	Redundancy
	Total	Departure				
		Costs				
	£000s	£000s	£000s	£000s	£000s	£000s
Balance at 1 April 2016	4,567	963	373	70	2,850	311
Arising during the year	500	72	181	0	110	137
Utilised during the year	(910)	(96)	(215)	(61)	(227)	(311)
Reversed unused	(47)	(3)	(37)	0	(7)	0
Unwinding of discount	45	13	0	0	32	0
Change in discount rate	388	68	0	0	320	0
Transfers to NHS Foundation Trusts on being authorised as FT	0	0	0	0	0	0
Transfers (to)/from other public sector bodies under absorption accounting	0	0	0	0	0	0
Balance at 31 March 2017	4,543	1,017	302	9	3,078	137
Expected Timing of Cash Flows:						
No Later than One Year	1.147	92	302	9	607	137
Later than One Year and not later than Five Years	907	368	0	0	539	0
Later than Five Years	2,489	557	0	0	1,932	ō

Amount Included in the Provisions of the NHS Litigation Authority in Respect of Clinical Negligence Liabilities:

	£000s
As at 31 March 2017	154,786
As at 31 March 2016	130,664

Provisions relating to Early Departure Costs covers pre 1995 early retirement costs. Liabilities and the timing of liabilities are based on pensions provided to individual ex employees and projected life expectancies using government actuarial tables. The major uncertainties rest around life expectancies assumed for the cases.

Legal claims cover the Trust's potential liabilities for Public and Employer liability. Potential liabilities are calculated using professional assessment of individual cases by the Trust's insurers. The Trust's maximum liability for any individual case is £10,000 with the remainder being covered by insurers.

Other provisions cover Injury Benefits £2,614,000, HMRC Off Payroll Engagement £325,000 and National Poisons potential expenditure of £74,653

Injury benefit provisions are calculated with reference to the NHS Pensions Agency and actuarial tables for life expectancy.

Redundancy provisions covers staff who will be made redundant as part of the Trust's ongoing restructuring scheme

The timing and amount of the cashflows is shown above but it must be pointed out that, in the case of provisions, there will always be a measure of uncertainty. However, the values listed are best estimates taking all the relevant information and professional advice into consideration.

#### 25. Contingencies

•	31 March 2017 £000s	31 March 2016 £000s
Contingent liabilities		
NHS Litigation Authority legal claims	(188)	(202)
Employment Tribunal and other employee related litigation	0	0
Redundancy	0	0
Other - Pension and Injury Benefits	(92)	(507)
Net value of contingent liabilities	(280)	(709)
Contingent assets		
Contingent assets	0	0
Net value of contingent assets	0	0

#### 26. Analysis of charitable fund reserves

The Trust has not consolidated charitable funds within this set of accounts

### 27. PFI and LIFT - additional information

The information below is required by the Department of Heath for inclusion in national statutory accounts

A contract for the development of a new hospital was signed by the Trust and its PFI partner on 11/12/2015. The purpose of the scheme is to deliver a modern, state of the art acute hospital facility on the Grove Lane site in Smethwick, Birmingham.

The Midland Metropolitan Hospital (MMH) will be fully operational in Spring 2019. The hospital is being delivered through PF2 and which involves an 30 year concession period ending in 2048/49. At the end of that concession period the asset shall pass into the ownership of the Trust or successor body.

The anticipated asset value of the hospital when brought into use will be £323,638,000

The Trust shall receive £97m of Public Dividend Capital which it expects to pay to its PFI partner as a contribution to the costs of the hospital development

The Trust is contractually committed to a total Unitary Payment cost in respect of the Midland Metropolitan Hospital of £698,443,000 payable over the life of the 30 year concession

Note 12.1 (Property, Plant and Equipment) includes £13,107,786 (2015/16 £10,283,792) as Assets under Construction in respect of the Midland Metropolitan Hospital. This represents costs incurred directly by the Trust in support of the hospital development

The Trust currently operates the Birmingham Treatment Centre (BTC) under a PFI concession and accounts for a Managed Equipment Service (MES) as a PFI scheme. The values below represent the financial obligations relating to the BTC and MES Scheme only

## **Birmingham Treatment Centre (BTC)**

Length of Contract is 30 Years

The purpose of the scheme was to provide a modern, acute facility on the City Hospital site which has now been fully operational since June 2005. The Trust is committed to the full unitary payment until 30th June 2035 at which point the building will revert to the ownership of the Trust

## Managed Equipment Scheme (MES)

Length of Contract is 10 Years

The Scheme provides for the maintenance and replacement of the Trust's Imaging Equipment. This contract was assessed against the scope of IFRC12 to establish the appropriate accounting treatment and it was determined that the criteria to account for the scheme as an on SOFP service concession arrangement had been met. The contract, with Siemens Healthcare Limited, commenced on 1st May 2016 and the Trust is committed to the full unitary payment until May 2026 at which point the ownership of the equipment will revert to the Trust

## Charges to operating expenditure and future commitments in respect of ON and OFF SOFP PFI

2016-17 £000s	2015-16 £000s
0	0
2,166	863
2,166	863
2,570	929
10,286	3,955
23,242	17,741
36,098	22,625
	2,166 2,166 2,166 2,570 10,286 23,242

0046 47

26,813

0

26.897

0045 40

The estimated annual payments in future years are not expected to be materially different from those which the Trust is committed to make during the next year.

## Imputed "finance lease" obligations for on SOFP PFI contracts due

	2016-17	2015-16
	£000s	£000s
No Later than One Year	(5,868)	2,638
Later than One Year, No Later than Five Years	12,546	8,760
Later than Five Years	34,439	31,134
Subtotal	41,117	42,532
Less: Interest Element	(14,304)	(15,635)
Total	26,813	26,897
Present Value Imputed "finance lease" obligations for on SOFP PFI contracts due	2016-17	2015-16
Analysed by when PFI payments are due	£000s	£000s
No Later than One Year	(7,140)	1,306
Later than One Year, No Later than Five Years	7,979	3,990
Later than Five Years	25,974	21,601

### Number of on SOFP PFI Contracts

Total

Total Number of on PFI contracts

Number of on PFI contracts which individually have a total commitments value in excess of £500m

# 28. Impact of IFRS treatment - current year

	201	6-17	201	5-16
The information below is required by the Department of Heath for budget reconciliation purposes	Income £000s	Expenditure £000s	Income £000s	Expenditure £000s
Revenue costs of IFRS: Arrangements reported on SoFP under IFRIC12 (e.g PFI / LIFT)  Depreciation charges Interest Expense Impairment charge - AME Impairment charge - DEL  Other Expenditure Revenue Receivable from subleasing Impact on PDC dividend payable  Total IFRS Expenditure (IFRIC12)  Revenue consequences of PFI / LIFT schemes under UK GAAP / ESA95 (net of any sublease revenue)  Net IFRS change (IFRIC12)	0	1,723 2,145 0 0 2,167 (140) 5,895 6,404 (509)	0	450 2,005 1,368 0 863 (284) 4,402 3,643 759
Capital Consequences of IFRS: LIFT/PFI and other items under IFRIC12 Capital expenditure 2015-16 UK GAAP capital expenditure 2015-16 (Reversionary Interest)		2,697 756		414 656
	2016-17 Income/ Expenditure IFRIC 12 YTD £000s	2016-17 Income/ Expenditure ESA 10 YTD £000s	2015-16 Income/ Expenditure IFRIC 12 YTD £000s	2015-16 Income/ Expenditure ESA 10 YTD £000s
Revenue costs of IFRS12 compared with ESA10 Depreciation charges Interest Expense Impairment charge - AME Impairment charge - DEL Other Expenditure	1,723 2,145 0 0		450 2,005 1,368 0	
Service Charge Contingent Rent Lifecycle Impact on PDC Dividend Payable	2,167 0 0 (140)	6,404	863 0 0 (284)	3,643
Total Revenue Cost under IFRIC12 vs ESA10	5,895	6,404	4,402	3,643
Revenue Receivable from subleasing  Net Revenue Cost/(income) under IFRIC12 vs ESA10	<u>0</u> 5,895	6,404	4,402	3,643
The state of the s	5,055	3,104	1, 702	5,546

### 29. Financial Instruments

### 29.1. Financial risk management

Financial reporting standard IFRS 7 requires disclosure of the role that financial instruments have had during the period in creating or changing the risks a body faces in undertaking its activities. Because of the continuing service provider relationship that the NHS Trust has with CCG's and the way those CCG's are financed, the NHS Trust is not exposed to the degree of financial risk faced by business entities. Also financial instruments play a much more limited role in creating or changing risk than would be typical of listed companies, to which the financial reporting standards mainly apply. The NHS Trust has limited powers to borrow or invest surplus funds and financial assets and liabilities are generated by day-to-day operational activities rather than being held to change the risks facing the NHS Trust in undertaking its activities.

The Trust's treasury management operations are carried out by the finance department, within parameters defined formally within the Trust's standing financial instructions and policies agreed by the board of directors. Trust treasury activity is subject to review by the Trust's internal auditors.

#### Currency risk

The Trust is principally a domestic organisation with the great majority of transactions, assets and liabilities being in the UK and sterling based. The Trust has no overseas operations. The Trust therefore has low exposure to currency rate fluctuations.

#### Interest rate risk

The Trust borrows from government for capital expenditure, subject to affordability as confirmed by NHS Improvement. The borrowings are for 1 – 25 years, in line with the life of the associated assets, and interest is charged at the National Loans Fund rate, fixed for the life of the loan. The Trust therefore has low exposure to interest rate fluctuations.

The Trust may also borrow from government for revenue financing subject to approval by NHS Improvement. Interest rates are confirmed by the Department of Health (the lender) at the point borrowing is undertaken.

The Trust therefore has low exposure to interest rate fluctuations.

#### Credit risk

Because the majority of the Trust's revenue comes from contracts with other public sector bodies, the Trust has low exposure to credit risk. The maximum exposures as at 31 March 2017 are in receivables from customers, as disclosed in the trade and other receivables note.

#### Liquidity risk

The Trust's operating costs are incurred under contracts with CCG's, which are financed from resources voted annually by Parliament . The Trust funds its capital expenditure from funds obtained within its prudential borrowing limit. The Trust is not, therefore, exposed to significant liquidity risks.

# 29.2. Financial Assets

29.2. Financial Assets	At 'fair value through profit and loss'	Loans and receivables	Available for sale	Total
	£000s	2000s	£000s	£000s
Embedded derivatives	0			0
Receivables - NHS		9,462		9,462
Receivables - non-NHS		5,415		5,415
Cash at bank and in hand		23,902		23,902
Other financial assets	0	0	0	0
Total at 31 March 2017	0	38,779	0	38,779
Embedded derivatives	0			0
Receivables - NHS		10,372		10,372
Receivables - non-NHS		3,665		3,665
Cash at bank and in hand		27,296		27,296
Other financial assets	0	0	0	0
Total at 31 March 2016	0	41,333	0	41,333
29.3. Financial Liabilities				
		At 'fair value through profit and loss'	Other	Total
		£000s	£000s	\$0003

Embedded derivatives
NHS payables
Non-NHS payables
Other borrowings
PFI & finance lease obligations
Other financial liabilities
Total at 31 March 2017
Embedded derivatives
Embedded derivatives NHS payables
NHS payables
NHS payables Non-NHS payables
NHS payables Non-NHS payables Other borrowings

Total at 31 March 2016

0		0
	13,774	13,774
	12,896	12,896
	0	0
	34,856	34,856
0	0	0
0	61,526	61,526
0		0
0	10,203	0 10,203
0	10,203 3,841	-
0	,	10,203
0	3,841	10,203 3,841
0	3,841 0	10,203 3,841 0
	3,841 0 26,897	10,203 3,841 0

# 30. Events after the end of the reporting period

There are no events to report that occurred after the reporting period

### 31. Related party transactions

During the year none of the Department of Health Ministers, trust board members or members of the key management staff, or parties related to any of them, has undertaken any material transactions with Sandwell & West Birmingham Hospitals NHS Trust.

The Department of Health is regarded as a related party. During the year 2016/17 Sandwell and West Birmingham Hospitals NHS Trust has had a significant number of material transactions with the Department, and with other entities for which the Department is regarded as the parent Department. These are listed below

NHS Sandwell & West Birmingham CCG
NHS Birmingham Cross City CCG
Health Education England
NHS Birmingham South & Central CCG
NHS Walsall CCG
NHS Litigation Authority
NHS Business Services Authority
The Dudley Group NHS Foundation Trust
Walsall Healthcare NHS Trust

In addition, the Trust has had a number of material transactions with other government departments and other central and local government bodies. Most of these transactions have been with Department for Education and Skills in respect of University Hospitals Birmingham NHS Foundation Trust, Sandwell MBC and Birmingham City Council.

The Trust has also received revenue and capital payments from a number of charitable funds including Sandwell & West Birmingham Hospitals NHS Trust Charity, certain of the trustees for which are also members of the Trust board. The summary financial statements of the Funds Held on Trust are included in this annual report and accounts.

## 32. Losses and special payments

The total number of losses cases in 2016-17 and their total value was as follows:		
	al Value Cases £s	Total Number of Cases
Losses	196,248	53
Special payments	144,805	76
Gifts	0	0
Total losses and special payments and gifts	341,053	129
The total number of losses cases in 2015-16 and their total value was as follows:		
· • •	al Value Cases £s	Total Number of Cases
Losses	150,889	125
Special payments	210,982	66
Total losses and special payments	361,871	191

Sandwell and West Birmingham Hospitals NHS Trust - Annual Accounts 2016-17

#### 33. Financial performance targets

The figures given for periods prior to 2009-10 are on a UK GAAP basis as that is the basis on which the targets were set for those years.

#### 33.1. Breakeven performance

2006-07 £000s	2007-08 £000s	2008-09 £000s	2009-10 £000s	2010-11 £000s	2011-12 £000s	2012-13 £000s	2013-14 £000s	2014-15 £000s	2015-16 £000s	2016-17 £000s
327,536	348,475	359,161	384,774	387,870	424,144	433,007	439,022	446,590	443,698	460,197
3,399	6,524	2,547	(28,646)	(6,885)	4,540	(3,441)	(2,505)	4,585	(4,254)	(6,996)
0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0
0	0	0	36,463	9,533	(2,395)	8,872	8,922	(263)	8,390	(5,161)
					358	1,092	334	331	(279)	224
			(557)	(455)	(640)	0	0	0	0	0
			( /	( /	(= -,	0	0	0	0	0
5,726	0	0	0	0	0	0	0	0	0	0
9,125	6,524	2,547	7,260	2,193	1,863	6,523	6,751	4,653	3,857	(11,933)
(4,402)	2,122	4,669	11,929	14,122	15,985	22,508	29,259	33,912	37,769	25,836
	\$000s 327,536 3,399 0 0 0 0 5,726 9,125	\$000s \$000s  327,536 348,475 3,399 6,524  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	£000s         £000s         £000s           327,536         348,475         359,161           3,399         6,524         2,547           0         0         0           0         0         0           0         0         0           0         0         0           0         0         0           0         0         0           0         0         0           0         0         0           0         0         0	£000s         £000s         £000s         £000s           327,536         348,475         359,161         384,774           3,399         6,524         2,547         (28,646)           0         0         0         0           0         0         0         0           0         0         0         0           0         0         0         36,463    (557)  5,726  0 0 0 0 0 0 7,260	£000s         £000s         £000s         £000s         £000s           327,536         348,475         359,161         384,774         387,870           3,399         6,524         2,547         (28,646)         (6,885)           0         0         0         0         0         0           0         0         0         0         0         0         0           0	£000s         £000s         £000s         £000s         £000s         £000s           327,536         348,475         359,161         384,774         387,870         424,144           3,399         6,524         2,547         (28,646)         (6,885)         4,540           0         0         0         0         0         0         0           0         0         0         0         0         0         0         0           0         0         0         0         0         0         0         0         0         0         0         0         0         0         358         358         (557)         (455)         (640)         640) <td< td=""><td>£000s         £000s         £000s         £000s         £000s         £000s         £000s           327,536         348,475         359,161         384,774         387,870         424,144         433,007           3,399         6,524         2,547         (28,646)         (6,885)         4,540         (3,441)           0         0         0         0         0         0         0         0           0         0         0         0         0         0         0         0           0         0         0         0         0         0         0         0         0           0         0         0         36,463         9,533         (2,395)         8,872           1         (557)         (455)         (640)         0         0         0           5,726         0         0         0         0         0         0         0           9,125         6,524         2,547         7,260         2,193         1,863         6,523</td><td>£000s         £000s         <th< td=""><td>£000s         £000s         <th< td=""><td>£000s         £000s         <th< td=""></th<></td></th<></td></th<></td></td<>	£000s         £000s         £000s         £000s         £000s         £000s         £000s           327,536         348,475         359,161         384,774         387,870         424,144         433,007           3,399         6,524         2,547         (28,646)         (6,885)         4,540         (3,441)           0         0         0         0         0         0         0         0           0         0         0         0         0         0         0         0           0         0         0         0         0         0         0         0         0           0         0         0         36,463         9,533         (2,395)         8,872           1         (557)         (455)         (640)         0         0         0           5,726         0         0         0         0         0         0         0           9,125         6,524         2,547         7,260         2,193         1,863         6,523	£000s         £000s <th< td=""><td>£000s         £000s         <th< td=""><td>£000s         £000s         <th< td=""></th<></td></th<></td></th<>	£000s         £000s <th< td=""><td>£000s         £000s         <th< td=""></th<></td></th<>	£000s         £000s <th< td=""></th<>

Due to the introduction of International Financial Reporting Standards (IFRS) accounting in 2009-10, NHS Trust's financial performance measurement needs to be aligned with the guidance issued by HM Treasury measuring Departmental expenditure. Therefore, the incremental revenue expenditure resulting from the application of IFRS to IFRIC 12 schemes (which would include PFI schemes), which has no cash impact and is not chargeable for overall budgeting purposes, is excluded when measuring Breakeven performance. Other adjustments are made in respect of accounting policy changes (impairments and the removal of the donated asset and government grant reserves) to maintain comparability year to year.

	2006-07 %	2007-08 %	2008-09 %	2009-10 %	2010-11 %	2011-12 %	2012-13 %	2013-14 %	2014-15 %	2015-16 %	2016-17 %
Materiality test (I.e. is it equal to or less than 0.5%):											
Break-even in-year position as a percentage of turnover	2.79	1.87	0.71	1.89	0.57	0.44	1.51	1.54	1.04	0.87	-2.59
Break-even cumulative position as a percentage of turnover	-1.34	0.61	1.30	3.10	3.64	3.77	5.20	6.66	7.59	8.51	5.61

The amounts in the above tables in respect of financial years 2005/06 to 2008/09 inclusive have not been restated to IFRS and remain on a UK GAAP basis.

Sandwell and West Birmingham Hospitals NHS Trust - Annual Accounts 2016-17

#### 33.2. Capital cost absorption rate

The dividend payable on public dividend capital is based on the actual (rather than forecast) average relevant net assets based on the pre audited accounts and therefore the actual capital cost absorption rate is automatically 3.5%.

#### 33.3. External financing

The Trust is given an external financing limit which it is permitted to undershoot.

	2016-17	2015-16
	£000s	£000s
External financing limit (EFL)	56,399	(1,217)
Cash flow financing	46,962	(1,431)
Finance leases taken out in the year	0	0
Other capital receipts	0	0
External financing requirement	46,962	(1,431)
Under/(over) spend against EFL	9,437	214

#### 33.4. Capital resource limit

The Trust is given a capital resource limit which it is not permitted to exceed.

	2016-17	2015-16
	£000s	£000s
Gross capital expenditure	19,029	20,347
Less: book value of assets disposed of	0	0
Less: capital grants	0	0
Less: donations towards the acquisition of non-current assets	(62)	(527)
Charge against the capital resource limit	18,967	19,820
Capital resource limit	18,968	19,860
(Over)/underspend against the capital resource limit	1	40

#### 34. Third party assets

The Trust held cash and cash equivalents which relate to monies held by the NHS Trust on behalf of patients or other parties. This has been excluded from the cash and cash equivalents figure reported in the accounts

	31 March	31 March
	2017	2016
	£000s	£000s
Third party assets held by the Trust - Patients' Monies	1	2

SWBTB (06/17) 22b

## Sandwell and West Birmingham Hospitals



**NHS Trust** 

Trust Headquarters Health & Wellbeing Centre Sandwell General Hospital Lyndon West Bromwich B71 4HJ

#### **Director of Finance**

Tel: 0121 507 4818 Fax: 0121 507 5636 Email: tonywaite@nhs.net

Andrew Bostock
Partner
KPMG LLP
One Snowhill
Snow Hill Queensway
Birmingham

1 June 2017

#### Dear Andrew

This representation letter is provided in connection with your audit of the Trust financial statements of Sandwell and West Birmingham Hospitals NHS Trust ("the Trust"), for the year ended 31 March 2017, for the purpose of expressing an opinion:

- as to whether these financial statements give a true and fair view of the state of the financial position of the Trust as at 31 March 2017 and of the Trust's income and expenditure for the financial year then ended; and
- whether the Trust's financial statements have been prepared in accordance with the Department of Health Group Accounting Manual (GAM).

These financial statements comprise the Trust Statement of Financial Position, the Statement of Comprehensive Income, the Statement of Cash Flows, the Statement of Changes in Taxpayers Equity and notes, comprising a summary of significant accounting policies and other explanatory notes.

The Board confirms that the representations it makes in this letter are in accordance with the definitions set out in the Appendix to this letter.

The Board confirms that, to the best of its knowledge and belief, having made such inquiries as it considered necessary for the purpose of appropriately informing itself:

#### **Financial statements**

1. The Board has fulfilled its responsibilities for the preparation of financial statements that:

- i. give a true and fair view of the financial position of the Trust as at 31 March 2017 and of the Trust's income and expenditure for that financial year; and
- ii. have been prepared in accordance with the GAM 2016/17.

The financial statements have been prepared on a going concern basis.

- 2. Measurement methods and significant assumptions used by the Board in making accounting estimates, including those measured at fair value, are reasonable.
- All events subsequent to the date of the financial statements and for which IAS 10 Events after the reporting period requires adjustment or disclosure have been adjusted or disclosed.
- 4. The effects of uncorrected misstatements are immaterial, both individually and in aggregate, to the financial statements as a whole. The total of unadjusted audit differences is acknowledged to be £0.4m which is not material to the financial statements.

#### Information provided

- 5. The Board has provided you with:
  - access to all information of which it is aware, that is relevant to the preparation of the financial statements, such as records, documentation and other matters;
  - additional information that you have requested from the Board for the purpose
    of the audit; and
  - unrestricted access to persons within the Trust from whom you determined it necessary to obtain audit evidence.
- 6. All transactions have been recorded in the accounting records and are reflected in the financial statements.
- 7. The Board confirms the following:
  - i. The Board has disclosed to you the results of its assessment of the risk that the financial statements may be materially misstated as a result of fraud.
    - Included in the Appendix to this letter are the definitions of fraud, including misstatement arising from fraudulent financial reporting and from misappropriation of assets.
  - ii. The Board has disclosed to you all information in relation to:
    - a) Fraud or suspected fraud that it is aware of and that affects the Trust and involves:
      - management;
      - employees who have significant roles in internal control; or
      - others where the fraud could have a material effect on the financial statements; and
    - allegations of fraud, or suspected fraud, affecting the Trust's financial statements communicated by employees, former employees, analysts, regulators or others.

In respect of the above, the Board acknowledges its responsibility for such internal control as it determines necessary for the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In particular, the Board acknowledges its responsibility for the design, implementation and maintenance of internal control to prevent and detect fraud and error.

- 8. The Board has disclosed to you all known instances of non-compliance or suspected non-compliance with laws and regulations whose effects should be considered when preparing the financial statements.
- 9. The Board has disclosed to you and has appropriately accounted for and/or disclosed in the financial statements, in accordance with IAS 37 Provisions, Contingent Liabilities and Contingent Assets, all known actual or possible litigation and claims whose effects should be considered when preparing the financial statements.
- 10. The Board has disclosed to you the identity of the Trust's related parties and all the related party relationships and transactions of which it is aware. All related party relationships and transactions have been appropriately accounted for and disclosed in accordance with IAS 24 Related Party Disclosures. Included in the Appendix to this letter are the definitions of both a related party and a related party transaction as we understand them and as defined in IAS 24.
- 11. The Board confirms that all intra-NHS balances included in the Statement of Financial Position (SOFP) at 31 March 2017 in excess of £100,000 have been disclosed to you and that the Trust has complied with the requirements of the Intra NHS Agreement of Balances Exercise. The Board confirms that Intra-NHS balances includes all balances with NHS counterparties, regardless of whether these balances are reported within those SOFP classifications formally deemed to be included within the Agreement of Balances exercise.

#### 12. The Board confirms that:

- a) The financial statements disclose all of the key risk factors, assumptions made and uncertainties surrounding the Trust's ability to continue as a going concern as required to provide a true and fair view.
- b) Any uncertainties disclosed are not considered to be material and therefore do not cast significant doubt on the ability of the Trust to continue as a going concern.
- 13. The Trust is required to consolidate any NHS charitable funds which are determined to be subsidiaries of the Trust. The decision on whether to consolidate is dependent upon the financial materiality and governance arrangements of the charitable funds. The Board confirms that, having considered these factors, it is satisfied that the charitable funds should not be consolidated.
- 14. The Board provides the following specific representations as follows:
  - a) The Trust confirms that the approach to the Modern Equivalent Asset (Alternative Site) valuation to apply a General Hospital approach adopted by the professional valuer is an appropriate representation of the existing service potential of the Trust's land and building assets.
  - b) The Trust has identified all potential obligating events arising as a result of its Long Term Workforce model and recognised these as required within the financial statements.

c) The Trust has identified all surplus assets and accounted for these in accordance with IFRS13 and IFRS 5.

This letter was challenged and confirmed as appropriate by the Audit & Risk Management Committee on 24 May 2017 and considered and agreed at the meeting of the Board of Directors on 1 June 2017.

Yours sincerely

#### **Antony M Waite**

Finance Director

For and on behalf of the Board of Sandwell and West Birmingham Hospitals NHS Trust



SWBTB (06/17) 22c

## Sandwell and West Birmingham Hospitals Mi

**NHS Trust** 

Trust Headquarters Health & Wellbeing Centre Sandwell General Hospital Lyndon West Bromwich B71 4HJ

#### **Director of Finance**

Tel: 0121 507 4818 Fax: 0121 507 5636 Email: tonywaite@nhs.net

Andrew Bostock
Partner
KPMG LLP
One Snowhill
Snow Hill Queensway
Birmingham B4 6GH

1 June 2017

Dear Andrew

#### **QUALITY ACCOUNTS 2016/17 - BOARD REPRESENTATION LETTER**

This representation letter is provided in connection with your limited assurance engagement regarding the Quality Accounts of Sandwell & West Birmingham Hospitals NHS Trust ("the Trust") for the year ended 31 March 2017 for the purpose of forming a conclusion, based on limited assurance procedures, on whether anything has come to your attention that causes you to believe that:

- the Quality Account is not prepared in all material respects in line with the criteria set out in the Regulations;
- the Quality Account is not consistent in all material respects with the sources specified in the NHS Quality Accounts Auditor Guidance 2014-15 ("the Guidance"); and
- the indicators in the Quality Account identified as having been the subject of limited assurance in the Quality Account are not reasonably stated in all material respects in accordance with the Regulations and the six dimensions of data quality set out in the Guidance.

#### The Board confirms that:

a) The Quality Account has been prepared in accordance with National Health Service (Quality Accounts) Regulations 2010 (as amended) and the Guidance;

- b) The content of the Quality Account is not inconsistent with the internal and external sources of information set out in the Guidance;
- c) The Quality Account presents a balanced picture of the NHS Trust's performance over the period covered;
- d) The performance information reported in the Quality Account is reliable and accurate;
- e) There are proper internal controls over the collection and reporting of the measures of performance included in the Quality Account, and these controls are subject to review to confirm that they are working effectively in practice; and
- f) The data underpinning the measures of performance reported in the Quality Report is robust and reliable, conforms to specified data quality standards and prescribed definitions, is subject to appropriate scrutiny and review;

This letter was presented and agreed at the meeting of the Board of Directors on 1 June 2017.

Yours sincerely

#### **Antony M Waite**

Finance Director

For and on behalf of the Board of Sandwell and West Birmingham Hospitals NHS Trust

## Sandwell and West Birmingham Hospitals WHS

**NHS Trust** 

TRUST BOARD		
DOCUMENT TITLE:	Application of the Trust Seal to Lease for the Independent Living Centre	
SPONSOR (EXECUTIVE DIRECTOR):	Alan Kenny – Director of Estates/New Hospital	
AUTHOR:	Rob Banks – Deputy Director of Estates/New Hospital	
DATE OF MEETING:	1 <sup>st</sup> June 2017	

#### **EXECUTIVE SUMMARY:**

In accordance with Trust practice the Board is asked to approve the affixation of the Trust seal to the following document:

Lease with Sandwell Borough Council for the use of accommodation in the Independent Living Centre, 100 Oldbury Road, Smethwick. Use of accommodation for Integrated Care Services (iCares) and Wheelchair Services.

The Key Terms are:

- 5 year lease from 2017 to 2022
- Rental charge is £8,000 per annum, payable quarterly in advance
- Trust reasonable contribution towards service charges
- Contracted out of Landlord & Tenant Act

#### **REPORT RECOMMENDATION:**

The Board are recommended to:-

Approve the application of the Trust Seal to the aforementioned document

#### **ACTION REQUIRED** (*Indicate with 'x' the purpose that applies*):

The receiving body is asked to receive, consider and:

Accept	Approve the recommendation	Discuss
X	X	
KEY AREAS OF IMPACT (Indicate with 5	x' all those that apply):	

Financial		Environmental		Communications & Media
Business and market share		Legal & Policy	Χ	Patient Experience
Clinian		Equality and		Workforce

Diversity

#### Comments:

Clinical

#### ALIGNMENT TO TRUST OBJECTIVES, RISK REGISTERS, BAF, STANDARDS AND PERFORMANCE METRICS:

#### PREVIOUS CONSIDERATION:

Full agreement with Community & Therapies, Integrated Care Services/Wheelchair Services Clinical Team Leader.

## Sandwell and West Birmingham Hospitals NHS Trust

## TRUST BOARD PUBLIC MEETING MINUTES

Venue:	Anne Gibson Board Room, City	Hospital	<u>Date:</u> 4 <sup>th</sup> May 2017, 0930 – 1300h	
Members	s Present:			
Ms O Dut	ton, Vice-Chair	(OD)		
Mr H Kan	g, Non-Executive Director	(HK)	In Attendance:	
Mrs M Pe	erry, Non-Executive Director	(MP)		
Cllr W Za	ffar, Non-Executive Director	(WZ)	Mrs C Rickards, Trust Convenor	(CR)
Mr T Lew	is, Chief Executive	(TL)	Mrs R Wilkin, Director of Communications	(RW)
Ms E Nev	vell, Chief Nurse	(EN)	Dr Chizo Agwu, Consultant Paediatrician in	
Dr R Sted	man, Medical Director	(RSt)	Diabetes & Endocrinology/Children & Young	
Mr T Wai	te, Finance Director	(TW)	People's Champion – item 2 only	(CW)
Ms R Barl	ow, Chief Operating Officer	(RB)	Nurse Liz Hudson, Paediatric Nurse – item 2 only	(LD)
Mrs R Go	odby, Director of OD	(RG)	Prof. Kate Thomas, Non-Executive designate	(KT)
Miss K Dł	nami, Director of Governance	(KD)		
			Secretariat:	
			Miss R. Fuller. Executive Assistant	(RF)

Minutes	Reference
1. Welcome, apologies and declaration of interests	Verbal

Apologies were received from Mr. Richard Samuda and Ms Dutton took the meeting chair. Ms. Dutton welcomed Prof Kate Thomas who will be the University appointed NED replacing Dr. P. Gill. Prof. Thomas is also a serving GP in Sutton Coldfield.

**Declarations of Interest**: there were no declarations received.

2. Staff Story	Verbal

The Board watched a video from a young patient – Jess who suffers from diabetes and how she is making the transition from childhood to adulthood treatment within the Trust.

Dr. Agwu talked through her new role as Young Persons Champion. This new post, created by the Trust, aims to ensure that a young person makes the transition from childhood clinical environment which is very family orientated into the adult clinical environment. The transition period typically begins when the young person is 16 years until 18. In our approach a key worker is assigned to help the navigation into the system and ensure they have the skills to be able to take responsibility of their condition.

The board discussed the use of digital technology which should be explored further as this was a medium already used by Jess in her consultations.

Ms. Barlow queried the catchment of the Trust included a high amount of students coming to the City's Universities for study and this type of service would be of benefit to them. Unfortunately, this service was not available to the

City's Universities but the Young Peoples Development Board were asked to discuss at a future meeting whether this might be an offer which could be put to UoB and Aston.

Mrs Perry asked if the transition service offered to young people fell foul of a postcode lottery. Dr. Agwu confirmed this could be the case. Her approach is to set some agreed standards for transition, which have been shared with the Board's quality and safety committee. The intent is to try and move towards those standards over the next 18 months. Dr. Stedman informed the board that many GPs treated asthma in children as a condition that they would grow out of and there were very few instances where children would attend care in a hospital environment other than an emergency episode, however deaths from asthma was high in the health economy. Dr Thomas noted the risks but suggested that there is more the Trust can do to help GPs in managing asthmas. Mr Lewis noted that under the 2014-17 public health plan all our paediatric nurses have been retrained in asthma.

Dr Agwu was asked about support to parents in relinquishing responsibility to the child. It was confirmed that parents are involved as much as the young adult, the aim is for the parent to become the parent consultant where they can provide advice and support from being the parent supervisor, the person who takes charge and makes all the decisions.

Following a further brief discussion Ms Dutton thanked Dr. Agwu and Nurse Hudson for sharing a positive story with the board of patient engagement with the Trust. Ms Dutton asked for thanks to be passed to Jess for her time in sharing her story.

#### **ACTION:**

• Service to reach out to University population – for discussion at the Young Peoples Development Board

#### 3. Questions from the public

Verbal

Mr. Hodgetts queried the following:

Were patients being encouraged to speak up and ask more questions in order to deter Never Events. Dr. Stedman confirmed as part of the safety checks the patient is briefed on their procedure at 2 stages, once with the doctor in outpatients and again on the day of procedure. Patients are also encouraged to make contact if they have any queries or questions. This exception to this 2 stage check is when a patient attends outpatient for a consultation and procedure on the same day and when a patient is referred from an outside the organisation. The most recent Never Event fall into the exception category where the patient attended outpatients. However, none of the investigations to date have found this interaction from patients to be the key issue in error.

Will the maternity services be staying at City or moving to Midland Met? Mr. Lewis confirmed the birthing service will move to Midland Met, a decision on the Halcyon Suite will be made in 6 months, but the correct statutory consultation will follow if necessary.

#### 4. Chair's opening comments

Verbal

The Chair reported no items for comment

#### Charitable Funds

SWBTB (05/17) 001 SWBTB (05/17) 002

Cllr Zaffar reported the key highlights.

- ➤ 5 year funding strategy incorporated of years 1 3 focusing on Midland Met. The Charity team were asked to review income targets at years 4 5.
- The Charitable fund policy is on track for completion over coming weeks
- Conversion to a single trust deed the merging of the linked charities into one main umbrella charity has been completed.
- ➤ Make-up of the Charitable Funds Committee discussion to consider staff representatives onto the committee

Mr. Lewis informed the Trust Board that he would be organising an event on the priorities of the charity committee in the next few months.

#### Minutes of the Charitable Funds Committee – 9<sup>th</sup> February 2017 were noted

6	. Audit and Risk Committee	SWBTB (05/17) 003
		SWBTB (04/17) 004

Mrs. Perry reported on the key highlights from the Audit Committee.

- ➤ Going Concern Assessment the 2017/18 annual accounts will be prepared as a going concern following a management assessment
- Draft annual accounts presented and no escalated issues were highlighted
- The reference cost submission for 2016/17 will be brought to the September Trust Board
- Internal Audit Plan 2017/18. It was established at the Committee that the plan had not been submitted for sign off by the full executive team. The Plan will be represented to the Committee in May.

Mr Waite commented that some of the audit recommendations still needed alignment but the Auditors will be producing an IS260 for presentation at the June board.

#### Minutes of the Audit & Risk Management Committee - 26th January 2017 were noted

7. Major Projects Authority	SWBTB (05/17) 005
	SWBTB (05/17) 006

Mr. Hoare highlighted the following from the meeting:

- Land Disposal there is a compliant bid and the land sale papers from the Land Sales Committee will be circulated to trust board members for information.
- > STC this has been signed off by the Committee including plans on the next phase. The BTC design needs to be completed to ensure no services are homeless.
- People Plan the Committee will review the plan to see if the chartered management programme could be expedited so managers could complete the training sooner.

Mr Lewis stated the Land Sales Committee comprising of Mr. Samuda, Mr Kang, Mrs Perry, Mr. Waite and Mr. Kenny, will meet with him to scrutinise the bid and any other options to obtain the best value for the Trust. The cash generated should still arrive in Q1.

#### Minutes of the Major Projects Authority Committee – 24<sup>th</sup> February 2017 were noted

#### **ACTION**:

Land sales committee papers to be circulated – Mr. Kenny

8.	Finance Committee	Verbal
		SWBTB (05/17) 008

Mr. Kang highlighted the following:

- Financial Performance Mr. Waite confirmed the Trust would be delivering a deficit at year end as forecast. The Committee challenged the outstanding income from the CCG how that played into the accounts but was satisfied that the position was reconciled. The contract for 2017/19 is still unsigned.
- Production Plan period 1 have indicated booked activity was in line with the production plan. A review of the maths will also be undertaken and the standards set by the Board need to be met.
- Financial Improvement Plan Ernst & Young have been engaged to secure immediate improvement of the financial run rate through tactical and quick wins and improved grip and control. This work will cost a six figure sum and their ongoing involvement will be reviewed in June.

#### Minutes of the Finance & Investment Committee - 31st March 2017 were noted

## 9. Quality and Safety Committee SWBTB (05/17) 007 SWBTB (05/17) 010

Ms Dutton highlighted:

- ➤ 2016/17 Clinical Audit 2 audits raised concern.
  - o DNACPR in patients showing lack of capacity involvement of friends and family fell short.
  - WHO checklist noted that in some instances not all members of the team were present to sign. Dr.
     Stedman reported although not all team members were present when sign off took place, it has been identified that the core team members will be present during sign off.
- ➤ Consistent Reds on IPR data a new approach is being taken to look at why some performance indicators continually just miss the performance target set. This will be discussed by the Executive Team and represented to the Board.
- NG Tube misplacement the Trust board is asked to note the compliance with the PSA relating to NG Tube misplacement. A delivery action plan will be monitored by the Committee

Mr Lewis identified an error on the 'matters presented for information or noting', - Ionising Radiation regulations annual report should read **Ionising Radiology regulations annual report**.

#### Minutes of the Quality & Safety Committee – 31st March 2017 were noted

#### 10. Chief Executive's Report

SWBTB (05/17) 011

Mr. Lewis highlighted the following from his report:

Eye casualty and patient experience: There will be a major change in the eye casualty in that approximately 70% of patients will be triaged to return for treatment on the following day. The key benefit of this system is patients will have an appointment to come back and see the correct clinician. Ms. Barlow and her team are monitoring the situation closely as it has the potential to be disruptive for long standing users of the service.

EPR Training: During August and September extra training will be undertaken but we need to ensure mandatory training is kept on track. The board discussed the operational impact with training in September and staff holidays. Mr. Lewis assured the board that notwithstanding holidays already booked the timetable has factored staff leave. The model was discussed at a recent Clinical Leadership Executive Committee meeting. There will be choice available for training and those staff who have leave booked there will be still be opportunity for them to train during this time.

Termination of the tertiary level gynae-oncology contract: This has been discussed at the private board and is now confirmed. The notice period goes to late October 2017 and the Trust is working constructively with NHS England to understand their future commissioning intentions.

Learning disabilities: Mr Lewis reported that progress had reduced in the last 4 months. The letters to GPs has not happened and he would pick this up with Ms. Claire Parker from the CCG. The training timetable for AMU staff has been revised to the end of June. Issues around the advisory service with the Black Country Partnership was noted mainly due to the absence of the right staff, however this will be updated and reported back at the July meeting.

#### **ACTION:**

Learning disabilities – update to the July meeting on the advisory service with the Black Country Partnership.

#### 11. Board Assurance Framework

SWBTB (05/17) 012

Ms Dhami provided the Board Assurance Framework for update and drew to the board's attention the amendment of O13-GUR, the rating has returned to red following the pausing of the work by Mr. Lewis. Mr. Lewis stated the risk has not changed but progress resolving it has stayed. He now intended to proceed by comparing what is

needed with what EPR can provide. The Board discussed the shape and additional benefits of EPR to the Trust and understood that it was looking at other providers i.e. The Wirral to understand operationally how some of our reports will be configured. Ms. Dutton noted the high work volume being undertaken by Mr. Lewis and Mr. Reynolds on EPR. Mr. Lewis reassured the board that the responsibility of the system rests with him; the information and reporting challenges falls between many different people. EPR is about all our jobs and the structure will be looked at to ensure the right resources and people are mobilised effectively.

Other areas highlighted by the board were:

<u>Caseloads</u> – it was unclear where this was going to be tracked. It was noted that the Primary Community & Therapies Group could annex the community caseload within the safe staffing of wards report, which annexes Mr Lewis' CEO report. Ms. Barlow agreed to take this forward.

<u>O17-21CI Sheldon Block</u> – The board asked for clarification on the risk. Mr. Lewis clarified proposal would not be delivered following the CCG reneging on the intermediate care agreement. Mr. Lewis now wants to satisfy himself that there is an out of hospital bed base which will support the activity and contracting model for Midland Met.

#### 12. Trust Risk Register

SWBTB (05/17) 013

Miss Dhami reported no risks being escalated from the Clinical Leadership Executive Committee. However, the project risks on Digital and MMH will be discussed at executive level. Dr. Stedman stated there were a high number of risks associated with digital and the risks impact on the whole organisation. Mr Lewis noted that project risks require visibility on safeguard and this needs to be organised in coming weeks.

BCG Vaccine: Mrs. Newell confirmed that all children have been recalled to attend for a vaccination and she was not aware of any issues with continued distribution of the vaccine. The Board asked the Risk Management Board to provide assurance that all outstanding vaccines have been delivered and confirm availability of future stocks.

#### **ACTION:**

• Risk Management Committee asked to provide assurance that all outstanding vaccines have been delivered and to confirm availability of future stocks.

#### 13. Integrated Performance Report

SWBTB (04/17) 014

Mr. Waite drew the boards attention to the new style cover report which now showed the IPR Summary scorecard for March. Positives to note were 62-day cancer, RTT, Stroke & Cardiology and also infection control.

A more detailed discussed took place at the Quality & Safety Committee who are reviewing the failing indicators and finding out why these targets are being narrowly missed.

The following was highlighted:

C sections: The trust is currently below the regional average which is above national norms. We have monitored our position following a spike, which has now stabilised. The Board agreed that the actions in place were sufficient.

Early booking: Mrs Newell confirmed the Trust is meeting the national target but it will now become difficult to improve as more publicity was needed and more input from our partner organisations of the CCG and Public Health as many pregnant women in the community don't present early or not until birth.

Patient safety thermometer: Mr. Lewis reported this measure was of no value to the Trust at it looked at a point in time, but as a national indicator it will be left in place. The 10:10 indicator was a better indicator of this measure as it provided daily information on our safety and not on a sampled basis.

Falls: Mrs Newell indicated to the board that she will be reviewing falls per 100 bed days and establishing a benchmark including fall with harms and pressure sores. A discussion outside of this meeting will take place.

WHO Safer Surgery: Dr. Stedman reported the 100% target was just being narrowly missed at 98/99% and it would be helpful to know why the target was being missed, which would be discussed at the Theatre Management Board and an action plan implemented. Mr. Lewis confirmed he would include an update in his regular CEO report.

Mortality Reviews: Improvements were reported for November and December 2016 but a dip January 2017. There was a recent Death Conference and the Trust is looking at the learning from that conference. Dr. Stedman informed the board that he is aiming to resource a cohort of staff to become expert reviews, the role will be similar to that of a medical examiner role. Therefore, all deaths will be reviewed daily and filtered to the appropriate work stream.

Sepsis: Mrs. Barlow reported there was a compliant plan with a 3 stage escalation process, departmental team, directorate and then the executive.

Cancellations: Cancellation rates are improving, but more work to be done and the Theatre Management Board will focus on this subject further during Q2. There is evidence of due process not being followed.

Theatre utilisation: Improving this sits behind the production plan and is also part of the work to improve our finances. More wok is needed to specify improvement actions. Ms Barlow is accountable for this work.

Hip Fractures: There has been really good progress, albeit small numbers make the percentage measure a crude proxy. The expectation is that we will deliver in the coming year.

Mrs Goodby reported on the formal notices from the CCG and reported an improvement in the safe guarding training for level 3 was 85% an improvement of 6%. Level 1 was almost at 100%.

#### **ACTION:**

Mortality – the medical examiner role to be discussed at the Safety QUOD meeting – Mr. Lewis

#### 14. Financial performance: P12 March 2017

SWBTB (05/17) 015

Mr. Waite reported the results for P12 reflected the full financial year are echoed in the draft annual accounts. Mr. Waite paid tribute to the capital team and the results realised on medical equipment.

Mr. Lewis update on **Birmingham City Council's** debt to the Trust. There is a provision in the accounts for the deficit and the Audit Committee are sighted on the problem. The amount is approximately £1m+ which relates to delayed transfers of care and goes back to 2015/16. It continues to mount and invoices continue to be issued.

Prof Thomas queried if the council had the ability to pay the debt. Mr. Lewis confirmed following a conversion with the CEO the debt is a statutory obligation and all organisations have to operate within that envelope. The Council has a greater borrowing ability than the Trust. Cllr Zaffar noted his conflict of interests to the Board as a member of the City Council. Mr Lewis also highlighted his concern regarding the 15-bed benefit for BCC residents assumed in the Chancellor's announcement in the autumn statement.

Other debtors: It was stated that writing off debts was a last resort and the finance team had a full suite of debt recovery methods available, i.e. visiting home, and chasing payments who have left this country. The provision in the accounts is approximately 80% but it was not expected to write off that amount of debt. There have been improved invoicing arrangements and obtaining more upfront money and the arrangements for identifying, billing and collecting debt has improved. The Audit & Risk Committee monitor debtors regularly at its meeting. Miss Dhami assured the Board that improvements have been made in identifying patients who need to pay but a more direct way was needed to be found to obtain payment as it was difficult and uncomfortable for staff to police. Mr. Lewis noted that our policy was to not proceed elective care until payments had been made and this should now enforced.

The Board discussed the difficulties of collecting money from patients not automatically entitled to NHS care and Ms Dhami and Mr. Waite would discuss at the next Audit & Risk Committee.

Delegated budgets: Mr. Lewis informed the board that teams who underspend in 2016/17 would receive that benefit in 2017/18 however they would still have new targets to meet. Teams that overspent would need to recover that the following year. Ms Barlow, Mr. Waite and Mr Lewis would only reset a budget if an overspend was deemed unrecoverable, however most groups were operating on a 6% savings plan. The majority of clinical groups had difficult and challenging budgets but the Executive team have some focused work and are meeting with teams on a fortnightly basis until July to crystallise the position.

Mr. Lewis updated the board that the contract with the CCG continues to remain unsigned.

#### 15. Production Plan: month 1 results

SWBTB (05/17) 016

Mr. Waite report delivery of planned care was on time which was an anchor to the financial plan for 2017/18. Referenced governance work will check all data to ensure it is fit and properly aligned. Ms Barlow stated that some areas are not performing as well as last year but she is meeting weekly to resolve issues. It was noted Liam Kennedy will commence as the new Deputy COO for Planned Care in the next few weeks.

Mrs Perry noted the good start to the year but some of the group show inconsistencies and underperformance notable in ENT. Ms. Barlow confirmed that ENT's failure was around the utilisation of sessions and the booking of lists, however there has been rescheduling and focused work done to re-correct the position by May.

Ms. Barlow stated there was approximately 10% of overbooking to counter balance DNAs, the planned numbers are higher than the production plan to allow for DNAs.

Following further discussion, the board asked for the 4-5 measures of board assurance to be available at the next board meeting and to ensure surgeons are have signed off on this approach.

#### **ACTION:**

The 4 – 5 measures of board assurance to be available for the next board meeting

#### 16. Emergency Department Improvement Plan

SWBTB (05/17) 017

Ms Barlow followed up from discussion at the Board Development Session of a stepped up approach to deliver 90% in 4 hour waits from 85%.

The final target is achieving 95% which equites to less than 50 breaches a day. There have been changes in how we use at Sandwell A&E but further concentrated work is required with the delivery team to change historic behaviour of staff. More developmentally there is a plan to improve access to GP appointments including direct booking from ED itself.

An urgent care week will take place wb May 29<sup>th</sup> and another week beginning June 20<sup>th</sup>. The first will focus on changed processing in ED. The latter on bed flow.

#### **ACTION:**

A&E scorecard to be available at the next Trust Board

#### 17. Public Health Plan: draft priorities 2017-20

Presentation

Mr. Lewis tabled a presentation on the Public Health Plan which has been shared with the Public Health Committee. The plan noted the objectives for the Trust and which had been achieved. The majority of the aims have been successful with the exception of:

- ➤ MECC this has been paused for 4 5 months until the right metric is in place to record conversations made as well as which patients have been referred.
- Alcohol This has not been delivered but a new peripatetic team is in place, funded via the the Charity, to try

and later admitting patterns. Work is continuing with Sandwell councillors to agree a pricing strategy based on an evidence-based model which shows real impact.

Smoking Cessation – the shelters have not been completed and the action stayed on the tracker in Mr Lewis' name.

The continued aim now was to make public health everyone's job and via the PMO format this will be translated into all clinical groups. The Warwick Business School will be assisting to evaluate the work and improvement works. The Improvement Team will be asked to assist with help with MECC and alcohol.

Mr Kang queried if organisations such as the AA were in partnership to assist with the alcohol objective. It was confirmed that the organisation is already working with the Trust.

The board discussed Sandwell's input and noted its objectives especially on life to years which the focus did not alight to the CCG as the Council looked at premature deaths i.e. infant mortality. The trust would continue to support the council but current initiatives like working with the homeless proved to improve residents' health outcomes in this health economy as living in isolation and becoming invisible contributed as a deterrent in patients not seeking health treatment. Future work on primary school age children and obesity would also be a focus of work.

Mr. Lewis was thanked for his presentation and noted the contents of the report which would be followed up with the Public Health Committee.

#### 18. 2016/17 Trust Annual Report - draft

SWBTB (05/17) 018

Mrs Wilkin presented a first draft of the annual report to give the board the opportunity to input to the publication prior to finalisation. Statutory requirement gave guidance on the contents which the Trust have complied with, this also contributed to its length. The theme of the report features the strong relationships the trust has with other organisations and will also incorporate the quality accounts. The board was asked to forward any amends or issues by the 19<sup>th</sup> May.

The board discussed if the report would be available electronically which was confirmed. However, a small print run would be commissioned for presentation at the AGM in June. An easy read summary version would also be available for view. The board asked for the document to be translated into other languages, but due to issues over quality the 4-page summary would be translated into other languages.

#### **ACTION:**

- Comments to Ms. Wilkin by 19<sup>th</sup> May
- Ms Wilkin to offer alternative language availability of the summary

#### 19. Minutes of the meeting held on 6th April

SWBTB (05/17) 019 SWBTB (05/17) 020

The Trust Board agreed the notes of the meeting held on the 6<sup>th</sup> April will the following amendments:

Page 4 – living wage. The minutes should continue to include: 'The new rate was agreed and the method confirmed until 2019.

#### **Action Log:-**

Trust Risk Register – incomplete still open

**Never Events** – The never events noted on the log would be updated by Ms. Newell and Dr. Stedman **Aspiring to Excellence** – a formal update would be presented to the June Board. The board was updated that 340 sessions have been booked, current feedback was positive. The May QHID topic will be the new PDR progress. Junior doctors are also included in this process.

**Emergency Planning** – the log to be amended as assigned to Ms. Barlow and now Miss Dhami.

Living Wage - now closed

MPA – Heads of Te	ms to be circulated, the draft has not yet been finalised	
CEO/Never Events	(10f) – Miss Dhami was still to issue the Review of Never Events	
Production Plan – T	he actions on the log can be closed	
Trust Risk Register	– IR35, item was considered at the April Board and can now be close	d
LD People's Parlian	nent – This item now closed	
Bed Trajectory for	Midland Met – Report to be presented to July board	
Localised suppliers	of multi-cultural/multi-faith meals – due to the specific nature, thi	s to be monitored via the
Public Health Comr	nittee. An update will be brought back in July.	
<b>Board Governance</b>	and actions contained. The written paper presented to the Board, Mi	ss Dhami asked to include
those actions with t	his Action Log.	
<b>Smoking</b> – highlight	ed at this board	
The board requeste	d Ms Dhami to review the action log and refresh as necessary	
ACTION:		
Miss Dhami to i	eview the action log and update	
20. Matters arising		
Birmingham 10K Ru	ın - Mrs Dutton thanked and paid tribute to Mr. Reynolds, Mr Lewis a	nd Mr Hoare who had ran
the Birmingham 10	c run for the Trust's charities and had raised over £500.	
21. Any other busing	ness	Verbal
		VCIDAI
There were no item	s of any other business.	VCINAI
There were no item  22. Date and time	·	VCINAI
22. Date and time	·	
<b>22. Date and time</b> The next public Trus	of next meeting	
<b>22. Date and time</b> The next public Trus City Hospital	of next meeting	
<b>22. Date and time</b> The next public Trus	of next meeting	
<b>22. Date and time</b> The next public Trus City Hospital	of next meeting	
<b>22. Date and time</b> The next public Trus City Hospital Signed	of next meeting	
<b>22. Date and time</b> The next public Trus City Hospital	of next meeting	
<b>22. Date and time</b> The next public Trus City Hospital Signed	of next meeting	
<b>22. Date and time</b> The next public Trus City Hospital  Signed  Print	of next meeting	
<b>22. Date and time</b> The next public Trus City Hospital Signed	of next meeting	
<b>22. Date and time</b> The next public Trus City Hospital  Signed  Print	of next meeting	
<b>22. Date and time</b> The next public Trus City Hospital  Signed  Print	of next meeting	

SWBTB (06/17) 025

# Sandwell and West Birmingham Hospitals NHS Trust

### **Public Trust Board**

### Action Log following meeting held on 4th May 2017

Minute number	Action	Assigned to	Due Date	Status	
From meeting held on 4 <sup>th</sup> May 2017:					
10	CEO Report: Learning Disabilities – update the July meeting on the advisory service with the Black Country Partnership	Toby Lewis	July 2017	Open	
12	<u>Trust Risk Register</u> : Confirmation to be sought via the Risk Management Committee that all outstanding BCG Vaccines have been delivered and availability of future stocks	Elaine Newell	June 2017	Open	
13	Integrated Performance Report: WHO checklist to be reflected in CEO report until compliance achieved	Roger Stedman	ongoing	Closed	
	Integrated Performance Report: Mortality, the medical examiner role to be discussed at the Safety QHOD meeting	Roger Stedman	June 2017	Closed	
15	<u>Production Plan: month 1 results</u> Board assurance 4 – 5 measures to be available for the next meeting	Tony Waite/Rachel Barlow	June 2017	Open	
16	ED Improvement Plan A&E scorecard to be available at the next meeting	Rachel Barlow	June 2017	Open	
18	2016/17 Trust Draft Annual Report: Comments on the report by 19 <sup>th</sup> May	Ruth Wilkin	June 2017	Closed	
	<u>2016/17 Trust Draft Annual Report:</u> Summary report to be available in alternative languages	Ruth Wilkin	June 2017	Open	
From meeting	ng held on 6 <sup>th</sup> April 2017:				
2	Staff story: Link between LGBT staff network and volunteering to be explored.	Ruth Wilkin	May 2017	Closed	
11	Trust Risk Register, Risk 328, clinical group recruitment: Executive Team to identify any clinical group leadership gaps.	Rachel Barlow	May 2017	Closed	

SWBTB (06/17) 025

## Sandwell and West Birmingham Hospitals **MHS**



#### **NHS Trust**

11	Trust Risk Register, Risk 1738, Ophthalmology outpatients (children): Steps	Roger Stedman	June 2017	Open
	to be taken to close down this risk.			
44	To all Bird Booking a Bird flooring and a second a second and a second	Kara Dhara'	1 1 2047	0
11	<u>Trust Risk Register:</u> High/low impact assessment to be completed on all risks on the Trust Risk Register.	Kam Dhami	July 2017	Open
	on the must hisk negister.			
EO report	Emergency planning and business continuity planning: Localised plans to be	Rachel Barlow	July 2017	Open
	presented to the Board.		·	
om meetir	ng held on 2 <sup>nd</sup> March 2017:			
6(a)	Public Health, Community Development & Equality Board: Diversity Pledges	Toby	June 2017	Closed
	to be returned to a future Trust Board meeting.	Lewis/Raffaela		
		Goodby		
9(a)	Major Projects Authority Committee: Heads of Terms to be circulated to the	Toby Lewis	May 2017	Open
	Board (action updated on 6 <sup>th</sup> April 2017).			
10(e)	CEO report/Consistency of care: Consistency of care reviews to be	Kam Dhami	July 2017	Open
	presented to the July 2017 Trust Board meeting.			
10(f)	CEO Report/ Never Event: Review of Never Events over the last few years to	Kam Dhami	June 2017	Closed
	be presented to the Trust Board including the event, how it was resolved,			
	changes in practice that resulted from the Never Event and how the Trust			
	disseminates new policies and changes across the Trust.			
15	Trust Risk Register: Risk assessment of imaging and pathology results	Roger Stedman	July 2017	Open
	reporting and acknowledging electronically by clinicians to be sent to CLE			
	and presented to Trust Board in April if required.			
CEO	Spring 2017 review will be conducted to confirm whether the Trust is on	Toby Lewis	Spring 2017	Open
	'bed trajectory' for Midland Met in October 2018.			

SWBTB (06/17) 025

## Sandwell and West Birmingham Hospitals **MHS**

#### **NHS Trust**

14	Localised suppliers of multi-cultural / multi-faith meals: matter to be resolved and reported to Trust Board.	Toby Lewis	Monthly verbal progress report until resolved	Open – verbal update with the CEO report	
From meeting held on 5 <sup>th</sup> November 2015:					
17	Smoking cessation: Matter to be resolved and reported to Trust Board.	Toby Lewis	Monthly verbal	Open – verbal	
			progress report	update with the	
			until resolved	CEO report	